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As you set out for Ithaca 
hope that your journey is a long one, 
full of adventure, full of discovery. 
Laistrygonians, Cyclops, 
angry Poseidon - don't be afraid of them: 
you' ll never find things like that on your way 
as long as you keep your thoughts raised high, 
as long as a rare excitement 
stirs your spirit and your body. 
Laistrygonians, Cyclops, 
wild Poseidon - you won't encounter them 
unless you bring them along inside your soul, 
unless your soul sets them up in front of you. 
Hope that your journey is a long one. 
May there be many summer mornings when, 
with what pleasure, what joy, 
you enter harbours you're seeing for the first time; 
may you stop at Phoenician trading stations 
to buy fine things, 
mother of pearl and coral, amber and ebony, 
sensual perfume of every kind - 
as many sensual perfumes as you can; 
and may you visit many Egyptian cities 
to learn and learn again from those who know. 
Keep Ithaca always in your mind. 
Arriving there is what you're destined for. 
But don't hurry the journey at all. 
Better if it lasts for years, 
so that you're old by the time you reach the island, 
wealthy with all you have gained on the way, 
not expecting Ithaca to make you rich. 
Ithaca gave you the marvelous journey. 
Without her you would not have set out. 
She has nothing left to give you now. 
And if you find her poor, Ithaca won't have fooled you. 
Wise as you’ll have become, so full of experience, 
you'll have understood by then what these Ithakas mean. 
 
Constantine Cavafi 
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Abstract 
Bone loss is a characteristic of many chronic inflammatory and degenerative diseases such 
as rheumatoid arthritis and osteoporosis. A major challenge is how to replace bone once it 
is lost. It is known that the immune system strongly regulates bone and investigations into 
these interactions have demonstrated that osteoclasts, the bone resorbing cells, are 
strongly regulated by the immune system. However, less is known about the regulation of 
osteoblasts, the bone forming cells. Mesenchymal stem cells are multipotent progenitors 
that can be induced in culture to form osteoblasts. The aim of this study was to investigate 
whether immune cells also regulate OB differentiation.  
 
Using in vitro cell cultures of human bone marrow-derived MSCs it was shown that 
monocytes/Mφs potently induced MSC differentiation to OBs evidenced by increased 
alkaline phosphatase and mineralisation. However, the ability of monocyte/Mφs to promote 
osteogenesis differed between CD14++CD16- and CD14+CD16+ monocyte subset as well as 
M-CSF and GM-CSF Mφs when activated; the CD16- monocytes and M-CSF Mφs still 
promoted differentiation whereas the CD16+ monocytes and GM-CSF Mφs inhibited it. The 
monocyte osteogenic effect was mediated by monocyte-derived soluble factors and 
required STAT3 signalling as well as COX2 upregulation and the production of PGE2. Finally, 
gene profiling microarray identified Oncostatin M as the mediator of monocyte-induced 
osteogenesis.  
 
This study established a role for monocyte/Mφs as critical regulators of osteogenic 
differentiation via OSM and STAT3 signalling. It also provides an insight into the interactions 
between MSCs and monocyte/Mφs in an inflammatory setting where OB differentiation will 
depend on the balance between pro-inflammatory versus anti-inflammatory 
monocyte/Mφs.  
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1.1 Bone 
Bone is a specialised connective tissue composed of a mineralised framework of inorganic 
calcium hydroxyapatite, which gives bone its rigidity, and organic collagen I which confers to 
its elasticity (Baron, 1999; Robey & Boskey, 2008; Rubin & Rubin, 1999). Bone serves major 
mechanical and metabolic functions. It provides structural integrity, protection of body 
structures and organs and aids locomotion through muscle attachment (Rubin & Rubin, 
1999). Additionally, the skeleton is a storehouse for calcium, a critical ion for a variety of 
metabolic processes, and participates in serum homeostasis by the absorption or release of 
calcium and other ions (Broadus, 1999; Green & Kleeman, 1991; Rodan, 1998). Finally, the 
medullary cavity of long bones harbours the marrow which is the major site of 
haematopoiesis (Purton & Scadden, 2008; Williams & Nelson, 1995).  
 
Bone development occurs along two pathways. Formation of the long bones such as the 
humerus, femur and tibia as well as of the vertebrae, begins in the embryo as a cartilaginous 
template that subsequently ossifies in a process called endochondral ossification (Rauch, 
2008; Ross et al, 2003; Yang, 2008). Alternatively intramembranous bone, of the flat bones 
such as the skull, scapula and ileum, forms from the condensation of mesenchymal cells 
which directly differentiate to osteoblasts (OB) (Rauch, 2008; Ross et al, 2003; Yang, 2008). 
There are two main histological types of endocondral bone, cortical bone and trabecular or 
cancellous bone (Baron, 1999). Cortical bone composes the hard outlayer of long bones, 
accounts for 80% of the skeleton and represents a compact structure with a well organised 
pattern of collagen fibrils aligned to provide maximum strength (Raisz et al, 2002; Ross et al, 
2003; Rubin & Rubin, 1999). Cortical bone is laid down in concentric circles, or lamellae, 
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surrounding central canals known as Haversian systems which contain blood vessels, 
lymphatics, nerves and connective tissue (Cooper et al, 1966). Trabecular or cancellous 
bone, found in the ends of long bones, is thinner with less organised structure (Baron, 
1999). However, it is ideally suited to withstand compressive stress and in some bones, like 
the vertebrae, it provides much of the structural integrity. Trabecular bone forms 
interconnecting plates and bars called trabeculae, which traverse the bone marrow space 
and have a large surface area to allow cellular interactions and metabolic processes to occur 
(Baron, 1999).  
 
Although seemingly inert, the bony skeleton is a metabolically active, dynamic structure 
undergoing constant remodelling (Hill, 1998; Mundy et al, 2003). The process of 
remodelling, whereby old bone is resorbed and replaced by new bone (Figure 1.1), is highly 
dependent on the co-ordinated actions of the cells of bone, the osteoclasts (OC) and the 
OBs, a phenomenon called coupling (Datta et al, 2008; Hartmann, 2009). Remodelling 
activity can be triggered by mechanical forces or microdamage thought to be detected by 
osteocytes buried in the bone matrix (Turner, 1998), bone cell turnover, as well as by 
hormonal changes in calcium and phosphorus levels (Mundy & Guise, 1999). These include 
the systemic calcium-regulating hormones parathyroid hormone (PTH) and 1,25(OH)2D3 
(vitamin D) as well as a number of local hormones and cytokines (Mundy et al, 2003). 
Additional systemic control is provided by sexual steroid hormones such as estrogens (Riggs 
et al, 1998), as well as leptin hormone which is synthesised by adipocytes and functions 
indirectly via binding to its receptor in the hypothalamus and subsequently signalling to 
bone (Ducy et al, 2000). A remodelling cycle begins with the retraction of the bone lining 
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cells from the endosteal surface and digestion of the endosteal collagenous membrane by 
matrix metalloproteinases (Eriksen, 1986; Mundy et al, 2003). OC progenitors are then 
recruited to the surface where they fuse to form multinucleated OCs and are activated to 
resorb the underlying bone matrix (Vaananen & Horton, 1995; Vaananen et al, 2000). Bone 
resorption is followed by bone formation by OBs that are recruited to the resorption cavity 
where they synthesise and deposit new osteoid which is subsequently calcified (Mundy et 
al, 2003; Mundy et al, 1982; Robey & Boskey, 2003). Bone remodelling maintains the 
integrity of the skeleton by removing old bone of high mineral density and high prevelance 
of fatigue micro-fractures through repetitive cycles of bone resorption and bone formation. 
This allows for the preservation of bone homeostasis, growth and repair. Conversely, any 
disruption of this co-ordinated remodelling balance towards increased resorption or 
formation can lead to osteoporosis or osteopetrosis respectively. 
 
Figure 1.1 Bone remodelling cycle 
 
 
 
 
Figure 1.1 To maintain bone homeostasis OB and OC actions are closely co-ordinated. Bone 
remodelling consists of a series of sequential steps where following bone resorption by the OCs, OBs 
migrate to a bone resorption lacuna and secrete new osteoid which subsequently mineralises thus 
forming new bone. Matrix secreting OBs that become embedded in the matrix represent the 
osteocytes. 
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1.1.1 Lineage of Osteoclast 
OCs are multinucleated cells formed by the fusion of precursor cells of the myeloid lineage, 
that are also the progenitors of macrophages (Mφ) and dendritic cells (DC) (Roodman, 1996; 
Ross, 2008; Suda et al, 1992). OCs are responsible for bone resorption by acid decalcification 
and proteolytic degradation of the bone matrix (Ross, 2008; Teitelbaum, 2000; Vaananen & 
Laitala-Leinonen, 2008) (Figure 1.2). 
 
Figure 1.2 Activated OC resorbing bone 
 
 
 
 
 
 
 
 
Figure 1.2 OCs recognize RGD-containing matrix proteins such as osteopontin and bone sialoprotein 
and attach to the bone surface through αVβ3 integrins. Association of the αVβ3 integrins leads to 
polarisation of the OC body and structural reorganization that result in the formation of the sealing 
zone - an isolated space between the OC and bone surface. Cl- and H+ are pumped in this space 
resulting in acid pH that allows the action of proteolytic enzymes such as cathepsin K (CtsK) to digest 
and solubilise the bone components leaving behind a resoption pit. CAII: carbonic anhydrase II 
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Being highly motile cells, OCs can move along the bone surface and attach to it through αVβ3 
integrins that are predominantly expressed on OCs and recognize the RGD-containing matrix 
proteins such as osteopontin and bone sialoprotein (Davies et al, 1989; Engleman et al, 
1997; McHugh et al, 2000; Miyauchi et al, 1991). Association of the αVβ3 integrins leads to 
intracellular signalling, increased intracellular Ca2+, tyrosine phosphorylation and free radical 
production, resulting in OC activation (Datta et al, 1995; Nakamura et al, 1998; Shankar et 
al, 1993). The OC cell body is polarised and undergoes internal structural changes leading to 
the formation of a specialised structure called the sealing zone, which is critical for the OC’s 
resorbing activity. This is mediated by the organization of adhesion structures called 
podosomes comprised of an F-actin core and surrounded by vinculin, talin, actinin, fimbrin, 
gelsolin and vimentin (Chellaiah et al, 2000; Marchisio et al, 1984; Teti et al, 1991).  
 
The sealing zone allows for the formation of an isolated space between the OC and the bone 
surface which is then acidified by the export of hydrogen ions from the cell’s resorptive 
surface (Ross, 2008). These hydrogen ions are produced by the action of carbonic anhydrase 
II and are pumped into the sealing zone through proton adenosine triphosphate (ATPase) 
pumps (Vaananen et al, 1990). Hydrogen ions are accompanied by chloride transferred 
through separate chloride channels to maintain electroneutrality (Vaananen & Laitala-
Leinonen, 2008). The acidic milieu mediates the breakdown of the inorganic hydroxyapatite 
component of bone but also allows the action of proteolytic enzymes on the organic matrix 
proteins. These enzymes include tartrate resistant acid phosphatase (TRAP) and cathepsin K 
and also metalloproteinases (MMPs), particularly MMP-9, which are released into the 
sealing zone (Gowen et al, 1999; Li et al, 1999; Roodman, 1999; Samanna et al, 2007) and 
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proceed to digest and solubilise the bone components leaving behind a resorption pit ready 
for the deposition of new osteoid. The products of bone degradation (collagen fragments 
and solubilised calcium and phosphate) are endocytosed by the OCs, transported to the cells 
antiresorptive surface and released into the circulation (Nesbitt & Horton, 1997; Salo et al, 
1997). 
 
1.1.2 Regulation of Osteoclast Differentiation 
Up until the late 1990’s the in vitro differentiation of monocytes to OCs required them to be 
co-cultured with OBs or other stromal cells with the addition of VitD3 and dexamethasone 
or VitD3 and prostaglandin E2 (PGE2) (Takahashi et al, 1988; Udagawa et al, 1990). It was 
subsequently shown that osteoclastogenesis is critically dependent on receptor activator of 
nuclear factor kappa B ligand (RANKL also known as TNF-related activation-inducing 
cytokine, TRANCE) and macrophage colony-stimulating factor (M-CSF) (Anderson et al, 
1997; Lacey et al, 1998; Wong et al, 1997; Yasuda et al, 1998b). These two factors are 
essential and sufficient to promote osteoclastogenesis and are produced primarily by bone 
marrow stromal cells, OBs and activated T cells (Anderson et al, 1997; Horwood et al, 1998; 
Horwood et al, 1999; Kong et al, 1999a; Kong et al, 1999b; Wong et al, 1997). M-CSF is 
thought to be critical for the proliferation and survival of the OC progenitors, by interacting 
with its receptor c-Fms expressed on monocytes and OC progenitors, whilst RANKL directly 
drives osteoclastogenesis by activating its cognate receptor RANK.  
 
The importance of RANK-RANKL interaction in osteoclastogenesis was verified in mice 
deficient for either RANK or RANKL; in both models the bone phenotype was identical with 
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severe osteopetrosis and complete lack of OCs (Dougall et al, 1999; Kong et al, 1999b). 
Additionally, these models showed that RANKL is also a critical regulator of lymph-node 
organogenesis and lymphocyte development since in RANKL deficient mice there was a 
complete lack of lymph nodes as well as a defect in early differentiation of T and B 
lymphocytes (Kong et al, 1999b). RANK is expressed on myeloid-derived dendritic cells (DC), 
chondrocytes, OC precursors and mature OCs (Anderson et al, 1997; Hsu et al, 1999; 
Nakagawa et al, 1998; Wong et al, 1997). RANKL also binds to a soluble decoy receptor, 
osteoprotegerin (OPG), produced by OBs, fibroblasts, activated T cells and NK cells (Lacey et 
al, 1998; Yasuda et al, 1998a). OPG acts as a potent anti-osteoclastogenic signal by 
sequestering RANKL, thus preventing its binding to cell surface RANK (Bucay et al, 1998; 
Simonet et al, 1997; Yasuda et al, 1998a).  
 
Activation of RANK initiates the expression of OC-specific genes during osteoclastogenesis, 
and the activation of resorption by mature OCs. At least five different signalling pathways 
have been shown to be mediating RANKL signalling and to be induced during 
osteoclastogenesis; inhibitor of NF-κB kinase (IKK), c-Jun N-terminal kinase (JNK), p38, 
extracellular signal-regulated kinase (ERK) and Src pathways. On activation, RANK interacts 
with adapter protein TNFR-associated cytoplasmic factor 6 (TRAF6) which binds to 
cytoplasmic domains of RANK (Armstrong et al, 2002; Kobayashi et al, 2001; Lomaga et al, 
1999). TRAF6 acts downstream to activate NF-κB and activator protein 1 (AP-1). The 
importance of NF-κB and AP-1 in osteoclastogenesis is illustrated by studies where targeted 
mutagenesis of the p50/p52 component of NF-κB (Franzoso et al, 1997; Xing et al, 2002) or 
the cFos component of AP-1 (Grigoriadis et al, 1994) blocked osteoclastogenesis leading to 
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osteopetrosis. Activation of NF-κB and AP-1 transcription factors can be induced by protein 
kinases IKK1/2 and JNK1 respectively (David et al, 2002; Karin et al, 2002). Mitogen-
activated protein kinase (MAPK) p38 is also involved in mediating RANK signals by activating 
transcriptional regulator mi/Mitf which controls the expression of the genes encoding for 
TRAP and cathepsin K (Li et al, 2002; Mansky et al, 2002; Matsumoto et al, 2000). ERK-1 
kinase is also activated by RANK signalling and it has been suggested that it is involved in 
negative regulation of osteoclastogenesis (Hotokezaka et al, 2002; Wei et al, 2002). The Src 
kinase has been shown to bind to TRAF6 and mediate RANK signalling through the 
phosphatidylinositol 3-OH kinase (PI3K) and the serine/threonine protein kinase (AKT) 
(Wong et al, 1999). Both molecules are known to act downstream of Src to induce survival, 
cytoskeletal rearrangements and motility.  
 
Finally, RANK signalling activates transcription factor nuclear factor of activated T cells 2 
(NFAT2, also known as NFATc1) (Cappellen et al, 2002; Gohda et al, 2005; Ishida et al, 2002; 
Takayanagi et al, 2002). NFATc1 is critical for osteoclastogenesis as its overexpression 
overrides the RANKL requirement for OC formation, whilst NFATc1 -/- monocytes fail to 
form OCs (Asagiri et al, 2005; Ikeda et al, 2004; Takayanagi et al, 2002). Activation of NFATc1 
requires mobilization of Ca2+ and activation of calcineurin but the exact mechanism is 
unclear. Ultimately RANK signalling results in the expression of key OC genes such as TRAP, 
cathepsin K, calcitonin receptor and the β3 intergrin leading to the development of mature 
OCs.  
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1.1.3 Lineage of Osteoblast 
OBs are the bone forming cells that secrete bone-matrix proteins and promote 
mineralisation (Aubin, 1998; Boskey, 1996). They are defined as post-proliferative, cuboidal, 
strongly alkaline phosphatase (ALP) positive cells lining the bone matrix at sites of active 
matrix production. OBs derive from mesenchymal progenitors, the mesenchymal stem cells 
(MSCs), first described to be residing in the bone marrow which can also differentiate into 
marrow stromal cells, adipocytes and chondocytes (Pittenger et al, 1999). The preosteoblast 
is considered the immediate precursor of the OB and it is identified in part by its localisation 
in the adjacent one or two cell layers distant from the OBs lining bone formation surfaces.  
 
The mature OB phenotype is characterised by the ability to secrete osteoid, the uncalcified 
bone matrix that mainly consists of collagen I, but also noncollagenous proteins such as ALP, 
osteocalcin, osteonectin, osteopontin, bone sialoprotein and proteoglycans (Johansen et al, 
1992; Robey, 2002). Collagen I is the major structural protein of bone (consisting 
approximately 90% of the total matrix) and provides resistance to fracture, while the 
noncollagen proteins have a variety of critical functions. For example, ALP and osteonectin 
promote mineralisation, osteocalcin may act as a chemoattractant for OCs and osteopontin 
and bone sialoprotein may facilitate the binding of OCs via the RGD motif (Golub & Boesze-
Battaglia, 2007; Roach, 1994; Robey, 2002; Termine, 1988). Osteoid matrix is subsequently 
calcified extracellularly under the influence of ALP. ALP functions to promote mineralisation 
by decreasing the concentration of calcification inhibitor pyrophosphate (ePPi) whilst 
increasing the concentration of mineralisation promoter, inorganic phosphate (Harmey et 
al, 2004; Orimo, 2010). ALP is routinely used as a marker for osteogenic differentiation and 
CHAPTER 1                                                                                                                                     INTRODUCTION 
30 
 
activity (Golub & Boesze-Battaglia, 2007), and its important role in mineralisation is 
exemplified by the genetic disease hypophosphatasia which leads to undermineralisation of 
bone due to mutations in the ALP gene (Orimo, 2010; Whyte, 1994). OBs are also 
characterised by their ability to synthesise a number of other molecules including certain 
hormones and hormone receptors such as prostaglandins and PTH receptor, cytokines and 
growth factors such as interleukin (IL)-6, IL-1 and granulocyte-macrophage colony-
stimulating factor (GM-CSF), transforming growth factor β (TGF-β), platelet derived growth 
factor (PDGF) and insulin-like growth factor (IGF) among others (Manolagas, 2000; Termine, 
1988).  
 
The matrix producing OBs can either transform into inactive bone lining cells, undergo 
apoptosis or become osteocytes, (Jilka et al, 1998; Manolagas, 2000; Noble et al, 1997; 
Parfitt, 1990). It is whilst secreting the bone matrix, that a small proportion of OBs 
(approximately 10-20%) become embedded in the newly formed mineralised matrix and are 
transformed into osteocytes (Aubin & Liu, 1996; Bonewald, 2008; Franz-Odendaal et al, 
2006). Osteocytes are contained in tiny spaces within the bone matrix called lacunae and 
are by far the most abundant cellular component of mammalian bones, representing 95% of 
all bone cells (Frost, 1960; Marotti, 1996). Osteocytes slow down and eventually cease the 
production of osteoid and the process of mineralisation; in fact it is thought that because of 
this decrease in osteoid production in comparison to neighbouring OBs, osteocytes are 
progressively buried in the bone matrix when osteoid is deposited on top of them (Franz-
Odendaal et al, 2006; Nefussi et al, 1991). Osteocytes also downregulate expression of ALP 
and osteocalcin whilst upregulating expression of dentin matrix protein 1 (DMP-1), 
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fibroblast growth factor (FGF), sclerostin and ORP150, a factor thought to protect against 
hypoxia (Feng et al, 2003; Guo et al, 2010; Liu et al, 2006; Mikuni-Takagaki et al, 1995; 
Winkler et al, 2003).  
 
Even though osteocytes were originally thought to be ‘passive placeholders in bone’, it is 
now better understood that they are important for a number of functions; they act as 
orcherstrators of bone remodelling, through regulation of OB and OC activity, and function 
as endocrine cells as well as mechanosensors in bone (Bonewald, 2002; Bonewald, 2011; 
Noble, 2008). Osteocytes form cellular projections, termed dendritic processes, with which 
they are connected to each other and to cells lining the bone surface (Palumbo et al, 1990a; 
Palumbo et al, 1990b). It is thought that via these processes osteocytes are able to regulate 
recruitment and activation of OCs to sites of bone remodelling (Kogianni et al, 2008), as well 
as to sense mechanical force and send signals that lead to a bone anabolic response 
mediated by production of nitric oxide (NO), ATP and PGE2 (Bakker et al, 2001; Forwood, 
1996; Genetos et al, 2005; Klein-Nulend et al, 1995). 
 
In the adult skeleton the majority of bone surfaces that are not being remodelled, meaning 
undergoing resorption or formation, are covered by flat, elongated, bone-lining cells which 
are thought to represent the inactive form of the OB in terms of matrix production. There is 
evidence that these cells can be reactivated to osteoid-producing OB in response to stimuli 
such as treatment with PTH (Dobnig & Turner, 1995).  
 
 
CHAPTER 1                                                                                                                                     INTRODUCTION 
32 
 
1.1.4 Regulation of Osteoblast Differentiation 
Even though considerable progress has been made in identifying morphogens, 
transcriptional regulators and signalling pathways regulating the differentiation of MSCs to 
OBs, they are still not completely understood. Osteogenic differentiation is under the 
control of bone-specific transcriptional regulators such as Runx2 and Osterix (Komori, 2008; 
Nakashima et al, 2002; Schroeder et al, 2005), and growth factors such as the Bone 
Morphogenetic Proteins (BMPs), members of the TGFβ superfamily (Bandyopadhyay et al, 
2006; Ducy & Karsenty, 2000; Friedman et al, 2006; Yamaguchi et al, 2000). The Wnt family 
members and canonical Wnt/β-catenin pathway are also implicated in skeletal development 
(Hartmann, 2007). Additionally, signalling via MAPK p38, JNK and ERK pathways has been 
reported to regulate osteogenic differentiation of MSCs (Jaiswal et al, 2000). Finally, a 
number of other factors influence MSC differentiation and bone formation including PTH 
(Blair et al, 2002; Fujita et al, 2001; Hollnagel et al, 1997; Wang et al, 2007), growth 
hormone (GH) (Haase et al, 2003; Menagh et al, 2010), prostaglandins (Forwood, 1996; Li et 
al, 2006b; Ninomiya et al, 2011; Suponitzky & Weinreb, 1998; Weinreb et al, 1997; Yoon et 
al, 2010) and IGF-1 (Levi et al, 2010a; Thaller et al, 1993). Osteogenic differentiation of MSCs 
can be driven in vitro with the addition of supplements (dexamethasone, ascorbic acid and 
β-glycerophosphate) in the culture medium (Pittenger et al, 1999). The time frame for the in 
vitro differentiation is 3 weeks and broadly consists of 3 stages; a proliferative phase (week 
1), a collagen matrix deposition phase (week 2) and a mineralisation phase (week 3) 
(Quarles et al, 1992). 
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1.1.5 Transcriptional Regulation of OB differentiation 
The differentiation of OBs from mesenchymal precursors requires a series of cell fate 
decisions controlled by a hierarchy of transcription factors and growth factors at different 
stages of differentiation (Figure 1.3). To date two transcription factors have been identified 
to be specifically involved in osteogenesis, Runx2 and Osterix (Komori, 2008; Nakashima et 
al, 2002; Schroeder et al, 2005).  
 
Runx2 and Osterix 
Runx2 was the first transcription factor to be identified as a master regulator of OB 
differentiation because it could bind to OB-specific cis-acting elements (OSE) in the 
promoter region of the OB-specific gene osteocalcin (Ducy et al, 1996; Ducy et al, 1997). 
Runx2 is a member of the runt homology domain transcription factor family that are 
conserved from C.elegans to human (Speck & Terryl, 1995). The expression of Runx2 is 
required for skeletal development, bone formation through endochondral ossicification and 
for multipotent MSCs to differentiate into OBs, while at the same time Runx2 also inhibits 
MSC differentiation into the adipocytic and chondrocytic lineages (Komori, 2006; Yoshida et 
al, 2004). Wnt/β-catenin, TGFβ/BMP and MAPK mediated signalling pathways regulate MSC 
osteogenic differentiation by promoting Runx2 expression (Gaur et al, 2005; Lee et al, 2002; 
Lee et al, 2000). 
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Figure 1.3 Osteogenic differentiation of MSCs 
 
 
 
 
 
 
 
  
 
Figure 1.3 A multipotent MSC has the potential to differentiate through osteoprogenitor and 
preosteoblast to mature metabolically active OB that secretes the bone matrix proteins and 
promotes mineralisation. Other terminally differentiated cell types of the osteblastic lineage are the 
bone lining cells and the osteocytes that are embedded in the bone matrix. Osteogenic 
differentiation is under the control of bone-specific transcription factors such as Runx2 and Osterix 
and influenced by growth factors such as TGFβ and BMPs. Differentiating OBs upregulate the 
expression of ALP and bone matrix proteins such as Collagen I, osteopontin and osteocalcin. 
Osteogenic differentiation can be induced in vitro using an osteogenic cocktail of β-
glycerolphosphate, ascorbic acid and dexamethasone (although the latter can be omitted) in MSC 
cultures. 
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Runx2 is the earliest and most specific marker of osteogenesis, essential for the 
development of the OB phenotype and expressed in the early mesenchyme of developing 
skeletal tissues (Aberg et al, 2004; Choi et al, 2001; Ducy et al, 1997; Komori et al, 1997; 
Lengner et al, 2002; Otto et al, 1997; Smith et al, 2005). During embryonic development 
Runx2 expression precedes OB differentiation and is restricted to MSCs destined to become 
either chondrocytes or OBs (Ducy et al, 1997). At this stage Runx2 regulates chondrocyte 
maturation and terminal differentiation during skeletogenesis (Enomoto et al, 2000), as 
shown by the maturational disturbance of chondrocytes seen in Runx2-/- mice (Inada et al, 
1999) as well as the induction of hypertrophic phenotype when Runx2 is continuously 
expressed in nonhypertrophic chondrocytes (Takeda et al, 2001). Subsequently, Runx2 
expression becomes restricted to the OBs, whilst expression in hypertrophic chondrocytes 
decreases (Kim et al, 1999). Runx2 is also expressed in odontoblasts, the OB homologs that 
synthesise dentin in the teeth (D'Souza et al, 1999).  
 
In support of a specific role in OB differentiation, Runx2 acts as a differentiation factor both 
in vitro and in vivo. Runx2 directs the expression of all the major OB-specific genes, including 
type I collagen, osteopontin, osteocalcin, bone sialoprotein and ALP (Ducy et al, 1999; Ducy 
et al, 1997; Harada et al, 1999; Karsenty et al, 1999; Kern et al, 2001). Furthermore, Runx2 
overexpression in vitro activates transcription of these OB-specific genes in mouse primary 
fibroblasts or even primary myoblasts (Ducy et al, 1997). In vivo, Runx2 -/- mice develop to 
term with normally patterned skeleton but which is made exclusively of cartilage because of 
a complete lack of OBs (Komori et al, 1997; Otto et al, 1997). In addition, these mice also 
lack OCs because osteoclastogenesis requires cells of the OB lineage. Runx2 is not only 
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required for OB differentiation and skeletogenesis but retains its role in mature OBs. 
Overexpression of an inactive form of Runx2 only in differentiated OBs led to decrease in 
bone mass, down regulation of Runx2 expression and also downregulation of bone matrix 
proteins (Ducy et al, 1999).  
 
To date not a great deal is known about which factors act upstream or downstream to 
regulate Runx2 expression and function. Runx2 activity is enhanced by a number of 
accessory nuclear co-factors such as CBFβ (Kundu et al, 2002; Miller et al, 2002; Yoshida et 
al, 2002a), ATF4 (Xiao et al, 2005) or SMAD proteins (Zhang et al, 2000) or post-translational 
modifications such as phosphorylation of critical serine residues in the 
proline/serine/threonine domain (Jonason et al, 2009; Shui et al, 2003; Xiao et al, 2002). 
Msx2, a homebox containing protein, is suggested to be acting upstream of Runx2 since its 
deletion causes severe skeletal abnormalities associated with a decrease in Runx2 
expression (Satokata et al, 2000). Similarly Bapx1, a mammalian homolog of the Drosophila 
bagpipe homeobox gene, may also act upstream of Runx2 since Runx2 expression is 
decreased in the skeleton of Bapx1 -/- mice (Tribioli & Lufkin, 1999). To fully delineate the 
regulation of Runx2 further investigations are required. 
 
Osterix is a second transcription factor that is essential for OB differentiation (Nakashima et 
al, 2002). Osterix -/- mice have a similar phenotype to the mice lacking Runx2 showing 
complete lack of endochondral or intramembranous ossification due a block in OB 
differentiation, whereas MSCs from Osterix -/- mice can differentiate to chondrocytes 
(Nakashima et al, 2002). The precise role of Osterix is not fully defined but it is thought to 
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act downstream of Runx2, because Osterix -/- MSCs express Runx2 but Osterix is not 
expressed in Runx2 -/- mice (Nakashima et al, 2002). Similarly to Runx2, Osterix expression 
can enhance bone-specific gene expression (Wu et al, 2010).  
 
Wnt/β-catenin signalling 
Wnt signalling comprises a family of 19 secreted glycoproteins that have varied functions 
related to cell growth, differentiation and apoptosis (Logan & Nusse, 2004; Pandur et al, 
2002). Wnt proteins signal through Frizzled receptors that transduce signalling either via the 
canonical β-catenin or non-canonical pathways (Logan & Nusse, 2004; Pandur et al, 2002). 
Wnt signal transduction results in stabilisation of intracellular β-catenin by inhibiting its 
phosphorylation by the glycogen synthase kinase 3 (GSK-3). Unphosphorylated β-catenin 
accumulates in the cytoplasm and translocates to the nucleus; there it binds T cell-factor 
(TCF)/ lymphoid-enhancer-factor (LEF) transcription factors and recruits transcriptional co-
activators thus activating transcription of downstream genes. In the absence of Wnt 
pathway activation, cytosolic β-catenin is phosphorylated by GSK3β which promotes its 
ubiquitination by E2 ligases and degradation by the proteasome. This results in low basal 
levels of cytosolic β-catenin thus preventing β-catenin nuclear translocation and activation 
of the Wnt responsive transcription factor TCF/LEF1. The scaffolding proteins axin, frat and 
dishevelled (Dsh) mediate the degradation of phosphorylated β-catenin by creating docking 
sites for F-box protein/E2 ligase complexes (Behrens et al, 1998; Jiang & Struhl, 1998).  
 
Both gain and loss of function mutations in Wnt signalling components have revealed critical 
requirements of these pathways for normal skeletogenesis. Activation of Wnt signalling 
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requires the low-density lipoprotein receptor-related protein 5 (LRP5) which forms the 
Frizzled/LRP5/6 receptor complex. An activating mutation in this gene results in high bone 
mass in humans (Boyden et al, 2002; Little et al, 2002), a phenotype also reproduced in mice 
(Akhter et al, 2004; Babij et al, 2003). In accordance, inactivating mutations of LRP5 resulted 
in osteopenia and decreased bone mass both in humans and mice (Gong et al, 2001; Kato et 
al, 2002). In conditional β-catenin mutants there was severe osteopenia whereas 
constitutive activation of β-catenin resulted in dramatically increased bone deposition 
(Holmen et al, 2005; Tamamura et al, 2005). Inactivation of β-catenin in MSCs blocked OB 
differentiation both in vitro and in vivo indicating that β-catenin is required for OB lineage 
differentiation (Day et al, 2005; Hill et al, 2005). OB precursors lacking β-catenin 
differentiated to chondrocytes suggesting that β-catenin is important to direct 
differentiation in favour of OBs instead of chondrocytes.  
 
Other regulators of Wnt signalling that act as negative regulators of OB differentiation are 
the Dickkopf family members (DKK1 and DKK2) and secreted frizzled related proteins (Sfrps), 
families of extracellular proteins that negatively modulate Wnt signalling. Sfrps bind directly 
to Wnts and prevent the association with the LRPs and Frizzled receptor, whereas DKKs 
sequester LRP5/6 into complexes with the transmembrane protein Kremens thus limiting 
their availability for association with Wnts and binding to Frizzled receptor. A null mutation 
of Sfrp1 results in increased bone mass in adult mice (Bodine et al, 2004).  
 
In summary, β-catenin directs OB differentiation at the pre-OB stage and enhances Runx2 
expression. Runx2 is required for MSC differentiation into pre-OB and for suppressing the 
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differentiation into adipocytes or chondrocytes. Osterix and β-catenin act by directing the 
differentiation of pre-OB into mature OBs and abolish their potential for differentiating into 
chondrocytes. 
 
1.1.6 Soluble factors regulating OB differentiation 
 
Bone morphogenetic proteins and transforming growth factor β 
Osteogenic differentiation is regulated by many soluble factors the most important of which 
are the bone morphogenetic proteins (BMPs). First identified as ostoinductive factors in 
demineralised bone matrix which promoted bone formation (Urist, 1965; Urist & Strates, 
1971), BMPs are growth factors that belong to the TGFβ superfamily and have an important 
role in bone formation (Bandyopadhyay et al, 2006; Yamaguchi et al, 2000). BMP2, BMP4 
and BMP7 can induce Runx2 and Osterix in MSCs and promote OB differentiation (Lee et al, 
2003a; Lee et al, 2003b). BMPs signal through serine/threonine kinase receptors composed 
of type I and type II subtypes that associate with and phosphorylate downstream molecules 
called Smad 1, 5 and 8 (Chen et al, 2004a). Phosphorylated Smad 1, 5 and 8 form a complex 
with Smad 4 and then translocate into the nucleus where they interact with other 
transcription factors such as Runx2 in OBs. BMP signalling is regulated at multiple levels by a 
variety of molecules such as Noggin, which antagonises BMP binding to their receptors 
(Groppe et al, 2002), Smad 6, which binds to BMP receptor and prevents its interaction with 
Smad 1, 5 and 8 (Imamura et al, 1997), and Smurf 1, which interacts with and mediates 
degradation of Smad 1 and 5 (Zhu et al, 1999) as well as Runx2 (Zhao et al, 2003). The 
involvement of these factors in the regulation of osteogenesis is illustrated from in vivo 
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studies in mice, where over-expression of Noggin in mature OBs caused osteoporosis (Devlin 
et al, 2003; Wu et al, 2003), whilst Smurf1 over-expression in OBs inhibited postnatal bone 
formation (Zhao et al, 2004).  
 
A member of the same superfamily as the BMPs, TGF-β1 also has a role in regulating 
osteogenic differentiation and bone formation (Joyce et al, 1990b; Marcelli et al, 1990). 
TGF-β is ubiquitously expressed and found in high concentrations in bone, cartilage and 
platelets (Chien et al, 1999; Hauschka et al, 1986; Hering et al, 2001; Lieberman et al, 2002). 
During fracture healing through endochondral ossification, TGF-β1 is expressed in periosteal 
tissue and in chondrocytes (Lieberman et al, 2002), and was found to play a role in 
undifferentiated mesenchymal cell proliferation, OB and OC precursor recruiting, 
chondrocyte differentiation and bone matrix production (Devescovi et al, 2008). 
Furthermore, sub-periosteal injections of TGF-β1 stimulated endochondral ossification of 
periosteal progenitor cells in a rat model (Joyce et al, 1990a). Even tough, TGF-β1 seems to 
be playing a role in bone formation in vivo, in in vitro rat calvaria cultures TGF-β 1 inhibited 
bone nodule formation and the expression of bone specific genes type I collagen, ALP, 
osteopontin and ostocalcin as well as expression of BMP2. This suggested that the in vivo 
effects of TGF-β1 on bone formation are likely mediated on OB precursors and not 
differentiated mineralising OBs (Harris et al, 1994). Indeed, TGF-β1 enhanced and 
accelerated osteogenic differentiation of rat bone marrow cells cultured on collagen type I 
matrices (Mizuno & Kuboki, 1995). Additionally, TGF-β1 increased expression of OB 
differentiation markers, Runx2, osteopontin and collagen I as well as ALP activity whilst 
decreasing expression of adipogenic markers Pparg2 and adiponectin in murine bone 
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marrow stromal cells (Zhao et al, 2010). Conversely, in murine adipose derived stromal cells 
TGF-β1 was found to significantly inhibit osteogenic differentiation and had no effect on the 
differentiation of human adipose derived stromal cells (Levi et al, 2010b). Another study 
showed that TGF-β1 inhibited BMP-2-induced osteogenesis of human adipose derived 
stromal cells (Mehlhorn et al, 2007). It is likely that in vitro systems cannot replicate the 
complexity of the in vivo setting where TGF-β1 effects are influenced by many other factors. 
Furthermore, TGF-β1 could have different effects on osteoprogenitors depending on 
whether they are derived from the bone marrow or adipose tissue since these populations 
might not be exactly equivalent. 
 
Hormones, growth factors and cytokines 
Other factors known to affect osteogenic differentiation include PTH, IGF1, PGE2 and 
connective tissue growth factor (CTGF), as well as cytokines, soluble mediators of the 
immune system, such as IL-1β, IL-6 and TNFα. PTH has been shown to inhibit OB apoptosis 
and to promote proliferation and osteogenic differentiation in several OB cell culture 
studies (Adelina Costa & Helena Fernandes, 2000; Blair et al, 2002; Fujita et al, 2001; 
Hollnagel et al, 1997; Ogita et al, 2008; Sammons et al, 2004; Wang et al, 2007). 
Importantly, PTH is used as an anabolic treatment for osteoporosis since administration 
increases bone mass in osteoporosis patients and in randomised clinical trials it has been 
shown to be useful in preventing osteoporosis-related fractures (Cosman & Lindsay, 2004; 
Cosman et al, 1998; Lindsay et al, 2007; Rosen & Rackoff, 2001). IGF-1 was shown to 
increase ALP, bone nodule formation as well as the expression of OB specific genes Runx2 
and osteocalcin in human adipose derived stromal cells but also increased adipogenic 
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differentiation in these cultures (Levi et al, 2010a). Additionally, Thaller and colleagues 
demonstrated healing of a critical size calvarial defect at six weeks with in vivo 
administration of IGF-1 in rats (Thaller et al, 1993). Prostaglandins, and specifically PGE2, 
have many important roles in bone regulating osteoclastogenesis, mechanotransduction, 
bone formation and fracture repair (Li et al, 2006b). Systemic or local injection of PGE2 
stimulates bone formation (Suponitzky & Weinreb, 1998; Weinreb et al, 1997), whilst 
increased bone formation following mechanical loading is mediated by PGE2 and can be 
completely abolished using COX2 inhibitors that inhibit PGE2 production (Duncan & Turner, 
1995; Forwood, 1996). A number of studies have also demonstrated that PGE2 and COX2 
directly regulate bone specific transcription factors Runx2 and Osterix (Ninomiya et al, 2011; 
Yoon et al, 2010; Zhang et al, 2002a). Finally, CTGF has been shown to have a role in bone 
formation and skeletal development (Kanaan et al, 2006). CTGF expression was found in 
bone tissue, in the fracture callus as well as in mineralising OB cultures in vitro, where 
treatment with anti-CTGF neutralising antibodies caused an inhibition of bone nodule 
formation (Safadi et al, 2003). Conversely, treatment of OB cultures with CTGF caused an 
increase in cell proliferation, ALP activity and calcium deposition which was recapitulated 
with in vivo administration of CTGF in femoral marrow cavity where it induced osteogenesis 
(Safadi et al, 2003). Apart from its effects on mature OBs, CTGF has also been shown to 
osteogenic differentiation of MSCs (Wang et al, 2009). 
 
Finally, many cytokines are also important regulators of bone formation and osteogenic 
differentiation of MSCs (Lee et al, 2008; Mundy et al, 1995). Cytokines are soluble mediators 
of many immune cell interactions, cellular communication and effector responses. They are 
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low molecular weight regulatory proteins or glycoproteins that are secreted primarily by 
immune cells but also other cell types in response to various stimuli. Cytokines act through 
binding to specific receptors on the cellular membrane of target cells in an autocrine (acting 
on the same cell that secreted the cytokine), paracrine (acting as short range mediators on 
adjacently situated cells) and also in certain cases an endocrine manner (entering the 
bloodstream and acting on distant target cells). A number of cytokines are known to 
influence OBs and bone formation such as IL-1, IL-6 and TNFα.  
 
IL-1 
The best known effect of IL-1 on OBs and bone marrow stromal cells is that it upregulates 
expression of RANKL and thus it is a potent stimulator of osteoclastogenesis (Hofbauer et al, 
1999). With regards to osteogenic differentiation there are contradictory findings. Lacey and 
colleagues showed that IL-1β inhibited bone mineralisation, ALP activity and expression of 
α1 procollagen, Runx2 and Osterix, but increased expression of osteopontin and osteonectin 
in murine MSCs treated with ostegeonic media (Lacey et al, 2009). Contradictory to this 
study, Ding and colleagues reported that in human MSC cultures, IL-1β stimulated ALP 
activity and mineralisation despite causing a decrease in Runx2 and collagen expression as 
well as decreasing osteocalcin secretion (Ding et al, 2009). Finally, Lin and colleagues 
showed that IL-1β had a biphasic effect on osteogenic differentiation of rat calvaria OBs; 
short treatment (2 days) resulted in a significant increase in mineralised bone nodules 
mediated by an increase in PGE2 and NO production, whereas with longer treatment (6 
days) there was significantly fewer bone nodules formed (Lin et al, 2010).  
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IL-6 
OBs and bone marrow stromal cells are major producers of IL-6 (Heymann & Rousselle, 
2000; Ogasawara et al, 1996). The effect of IL-6 on OBs and their progenitors is minimal in 
the absence of its soluble receptor, sIL-6R, but when added together the IL-6/sIL-6R complex 
promoted osteogenic differentiation of human and murine osteoblastic cell line MG-63 and 
MC3T3-E1 respectively, as well as primary murine calvaria cells and human bone marrow 
derived MSCs (Bellido et al, 1996; Erices et al, 2002; Nishimura et al, 1998). Taguchi and 
colleagues also showed that IL-6/sIL-6R could promote osteogenic differentiation of murine 
embryonic fibroablasts but not differentiation towards chondrocytes, adipocytes or muscle 
cells (Taguchi et al, 1998). IL6/sIL-6R may promote OB differentiation indirectly through 
promoting IGF-1 and BMP-6 synthesis in rat OBs (Franchimont et al, 2005), as well as PTHrP 
expression by human OBs (Guillen et al, 2004). Contradictory to a role in promoting 
osteogenic differentiation, Pricola and colleagues showed that IL-6 is important for the 
maintenance of MSCs in an undifferentiated state, with MSCs producing high levels of IL-6 
which dramatically decrease during osteogenic differentiation (Pricola et al, 2009).  
 
TNFα 
In early experiments TNFα was found to be inhibitory of bone collagen synthesis in organ 
cultures of fetal rat calvariae as well as inhibiting ALP activity and collagen synthesis in rat 
osteosarcoma cells (Bertolini et al, 1986), and primary rat calvaria OB cultures (Centrella et 
al, 1988). Further studies also showed that TNFα is inhibitory of osteogenic differentiation; 
when added in combination with osteogenic media (containing ascorbic acid and β-
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glycerolphosphate) in murine fetal rat calvaria cells or the osteoblastic cell line MC3T3-E1, 
TNFα reduced formation of mineralised nodules as well as secretion of bone specific matrix 
protein osteocalcin (Gilbert et al, 2000). TNFα was also shown to be inhibitory of ALP 
activity, osteocalcin expression and bone nodule formation induced by osteogenic media in 
murine bone marrow cells, an effect shown to be mediated through the TNF receptor 1 
(P55) (Abbas et al, 2003; Gilbert et al, 2005). The inhibitory effects of TNFα on OB 
differentiation where shown to be due to inhibition of bone specific transcription factor 
Runx2, since TNFα blocked Runx2 expression by destabilizing its mRNA and suppressing its 
transcription (Gilbert et al, 2002; Kaneki et al, 2006). Furthermore, TNFα is thought to be 
pro-apoptotic for OBs through Fas-Fas ligand signalling (Jilka et al, 1998; Kawakami et al, 
1997). Despite the mostly inhibitory role for TNFα in OB differentiation reported in 
literature, there is some evidence that TNFα may be stimulatory of ALP activity and 
mineralisation at low concentrations (0.1-10 ng/ml) (Ding et al, 2009; Glass et al, 2011).  
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1.2 Stem Cells 
A stem cell is defined by two fundamental properties; the ability for self renewal and the 
capacity for differentiation into mature cells that can reconstitute an entire tissue (Potten & 
Loeffler, 1990; Schipani & Kronenberg, 2008). According to differentiation potential the 
stem cell repertoire ranges from the totipotent zygote (which can develop to a whole 
organism including extraembryonic tissues such as the placenta) to the lineage restricted 
unipotent precursor cells of specific tissues (which can give rise to only one cell type), such 
as neural stem cells and epidermal stem cells (Figure 1.4). Embryonic Stem (ES) cells, also of 
embryonic origin but with a more limited differentiation potential than the zygote, are 
derived from the inner cell mass of the developing blastocyst (De Miguel et al, 2010; Evans 
& Kaufman, 1981). ES cells are pluripotent, meaning that they can give rise to mature cells 
of all three germ layers endoderm, mesoderm and ectoderm and hence to any foetal or 
adult cell type but not extraembryonic tissues. This extraordinary ability makes ES cells an 
attractive tool for regenerative medicine; however ethical issues exist regarding their 
isolation and use. 
 
The majority of differentiated somatic cells have a limited ability for self-renewal. 
Consequently, the existence of post-natal adult stem cells can be inferred from the ability of 
certain tissue types (such as blood, skin and the gastrointestinal tract) to continuously 
regenerate throughout life. Adult or somatic stem cells - where somatic refers to non-germ 
line cells of the body, have been identified in many organs and tissues, including brain, bone 
marrow, peripheral blood, blood vessels, skeletal muscle, skin, teeth, heart, gut and liver.  
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Figure 1.4 Hierarchy of stem cells 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 At the apex of stem cell hierarchy is the totiopotent zygote, followed by the pluripotent 
ESCs isolated from the blastocysts of developing embryos. MSCs and HSCs represent the two 
types of adult stem cells present in the bone marrow; MSCs gives rise to cell types of 
mesenchymal tissues such as OBs, adipocytes and chondrocytes whilst the HSC is the 
progenitor of all the cells found in the bood. 
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As opposed to the pluripotent embryonic or foetal stem cells, adult stem cells are 
multipotent meaning that they have a limited differentiation potential. This potential is 
often restricted to mature cells of only one germ line (endoderm, mesoderm, ectoderm). 
Epithelial stem cells lining the digestive tract can differentiate into several endoderm cell 
lines such as absorptive cells, goblet cells, paneth cells and enteroendocrine cells. 
Mesenchymal stem cells (MSC) give rise to cells of the mesoderm lineage such as bone, 
cartilage and fatty tissue, as well as other kinds of connective tissue such as tendons. Neural 
stem cells in the brain give rise to three major ectoderm cell lines, neurons, astrocytes and 
oligodendrocytes. These adult stem cells persist throughout life, fulfilling functions such as 
repairing or replacing cells in response to injury or as part of the natural cell turnover.  
 
Of the diverse range of adult stem cells two major types, and the first ones to be identified 
are the HSCs and the MSCs, both residing in the bone marrow (Bonnet, 2003). HSCs, the 
best characterised of all the known types of stem cells (Orkin & Zon, 2008), was first defined 
as having the ability to reconstitute the haematopoietic system and hence rescue lethally 
irradiated recipient animals (Siminovitch et al, 1963). Using serial transplantation, it was also 
shown that HSCs have self-renewal ability (Siminovitch et al, 1963). HSCs are thus defined as 
cells with the ability to self-renew but also to generate differentiated progeny of all cell 
lineages of the blood and immune system including T and B lymphocytes, monocytes, 
granulocytes, erythrocytes and megakaryocytes (Morrison et al, 1995b; Weissman, 2000). 
HSCs are also the progenitors of the bone resorbing OCs which derive from the monocyte-
Mφ lineage (Bar-Shavit, 2007).  
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HSCs can be isolated using a cocktail of monoclonal antibodies specific for cell surface 
proteins. Expression of stem-cell antigen 1 (Sca-1) and c-Kit and but not lineage (Lin) defines 
a Sca-1+Lin-c-Kit+ HSC-containing population where one in five cells has the property of long-
term engraftment and multilineage reconstitution following transplantation in irradiated 
mice (Morrison et al, 1995a; Osawa et al, 1996; Spangrude et al, 1995; Wagers et al, 2002). 
Recently the use of SLAM family markers, CD48 and CD150 was shown to result in more 
highly purified HSCs, described as CD48-CD150+ (Kiel et al, 2005; Yilmaz et al, 2006). The 
second type of bone marrow stem cell, the MSC, can differentiate into a variety of 
mesenchymal lineages such as OBs, chondrocytes and adipocytes and will be the subject of 
the following section.  
 
1.2.1 Mesenchymal stem cells: characterisation and definition 
The presence of a non-hematopoietic stem cell residing in the bone marrow, far from being 
a novel idea, was first proposed by Cohneim about 130 years ago, who suggested that 
fibroblasts from the bone marrow can contribute to wound healing in peripheral tissues 
(Prockop, 1997). Further evidence was provided in the early 1970’s by studies of the 
regeneration of bone marrow following tissue ablation (Knospe et al, 1972; Patt & Maloney, 
1975), as well as by studies demonstrating the development of a bone marrow organ 
following ectopic transplantation of bone marrow in rodents (Amsel & Dell, 1971; Tavassoli 
& Crosby, 1968). However, it was Friedenstein and colleagues who first definitively 
characterised a bone marrow-derived, adherent, fibroblast-like heterogeneous population 
with the ability to form distinct colonies (colony forming unit fibroblastic, CFU-F) 
(Friedenstein, 1980; Friedenstein et al, 1970; Owen & Friedenstein, 1988). These cells could 
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also differentiate to OBs and when transplanted subcutaneously formed ectopic bone and 
reconstituted a haematopoietic microenvironment (Friedenstein, 1980). Friedenstein’s 
experiments were subsequently repeated and expanded by many groups to show that these 
cells could also be isolated in humans, and differentiated in vitro into a variety of 
mesenchymal lineages including OBs, chondrocytes, adipocytes, myoblasts and other tissues 
(Bianco et al, 2008; Caplan, 2007; Pittenger et al, 1999; Prockop, 1997) as shown in a 
diagram taken from a 2001 review by Caplan and Bruder (Figure 1.5).  
 
Figure 1.5 MSC multilineage differentiation potential 
 
 
 
 
 
 
Figure 1.5 MSC have the ability to differentiate into a range of mesenchymal tissue and cell types 
including bone, cartilage, adipose, muscle, stroma and tendon. There is also evidence suggesting 
that they may have a greater plasticity to differentiate into non-mesenchymal tissues including liver, 
heart, skin and nervous tissues. From Caplan and Bruder, 2001. 
 
Based on the notion of this multipotent stem cell the term mesenchymal stem cells (MSC) 
was popularised by Caplan and colleagues in the early 1990’s (Caplan, 1991; Caplan, 2007; 
Caplan & Bruder, 2001). However, many investigators question the use of the term ‘stem’ 
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due to the lack of convincing data supporting the ‘stemness’ of the unfractionated plastic-
adherent populations (Horwitz & Keating, 2000). Indeed these populations are highly 
heterogenous with varying proliferation and differentiation potential. In Pittenger’s cultures 
not all MSC colonies could undergo tri-lineage differentiation with some clones being 
restricted to just osteogenic differentiation, while Colter et al. identified at least two 
morphologically distinct populations of MSCs: a small rapidly self-renewing (RS) population 
with enhanced differentiation potential and a larger, more mature, slowly replicating 
population (Colter et al, 2000; Colter et al, 2001; Prockop et al, 2001). Consequently an 
increasingly confusing nomenclature has been used which in addition to ‘MSC’ includes 
‘bone marrow mesenchymal stromal cells’ (Bianco et al, 2008; Keating et al, 1998), 
‘multipotent mesenchymal stromal cells’ (Bouffi et al, 2009), ‘mesenchymal progenitor cells’ 
(Jackson et al, 2009), ‘marrow-isolated adult multilineage inducible cells’ (MIAMI) (D'Ippolito 
et al, 2004; Rahnemai-Azar et al, 2011) and ‘multipotent adult progenitor cells’ (MAPCs) 
(Jiang et al, 2002; Reyes et al, 2001).  
 
Even though all these populations seem to process roughly the same characteristics it is 
difficult to assess whether they represent equivalent populations and their relevance in vivo. 
For example, MAPCs were isolated from both human and murine bone marrow 
mononuclear cells, have a fibroblastic morphology similar to MSCs and were the only 
population of bone marrow derived cells that could contribute to all the three germ layers 
upon injection into blastocysts in rodents (Jiang et al, 2002; Reyes et al, 2001). MIAMI cells 
were isolated also from human bone marrow but by culturing on fibronectin-coated plates 
in 5% oxygen, which is likely more representative of the bone marrow environment; these 
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cells were shown to express markers for cells derived from all three germ layers (D'Ippolito 
et al, 2004). Finally, Kucia et al. identified a population in vivo expressing markers 
characteristic of pluripotent stem cells found during embryogenesis in the epiblast of the 
embryo which they termed ‘very-small embryonic-like stem cells’ (VSELs) (Kucia et al, 2006; 
Ratajczak et al, 2007). It is clear that further investigations are required to uncover how 
these populations are related to each other as well as their in vivo phenotypic 
characterisation.  
 
The bone marrow was the original source of MSCs but equivalent populations have 
subsequently been isolated from many different tissues such as adipose tissue, umbilical 
cord blood, amniotic fluid, placenta, dental pulp, tendons, synovial membrane and skeletal 
muscle (Bi et al, 2007; Bieback & Kluter, 2007; Crisan et al, 2008; De Bari et al, 2001; Igura et 
al, 2004; Rogers & Casper, 2004; Shi & Gronthos, 2003; Tsai et al, 2004; Xu et al, 2005). 
However, the complete equivalency of these populations has not yet been definitively 
demonstrated. Furthermore, MSC cultures with similar morphological, immunophenotypic 
and functional properties have been established from brain, kidney, liver, spleen, lungs, 
thymus and pancreas of mice (da Silva Meirelles et al, 2006). One novel hypothesis that may 
explain why MSCs can be isolated from all tissues states that these cells are situated 
throughout the body as pericytes, suggesting the perivascular zone as the MSC niche in vivo 
(Crisan et al, 2008; da Silva Meirelles et al, 2008; Dennis & Charbord, 2002; Jones & 
McGonagle, 2008; Modder & Khosla, 2008). This association of MSCs with the vasculature 
would allow them to function as a source of new cells for physiological turnover, stabilise 
blood vessels and contribute to tissue and immune system homeostasis under physiological 
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conditions, but also to assume a more active role in the repair of local tissue injury since 
damage to any tissue would release the MSCs from their perivascular site (da Silva Meirelles 
et al, 2008). Although, the pericyte hypothesis for MSCs is attractive it remains to be seen 
whether it will be established as the true MSC niche in vivo. Other localisations for MSCs 
that raise additional questions for their origin is the periosteum of bones which is also a 
source of MSCs and is critical for fracture repair (Modder & Khosla, 2008).  
 
1.2.2 The surface phenotype of MSCs 
Importantly no exclusive marker for specific identification and isolation of MSCs has been 
identified to date. The varied sources and methodologies used may thus result in 
unequivalent populations and makes direct comparisons of reported biologic properties and 
experimental results problematic. In an effort to address these issues the Mesenchymal and 
Tissue Stem Cell Commitee of the International Society for Cellular Therapy proposed a set 
of minimal criteria to define MSCs (Dominici et al, 2006). According to these, MSCs must be 
plastic-adherent when maintained in standard culture conditions, they must express CD105 
(known as endoglin and originally recognised by the MAb SH2), CD73 (known as ecto 5’ 
nucleotidase and originally recognised by MAb SH3 and SH4) and CD90 (also known as Thy-
1), lack expression of CD45 (a pan-leukocyte marker), CD34 (an HSC marker), CD14 or CD11b 
(prominently expressed on monocytes and Mφs), CD79α or CD19 (markers for B cells) and 
HLA-DR molecules, and finally they must differentiate to OBs, adipocytes and chondroblasts 
in vitro. In addition to the minimal criteria for cell surface antigen expression, the surface 
phenotype of MSC has been extensively studied and reported and a summary of antigen 
expression of human MSCs is given in Table 1.1 together with the relevant references. 
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Table 1.1 Surface phenotype of MSCs 
Surface 
antigen 
Aliases Function/Expression Reference 
CD11b- Integrin alpha M, 
Mac-1 
Mediates adhesion to substrates by opsonization and 
phagocytosis, neutrophil aggregation, 
chemotaxis/Granulocytes, monocyte, Mφs, NK cells 
(Colter et al, 2001) 
CD14- LPS-R Endotoxin (LPS) receptor/monocytes, Mφs / 
granulocytes  
(Pittenger et al, 1999) 
CD19- Co-receptor with 
CD21 
B cell development, activation and 
differentiation/Folllicular DC, B lymphocytes 
(Pittenger et al, 1999) 
CD34-  Binds CD62L/HSC, endothelial cells (Pittenger et al, 1999) 
CD44+ H-CAM, Hermes, Pgp-
1, HUTCH-1 
Hyaluronan receptor/Most cell types (Colter et al, 2001; 
Pittenger et al, 1999) 
CD45- LCA TCR and BCR activation/Haematopoetic cells (Pittenger et al, 1999) 
CD58+ LFA-3 Mediates adhesion between NK cells and target 
cells/Leukocytes, erythrocytes, endothelial cells, 
fibroblasts, cardiac muscle 
(Tse et al, 2003) 
CD61+ β3 integrin chain Platelets, Mφs (Vogel et al, 2003) 
CD71+ Transferin receptor Iron uptake/All cells (Xu et al, 2004) 
CD73+ Ecto 5’-nucleotidase 
(recognised by SH3 
and SH4 antibody) 
Activation of B lymphocytes/T and B lymphocytes (Barry et al, 2001; 
Pittenger et al, 1999) 
CD80- B7-1 T cell co-stimulation via CD28 and CTLA-4/B cells, APC (Tse et al, 2003) 
CD86- B7-2 T cell co-stimulation via CD28 and CTLA-4/B cells, APC (Tse et al, 2003) 
CD90+ Thy-1 Thymocytes, HSC, endothelial cells, fibroblasts (Pittenger et al, 1999) 
CD105+ Endoglin (recognised 
by SH2 antibody) 
TGFβ receptor /endothelial, macrophages, stromal cells (Barry et al, 1999; 
Pittenger et al, 1999) 
CD106+ VCAM-1 Ligand for VLA-4 (α4β1) (Majumdar et al, 2003; 
Pittenger et al, 1999) 
CD109+ Platelet activating 
factor 
Activated T cells, platelets, endothelium (Vogel et al, 2003) 
CD117- c-Kit  Stem cell factor receptor/HSC, mast cells (Colter et al, 2001; 
Vogel et al, 2003) 
CD140α+ PDGF receptor α Platelet derived growth factor receptor (Morikawa et al, 
2009a; Morikawa et al, 
2009b) 
CD140b+ PDGF receptor b Platelet derived growth factor receptor (Vogel et al, 2003) 
CD146+ MCAM,MUC-18 Pericytes, endothelium, BM stromal cells (Sacchetti et al, 2007) 
CD164+ MUC-24 Monocytes, endothelium, BM stromal cells (Vogel et al, 2003) 
CD166+ ALCAM (recognised 
by SB-10 antibody) 
CD6 ligand/Endothelial cells, Mφs, stromal cells (Bruder et al, 1998c) 
CD200+ OX2 Thymocytes, T and B lymphocytes, endothelial cells (Delorme et al, 2008) 
CD271+ p75, LNGFR Low affinity nerve growth factor receptor (Jones et al, 2004) 
MHC class 
I+ 
 All nucleated cells (Le Blanc et al, 2003a) 
MHC class 
II- 
 APC, B and T lymphocytes (Le Blanc et al, 2003a) 
STRO-1+  Unknown  (Dennis et al, 2002; 
Gronthos et al, 1994; 
Simmons & Torok-
Storb, 1991) 
Table 1.1. Markers expressed by MSCs. + and – indicate presence and absence of marker, 
respectively. The most widely accepted markers are denoted in red.   
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The elusive problem of the lack of specific MSC markers has been met by increasing number 
of studies aimed at this issue, the solution of which will also lead to more efficient MSC 
isolation protocols. Stro-1 is the best known MSC marker first identified by Simmons et al., 
who showed that the CFU-F cells are present exclusively in the Stro-1 positive fraction of 
bone marrow stroma (Simmons & Torok-Storb, 1991). Stro-1 positive cells can differentiate 
to HSC-supporting fibroblasts, smooth muscle cells, adipocytes, OBs and chondrocytes 
(Dennis et al, 2002). However, Stro-1 is not exclusively expressed on MSCs and its 
expression is lost during culture. Other studies have shown that stage-specific embryonic 
antigen 1 (SSEA-1) and SSEA-4, thought previously to be restricted to ES cells, can be used as 
markers for human and murine bone marrow MSCs (Anjos-Afonso & Bonnet, 2007; Gang et 
al, 2007).  
 
Even though these markers and those listed in Table 1.1, have been shown to be expressed 
in multipotent cells they are also expressed on other cell types, hence they cannot be used 
in isolation. For the most efficient and accurate isolation strategies the use of multiple 
markers is required. For example, Gronthos and colleagues used Stro-1 in combination with 
CD106, also known as vascular cell adhesion molecule 1 (VCAM-1). Of the cells selected as 
Stro-1 positive, 1.4% were also positive for VCAM-1 and this further purified population had 
increased CFU-F frequency of 1 in 3; these VCAM-1 positive cells were all highly Stro-1 
expressing cells and the only with multipotential properties (Gronthos et al, 2003). Another 
study using fluorescence-activated cell sorting of human bone marrow mononuclear cells 
based on the presence of CD49b, CD105, CD90, CD73, CD130, CD146, CD200 and αV/β5 
integrin resulted in 23-, 50-, 60-, 100-, 256- 278-, 333- and 1750- fold enrichment of CFU-Fs 
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respectively (Delorme et al, 2008). Finally, Horwitz and colleagues reported the neural 
ganglioside GD2 as the first single surface marker that uniquely distinguishes MSCs from all 
other bone marrow cells (Martinez et al, 2007), but this finding remains to be validated by 
other investigators. The relationship between the different populations isolated using these 
purification strategies and whether any have superior biological effects in clinical 
applications remains to be established. 
 
There is also increasing interest to phenotypically identify MSC populations in vivo, in 
contrast to the thus far in vitro identification. An interesting study by Paolo Bianco’s group 
showed that CD146 (MCAM) positive cells isolated from the human bone marrow stroma 
were the only cell population that was both plastic-adherent and clonogenic in vitro and 
could generate bone and a hematopoietic supportive microenviroment in subcutaneous 
transplants in mice (Sacchetti et al, 2007). These cells reside in the wall of the sinusoidal 
blood vessels of the bone marrow and were also positive for angiopoietin-1, a critical 
regulator of vascular remodelling. This study represented one of the first attempts to 
histologically localise MSC populations and characterise them in vivo and further supported 
the hypothesis for a perivascular niche for the MSC. More recently, Morikawa and 
colleagues also attempted to identify and localise MSCs in vivo. Using a combination of 
PDGFα+Sca-1+CD14-TER119- expression they identified and isolated an MSC population 
within mouse bone marrow that was enriched for CFU-Fs with differentiation potential both 
in vitro and when transplanted in vivo (Morikawa et al, 2009a). Furthermore, they showed 
that these PDGFα+Sca-1+ populations resided in the perivascular region in vivo and they also 
expressed angiopoietin-1 which was in agreement with the work by Bianco’s group. 
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In addition to the cell surface molecules described so far, MSCs express a wide range of 
other functional receptors such as growth factor receptors, adhesion molecules, cytokine 
and chemokine receptors on their cell surface, although expression can vary or even be lost 
with prolonged in vitro culture. PDGFR receptor, epidermal growth factor receptor (EGFR), 
FGF receptor, IGF receptor, hepatocyte growth factor receptor (HGFR), and TGFβ receptor I 
and TGFβRII are expressed on MSCs and have roles in MSC self-renewal and differentiation 
(Leo & Grande, 2006; Ponte et al, 2007). Both human and murine MSC have been shown to 
express a broad range of the pattern recognition receptors Toll-like receptors (TLR) including 
TLR1-9 and also respond to various TLR ligands by activating established TLR signalling 
pathways such as NFκB, AKT and MAPK, as well as the secretion of cytokines and 
chemokines (Liotta et al, 2008; Pevsner-Fischer et al, 2007; Tomchuck et al, 2008). MSCs 
also express cell adhesion molecules including ICAM-1, ICAM-2, VCAM-1 (CD106), and LFA-3 
(Honczarenko et al, 2006; Majumdar et al, 2003), as well as various integrin α and β subunits 
(Docheva et al, 2007). Importantly, MSCs express a broad range of chemokine receptors that 
play a crucial role in their migratory abilities. CXCR4, the receptor for stromal-derived factor-
1 (SDF-1), as well as CCR1-5, CCR7, CCR9, CXCR3-6 and CX3CR1, all have been shown to be 
expressed on MSCs. Chemokine receptor expression as well as their chemokine ligands and 
chemokines produced by MSCs are listed in Table 1.2 together with relevant references. 
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Table 1.2 Chemokine receptor expression on MSCs 
Chemokine 
receptor 
Chemokine ligands Ref 
CCR1 CCL3 (MIP-1α) CCL5 (RANTES) CCL7 (MCP-3) 
CCL9/10 CCL14 CCL15 CCL16 CCL23  
(Honczarenko et al, 2006; Sordi et 
al, 2005) 
CCR2 CCL2(MCP-1) CCL7 (MCP-3) CCL13 CCL 16 (Ji et al, 2004; Ponte et al, 2007; 
Ringe et al, 2007) 
CCR3 CCL5 (RANTES) CCL7 (MCP-3) CCL8 CCL11 CCL13 
CCL15 CCL24 CCL26 (eotaxin-3) CCL28 
(Ponte et al, 2007) 
CCR4 CCL17 CCL22 (Ponte et al, 2007) 
CCR5 CCL3 (MIP-1α)CCL4 (MIP-1β) CCL5 (RANTES) 
CCL8 CCL14 CCL15 
(Ji et al, 2004) 
CCR7 CCL19 CCL21 (Honczarenko et al, 2006; Sordi et 
al, 2005) 
CCR8 CCL1 (Ringe et al, 2007) 
CCR9 CCL25 (Honczarenko et al, 2006) 
CX3CR1 CX3CL1 (fractalkine) (Croitoru-Lamoury et al, 2007; Ji 
et al, 2004; Sordi et al, 2005) 
CXCR1 CXCL8 (IL-8) (Ringe et al, 2007) 
CXCR2 CXCL5, CXCL8 (IL-8) (Ringe et al, 2007) 
CXCR3 CXCL9 CXCL10 (IP-10) CXCL11 (Croitoru-Lamoury et al, 2007; Ji 
et al, 2004) 
CXCR4 CXCL12 (SDF-1) (Croitoru-Lamoury et al, 2007; 
Honczarenko et al, 2006; Ponte et 
al, 2007; Sordi et al, 2005) 
CXCR5 CXCL13 (Honczarenko et al, 2006) 
CXCR6 CXCL16 (Honczarenko et al, 2006; Sordi et 
al, 2005) 
Table 1.2 Chemokine receptors expressed by MSCs. MSCs can be stimulated by the chemokines 
listed next to their respective receptors. Chemokines secreted by MSCs are depicted in red. MIP-1α: 
macrophage inflammatory protein 1α, RANTES: regulated upon activation normal T cell expressed 
and secreted, MCP-3: macrophage chemoattractant protein 3, MCP-1: macrophage chemoattractant 
protein 1, MIP-1β: macrophage inflammatory protein 1β, SDF-1: stromal-derived factor 1, IP-10: 
interferon-inducible protein 10. 
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1.2.3 The immunoregulatory role of MSCs  
MSCs, and cells of mesenchymal origin such as the OBs and adipocytes, are important 
contributors to the bone marrow niche where they strongly influence haematopoiesis (Calvi 
et al, 2003; Dazzi et al, 2006; Scadden, 2007). By providing necessary cytokines, growth 
factors, chemokines and extracellular matrix molecules as well as through cell contact 
interactions, bone marrow stromal cells regulate the survival, self-renewal, migration and 
differentiation of HSCs (Dazzi et al, 2006; Dorshkind, 1990; Purton & Scadden, 2008). The 
critical role of MSCs in haematopoietic development is also highlighted by the fact that in 
both animal studies and human tissue sections, MSCs are always found in foetal liver and 
bone marrow just prior to the onset of definitive haematopoiesis in these sites (Charbord et 
al, 1996; Mendes et al, 2005; Van den Heuvel et al, 1987). In experimental animal models, 
supplementary and simultaneous injection of donor MSCs with HSCs promotes the 
engraftment of HSCs and accelerates the recovery of haematopoiesis after lethal total body 
irradiation (Noort et al, 2002; Zhang et al, 2004). Similarly, in vitro bone marrow stromal 
cells form adherent layers and provide support for haematopoiesis in long-term (several 
months) bone marrow cultures (Dexter et al, 1977a; Dexter et al, 1977b).  
 
Similarly to regulation of haematopoiesis in the bone marrow niche, MSCs have an 
important role in the maturation of T lymphocytes in the thymus. MSCs control the 
differentiation and proliferation of thymic epithelial cells, responsible for the positive 
selection of thymocytes that recognise self-peptide/MHC complexes, by the production of 
FGF (Jenkinson et al, 2003; Revest et al, 2001). They also directly regulate T lymphocytes by 
secreting IL-7 neccessary for the maturation of CD4-/CD8-/CD25+/CD44+ T lymphocyte 
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precursors (Banwell et al, 2000). Furthermore, thymic mesenchyme seems to derive from 
bone marrow MSCs, as bone marrow could support T lymphocyte development in the 
absence of thymus (Dejbakhsh-Jones et al, 1995), while in a murine model of bone marrow 
transplantation, donor bone marrow stromal cells were found to migrate to the thymus 
where they participated in the positive selection of thymocytes (Li et al, 2000).  
 
1.2.4 MSCs have Immunosuppressive properties  
Perhaps the most surprising and extraordinary feature of MSCs is their immunosuppressive 
properties (Figure 1.6). There is now a wealth of data demonstrating that MSCs can inhibit T 
cell proliferation stimulated by allogeneic T cells in mixed lymphocyte reaction (MLR) (Le 
Blanc et al, 2003b), non-specific polyclonal stimuli (Bartholomew et al, 2002; Di Nicola et al, 
2002) as well as cognate antigen stimuli (Krampera et al, 2003) in vitro. MSCs exert an effect 
which is anti-apoptotic, anti-proliferative, non-cognate dependent and non-selective 
meaning that it affects both CD4+ and CD8+ T cells and both naïve and memory cells 
(Rasmusson et al, 2005). MSCs cause T helper 1 (TH1) cells to decrease interferon γ (IFNγ) 
but conversely cause TH2 cells to increase secretion of IL-4 (Aggarwal & Pittenger, 2005), 
suggesting a skewing towards TH2 responses.  
 
Despite the general consensus concerning the ability of MSCs to inhibit T cell proliferation, 
little is known of the molecular mechanism(s) involved, which are likely to be complex and 
involve multiple pathways. Several groups have suggested mechanisms but none of these 
are yet to be definitive. MSC-induced T cell inhibition does not seem to depend on the 
induction of apoptosis of proliferating T cells (Di Nicola et al, 2002; Krampera et al, 2006; 
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Zappia et al, 2005). Alternatively, Glennie et al. showed that inhibition of proliferation of 
activated T cells in the presence of MSCs is due to an arrest in the G0/G1 phase of the cell 
cycle, with a downregulation of cyclin D2 and an increase in the cyclin-dependent kinase 
inhibitor p27kip1 (Glennie et al, 2005). In vitro studies to date have described a role for both 
soluble factors and cell-cell interactions being required for MSCs to exert their 
immunosuppresion (Di Nicola et al, 2002; Djouad et al, 2003; Rasmusson et al, 2003; Tse et 
al, 2003). Numerous factors have been proposed to be involved including IL-10 (Batten et al, 
2006), IL-1β and TGFβ (Groh et al, 2005), indoleamine 2,3-dioxygenase (IDO) (Meisel et al, 
2004), PGE2 (Aggarwal & Pittenger, 2005)
 and nitric oxide (NO) (Sato et al, 2007).  
 
Ren et al. recently proposed an interesting model showing that an inflammatory 
environment is required to induce immunosuppresion by MSCs (Ren et al, 2008). According 
to this model pro-inflammatory cytokines IFNγ and TNFα, IL-1α or IL-1β lead to the 
induction of chemokine and NO expression by MSCs in an independent manner. Under the 
influence of MSC-derived chemokines, CXCR3R+ immune cells migrate towards MSCs where 
NO causes suppression of T cells. NO had been previously shown to inhibit T cell 
proliferation via suppression of signal transducer and activator of transcription 5 (STAT5) 
phosphorylation leading to cell cycle arrest (Sato et al, 2007). An indirect mechanism by 
which MSCs may modulate an immune response is through the induction of regulatory T 
cells (Treg). MSCs have been reported to induce formation of CD8+ Treg responsible for 
inhibiting allogeneic lymphocyte proliferation (Djouad et al, 2003). Additionally, MSCs 
caused an increase of CD4+CD25+FoxP3+ population in mitogen-stimulated peripheral blood 
mononuclear cell (PBMC) cultures (Aggarwal & Pittenger, 2005; Maccario et al, 2005). 
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In addition to their effects on T cells, MSCs also have inhibitory effects on B cells, DCs, Mφs 
and natural killer (NK) cells summarised in Figure 1.6. However, contrary to the effects on T 
cells, limited data exist regarding these interactions. MSCs inhibit the proliferation of B cells 
in response to anti-CD40 stimulation and IL-4, both in the human and mouse system (Asari 
et al, 2009; Corcione et al, 2006; Glennie et al, 2005; Tabera et al, 2008), and similarly to T 
cells, B cell proliferation is inhibited through an arrest in the G0/G1 phase of the cell cycle 
(Glennie et al, 2005). Furthermore, MSCs also inhibited the production of IgM, IgA and IgG 
by B cells meaning that MSCs can inhibit B cell differentiation to antibody secreting plasma 
cells (Corcione et al, 2006). MSCs have also been shown to inhibit DC differentiation and 
migration (English et al, 2008; Jiang et al, 2005; Jung et al, 2007; Li et al, 2008), and impair 
DC ability to present antigens (Ramasamy et al, 2007). More specifically, in the presence of 
MSCs DCs reduced the expression of the maturation marker CD83, presentation molecules 
HLA-DR and CD1a, co-stimulatory molecules CD80, CD86 and CD40, chemokine receptor 
CCR7 as well as the production of pro-inflammatory cytokines TNF-α, IFN-γ and IL-12, and 
increased production of IL-10 (Aggarwal & Pittenger, 2005; English et al, 2008; Jiang et al, 
2005). Cell-cycle analysis showed a blockage of cells entering G1 resulting in a progressive 
accumulation of monocytes in the G0 phase over time, probably due to the downregulation 
of cyclin D2 (Ramasamy et al, 2007). This has similarities with the MSC effect on T and B 
lymphocytes, where arrest in the G0/G1 phase of the cell cycle was also observed, (Corcione 
et al, 2006; Glennie et al, 2005), and may be the common denominator of the MSCs 
immunosuppressive action.  
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Figure 1.6 Immune modulation by MSCs 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 1.6 Schematic representation of the regulation of T cell, B cell, DC, Mφ and NK cell functions 
by MSCs as described in the text. MSCs inhibit the proliferation, differentiation, activation and 
function of almost all cells of the immune system.  
 
Interactions between MSCs and Mφs have also been studied. Mφs co-cultured with MSCs 
showed an increased expression of CD206, increased production of IL-10 and IL-6 and 
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reduced production of TNFα and IL-12 (Kim & Hematti, 2009; Nemeth et al, 2009); a Mφ 
phenotype resembling alternatively activated Mφs defined as M2 Mφs (Gordon, 2003; 
Verreck et al, 2006). Finally MSCs inhibited IL-2 or IL-15 driven proliferation, IFNγ secretion 
and cytotoxic activity of NK cells (Krampera et al, 2006; Sotiropoulou et al, 2006; Spaggiari et 
al, 2006). As evident by the effects of MSCs described on almost most immune cells, it is 
likely that in vivo there is a complex interplay between MSCs and T cells, DCs and 
monocyte/Mφs that contribute to MSC immunosuppression. Interestingly, Groh et al. have 
reported that interactions between MSCs and monocytes are required for the MSC-
immunosuppression on T cells (Groh et al, 2005).   
 
1.2.5 MSCs as therapeutics for bone disease 
Several defining characteristics make MSCs very promising candidates for therapeutic 
applications. Firstly, MSCs possess self-renewal capacity and multipotent potential to 
differentiate to various tissues including adipose tissue, bone and cartilage. Additionally, 
unlike ESCs, the use of MSCs in clinical applications is not complicated by immunologic 
incompatibility, possible development of malignant neoplasms or teratomas from 
administered cells (Hentze et al, 2007; Togel & Westenfelder, 2007), or the legal and ethical 
issues surrounding the derivation of ESC from human embryos. Importantly, MSCs are easily 
isolated from a great variety of tissues meaning that they are easily accessible for clinical 
use. However, the major advantage of using MSCs for in vivo therapeutic applications is the 
fact that their immune phenotype (MHC I+, MHC II-, CD40-, CD80-, CD86-) renders them non-
immunogenic and therefore transplantation into an allogeneic host should not require 
immunosuppression (Le Blanc & Ringden, 2005). Finally, in addition to being 
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immunoevasive, MSCs can modulate immune responses by for example suppressing T cell 
proliferation and activation (Bartholomew et al, 2002; Di Nicola et al, 2002) as disucced 
above. Owing to these unique features MSCs show great promise for therapeutic 
intervention and their potential use in the clinical setting is a subject of increasing interest in 
recent years (Bianco & Robey, 2001; Dazzi & Horwood, 2007; Parekkadan & Milwid, 2010). 
Currently there are more than 100 registered clinical trials investigating the use of MSCs in a 
range of diseases including liver cirrhosis, steroid resistant graft-versus-host disease (GVHD), 
spinal cord injury, articular cartilage repair, acute myocardial infarction, Crohn’s disease, 
osteogenesis imperfecta (OI) and multiple sclerosis (MS) (http://www.clinicaltrials.gov).   
 
Administration of MSCs has been successful in several clinical applications including the 
treatment of severe steroid-resistant GVHD (Le Blanc et al, 2008; Le Blanc et al, 2004), bone 
marrow transplantation (Lazarus et al, 1995), amyotrophic lateral sclerosis (Mazzini et al, 
2003), metachromatic leukodystrophy (Koc et al, 2002) as well as myocardial infarction 
where MSC administration led to improved cardiac function (Chen et al, 2004b; Chen et al, 
2004c; Le Blanc et al, 2008; Le Blanc et al, 2004). MSCs have also been used with 
encouraging results in experimental models of MS (Rafei et al, 2009; Zappia et al, 2005), 
acute renal failure (Kale et al, 2003; Morigi et al, 2008), type I diabetes (Lin et al, 2009; 
Madec et al, 2009), systemic lupus erythematosus (Sun et al, 2009) and rheumatoid arthritis 
(RA). In the collagen induced arthritis (CIA) model of RA, a single injection of MSCs 
prevented the occurrence of severe, irreversible damage to bone and cartilage (Augello et 
al, 2007).  
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In addition to the studies mentioned above, an increasing amount of investigations are 
focusing on the use of MSCs for the regeneration of bone tissue for genetic bone diseases 
such as OI and hypophosphatasia, metabolic bone disorders such as osteoporosis as well as 
for bone repair in fracture non-union and bone defects (Bianco & Robey, 2001; Jethva et al, 
2009; Undale et al, 2009). Indeed, the first and most promising clinical trial was that 
conducted on OI, a genetic disorder of collagen I leading to bone fragility and severe bone 
deformities. In three separate clinical trials Horwitz et al. showed that allogeneic bone 
marrow MSCs transplanted into OI patients could engraft in the bone and stimulate new 
bone formation and growth (Horwitz et al, 2002; Horwitz et al, 1999; Horwitz et al, 2001). 
This led to increased total body bone mineral content and growth velocity while reducing 
the frequency of bone fractures. Further to these trials, Le Blanc et al. transplanted 
allogeneic HLA-mismatched MSCs isolated from fetal liver into the uterus at 32 weeks of 
gestation to treat a fetus with severe OI (Le Blanc et al, 2005). They showed donor cell 
engraftment as well as the presence of osteocalcin-, osteopontin- and bone sialoprotein-
positive cells of donor origin in the bones more than nine months after transplant. This 
indicated that the donor MSCs could engraft and differentiate into bone in the fetus. The 
efficiency of intrauterine transplantation of MSCs for the treatment of OI was further 
validated by Guillot and colleagues who showed that transplantation of human fetal MSCs 
repaired bone and markedly reduced fractures in OI mice (Guillot et al, 2008). In other 
clinical trials MSCs have been used for the treatment of hypophosphatasia, a disease of 
defective bone mineralisation due to deactivating mutations in ALP enzyme, where bone 
marrow MSC transplantation led to improved skeletal mineralisation (Cahill et al, 2004; 
Cahill et al, 2007; Whyte et al, 2003). MSCs have also been used in a mouse model of 
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osteoporosis where transplantation led to improved bone density and quality, evidence of 
decreased resorption and at least partial correction of the regulatory mechanisms of bone 
turnover (Ichioka et al, 2002; Takada et al, 2006).  
 
MSC therapy for fracture repair in cases of non-union is receiving considerable attention. 
Importantly, the use of MSCs for fracture repair has already been used successfully in a 
multitude of animal models. In the simplest procedure proposed for bone regeneration, 
MSCs isolated from bone marrow are expanded ex vivo, loaded onto appropriate carrier, 
usually three-dimensional scaffolds made of synthetic hydroxyapatite/tricalcium 
phosphates, and locally transplanted (Bianco & Robey, 2001). Such procedures have been 
shown to result in the effective repair of critical size defects, those that are larger than the 
resident cells can repair (Arinzeh et al, 2003; Bruder et al, 1998a; Bruder et al, 1998b; 
Kadiyala et al, 1997; Kon et al, 2000; Krebsbach et al, 1998; Petite et al, 2000; Viateau et al, 
2007). Clinical use of in vitro expanded MSCs in conjuction with porous hydroxyapatite 
scaffolds has been reported in the treatment of patients with diaphyseal segmental defects 
(Marcacci et al, 2007; Quarto et al, 2001). Researchers reported new bone formation inside 
the scaffolds and vascular ingrowth leading to a complete integration of the implants into 
the existing bone. Furthermore, all patients experienced recovery of limb function. Finally, 
Hernigou et al demonstrated the successful use of percunatenous autologous bone marrow 
grafting, without the need for a porous scaffold, for the treatment of atrophic diaphyseal 
non-unions (Hernigou et al, 2005). They showed a positive correlation between the volume 
of mineralised callus and the number and concentration of CFU-F in the graft. Collectively all 
the findings described above illustrate the great promise for MSCs in bone regeneration. 
CHAPTER 1                                                                                                                                     INTRODUCTION 
68 
 
1.3 The Immune system  
The immune system, one of the most complex systems in animals, has evolved as a 
remarkably versatile defence mechanism against invading pathogenic microorganisms 
(Janeway et al, 2001d). This versatility is a result of the concerted actions of a variety of cells 
and molecules, components of the immune system, that form a dynamic network with the 
ability to identify and eliminate an endless variety of invaders thus protecting against 
infection and restoring homeostasis. Disorders of the immune system can lead to 
immunodeficiency or inflammatory disease and cancer. Autoimmune diseases occur when 
the immune system fails to discriminate self antigens from non-self antigens thus mounting 
immune responses against its own tissues. 
 
The immune system is made up of two arms; the innate immune system and the adaptive 
immune system (Janeway & Medzhitov, 2002). The innate immune system encompasses the 
physical barriers such as the skin or the gastrointestinal track, that prevent pathogens 
entering the body, as well as soluble proteins and bioactive small molecules that are either 
constitutively present in biological fluids (such as defensins, lysozyme or the complement 
system) or produced by activated cells (such as cytokines, chemokines or lipid mediators of 
inflammation) (Janeway et al, 2001c; Nester et al, 2004). Most importantly, the innate 
immune system includes special cell surface receptors that recognise conserved molecular 
patterns on the surface of invading microbes known as pathogen-associated molecular 
patterns (PAMPs) or the more recently identified damage-associated molecular patterns 
(DAMPs) (Beutler, 2007; Gordon, 2002; Matzinger, 1994; Medzhitov & Janeway, 2002). 
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These are endogenous molecules present upon tissue injury and are usually intracellular 
proteins, such as heat shock proteins (i.e. HSP70) and the S100 proteins, or DNA and 
chromatin associated proteins, such as the high-mobility group box 1 (HMGB1), that act as 
danger signals and can trigger immune responses (Bianchi, 2007). All these components 
provide a rapid, first-line defence against injurious insults, however they are not specific. In 
contrast, the adaptive immune system uses slower but specific responses tailored against 
each specific pathogen. It also confers immunological memory, an important aspect of 
immunity mediated by long-lived cells that persist for the entire life of the organism and can 
generate a faster and enhanced response to a secondary encounter with a particular 
antigen (Janeway et al, 2001a). Immunological memory also forms the basis of vaccination. 
An overview of the adaptive and innate immune system is shown in Table 1.3. 
 
1.3.1 Adaptive Immune System 
Unlike the innate immune system, the adaptive immune system manifests exquisite 
specificity for its target antigens. This occurs by virtue of the antigen-specific receptors 
expressed on the surface of its main effector cells, the T and B lymphocytes. These receptors 
are a product of rearrangement of germline gene elements to form intact T-cell receptor 
(TCR) and immunoglobulin genes, and allows for the generation of millions of different 
antigen receptors with unique antigen specificities from only a few hundred gene elements 
(Janeway et al, 2001b; Pancer & Cooper, 2006). Both T and B lymphocytes derive from the 
same progenitor, the HSC, that resides in the bone marrow (Morrison et al, 1995b).   
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Table 1.3 Innate and adaptive immunity 
 Innate Immune System Adaptive Immune System 
Presence In nearly all life forms Only in jawed vertebrates 
Specificity Non-specific response Antigen-specific response 
Speed Exposure leads to immediate 
maximal response 
Lag time between exposure and 
maximal response 
 
 
Components 
Cell-mediated Humoral Cell-mediated Humoral 
Granulocytes 
(Neutrophils, 
Eosinophils, 
Basophils) 
Macrophages, 
Dendritic Cells, 
NK cells 
Complement T lymphocytes: 
CD4+ (TH1, TH2, 
TH17), CD8
+ CTL, 
γδT, Treg                   
B lymphocytes  
Dendritic cells 
Antibodies 
Immunological 
memory 
No immunological memory Exposure leads to immunological 
memory 
Receptors Fixed in genome, rearrangement 
not necessary 
Encoded in gene segments, 
rearrangement necessary 
Distribution Non-clonal, all cells of a class 
identical 
Clonal, all cells of a class distict 
Recognition Conserved molecular patterns (LPS, 
LTA, mannans, glycans) 
Details of molecular structure 
(proteins, peptides, carbohydrates) 
Self-Non self 
discrimination 
Perfect, selected over evolutionary 
time 
Imperfect, selected in individual 
somatic cells 
Response Co-stimulatory molecules 
Cytokines (IL-1β, IL-6)    
Chemokines (IL-8) 
Clonal expansion or anergy            
IL-2                                            
Effector cytokines (IL-4, IFN-γ) 
Table 1.3 Table comparing the characteristics, components and function of the innate and adaptive 
immune responses. Adapted from Janeway and Medzhitov, 2002. 
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Expression of CD4 and CD8 distinguishes functional subpopulations of T cells; activated CD4+ 
regulate the cellular and humoral immune responses and are also known as T helper (TH) 
cells whereas activated CD8+ T cells act to kill cells infected with intracellular microbes and 
are known as T cytotoxic (Tc) (Viret & Janeway, 1999). Upon engagement of their T cell 
receptor and co-stimulatory molecules, T cells mature and exert their effector functions. TH 
cells divide clonally resulting in the generation of a population of cells specific for the same 
antigen and also secrete various cytokines important in the generation of the immune 
response which further differentiates them to TH1 and TH2 (Mosmann et al, 1986; Mosmann 
& Coffman, 1989). A TH1 response produces cytokines such as IFN- γ, that are responsible 
for killing intracellular parasites, support inflammation and activate T cells and Mφs (Abbas 
et al, 1996). A TH2 response, which produces cytokines such as IL-4, IL-5 and IL-10, is anti-
inflammatory and activates mainly B cells and immune responses that depend on antibodies 
(Coffman, 2010). Activation of Tc cells results in their differentiation into effector cells called 
cytotoxic T lymphocytes (CTL) which secrete few cytokines but have the ability to recognize 
and eliminate altered self-cells. Many more T cell subsets exist that possess distinct 
functional abilities, for example the T regulatory cells (Treg) (CD4+CD25+Foxp3+), which 
suppress immune responses (Fontenot et al, 2003; Hori et al, 2003; Khattri et al, 2003), and 
the TH17, a special type of TH cell that predominantly secretes IL-17 and is implicated in 
inflammatory diseases (Korn et al, 2009; Weaver et al, 2006). Finally, another type of T cells 
are the γδ T cells which possess an alternative TCR made of different chains to those of the 
CD4+ and CD8+ αβ TCR (Hayday & Tigelaar, 2003; Xiong & Raulet, 2007).  
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B lymphocytes are major effector leukocytes of the adaptive immune response responsible 
for the production of antibodies known as humoral immunity (Ghia et al, 1998). Similarly to 
the T cells, B cells express their own B cell receptor (BCR) which is effectively a membrane 
bound immunoglobulin. The BCR specifically recognises and binds only to one antigen and is 
generated in a similar way to the TCR, through a process of gene rearrangement called V(D)J 
recombination (Hesslein & Schatz, 2001; Nemazee, 2000). Upon activation, B cells undego 
clonal expansion and mature into antibody producing plasma cells. Produced antibodies are 
released into the circulation where they can bind to their cognate antigens and mediate 
elimination of pathogens, through the actions of the complement system and phagocytes.  
 
1.3.2 Innate Immune System 
Innate immune system recognition relies on a limited number of germline-encoded pattern 
recognition receptors (PRRs) that have evolved to recognise conserved structures or 
metabolic products of microbial pathogens. Toll-like receptors (TLRs) play a major role in 
pathogen recognition and are important for triggering of inflammatory and immune 
responses (Janeway & Medzhitov, 2002). In humans ten different TLRs (TLR1-10) have been 
identified (Takeda et al, 2003). Most are cell-surface transmembrane proteins, but TLR3, 
TLR7, TLR8 and TLR9 are expressed intracellularly (Yamamoto & Takeda, 2010). TLRs signal 
in response to PAMPs such as peptidoglycan (Takeuchi et al, 1999), lipoteichoic acid 
(Schwandner et al, 1999) or zymosan (Underhill et al, 1999) recognised by TLR2, double-
stranded DNA -a molecular pattern associated with viral infection- such as synthetic poly I:C  
(TLR 3) (Alexopoulou et al, 2001), lipopolysaccharide (LPS) from Gram negative bacteria 
(TLR4) (Hoshino et al, 1999; Poltorak et al, 1998; Qureshi et al, 1999), flagellin (TLR5) 
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(Hayashi et al, 2001), single-stranded RNA (TLR7/8) (Heil et al, 2004; Lund et al, 2004) or 
unmethylated bacterial CpG DNA (TLR9) (Hemmi et al, 2000). TLR signalling results in the 
enhanced expression of inflammatory cytokines and antimicrobial genes (Aderem & 
Ulevitch, 2000; Takeda et al, 2003; Yamamoto & Takeda, 2010). TLRs are primarily 
expressed on Mφs and DCs but also on neutrophils, eosinophils and NK cells (Takeda et al, 
2003). Monocytes and Mφs constitute important effector cells of the innate immune system 
and they will be discussed in detail below. 
 
Monocytes  
Monocytes are a population of blood mononuclear leukocytes that develop in the bone 
marrow from the common CD34+ myeloid progenitors for Mφs, DCs and granulocytes (Fogg 
et al, 2006). Similarly to other leukocyte populations, monocytes are comprised of 
physiologically distinct subsets. Ziegler-Heitbrock and colleagues introduced the use of CD14 
(which is part of the receptor for LPS) and CD16 (also known as low affinity Fc receptor 
FcγRIII) antibodies for the identification of blood monocyte subsets (Passlick et al, 1989; 
Ziegler-Heitbrock et al, 1988), which are now widely accepted to comprise of a major 
CD14++CD16- subset, termed classical monocytes, an intermediate CD14++CD16+ subset and 
a CD14+CD16++ subset termed nonclassical monocytes (Gordon & Taylor, 2005; Grage-
Griebenow et al, 2001). The CD14++CD16- classical monocytes account for 90% of total blood 
monocyte populations whereas the somewhat smaller CD16+ monocytes represent only 
10% of all monocytes. Both the classical CD16- and non classical CD16+ monocytes share 
morphology, cytochemistry and many cell-surface markers and their close relationship has 
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been substantiated in studies using gene profiling and hierarchical clustering (Ancuta et al, 
2009; Robbins et al, 2008).  
 
Nevertheless, the CD16- and CD16+ monocytes represent distinct subsets with distinct 
biological functions; CD16+ monocytes express higher levels of MHC class II and CD32 
(FcγRIIα) and it was suggested that these cells resemble mature tissue Mφs (Ziegler-
Heitbrock et al, 1993). Monocyte subsets also differ in chemokine receptor expression and 
chemotactic activity; CD16- cells express CCR2 and hence show higher chemotactic 
migration responsiveness to MCP-1, whereas CD16+ cells do not express CCR2 but show 
higher expression of CCR5 and migrate in response to MIP-1α (Weber et al, 2000). 
Additionally, CD16+ cells migrate to CX3CL1 (also known as fractalkine) and CXCL12 (also 
known as SDF1α) since the receptors for these ligands are preferentially expressed by this 
subset (Ancuta et al, 2003). Monocyte subsets also differ in cytokine production with the 
CD16+ monocytes producing higher levels of the pro-inflammatory IL-1, IL-6, IL-12, TNFα and 
low to absent levels of the anti-inflammatory IL-10 after TLR stimulation (Belge et al, 2002; 
Serbina et al, 2009; Szaflarska et al, 2004; Ziegler-Heitbrock et al, 1992) ,which prompted 
the characterization of the CD16+ subset as ‘pro-inflammatory’. Interestingly, the CD16+ 
monocytes have been shown to be expanded in various infectious and inflammatory 
diseases such as bacterial infections and sepsis (Blumenstein et al, 1997; Fingerle et al, 
1993; Herra et al, 1996), HIV infection (Fischer-Smith et al, 2008; Thieblemont et al, 1995), 
atherosclerosis (Hakkinen et al, 2000) and RA (Baeten et al, 2000; Hepburn et al, 2004; 
Kawanaka et al, 2002; Wijngaarden et al, 2003). The majority of these studies suggested 
that CD16+ monocytes can represent a useful marker for disease progression, for example in 
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RA patients CD16+ monocyte levels were found to correlate with erythrocyte sedimentation 
rate and C-reactive protein levels (Baeten et al, 2000), the rise in CD16+ cell number was 
more pronounced in active disease (Hepburn et al, 2004; Kawanaka et al, 2002; 
Wijngaarden et al, 2003) and furthermore numbers diminished in response to therapy 
(Fingerle-Rowson et al, 1998). 
 
Studies on monocyte subsets were extended in the mouse system where Geissmann and 
colleagues, using mice where green fluorescent protein (GFP) was knocked-in to CX3CR1 
(the receptor for fractalkine), showed a monocyte subset expressing CCR2, CD62L (also 
known as L-selectin) and low amounts of CX3CR1, and a second subset which did not 
express CCR2 or CD62L but expressed high amounts of CX3CR1 (Geissmann et al, 2003). The 
first subset was found to migrate as expected to CCR2 ligand MCP-1. In addition, Geissmann 
and colleagues identified Ly6C (which is part of the epitope of Gr-1) as an additional marker 
for the CCR2+ monocytes (Geissmann et al, 2003). In functional studies using monocyte 
adoptive transfer they also showed that the CCR2+CX3CR1low monocytes were rapidly 
recruited to sites of experimentally induced inflammation whereas the CCR2-CX3CR1high 
monocytes gave rise to tissue Mφs (Geissmann et al, 2003). Sunderkotter and colleagues 
further showed that during replenishment of blood monocytes following in vivo monocyte 
depletion using clodronate liposome administration, the CCR2+Ly6C+ population appears 
first and argued that the CCR2+ and CCR2- populations represent a differentiation sequence 
(Sunderkotter et al, 2004). This hypothesis was supported by subsequent studies (Nikolic et 
al, 2003). More recent reports have identified CD43 as another marker for mouse monocyte 
subsets and showed that CD43 highly expressing cells displayed a selective ability to 
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produce inflammatory cytokines such as TNFα (Burke et al, 2008), which was reminiscent of 
the CD16+ subset in humans. The general consensus now is that monocyte subsets in mouse 
are identified as Ly6C++CD43+, Ly6C++CD43++ and Ly6C+CD43++ equivalent to the classical 
CD14++CD16-, intermediate CD14+CD16+ and non classical CD14+CD16++ respectively in 
humans (Ziegler-Heitbrock et al, 2010) (Figure 1.7). According to markers previously used 
for mouse monocyte subsets the classical monocytes are also CCR2highCX3CR1low, whereas 
the non classical monocytes are also CCR2lowCX3CR1high (Geissmann et al, 2003; Ziegler-
Heitbrock et al, 2010). 
 
Macrophages 
Mφs derive from circulating monocytes that are released from the bone marrow to the 
blood stream where they circulate as non dividing cells for a few days before migrating into 
tissues where they can differentiate into various types of Mφs (Volkman & Gowans, 1965) 
and also into OCs (Bar-Shavit, 2007). During inflammatory response through their 
phagocytic actions Mφs can engulf and eliminate pathogenic microbes which they recognise 
using a variety of Fc receptors and complement receptors (Hume, 2008; Xu et al, 2006a). In 
this way they serve as nonspecific defence against pathogenic organisms, but they also 
contribute to adaptive immunity by influencing the function of other immune cells through 
the production of various immune factors such as cytokines, chemokines and complement. 
Additionally, Mφs together with DCs are instrumental for the clearance of apoptotic or 
necrotic cells through phagocytosis (Xu et al, 2006a). 
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Figure 1.7 Monocyte and Mφ Heterogeneity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Monocyte subsets have been identified in humans and their equivalent populations also 
identified in mice. Mφs can be polarised to acquire classical (M1) or alternative (M2) activation 
phenotypes activation which lead to differences in cytokine, iNOS and ROI production as well as 
different expression of surface receptors. iNOS: inducible nitric oxide synthase, ROI: Reactive oxygen 
intermediates 
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Mφs are not only important effectors of the immune system but also have central roles in 
many aspects of embryonic development, tissue homeostasis and wound repair. These 
diverse functions are reflected in the large range of heterogeneity of Mφ populations found 
in different organs, where they become adapted to perform particular functions, such as 
alveolar Mφs in the lungs, Kuppfer cells in the liver, white and red pulp Mφs in the spleen, 
peritoneal Mφs in the peritoneum and microglia in the nervous system (Gordon & Taylor, 
2005; Taylor et al, 2005). Examples of the diverse functions of Mφs in different tissues are 
the Langerhans Mφs of the epidermis which form the centre of the epidermal proliferative 
units and control the proliferation and differentiation of keratinocytes (Potten, 1981; Potten 
& Allen, 1975; Potten & Allen, 1976). Additionally, Mφs that line the surfaces of bone are 
important for OB function (Chang et al, 2008), and Mφs in the developing embryo can 
control organogenesis for example the development of the kidneys (Rae et al, 2007).  
 
The growth and differentiation of Mφs depends on lineage-determining cytokines such as 
macrophage colony-stimulating factor (M-CSF) and granulocyte/macrophage colony-
stimulating factor (GM-CSF) (Gordon, 2003; Wiktor-Jedrzejczak & Gordon, 1996). M-SCF 
circulates at detectable levels in the steady state and is constitutively expressed by 
monocytes/Mφs, fibroblasts, OBs, smooth muscle cells endothelial cells, while GM-SCF is 
produced under inflammatory and pathogenic conditions by activated T cells, fibroblasts, B 
cells and Mφs (Bartocci et al, 1987; Metcalf & Nicola, 1995). It has therefore been suggested 
that M-CSF drives Mφ differentiation under steady-state situations whereas GM-CSF directs 
Mφs during infection and inflammation (Hamilton, 2008). Further pointing towards a 
significant homeostatic contribution of M-CSF to Mφ-lineage development, Csf1op/Csf1op 
CHAPTER 1                                                                                                                                     INTRODUCTION 
79 
 
mice with an inactivating mutation in M-CSF, have a deficiency in several Mφ populations 
including OCs (Cecchini et al, 1994; Wiktor-Jedrzejczak et al, 1990). In contrast, GM-CSF 
deficient mice do not have a marked deficiency in myeloid cell development, except for 
compromised maturation of alveolar Mφs which leads to pulmonary alveolar proteinosis 
(Cook et al, 2004; Stanley et al, 1994).  
 
Mφ activation in response to microbial agents and cytokines, IFN-γ in particular, has long 
been recognised (Hamilton, 2002b). It is now widely described that IFNγ and IL-4 activate 
distinct functional programs in Mφs inducing either a classical (M1) or alternative  (M2) 
activation phenotype respectively, mirroring the TH1/TH2 dichotomy (Gordon, 2003; Gordon 
& Martinez, 2010; Mantovani et al, 2002; Martinez et al, 2009; Mosser, 2003; Mosser & 
Edwards, 2008). Classical activation mediated by a priming stimulus of IFNγ and followed by 
a microbial trigger such as LPS, polarises the Mφ to a phenotype associated with pro-
inflammatory cytokine and nitric oxide production and associated with microbial killing and 
tissue damage. In contrast, alternative activation which is associated with TH2 responses, 
leads to upregulation of arginase and has been linked to tissue remodelling and repair, 
immunoregulation and tumour promotion (Gordon, 2003; Martinez et al, 2008) (Figure 1.7).  
 
Interestingly, it has been shown that depending on whether they are differentiated in the 
presence of GM-CSF or M-CSF, Mφs can be polarised in vitro into pro-inflammatory M1-like 
or anti-inflammatory M2-like phenotype respectively. More specifically it was shown that 
following LPS stimulation, GM-CSF M1 Mφs are characterised by a high production of pro-
inflammatory cytokines including IL-1β, IL-12, IL-23, IL-6 and TNFα whereas M-SCF M2 Mφs 
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are characterised by high production of IL-10 and low levels of pro-inflammatory cytokines 
(Fleetwood et al, 2007; Smith et al, 1998; Verreck et al, 2004; Verreck et al, 2006; Xu et al, 
2006b). M1 Mφ cytokines support Th1 responses while M2 Mφs through IL-10 inhibit Th1 
function. These findings suggest that the relative abundance of GM-CSF to M-CSF, and 
hence of one Mφ type to the other, can skew host responses towards a pro- or anti-
inflammatory nature. These evidence also further compliment the model proposed by John 
Hamilton postulating that M-CSF-driven Mφ differentiation under steady-state situations 
will resemble the M2 polarised state, whilst during inflammation or infection increasing 
levels of GM-CSF, IFNγ and LPS will overcome M-CSF polarization and lead to an M1 
phenotype (Hamilton, 2008). This hypothesis also proposes that when the levels of pro-
inflammatory stimuli wane, M-CSF will assist the resolution of the lesion by favouring the 
M2 Mφ phenotype (Hamilton, 2008). In agreement with this hypothesis, it has been 
demonstrated that GM-CSF treatment of Mφs previously differentiated using M-CSF can 
skew their phenotype towards the pro-inflammatory phenotype associated with GM-CSF 
Mφs and vica versa (Krausgruber et al, 2011).  
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1.4 Bone and the Immune System: The Birth of Osteoimmunology 
Osteoimmunology, a term coined and first used only about 10 years ago by Arron and Choi 
in an article published in Nature, encompasses the study of the interactions between the 
immune and skeletal systems (Arron & Choi, 2000). Observations have long suggested that 
the immune and skeletal systems’ functions are closely intertwined both in health and 
disease. For example, bone loss is a hallmark of diseases of chronic inflammation 
subsequent to an excessive immune reaction, with prominent examples such as RA, Crohn’s 
disease and periodontal disease (Goldring & Gravallese, 2000; O'Gradaigh & Compston, 
2004). Conversely, the bones harbour the bone marrow which represents the major site of 
haematopoiesis where all cells of the immune system derive (Purton & Scadden, 2008). 
However, the first definitive link between immune and bone cells came from the 
identification of RANKL, initially identified as a cytokine expressed by activated T, an 
activator of DCs and critical for lymphocyte development and lymph node organogenesis, as 
the key differentiation signal for osteoclastogenesis (Anderson et al, 1997; Kong et al, 
1999b; Lacey et al, 1998; Wong et al, 1997; Yasuda et al, 1998b). Following this seminal 
finding the field of Osteoimmunology was established and a great surge of research in this 
field ensued. To date the interactions between immune and bone cells are still not fully 
understood, however it is well recognised that multiple components of the immune system 
such as immune cells, molecular mediators such as cytokines and chemokines also regulate 
bone and its cellular components. These interactions are critical for the preservation of 
bone homeostasis and are also critically implicated in the development of disease.  
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1.4.1 Bone and immune interactions in health  
Both the immune and skeletal systems have developed complex regulatory networks that 
although originally viewed in isolation are now studied as an integrated system (Lorenzo et 
al, 2008; Walsh et al, 2006). A number of studies have provided examples of the close 
interactions of bone and the immune system both in health and disease. Firstly, the OC 
belongs to the monocyte-Mφ lineage (Bar-Shavit, 2007) meaning that it shares a common 
myeloid progenitor with monocytes, Mφs and DCs. This directly links bone remodelling to 
the innate immune system. In addition to the original investigations into RANKL, another 
major signalling pathway was found to be directly linking the immune system with bone 
biology, specifically myeloid cells and osteoclasts. The identification that immunoreceptor 
tyrosine-based activation motifs (ITAM)-induced signalling, which is important for activation 
of macrophages, NK cells, APCs and T cells, also participates in the activation of bone 
resorption further strengthen the idea that the OC may not just be a bystander but an 
intergral component of the immune and inflammatory responses (Baron, 2004). In addition 
to the requirement for RANKL, it is now known that similarly to immune cell activation, OCs 
require co-stimulatory signals that are mediated by ITAMS; this co-stimulation is needed for 
RANKL-induced differentiation and bone resorption. Indeed it was previously shown that 
mice deficient in ITAM-bearing DNAX activation protein of 12kDa (DAP12) have moderate 
osteopetrosis and their OC do not respond to RANKL(Kaifu et al, 2003). DAP12 is an ITAM- 
bearing adapter which couples to the triggering receptor expressed on myeloid cells (TREM); 
triggering via TREM results in the production of pro-inflammatory cytokines such as IL-8, 
MCP-1 and TNFα (Klesney-Tait et al, 2006). In a seminal paper Koga et al. showed that the 
ITAM motifs on adaptor protein DAP12, associated with TREM, but also FcReceptor γ, 
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coupled with osteoclast associated receptor (OSCAR), are required for OC differentiation 
and resorption since mice deficient in both pathways (DAP12-/- FcRγ-/-) had skeletal 
phenotypes much more severe than mice lacking either pathway individually, with severe 
OC impairment and osteopetrosis (Koga et al, 2004). Interestingly, osteoclastogenesis is 
markedly enhanced in mice lacking the tyrosine phosphatases SHP-1 (Aoki et al, 1999) or 
SHIP-1 (Takeshita et al, 2002), both of which inhibit ITAM signalling in the immune system. 
The OC is beginning to look even more like an immune cell. 
 
Bone is also the homing organ for the long-lived plasma cells and the professional memory T 
cells and therefore becomes a key player in the maintenance of immunological memory 
(Moser et al, 2006; Tokoyoda et al, 2010). Furthermore, the formation and regulation of the 
bone marrow niche as well as the process of haematopoiesis are critically dependent on 
bone cells; OBs, their mesenchymal progenitors the MSCs and OCs (Calvi et al, 2003; Dazzi et 
al, 2006; Lymperi et al, 2011; Visnjic et al, 2004). OBs in particular are critical regulators of 
the bone marrow haematopoetic niche (Calvi et al, 2003; Visnjic et al, 2004; Zhang et al, 
2003). They produce a vast array of growth factors and cytokines important for the 
maturation of haematopoietic progenitors such as GM-CSF, M-CSF, IL-1, IL-6, IL-7, leukemia 
inhibitory factor (LIF), stem cell factor (SCF) and c-kit ligand amongst others (Benayahu et al, 
1992; Bilbe et al, 1996; Felix et al, 1988; Hanazawa et al, 1985; Hassan & Zander, 1996; 
Horowitz & Lorenzo, 2002; Keeting et al, 1991; Marusic et al, 1993; Namen et al, 1988; 
Ohsaki et al, 1992; Taichman & Emerson, 1994; Wu et al, 2008; Zhu et al, 2007). Additonally, 
several investigators have shown that HSCs in the bone marrow are located adjacent to the 
endosteal surfaces of bone, in close proximity or even attached to OBs (Arai et al, 2004; 
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Carsten & Bond, 1968; Gong, 1978; Kiel et al, 2005; Lord et al, 1975; Zhang et al, 2003). It is 
thought that these OBs are at an early stage of their commitment from MSCs to the 
osteoblastic lineage. HSC differentiation was also demonstrated to occur near to these 
endosteal OBs (Lord, 1990). In a seminal study, Calvi and colleagues used administration of 
PTH or transgenic mice expressing OB-specific activated PTH and PTH-related receptors, and 
showed that increased number of OBs led to a parallel selective expansion in the HSC pool 
(Calvi et al, 2003). The observation that conditional ablation of OBs resulted not only in 
bone loss but also to the progressive loss of lymphoid, erythroid and myeloid progenitors as 
well as a decrease in the number of HSCs, confirmed the critical role of OBs in the HSC niche 
(Calvi et al, 2003; Visnjic et al, 2004). It was subsequently shown that Angiopoietin-1 
expressed on the surface of OBs regulates HSC numbers through the activation of Tie-
2/Ang-1 signalling (Arai et al, 2004), whereas the Notch receptor ligand, Jagged 1 modulates 
HSC renewal (Mancini et al, 2005).  
 
OCs also have an important role in the HSC niche as they have been demonstrated to 
actively participate in the mobilization of HSCs from the bone marrow to the circulation, 
both in homeostatic and stress-induced conditions, through cathepsin-K mediated cleavage 
of SDF-1 (Kollet et al, 2006). Additionally, treatment with RANKL resulted in increased levels 
of circulating colony-forming progenitors including the Lin-Sca-1+c-kit+ progenitor cells while 
inhibition of OC formation using calcitonin had the reverse effect in mice (Kollet et al, 2006). 
Further proof for the fundamental role of OC function in the HSC niche came from a study 
which showed that alendronate-mediated inhibition of OC bone resorption reduced the 
numbers of primitive HSCs favouring the expansion of haematopoietic progenitors (Lymperi 
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et al, 2011). Furthermore, the administration of ALN abolished the ability of PTH to increase 
the primitive HSC pool size and to enhance the capacity of HSCs to reconstitute the niche of 
irradiated recipients (Lymperi et al, 2011). 
 
1.4.2 Bone and immune interactions in disease  
The relationship between bone and immune system is not unidirectional as illustrated in 
disease where deregulation of the immune system has dramatic consequences on bone 
(Arron & Choi, 2000). It is well known that bone loss is a hallmark of diseases with an 
inflammatory component such as chronic viral infections, allergic diseases, metastatic breast 
and lung cancers, inflammatory disorders of the gut such as Crohn’s disease and ulcerative 
colitis, periodontal disease and post menopausal osteoporosis (Mundy, 2002; Weitzmann & 
Pacifici, 2007). Pathologic bone loss is also observed in patients suffering from autoimmune 
diseases like RA, diabetes mellitus and lupus erythematosus (Goldring & Gravallese, 2000; 
O'Gradaigh & Compston, 2004; Walsh et al, 2005).  
 
RA is the prototypic autoimmune disease that leads to severe bone destruction and an 
excellent example of how immune cells and mediators directly influence bone. The role of 
immune cells and particularly T cells in driving the OC-induced bone destruction has been 
extensively studied (Goldring & Gravallese, 2000; O'Gradaigh & Compston, 2004). Although 
originally thought to be a TH1 driven inflammatory disease (McInnes & Schett, 2007), more 
recent findings suggest that the balance between pro-inflammatory TH17 and Treg cells is 
crucial for the development of RA and the subsequent bone loss (Boissier et al, 2008; Nistala 
& Wedderburn, 2009). In agreement with this hypothesis, TH17 cells are now considered to 
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be the main osteoclastogenic T cells; IL-17 produced by TH17 is a potent stimulator of 
osteoclastogenesis (Kotake et al, 1999) and in in vitro cultures TH17 cells were shown as the 
exclusive osteoclastogenic TH cell, whereas TH1 and TH2 cells strongly inhibited 
osteoclastogenesis (Sato et al, 2006). The implication of TH17 in autoimmune inflammation 
is further supported by studies showing that IL-23, which is required for the induction of 
TH17 cells, is more specifically relevant than IL-12 in autoimmune diseases (Kastelein et al, 
2007). Finally, Treg cells have been shown to protect against local and systemic bone 
destruction in a mouse model of arthritis (Zaiss et al, 2010). In the RA joint there is also an 
accumulation of non classical CD14++CD16- monocytes (Baeten et al, 2000) as well as the 
inflammatory M1 macrophages (Hamilton, 2008; Hamilton & Tak, 2009) that contribute to 
the enhancement of the inflammatory milieu and development of disease by the production 
of inflammatory mediators such as IL-23 that promotes TH17 generation as well as TNFα and 
IL-1 that mediate bone destruction. 
 
The key mediator of inflammation and bone destruction in the RA joint is TNFα (Feldmann & 
Maini, 2003; Williams et al, 1992). It has been shown that TNFα overexpression in transgenic 
mice is sufficient to induce the development of all symptoms of inflammatory arthritis, 
namely synovitis and local cartilage and bone erosion as well as systemic osteopenia (Keffer 
et al, 1991; Schett et al, 2003). These findings provided more evidence for the direct 
involvement of TNFα in the pathogenesis of RA, and further demonstrated that an 
imbalanced immune system can be the direct cause of systemic bone loss. The relevance of 
TNFα in RA is underpinned by the efficacy of neutralising antibodies against TNFα which 
have revolutionised the treatment of RA in the last 10 years (Feldmann & Maini, 2010). 
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TNFα mediates bone pathology in RA by promoting bone destruction while at the same time 
inhibiting bone formation. TNFα influences OCs and their function on many levels, both 
directly and indirectly. Indirectly, TNFα enhances OC formation by upregulating the stromal 
cell production of RANKL and M-CSF (Hofbauer et al, 1999; Sherman et al, 1990). Directly, 
TNFα regulates the abundance of OC precursor cells in the bone marrow by increasing 
expression of c-fms, the receptor for M-CSF (Yao et al, 2006). It also appears to enhance 
RANK signaling increasing OC differentiation (Danks et al, 2011; Lam et al, 2000) and is also a 
potent stimulator of bone resorbing activity together with IL-1 (Bertolini et al, 1986; 
Stashenko et al, 1987; Tashjian et al, 1987; Wei et al, 2005). While enhancing bone 
resorption, TNFα has a detrimental effect on bone formation by inducing the apoptosis of 
OB progenitors, blocking OB differentiation and inducing apoptosis of osteocytes (David & 
Schett, 2010). The effects of TNFα that result in increased bone resorption coupled with 
decreased bone formation contribute to the pathologic bone destruction in diseases like RA.  
 
1.4.3 Immune Cells Regulate OC differentiation and function 
While the studies described above offer some evidence of how immune cells affect bone in 
the context of disease, the full extent of immune and bone cell interactions are poorly 
understood. Because of the critical role of OCs in the pathology of diseases like RA (Goldring 
& Gravallese, 2000; Gough et al, 1998; O'Gradaigh & Compston, 2004), the majority of 
studies in the field of osteoimmunology have focused on the regulation of OC differentiation 
and activity by immune cells and mediators. A schematic representation of the regulation of 
OCs by immune cells in shown in Figure 1.8. 
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Figure 1.8 Regulation of OCs by immune cells 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Activated T cells are induced to express RANKL which acts on RANK expressing osteoclast 
progenitors and leads to increased osteoclastogenesis. Inflammatory cytokines such as IL-1 and 
TNFα produced during successful T cell immune responses, as well as calciotropic factors such as 
VitD3 and PGE2 induce RANKL expression by OBs which further enhances OC differentiation. RANKL 
signalling in mature OCs induces bone-resorbing activity. OBs also produce OPG, which sequesters 
RANKL and blocks its binding to RANK thus negatively regulating osteoclastogenesis. IFN-γ and IL-4 
produced by effector T cells also inhibit RANK signalling. Resting T cells also inhibit 
osteoclastogenesis through IFNγ and GM-CSF. OC differentiation and activity is also negatively 
regulated by resting B cells but the mechanisms are unclear. Figure adapted from Walsh et al., 2006. 
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A number of studies have shown that activated T cells support OC formation in vitro and in 
vivo (Horwood et al, 1999; Kong et al, 1999a) while interestingly, resting T cells have been 
shown to in turn inhibit osteoclastogenesis (Shinoda et al, 2003). In in vitro experiments 
activated T cells or supernatants from activated T cell cultures could promote 
osteoclastogenesis because T cell activation caused a rapid upregulation of RANKL on the 
surface of activated T cells that could also be cleaved and be present in activated T cell 
supernatants (Kong et al, 1999a). In vivo activated T cells mediate bone destruction in RA, as 
discussed above, but they also have a role in the pathogenesis of osteoporosis following 
ovariectomy in mice (Cenci et al, 2000; Ryan et al, 2005) as well as alveolar bone loss in 
periodontitis (Teng et al, 2000). The important role of activated T cells in regulating OCs was 
illustrated in vivo using mice lacking CTLA4, in which T cells are systemically activated, which 
exhibited an osteoporotic phenotype associated with increased OC numbers (Kong et al, 
1999a). In the same study, transfer of CTLA4-/- T cells in RAG2-/- mice, which lack all mature 
lymphocytes, led to decreased bone density over time which could be prevented using OPG. 
Additionally, in another study, overexpression of RANKL resctricted to T and B cells in 
transgenic mice was sufficient to partially correct the osteopetrotic phenotype of mice 
lacking RANKL (Kim et al, 2000). All these studies established the role of T cells in influencing 
bone homeostasis through expression of RANKL. However, in addition to RANKL, T cells 
produce a variety of other cytokines that modulate osteoclastogenesis. Stimulators of bone 
resorption include IL-1, TNFα and IL-17 as discussed above but also IL-6, IL-11, IL-15 and IL-
23 (Martin et al, 1998). Most of these factors exert the majority of their ostoclastogenic 
activity by inducing RANKL expression by OBs. However, T cell responses also result in the 
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production of cytokines such as IL-4, IL-10, IL-13 or IFNγ that are inhibitory of OC 
differentiation (Takayanagi, 2009; Takayanagi et al, 2000). 
 
The role of other immune cells such as B cells in regulating OCs and OBs is poorly 
understood and certainly not as well as that of T cells. A limited amount of studies suggest a 
role for B cells in bone regulation but the exact contribution and mechanisms remain 
controversial and not fully elucidated. Cells of the OB lineage are critical for B cell 
differentiation in bone marrow niches, and conversely many transcription factors that are 
required for B cell differentiation are important for bone since their elimination caused 
profound changes in the bone phenotype (Horowitz et al, 2010). Deficiency in transcription 
factors important for the early stages of B cells differentiation, such as PU.1, E2A or EBF, 
also a have detrimental effect on OC differentiation but this is because they also affect the 
common multipotential progenitor (MPP), for both the lymphoid and myeloid lineages, or 
the common lymphoid progenitor that gives rise to both B and T cells (Hesslein et al, 2009; 
Scott et al, 1997; Semerad et al, 2009; Tondravi et al, 1997). Deficiency in Pax5, a 
transcription factor specific for the B cell lineage, resulted in a profound decrease in 
trabecular bone shown to be a result of an increase in OC numbers and bone resorption 
(Horowitz et al, 2004), whereas OB numbers were not significantly affected. Even though 
these data were suggestive of an inhibitory role for B cells in OC differentiation and function 
the researchers went further to show that this was not the case. Pax5 deficiency 
preferentially diverted differentiation of progenitors to Mφ and OC lineage cells because it 
caused the expression of genes such as c-fms (Montecino-Rodriguez et al, 2001; Nutt et al, 
1999). This suggested that the increase in OCs was a direct result of the increased 
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progenitors and not due to the abolition of an inhibitory effect of B cells. A study by Li and 
colleagues used a different model, the µMT heavy chain-deficient mice, which lack mature B 
cells, and showed that these mice had an osteopenic phenotype due to increased bone 
resorption caused by a decrease in B cell secreted OPG (Li et al, 2007b). The bone 
phenotype of B cell deficient mice could be reversed by adoptive transfer of B cells from wt 
mice. In contrast, a different study contradicted this finding showing that the µMT heavy 
chain-deficient mice do not have an obvious bone phenotype (Horowitz et al, 2004). Taken 
together, these data do not present a definitive role for B cells in bone homeostasis and 
surely further investigations are required. 
 
While the role of B cells during normal bone remodelling is not fully clarified, activated B 
cells play an important role in many inflammatory diseases with associated bone loss and 
are involved in the development of inflammatory arthritis and periodontitis (Kawai et al, 
2006; Schett, 2009). Activated B cells can produce RANKL as well as other cytokines involved 
in the regulation of bone resorption and formation (Hayer et al, 2008; Schett, 2009). 
Furthermore, B cell related malignancies such as multiple myeloma, a malignancy of plasma 
cells, produce factors such as RANKL or DDK1 than result in enhanced bone resorption and 
decreased bone formation (Pearse et al, 2001; Roodman, 2010; Sezer et al, 2002). B cell 
lymphomas also produce RANKL and cause bone loss and hypecalcemia (Shibata et al, 
2005).  
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1.4.4 Immune Cells Regulate OB differentiation and function 
In stark contrast to the abundance of studies investigating the regulation of OCs by immune 
cells, limited amount of studies exist regarding the regulation of OBs. These limited studies 
have provided some evidence that OB differentiation could be influenced by cells of the 
immune system. Jung and colleagues have shown that HSCs, the progenitors of all immune 
cells, could promote the osteogenic differentiation of MSCs through HSC-derived BMP2 and 
BMP6, and thus actively participate in the formation and homeostasis of their niche (Jung et 
al, 2008). Additionally, T and B lymphocytes have been shown to have a role in normal bone 
turnover, maintenance of bone homeostasis and possibly new bone formation (Li et al, 
2007b). In spite of the evidence provided in the report by Li and colleagues, studies 
investigating a role for T and B cells in directly influencing OB differentiation and function 
are still lacking. In a preliminary study by Rifas and colleagues, products of activated T cells 
were shown to induce human bone marrow stromal cells to become OBs (Rifas et al, 2003), 
however these findings have yet to be validated by other investigators.  
 
A role for myeloid lineage cells in regulating OB differentiation has also been proposed. 
Nakagawa and colleagues reported an increase in ALP activity in marrow stromal cells when 
co-cultured with monocyte/Mφ lineage cells in Wistar rats and proposed a role for 
monocyte/Mφ derived soluble factors (Nakagawa et al, 1993). More recent data by Chang 
and colleagues have identified a discrete population of resident tissue Mφs, which they 
termed osteomacs, to be intercalated throughout murine and human osteal tissues and 
proposed a role of these cells in bone homeostasis (Chang et al, 2008). These cells were co-
isolated with OBs from murine bone explants and calvaria preparations, and were shown to 
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be required for efficient mineralisation of mature OBs in vitro (Chang et al, 2008). 
Osteomacs were also shown to be closely associated with areas of bone remodelling in situ 
and furthermore, in vivo depletion of OsteoMacs, using the Mφ-Fas-induced apoptosis 
(MAFIA) mouse, caused a complete loss of OB bone forming surface on bone remodelling 
sites (Chang et al, 2008). This study identified a crucial role for the Mφ lineage in regulating 
OB function and thus in bone homeostasis (Chang et al, 2008; Pettit et al, 2008).  
 
Even though there is some evidence describing the regulation of OB differentiation and 
function by the immune system and immune cells, there exist great gaps in our 
understanding of these interactions. Diseases like RA and osteoporosis affect a large part of 
the population stressing the importance for research into strategies of preventing bone loss 
or replacing it once it is lost. Extensive research into the regulation of OC bone resorption 
both in steady state and in disease settings have brought us a long way in understanding the 
mediators of bone destruction, and also devising therapeutic strategies to inhibit it in 
diseases such as RA where treatment with biologicals significantly decreases bone loss. The 
logical next step required is to better understand the regulation of bone formation since 
that would allow its potential manipulation towards damaged sites where bone repair is 
desired. The ideal outcome would be to combine the immunomodulatory abilities of MSCs 
with targeted differentiation; that could mean manipulation of the immune system towards 
a phenotype that is favourable for resolution of inflammatory responses, reinstating 
homeostasis and ultimately promoting bone repair through enhanced differentiation of 
mesenchymal progenitors. A better understanding of how OB differentiation is regulated by 
immune cells could also explain the mechanisms behind the lack of bone formation that 
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persists in settings like the RA joint where the excessive bone resorption should lead 
through coupling to increased bone formation.  
 
1.5 Hypothesis 
Overwhelming evidence supports the notion of a strongly reciprocal relationship between 
immune and bone cells both in health and disease. However the knowledge concerning OB 
differentiation is limited with only a handful of indications to answer the key question of 
when an MSC becomes an OB (Figure 1.9). Better understanding of these matters could 
translate to a greater ability to clinically manipulate bone formation and achieve the holy 
grail of how to replace bone once it is lost. We hypothesise that immune cells regulate MSC 
differentiation towards OBs. The effect can differ depending on the activation state of the 
immune cells or be attributable to a specific functional subset. Immune cell regulation of 
MSC-OB differentiation is mediated by cellular interactions and could also involve soluble 
mediators such as cytokines.  
 
1.6 Aims and Objectives 
The aims of this study are:  
• To establish the effect of immune cells on MSC-OB differentiation. 
• To define precisely which population and subset of immune cells exerts the observed 
effect on OB differentiation. 
• To determine the mechanism of immune cell regulation of OB differentiation  
• To identify the nature of the stimulus and identify candidate factors regulating MSC-
OB differentiation. 
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Figure 1.9 Hypothetical interactions regulating OB differentiation 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 OC differentiation and activity is regulated by T cells and B cells (Figure 1.8) but the 
regulation of OB differentiation and function by immune cells is poorly investigated. OBs are 
influenced by immune cells and their products to upregulate RANKL expression and thus contribute 
to osteoclastogenesis and OC bone-resorbing activity. OBs derive from mesenchymal progenitors, 
the MSCs, which reside in the bone marrow and give rise to the OB lineage. OBs and MSCs are 
important regulators of the bone marrow niche and the process of haematopoiesis. Additionally, 
MSCs have well documented immunosuppressive effects on immune cells namely they potently 
inhibit T cells activation and proliferation, but also inhibit DC, Mφ and B cell differentiation, 
activation and function. Conversely, the effect of immune cells on MSC their differentiation to OB 
has not been investigated.    
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2.1 Materials 
2.1.1 Recombinant proteins 
Table 2.1 
Protein Formulation ED50 CatalogueNo Supplier 
IL-1β Lyophilised <12 pg/ml 201-LB R&D Systems, Abington, UK 
IL-4 Lyophilised ≤ 0.2 ng/ml 200-04 PeproTech Inc., Rocky Hill NJ 
IL-6 Lyophilised 0.2-0.8 ng/ml 206-IL R&D Systems, Abington, UK 
IL-8 
(CXCL-8) 
Lyophilised 10-100 ng/ml 200-08 PeproTech Inc., Rocky Hill NJ 
IL-10 Lyophilised ≤ 2.0 ng/ml 200-10 PeproTech Inc., Rocky Hill NJ 
IL-19 Lyophilised ----- 200-19 PeproTech Inc., Rocky Hill NJ 
IL-20 Lyophilised ----- 200-20 PeproTech Inc., Rocky Hill NJ 
IL-22 Lyophilised ----- 200-22 PeproTech Inc., Rocky Hill NJ 
IL-24 Lyophilised 0.1-0.3 ng/ml 1965-IL-025 R&D Systems, Abington, UK 
IFN-λ2  
(IL-28A) 
Lyophilised ----- 300-02K PeproTech Inc., Rocky Hill NJ 
IFN-λ1  
(IL-29) 
Lyophilised ----- 300-02L PeproTech Inc., Rocky Hill NJ 
TNFα Lyophilised 25-100 pg/ml 210-TA R&D Systems, Abington, UK 
IFN-α Lyophilised ≤ 0.01 ng/ml 300-02A PeproTech Inc., Rocky Hill NJ 
IFN-β Lyophilised 20-30 ng/ml 300-02BC PeproTech Inc., Rocky Hill NJ 
IFN-γ Lyophilised 5-10 ng/ml 300-02 PeproTech Inc., Rocky Hill NJ 
CXCL5 
(ENA-78) 
Lyophilised 5-10 ng/ml 300-22 PeproTech Inc., Rocky Hill NJ 
EREG Lyophilised ≤ 2 ng/ml 100-04 PeproTech Inc., Rocky Hill NJ 
OSM Lyophilised ≤ 2 ng/ml 300-10 PeproTech Inc., Rocky Hill NJ 
MCSF Lyophilised ≤ 1 ng/ml 300-25 PeproTech Inc., Rocky Hill NJ 
GMCSF Lyophilised ≤0.1 ng/ml 300-03 PeproTech Inc., Rocky Hill NJ 
CHAPTER 2                                                                                                                MATERIALS AND METHODS 
98 
 
2.1.2 Conjugated flow cytometry antibodies 
Table 2.2 
Specificity Antibody Conjugate Clone 
No 
Catalogue 
No 
Supplier 
CD3 Mouse IgG1 FITC SK7 345763 BD Biosciences, 
Franklin Lakes, NJ, USA 
CD19 Mouse IgG1 FITC 4G7 345776 BD Biosciences, 
Franklin Lakes, NJ, USA 
CD14 (MY4) Mouse 
IgG2B 
FITC 322A-1 6603511 Beckman Coulter Ltd, 
High Wycombe, UK 
CD16 Mouse IgG1 PE 3G8 A07766 Beckman Coulter Ltd, 
High Wycombe, UK 
CD45 Mouse IgG1 APC 2D1 340910 BD Biosciences, 
Franklin Lakes, NJ, USA 
 
2.1.3 Neutralising antibodies and isotype controls 
Table 2.3 
Specificity Antibody Clone No CatalogueNo Supplier 
IL-1β Mouse IgG1 2805 MAB601 R&D Systems, Abington, UK 
IL-6 Mouse IgG1 6708 MAB206 R&D Systems, Abington, UK 
IL-10 Mouse IgG2B 25209 MAB2171 R&D Systems, Abington, UK 
TNFα Mouse IgG1 6401 MAB2101 R&D Systems, Abington, UK 
IL-22 Mouse IgG1 142928 MAB7821 R&D Systems, Abington, UK 
IFN-λ2 (IL-28A) Mouse IgG1 248526 MAB1587 R&D Systems, Abington, UK 
IFN-λ1 (IL-29) Mouse IgG2A 247801 MAB15981 R&D Systems, Abington, UK 
IFN-α Mouse IgG1 MMHA-2 21100-1 R&D Systems, Abington, UK 
IFN-β Mouse IgG1 76703 MAB814 R&D Systems, Abington, UK 
IFN-γ Mouse IgG2A 25718 MAB285 R&D Systems, Abington, UK 
IgG1 Mouse IgG1 11711 MAB002 R&D Systems, Abington, UK 
IgG2A Mouse IgG2A 20102 MAB003 R&D Systems, Abington, UK 
IgG2B Mouse IgG2B 20116 MAB004 R&D Systems, Abington, UK 
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2.1.4 Antibodies for Western Blot analysis 
Table 2.4 
Antibody Specificity Molecular 
Weight 
kDa 
Source Catalogue 
No 
Supplier 
Phospho-Stat3  Tyr705 79, 86 Rabbit 9131 Cell Signaling 
Technology 
Stat3 Total Stat3 92 Mouse 610190 BD Biosciences, 
Franklin Lakes, NJ, 
USA 
Phospho-p44/42 
MAPK (Erk1/2) 
Thr202/Ty
r204 
42, 44 Rabbit 9101 Cell Signaling 
Technology 
Phospho-SAPK/JNK Thr183/Ty
r185 
46, 54 Rabbit 9251 Cell Signaling 
Technology 
IκBα (C15)  37 Rabbit Sc-203 Santa Cruz 
Biotechnology Inc. 
Phospho-p38 MAP 
Kinase 
Thr180/Ty
r182 
43 Rabbit 9211 Cell Signaling 
Technology 
COX-2 Mab  72 Mouse 160112 Cayman Europe 
β-tubulin Mab 
clone AA2 
 50 Mouse T8328 Sigma-Aldrich UK 
Ltd, Dorset, UK 
Polyclonal Swine 
Anti-Rabbit 
Immunoglobulins/H
RP  
Rabbit IgG ---- Swine 2014-12 DAKOCytomation 
Denmark A/S 
ECLTM Anti-mouse 
IgG, Horseradish 
Peroxidase  linked 
whole antibody 
(from sheep) 
Mouse IgG ---- Sheep NA931V GE Healthcare UK 
Ltd., 
Buckinghamshire, 
UK 
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2.1.5 Reagents and consumables for Western Blot analysis 
Table 2.5 
Product Catalogue No Supplier 
BCATM Protein Assay Kit 23227 ThermoFischer Scientific Ltd., 
Leicestershire, UK 
Complete Mini Protease 
Inhibitor Cocktail Tablets 
04693124001 Roche Diagnostics Ltd., West Sussex, 
UK 
NuPAGE® 10% Bis-Tris Gel 
1.0mmX10well 
NP0301BOX Invitrogen Corp., Carlsbad, Ca., USA 
NuPAGE® MOPS SDS Running 
Buffer 20x 
NP0001 Invitrogen Corp., Carlsbad, Ca., USA 
Amersham Full-Range Rainbow 
Molecular Weight Markers 
(12000-225000 Da) 
RPN800E GE Healthcare UK Ltd., 
Buckinghamshire, UK 
Amersham HybondTM-P  RPN303F GE Healthcare UK Ltd., 
Buckinghamshire, UK 
Whatman Chromatography 
Paper 3MM CHR 
3030-861 VWR International Ltd., Lutterworth, 
Leicestershire, UK 
AmershamTM ECLTM Western 
Blotting Detection Reagents  
RPN2106 GE Healthcare UK Ltd., 
Buckinghamshire, UK 
AmershamTM ECL Plus Western 
Blotting Detection System 
RPN2132 GE Healthcare UK Ltd., 
Buckinghamshire, UK 
Fuji RX Medical X Ray 18x24cm JTS010 Labtech International Ltd., East 
Sussex, UK 
Re-blot Plus Strong Antibody 
Stripping Solution 10x 
2504 Millipore UK Ltd., Watford, UK 
 
 
 
CHAPTER 2                                                                                                                MATERIALS AND METHODS 
101 
 
2.1.6 Commercial assays and kits 
Table 2.6 
Product CatalogueNo Supplier 
ALP quantification assay kit 291-58601 WAKO pure chemical Ltd., Osaka, Japan 
Dynabeads® CD3 111.51D Invitrogen Dynal AS, Oslo, Norway 
Dynabeads® CD19 (panB) 111.43 Invitrogen Dynal AS, Oslo, Norway 
Dynabeads® CD14 
(monocytes/macrophages) 
111.49D Invitrogen Dynal AS, Oslo, Norway 
Dynal® T Cell Negative Isolation 
Kit Ver II 
113.37D Invitrogen Dynal AS, Oslo, Norway 
Dynal® B Cell Negative 
Isolation Kit 
113.13D Invitrogen Dynal AS, Oslo, Norway 
Dynabeads® MyPureTM 
Monocyte Kit2 for untouched 
human cells 
113.35D Invitrogen Dynal AS, Oslo, Norway 
Prostaglandin E2 ParameterTM 
Assay Kit 
KGE004B R&D Systems, Abington, UK 
QIAamp RNA Blood Mini Kit 
(50) 
52304 QIAGEN Ltd., Crawley, West Sussex, UK 
Foxp3 Staining Buffer Set 00-5523 eBioscience, Ltd. Hatfield, UK 
 
2.1.7 Commercial Luminex assay 
Table 2.7 
Product Catalogue No Supplier 
Human Cytokine 30-plex LHC6003 Invitrogen Corp., Carlsbad, CA., USA 
Cytokines detected:   
IL-1β, IL-1RA. IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17, 
TNFα, IFNα, IFNγ, GM-CSF, MIP-1α, MIP-1β, IO-10, MIG, Eotaxin, RANTES, MCP-1, VEGF, 
G-CSF, EGF, FGF-basic, HGF 
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2.1.8 Inhibitors and receptor agonists  
Table 2.8 
Inhibitor/Agonist Specificity IC50 μM Catalogue 
No 
Supplier 
Indomethacin COX 1.67  I8280 Sigma-Aldrich UK Ltd, 
Dorset, UK 
NS-398 COX-2 1.77 70590 Cayman Chemical, Ann 
Arbor, MI, USA 
Baicalein LOX ----- 465119 Sigma-Aldrich UK Ltd, 
Dorset, UK 
PD146176 12/15-LOX ----- P4620 Sigma-Aldrich UK Ltd, 
Dorset, UK 
BW B70C 5-LOX 0.2 B4558 Sigma-Aldrich UK Ltd, 
Dorset, UK 
AA-861 5-LOX 0.8  A3711 Sigma-Aldrich UK Ltd, 
Dorset, UK 
Tranilast Endotoxin-induced 
PGE2/Thromboxane 
B2/TGF-β1/IL-8 
 1-20 
/10-
50/100-
200/100 
T0318 Sigma-Aldrich UK Ltd, 
Dorset, UK 
Butaprost PGE2 EP2 5 13740 Cayman Chemical, Ann 
Arbor, MI, USA 
Misoprostol PGE2 EP2/3/4 0.3 13820 Cayman Chemical, Ann 
Arbor, MI, USA 
Sulprostone PGE2 EP1/3 0.5 14765 Cayman Chemical, Ann 
Arbor, MI, USA 
 
2.1.9 Eicosanoids 
Table 2.9 
Eicosanoid Formulation Catalogue 
No 
Supplier 
PGE2 Solution in Ethanol 14010 Cayman Chemical, Ann Arbor, 
MI, USA 
Leukotriene B4 Solution in Ethanol 20110 Cayman Chemical, Ann Arbor, 
MI, USA 
5(S), 6(R), 15(R)- 
Lipoxin A4 
Solution in Ethanol 90415 Cayman Chemical, Ann Arbor, 
MI, USA 
5(S), 6(R)- Lipoxin A4 Solution in Ethanol 90410 Cayman Chemical, Ann Arbor, 
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MI, USA 
17(S)-HpDoHE Solution in Ethanol 13815 Cayman Chemical, Ann Arbor, 
MI, USA 
17(R)-Resolvin D1 Solution in Ethanol 13060 Cayman Chemical, Ann Arbor, 
MI, USA 
Resolvin D2 Solution in Ethanol 10007279 Cayman Chemical, Ann Arbor, 
MI, USA 
Resolvin E1 Solution in Ethanol  Cayman Chemical, Ann Arbor, 
MI, USA 
 
2.1.10 Cell culture media/Media supplements/Commercial solutions/Cellular stains 
Table 2.10 
Product Catalogue 
No 
Supplier 
Gibco® Dulbecco’s  
Modified Eagle Media  
(DMEM) +GlutaMAXTM 
32430-100 Invitrogen Corp., Carlsbad, Ca., USA 
Roswell Park Memorial Institute 
(RPMI) 1640 Media 
E15-840 PAA Laboratories GmbH, Pasching, 
Austria 
Fetal Bovine Serum (FBS) S1810 Biosera, East Sussex, UK 
Penicillin/Streptomycin 100x P11-010 PAA Laboratories GmbH, Pasching, 
Austria 
L-Glutamine 200mM M11-004 PAA Laboratories GmbH, Pasching, 
Austria 
β-glycerol phosphate G9422 Sigma-Aldrich UK Ltd, Dorset, UK 
L-Ascorbic acid 2-phosphate 
sesquimagnesium salt hydrate 
A8960 Sigma-Aldrich UK Ltd, Dorset, UK 
Dexamethasone D2915 Sigma-Aldrich UK Ltd, Dorset, UK 
NH ChonDiff medium 130-091-679 Miltenyi Biotec, Bergisch Gladbach, 
Germany 
hMSC Adipogenic Bulletkit PT-3004 Lonza Group, Basel, Switzerland 
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Trypsin-EDTA (1x) 0.05%/0.02% in 
PBS 
L11-004 PAA Laboratories GmbH, Pasching, 
Austria 
Cell Dissociation Solution (1x) 
Non-Enzymatic 
C5914 Sigma-Aldrich UK Ltd., Dorset, UK 
Lympholyte® Cell Separation 
Media 
CL5020 CEDARLANE Laboratories Ltd., 
Burlington NC, USA 
Ethanol 200 proof (absolute)  
for molecular biology 
E7023 Sigma-Aldrich UK Ltd, Dorset, UK 
Hank’s Balanced Salt Solution 
(HBSS) 
14170-112 Invitrogen Corp., Carlsbad, Ca., USA 
LPS from E.coli, Serotype 
EH100(Ra) (TLR gradeTM) (Ready-
to-Use) 
581-010-L002 ALEXIS® Biochemicals, Lausen, 
Switzerland 
Dimethylsulphoxide (DMSO) D2650 Sigma-Aldrich UK Ltd, Dorset, UK 
Phosphate Buffered Saline (PBS) 
10x 
4371 7K VWR International Ltd., Lutterworth, 
Leicestershire, UK 
SIGMAFASTTM BCIP®/NBT ALP 
stain 
B-5655 Sigma-Aldrich UK Ltd, Dorset, UK 
Alizarin Red S A5533 Sigma-Aldrich UK Ltd, Dorset, UK 
Oil Red O O0625 Sigma-Aldrich UK Ltd, Dorset, UK 
Alcian Blue 8GX A5268 Sigma-Aldrich UK Ltd, Dorset, UK 
Crystal Violet Solution HT90132 Sigma-Aldrich UK Ltd, Dorset, UK 
 
2.1.11 Constituents of cell culture media and miscellaneous solutions 
Table 2.11 
Solution Constituents Volume/Concentration 
Culture Medium for MSC Gibco® DMEM 
Biosera FBS 
Penicillin/Streptomycin 
500ml 
50ml (10%) 
5ml (1%) 
Osteogenic Differentiation 
Medium 
Culture Medium for MSC 
β-glycerol phosphate 
Ascorbic Acid 
50ml 
1mM 
0.05nM 
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Dexamethasone 100nM 
Culture Medium for 
Hematopoietic Cells 
RPMI 1640 
Biosera FBS 
Penicillin/Streptomycin 
L-Glutamine 
500ml 
50ml (10%) 
5ml (1%) 
5ml (1%) 
Cell Freezing Media FBS 
Dimethylsulphoxide 
(DMSO) 
9ml 
1ml (10%) 
FACS wash buffer PBS 
Biosera FBS 
500ml 
5ml (1%) 
Cell Selection Buffer PBS  
Bovine Serum Albumin 
(BSA)   
EDTA 
250ml 
250mg (0.1%) 
2mM  
Cell Lysis Buffer for Western 
Blotting (solution in dH20) 
EDTA 
Tris-HCl pH 7.5 
NaCl 
Triton 
NaF 
Na3VO4 
Protease inhibitor cocktail 
1mM 
50mM 
70mM 
1% 
50mM 
1mM 
7x 
Sample Buffer for WB (solution 
in dH20) 
Tris-HCl 
Glycerol 
SDS 
EDTA 
DTT 
Bromophenol blue 
250mM 
40% (v/v) 
8% (w/v) 
1mM 
50mM 
0.05% (w/v) 
MTT reagent (solution in PBS) Methyltetrazolium 250µg/ml 
 
2.1.12 Consumables 
Table 2.12 
Product Catalogue No Supplier 
0.4μm transwell inserts 353095 VWR International Ltd., Lutterworth, 
Leicestershire, UK 
8μm transwell inserts 353097 VWR International Ltd., Lutterworth, 
Leicestershire, UK 
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2.2 Methods 
2.2.1 Cell culture of hMesenchymal Stem Cells (MSC) 
All cell culture procedures were performed under sterile conditions in a laminar flow cabinet 
(Class II microbiological safety, Gelaire, Flow). Adult human MSCs were isolated from bone 
marrow aspirates of healthy donors (kindly donated by Prof. Francesco Dazzi) or were 
commercially purchased (Product No PT-2501 from Lonza Group, Basel, Switzerland). MSCs 
were maintained in DMEM Glutamax media supplemented with 10% FBS and 1% 
penicillin/streptomycin. Cell cultures were maintained at 37°C in a humidified atmosphere 
of 5% CO2. When 70-80% confluent, cell cultures were washed twice with HBSS to remove 
the serum, and detached using 0.05% trypsin EDTA for 5min at 37°C. MSCs were expanded 
to at least passage three to ensure elimination of contaminating hematopoietic cells, and 
were also tested for their ability to differentiate to OBs, adipocytes and chondrocytes before 
using in experiments. MSCs were used in experiments up to passage eight. 
 
2.2.2 In vitro differentiation of MSC 
2.2.2.1 Osteogenic differentiation 
 
Staining of MSC for Alkaline Phosphatase 
Alkaline phosphatase (ALP) expression was used as an early marker for differentiation along 
the osteogenic pathway. For ALP staining, 1x104 MSCs were seeded to wells of a 24-well 
plate in duplicate and left overnight to adhere. Then, cultures were either kept in normal 
(control) media or the media was replaced with 1ml osteogenic media, with media changes 
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every 3 days thereafter. At day 7 the monolayer was washed with PBS, fixed with 1:1 
100%acetone:100% ethanol for 5min and stained with SIGMA FASTTM BCIP/NBT (1 tablet 
dissolved in 10ml dH2O) for 30min at 37°C. Cells expressing ALP appear dark purple under 
light microscope. 
 
Alkaline phosphatase quantification assay 
For ALP quantification, 1x104 MSCs were added to the wells of a 96-well plate in triplicate in 
200μl of media and left overnight to adhere. Subsequently, the media was removed and 
replaced with either DMEM media, osteogenic media, media containing mononuclear cells, 
media supplemented with soluble factors or cell culture supernatants. Media was changed 
every 3 days. At day 7 ALP was quantified using the LabAssayTM ALP Kit (Wako pure 
chemical, Japan) according to manufacturer’s instructions. This assay uses p-
Nitrophenylphosphate as a substrate which is hydrolysed into p-nitrophenol and phosphoric 
acid in the carbonate buffer (pH 9.8) in the presence of ALP in the sample. Released p-
Nitrophenol showing yellow colour is optically measured at 405nm wavelength as the 
enzyme activity. A standard curve standard is generated using p-Nitrophenol standard 
solution. Briefly, the culture media was removed; cell cultures were washed with PBS and 
lysed in 20μl NP40 protein lysis buffer. Standard p-Nitrophenol solution (0.5mmol/L) was 
serially diluted with dH2O to concentrations of 0.25, 0.125 and 0.0625 mmol/L. To empty 
wells, 20μl of each calibration solution as well as 20μl of dH2O as blank control were added. 
Subsequently 100μl of Substrate solution (p-nitrophenylphosphate disodium) was added in 
all of the wells and the plate was incubated for 15min at 37°C. To terminate the enzymatic 
reaction 80μl of stop solution (Sodium Hydroxide) was added to each well and the plate was 
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read at 405nm in a microplate reader. ALP content was determined using the standard 
curve and was expressed as p-Nitrophenol (mmol/L).  
 
Staining for bone nodule formation and quantification 
Bone nodule formation is the ultimate indication of osteogenic differentiation and bone 
nodules can be visualised when stained for calcium rich deposits of cells in culture. In this 
study Alizarin Red S stain was used for the visualisation and quantification of bone nodule 
formation according to Gregory et al. (Gregory et al, 2004). For bone nodule formation, 
1x104 MSCs were seeded to wells of a 24-well plate in duplicate and left overnight to 
adhere. Then cultures were either kept in normal media as control or media replaced with 
1ml osteogenic media. Cultures were kept for 21 days, with media changes every 3 days. 
Subsequently, cultures were washed with PBS, fixed with 10% formaldehyde for 15min at 
room temperature, washed twice with excess PBS and stained with a 40mM solution of 
Alizarin Red (adjusted to pH 4.1 using 10% v/v ammonium hydroxide) for 20min with gentle 
agitation at room temperature. Excess dye was aspirated off and cultures washed four times 
with dH20. Bone nodules, appearing red, were visualised under light microscope and 
photographed. For quantification, the dye was eluted from the cultures by acid elution. 
Briefly, 10% (v/v) acetic acid was added to each well and the plate incubated at room 
temperature for 30min with gentle agitation. Subsequently the monolayer was scraped, 
transferred to eppendorf tubes and heated at 85°C on a heat block for 10min after which 
tubes were cooled on ice for 5min. The slurry was centrifuged at 1500rpm for 15min and an 
aliquot of the supernatant transferred to new eppendorf tubes in which 10% (v/v) 
ammonium hydroxide was added to neutralise the acid. Aliquots of the neutralised elute 
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were transferred to 96 well plate in triplicate and dye levels detected at 405nm on a 
microplate reader.  
 
2.2.2.2 Adipogenic differentiation 
For the induction of adipogenenic differentiation the hMSC Adipogenic BulletKit kit was 
used (Lonza Group, Basel, Switzerland). 1x104 MSCs were seeded to wells of a 24-well plate 
in duplicate and left overnight to adhere. Media was then replaced with 1ml adipogenic 
induction media. At day 3 the media was removed and replaced with 1ml maintenance 
media. The cultures were kept for 21 days, during which media was changed every 3 days 
alternating between induction and maintenance media. At day 21, differentiation was 
assessed using Oil Red O staining for the visualisation of lipid droplets in the cell cytoplasm. 
Dye was prepared by dissolving 0.5g of Oil Red O (Sigma-Aldrich UK Ltd, Dorset, UK) in 
100ml isopropanol, diluted 3:2 with dH20 and filtered. Cells were fixed with 10% formalin in 
PBS and stained with Oil Red O stain for 1h with gentle agitation in room temperature. 
Excess dye was washed off with dH20 and lipid droplets in the cell cytoplasm, which appear 
red, visualised under light microscope and photographed.  
 
2.2.2.3 Chondrogenic differentiation 
Chondrogenic differentiation was stimulated using NH ChondroDiff Medium for human 
MSCs (Miltenyi Biotec, Bergisch Gladbach, Germany) with the microsphere method. 2x105 
MSCs were added to a 15ml corning tube and centrifuged at 1500rpm for 5min. The media 
was removed and to the remaining cell pellet either chondrogenic differentiation media or 
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normal media as control were added. Culture medium was changed every 3 days and 
cultures were kept for 21 days. Chondrogenic nodules or control cell pellets were then fixed 
by immersion in 10% formaldehyde solution for at least 1h, cut into sections and stained 
using Alcian Blue (courtesy of Mr David Essex, Department of Histopathology, Charing Cross 
Hospital).  
 
2.2.3 Peripheral Blood Mononuclear Cells (PBMCs) 
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from buffy coats of healthy 
donors purchased from the National Blood Service (Colindale, Edgware London) using 
density gradient centrifugation. Briefly, buffy coats were diluted 1:1 in HBSS and layered on 
top of Lympholyte® Cell Separation Media (CEDARLANE Laboratories Ltd., Burlington NC, 
USA) in 50ml falcon tubes which were subsequently centrifuged at 2500rpm for 30min at 
10°C on low acceleration and deceleration (Figure 2.1).  
 
After centrifugation, the phase containing the mononuclear cells was carefully aspirated, 
added to a new falcon tube containing HBSS and washed twice (first wash at 1800rpm for 
10min and second wash at 1500rpm for 5min) to remove residual Lympholyte® Media. Cells 
were either immediately used in culture or cryopreserved in freezing media (10% dimethyl 
sulphoxide (DMSO) in FBS) for later use. The isolated mononuclear layer was also used for 
the further separation of lymphocytes and monocytes via elutriation. 
 
CHAPTER 2                                                                                                                MATERIALS AND METHODS 
111 
 
Figure 2.1 Isolation of PBMCs using density gradient centrifugation 
 
 
 
 
 
 
Figure 2.1 A cell suspension of buffy coat diluted 1:1 with HBSS is carefully layered on top of 
Lympholyte® media and after centrifugation PBMC are collected from the interface found between 
plasma and Lympholyte® media.  
 
2.2.3.1 Depletion and enrichment of PBMC populations 
Depletion of T cells, B cells and monocytes was performed using CD3, CD19 and CD14 
Dynabeads (Invitrogen Dynal AS, Oslo, Norway) according to manufacturer’s instructions. 
Briefly, PBMCs isolated by density gradient centrifugation as described in section 2.2.3, were 
washed with cell separation buffer (PBS containing 0.1% BSA and 2mM EDTA) and incubated 
with the magnetic beads (2x107 beads/1x107 PBMCs) for 30min at 4°C with gentle tilting and 
rotation. Subsequently, the tube containing the cells and bead mix was placed in a magnet 
for 1min. The bead bound cells that are retained by the magnet represent the depleted 
population whilst the supernatant containing all the cell populations except the depleted 
one was collected and used in subsequent experiments.  
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For the isolation of untouched populations of T cells, B cells and monocytes negative 
selection kits; Dynal® T cell Negative Isolation Kit Ver II for T cells,  Dynal® B Cell Negative 
Isolation Kit for B cells and Dynabeads® MyPure™ Monocyte Kit 2 for monocytes (Invitrogen 
Dynal AS, Oslo, Norway) were used according to manufacturer’s instructions. Briefly, PBMCs 
were incubated for 10min at 4°C with blocking solution and antibody mix against CD 
markers of all other cell types except the cell type of interest. Cells were then washed with 
cell separation buffer (PBS containing 0.1% BSA and 2mM EDTA) and depletion Dynabeads 
recognizing all mouse IgG subclasses added. Unwanted cell types that were now bead 
bound were removed using magnet, while untouched target population left behind in the 
supernatant. Purified populations were then counted and used in experiments.  
 
2.2.3.2 Monocyte isolation  
 
Isolation of total monocytes from PBMC 
PBMCs were subjected to centrifugal elutriation in a Beckman JE6 elutriator (Beckman 
Coulter, High Wycombe, UK) at 2500rpm to obtain enriched monocyte fractions. PBMCs 
were pumped into the elutriation chamber at an increasing flow rate where they were 
subjected to the opposing forces of the centrifugal force and the flow velocity. Since the 
centrifugal force is constant, by increasing the flow of media into the centrifuge using a 
pump, the separation of cells according to their size and granularity is possible. Monocyte 
purity was subsequently assessed by FACS with monocyte fractions typically containing 
≥80% CD14+ cells. Monocytes were then either co-cultured with MSCs, further sorted into 
monocyte subsets or differentiated in vitro.  
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Monocyte sorting into CD14++CD16- and CD14+CD16+ subsets 
To determine the effect of the different monocyte subsets on MSC osteogenic 
differentiation purified populations of monocyte subsets were isolated. Using flow 
cytometry cell sorting, total monocytes were separated into subsets on the basis of their 
surface expression of CD14 and CD16. A cell sorter is a flow cytometer that is able to select 
target cells and collect these separately from the rest of the cell suspension. Cell sorters 
have the ability to electronically deflect cells (sort) with defined properties into separate 
collection tubes, plates or slides. The purity of sorted cells may be validated by rerunning 
the sorted fraction. Total monocytes isolated by centrifugal elutriation were stained with a 
cocktail of CD14-FITC and CD16-PE conjugated antibodies. The monocyte populations shown 
to be expressing either only CD14 or both CD14 and CD16 were gated on and sorted into 
separate fractions. The purity of isolated cells was validated at 97-99 % by rerunning the 
purified fractions on flow cytometer. Monocyte subsets, CD14++CD16- and CD14+CD16+ were 
added to MSC culture and MSC differentiation was assessed as before. For cytokine analysis, 
monocyte subsets were treated with 10ng/ml of LPS (ALEXIS® Biochemicals, Lausen, 
Switzerland) overnight. After incubation supernatants were collected, filtered and kept at -
20°C until further analysis. 
 
In vitro differentiation to M-CSF and GM-SCF macrophages 
For in vitro differentiation monocytes were cultured in petri dishes or flasks at a density of 
106 cells/ml, in RPMI medium supplemented with 10% FBS, 1% penicillin/streptomycin and 
1% L-glutamine and in the presence of 100ng/ml of MCSF to generate MSCF Mφs, or 
50ng/ml of GMCSF, to generate GMCSF Mφs. Differentiated Mφs were used after 3-5 days 
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of differentiation. To further polarise Mφs differentiation to the M1 or M2 phenotypes 
20ng/ml of IL-4 to M-CSF and 20ng/ml of IFNγ to GM-SCF Mφs were added for the last 24h 
of differentiation. 
 
2.2.4 Cell surface or intracellular staining and flow cytometry analysis 
Cell surface marker expression of mononuclear cell populations or MSCs was evaluated by 
standard flow cytometry using a BD-LSR II flow cytometer (Becton-Dickinson Biosciences, NJ, 
USA) and data obtained using FACS Diva software. Aliquots of 1x105 cells were incubated 
with appropriate concentrations (as per manufacturer’s instructions, usually 10-20µl) of 
fluorescently conjugated antibodies or isotype controls for each antibody and fluorochrome 
in FACS buffer (PBS containing 1%FBS). Alternatively, for intracellular staining cells were first 
incubated with fixation/permeabilization buffer (eBioscience Ltd., Hatfield, UK), washed and 
then incubated with fluorescently conjugated antibodies or isotype controls. The 
suspensions were vortexed and incubated for 30min on ice in the dark. The cells were then 
washed, resuspended in 1ml of FACS buffer and analysed on the BD-LSR flow cytometer. 
Typically 10,000 events were recorded and data were analysed using Flowjo software (Tree 
Star Inc.).  
 
For evaluation of PBMC populations before and after depletions and purifications, 
antibodies against CD3 (conjugated with FITC), CD14 (conjugated with PerCP-A) and CD19 
(conjugated with FITC) were used. For the isolation of monocyte subsets using fluorescence-
activated cell sorting, CD14 My4-FITC, CD16-PE antibodies and isotype controls were used. 
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Finally, antibodies for CD45-APC and COX2-FITC were used for the assessment of COX2 
expression in monocytes from co-cultures with MSCs.  
 
2.2.5 Mononuclear cells – MSC co-culture experiments 
 
2.2.5.1 Co-cultures in contact 
The various populations of primary mononuclear cells described above were used in co-
cultures with MSCs. Firstly, MSCs were plated in 96-well plates at a concentration of 1x104 
cells per 200μl and left overnight to adhere. The following day populations of whole PBMCs, 
PBMCs depleted of T cells or B cells or monocytes as well as enriched populations of the 
above, monocyte subsets, Mφs or co-culture supernatants were added on top of the MSCs 
along with fresh control or differentiation media. At first cells were added in ratios of 1:1, 
2:1, 5:1 and 10:1 mononuclear cells to MSCs. Subsequently the 10:1 ratio was chosen as 
optimal and used in further experiments. As control, wells that only contained MSCs or the 
mononuclear cells were included. Co-cultures were kept for 7 days for ALP staining and 
quantification or 21 days for bone nodule formation with a media change every 3 days.  
 
2.2.5.2 Cell fixation 
Cell fixation of mononuclear cells was performed using a 1min incubation in 2ml of 0.05% 
glutaraldehyde (Sigma-Aldrich UK Ltd, Dorset, UK), followed by a 1min incubation in 0.2M 
glycine (Sigma-Aldrich UK Ltd, Dorset, UK). Cells were then washed twice using culture 
medium, counted and added to cultures. 
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2.2.5.3 Co-cultures in transwell 
To identify the implication of soluble factors or cell contact in the monocyte/MSC co-
cultures, a transwell system was used where special inserts (Falcon, Becton Dickinson) 
separate cell populations through a semi permeable membrane with a 0.4μm pore size. This 
allowed for soluble factors to permeate the entire well but at the same time prevented cell 
contact between cell populations. Firstly, 1x104 MSCs were plated in 24-well plates and left 
overnight to adhere. Then monocytes were added on the insert membrane of the transwell 
system. Cultures of MSCs and monocytes in contact were also used to allow comparisons. 
After 7 days, the ALP levels of the MSCs cultures present in the bottom of the wells were 
quantified. 
 
2.2.5.4 Co-culture supernatants 
To further verify the role for soluble factors in inducing MSC differentiation, supernatants 
from either 10:1 monocyte/MSC co-cultures or MSC and monocyte monocultures were 
produced. Co-cultures were set up and incubated for 24h at 37°C before the supernatant 
being collected, filtered to remove any cells and used in subsequent experiments. These 
supernatants were assessed for their ability to induce ALP and bone nodule formation when 
they were added on top of fresh MSC cultures and cultured for 7 days or 21 days 
respectively. The effect of 10:1 supernatants on MSC signalling was also investigated using 
Western blotting analysis. 
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2.2.6 MSC proliferation assay – Cell count method 
1x104 MSCs were added to each well of a 96-well plate in triplicate and left overnight to 
adhere. The next day either PBMCs or monocytes were added to the wells containing the 
MSC, at ratios of 1:1, 2:1, 5:1 and 10:1 PBMC/monocyte:MSC in 200µl of control DMEM 
media or osteogenic media. There were also wells where monocytes were not added on top 
of the MSC as control. At day 7 of cell culture, media was aspirated off and monolayer 
washed three times to remove the majority of PBMC or monocytes. The MSCs were then 
detached using trypsin digestion, and counted using a haemocytometer and trypan blue 
stain to also assess cell viability (dead cells stain blue). Mean values for each condition were 
plotted as number of cellsx104/ml.  
 
2.2.7 MSC migration assay 
The ability of MSCs to migrate towards monocytes was assessed using 8µm pore transwell 
membranes (VWR international Ltd, Lutterworth, Leicestershire, UK). Firstly, to the wells of 
24-well plate different conditions, namely FBS free media as a negative control for 
migration, 20% FBS containing media as a positive control for migration and monocytes 
were added, all at a volume of 500µl (enough to immerse the traswell membrane 
sufficiently). All conditions were set up in duplicate. Subsequently the 8µm pore transwells 
were placed in each well and 1x104 MSCs in FBS free media added in the upper chamber of 
each transwell. Cell cultures were kept overnight at 37°C with 5% CO2. Then the transwells 
were removed from the wells and the upper chamber wiped clean using cotton wool in 
order to remove MSC that did not migrate to the underside of the membrane. The 
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membranes were then gently washed in PBS, fixed in 10% formaldehyde for 10min at room 
temperature and finally stained with 1% crystal violet solution for 15min. Excess dye was 
removed and membranes observed under light microscope. The number of cells in 8 
random fields of view was counted at 20x magnification and the mean calculated for each 
membrane. 
 
2.2.8 Viability Test - MTT assay 
Cell viability was measured using the MTT assay. The 3-(4,5 dimenthylthiazol-2yl)-2,5-
tetrazolium bromide (MTT) is converted to an insoluble formazan by cleavage of the 
tetrazolium ring by dehydrogenase enzymes. In living cells, active dehydrogenase will cause 
the conversion whilst in dead cells it will not. MTT reagent was added in cultures to equal 
one tenth of the culture medium (10µl in 90µl of medium per well of a 96-well plate) for the 
last 24h of the experiment and incubated at 37°C. At the end of the incubation, lysis buffer 
was added in each well (100µl per well), to release the formazan from the cells, and 
absorbance read at 620nm.   
 
2.2.9 Gel Filtration – FPLC 
Gel filtration separates molecules according to differences in size as they pass through a gel 
filtration medium packed in a column. The gel filtration medium is made up of porous gel 
beads, with a pore size chosen to permit small molecules to enter the beads but to exclude 
large molecules. As large molecules cannot enter the beads, they exit the column first while 
the smaller molecules take a much longer route through the gel beads’ pores and exit later 
(Figure 2.2).  
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Figure 2.2 Gel-filtration chromatography 
 
 
 
 
 
Figure 2.2 A gel filtration column was set up and run using the Amercham Akta FPLC system to 
analyse the 10:1 co-culture supernatant to its constituent proteins. The column allows for the 
separation of proteins according to size since bigger proteins unable to diffuse into the porous beads 
exit first while smaller proteins take a longer route through the extended system of pores and exit 
last.   
 
This method was used in an attempt to separate the 10:1 co-culture supernatant to its 
constituent proteins by molecular size. This set up used a XK 16/100 column, packed with 
750ml SephacrylTM S200 HR (GE Healthcare, Little Chalfont, Buckinghamshire, UK) which was 
connected to the Amersham Akta FPLC system. The column was equilibrated with sterile 
PBS prior to injecting 0.5 ml of 10:1 co-culture supernatant to the system using the loading 
coil, and flow immediately switched back to PBS to allow supernatant to be applied to the 
column. The flow rate was set to 1ml/min and the pressure to 0.5mPa. The flowthrough was 
collected in 96well fraction collection plates with capacity of 1ml/well. The separation 
occurs according to molecular size with the larger molecules exiting the column first 
immediately after one volume of the column has passed through, followed by molecules of 
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decreasing molecular size. Protein content is detected by a UV detector connected at the 
exit of the column and readings plotted on a trace against the volume of the followthrough 
that also corresponds to time since flow equals 1ml/min. The resulting spectrum of the 
flowthrough consisted of 4 peaks each representing a group of proteins with similar 
molecular weight. Fractions corresponding to each peak were pooled and assigned as 
Fractions 1-4. The pooled fractions were then concentrated in Vivaspin-15R centrifugal 
filtration columns (100kDa cutoff) (Sartorius Stedim Biotech S.A., Aubagne Cedex, France) to 
approximately 0.2ml, reconstituted up to 1ml with DMEM complete media, filter-sterilized 
and added to MSC cultures. After 7 days ALP activity was assessed. A small aliquot of each 
concentrated protein fraction was resolved using SDS PAGE electrophoresis.   
 
2.2.10 SDS PAGE electrophoresis and silver staining 
One dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) 
was performed using a 10% NuPAGE® Bis-Tris gel (Invitrogen Corp., Carlsbad, Ca., USA) to 
which samples were loaded, each consisting of 15µl of supernatant and 5µl of 4x sample 
buffer. A protein marker was also added to the outmost well. Gels were run for 2h at 120V. 
For silver staining, the SDS-PAGE gel was fixed in a solution containing 50% methanol/5% 
acetic acid for 20min, then washed in 50% methanol for a further 10min and then rinsed in 
distilled water for at least 1 h or preferably overnight. Subsequently, the gel was washed in 
a sensitizing solution of 0.02% sodium thiosulphate for 1min, rinsed twice in distilled water 
and then incubated in a cold solution of 0.1% silver nitrate at 4°C for 20min and rinsed again 
with distilled water. The gel was then developed in a solution containing 0.04% formalin in 
2% sodium carbonate for 5-10min, until protein bands were clearly visible. During the 
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developing step, the developing solution was replaced if it became cloudy (usually after 3-
4min). The development process was stopped with the addition of 5% acetic acid for 5min. 
Finally, the gel was washed with distilled water for 2 further incubations of 30min. 
 
2.2.11 Determination of cytokine levels in culture supernatants 
2.2.11.1 Luminex methodology 
Luminex allows for the simultaneous determination of multiple (up to 100 different 
molecules) cytokine molecules in a given solution. For each cytokine to be investigated a 
special bead conjugated with a chromophore is coupled with an antibody against a specific 
cytokine. All beads were purchased from Bio-Rad Laboratories Ltd. Hertfordshire, UK, while 
antibodies against IL-1β, IL-6, IL-6Rs, IL-8, IL-10 and TNFα were all from R&D Systems, 
Abington, UK. Briefly, 96-well filter plates (Millipore UK Ltd., Watford, UK) were pre wet 
with PBS, PBS is then removed and 50μl of samples or standards added to each well. Beads 
conjugated with different chromophores were prepared for each cytokine molecule and a 
cocktail of the various beads was added to the supernatants to be investigated. The same 
beads were also added to solutions containing known concentrations of all the cytokines to 
be investigated. This allows for the generation of the standard curve against which the 
values of the unknown solutions will be put in order to give the values for each cytokine 
present in the solution. Following 2h incubation at room temperature in the dark, plates 
were washed with PBS + 0.05% Tween 20. Biotinylated secondary antibody was then added 
to all wells at a concentration of 0.5μg/ml in PBS+1% BSA and mixed for 1h at room 
temperature. After a wash with PBS + 0.05% Tween 20, 2μg/ml streptavidin in PBS+1% BSA 
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was added in all wells and incubated for 30min. The plate was washed, beads were 
resuspended in luminex buffer and plates read on a Luminex100 (Luminex Corp, Austin Tx). 
 
2.2.11.2 ELISA 
Commercially available ELISA kits were used in order to measure the levels of bone 
morphogenetic proteins (BMPs), TGFβ1 and PGE2 in supernatants from monocyte and MSC 
co-cultures according to manufacturer’s instructions. Briefly, a purified antibody specific for 
the antigen under investigation, was pre-coated onto a 96-well microplate. The 
supernatant, containing the protein (antigen), was added to the well and incubated for 1h at 
room temperature so that it can interact with the immobilized antibody and be bound to it. 
Concurrently, a standard curve was generated using solutions of known concentrations of 
the antigen that are added to separate wells and are also allowed to bind to the antibody. 
After incubation, the plate was washed and an enzyme-linked polyclonal antibody specific 
for the antigen was added to all wells. After incubation, any unbound enzyme-linked 
antibody was removed, wells washed and a substrate solution added to the wells. The 
chemical reaction between the substrate and the enzyme results in a colour change which is 
proportional to the amount of enzyme-linked antibody present and thus the amount of 
antigen. The colour was left to develop for 10-15min after which the reaction was stopped 
with the addition of 2N H2SO4 acid solution. Plates were then read on a plate reader at 
450nm and absorbance equated to the amount of bound antigen was calculated using the 
standard curve which was generated by the known antigen concentrations.      
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2.2.12 Western Blotting (WB) Analysis 
To investigate intracellular signaling events in MSCs and monocytes, whole cell protein 
extracts were prepared and analysed using Western Blot. Routinely, 2x105 MSCs or 1-3x106 
monocytes were lysed in 50µl protein lysis buffer on ice for 30min. Subsequently, lysates 
were centrifuged for 15min at 4°C and lysates free of cellular debris were transferred into 
new eppendorf tubes that were stored at -20°C until analysis. Protein concentration was 
determined using BCATM protein assay kit (ThermoFisher Scientific) according to 
manufacturer’s instruction. Briefly, 2µl of each lysate as well as 10µl of bovine serum 
albumin (BSA) serially diluted standards (2, 1, 0.5, 0.25, 0.125 and 0.0625 mg/ml) or water 
as blank were added to 200µl of assay working solution (50:1 reagent A:B) in a 96-well elisa 
plate and incubated for 30min at 37°C. Protein concentration was determined from the 
absorbance values at 540nm.  
 
Prior to gel electrophoresis, 4x sample buffer was added to an aliquot of 10µg of protein, 
from each sample, which were subsequently heat denatured for 5min at 95°C. The 
denatured proteins were resolved on a 10% NuPAGE® Bis-Tris gel (Invitrogen Corp., 
Carlsbad, Ca., USA) and transferred to Amersham HybondTM-P polyvinyldene fluoride (PVDF) 
membranes (GE Healthcare UK Ltd.) using a Novex X-Cell II Mini Cell (Biorad, U.K.). Following 
transfer, membranes were blocked with blocking buffer (5% (w/v) fat-free milk and 0.1% 
(v/v) Tween 20 in TBS) for 1h at room temperature, followed by overnight incubation at 4°C 
with primary antibody diluted 1:1000 in blocking buffer. Probing with a primary antibody 
against β-tubulin was used as loading control. Membranes were then incubated with a 
secondary peroxidase-conjugated antibody at a 1:5000 dilution prior to detection using 
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chemiluminescence reagents ECLTM or ECLTM plus (GE Healthcare UK Ltd.). Bound antibody 
was visualized on X-ray film (Fuji RX Medical X Ray, Labtech International Ltd.). Membranes 
were usually re-probed with a different primary antibody following treatment with stripping 
solution (Millipore UK Ltd., Watford, UK) for 15min at room temperature and re-blocking.   
 
2.2.13 Adenoviral constructs 
To investigate the role of STAT3 in the osteogenic differentiation of MSCs, recombinant 
replication-deficient adenoviral constructs encoding a constitutively active (CA) or a 
dominant negative (DN) form of STAT3 were used. As described by Bromberg et al., 
substitution of the cysteine residues C661A and C663N results in STAT3 dimerization and 
activation and thus STAT3 being constitutively active (Bromberg et al, 1999). Conversely, the 
DN mutant results from a substitution of Y705F which prevents phosphorylation and hence 
activation of STAT3 (Kunisada et al, 1998; Williams et al, 2004). All adenoviral constructs 
were kindly donated by Dr. Lynn Williams, Imperial College London, and they were purified 
and concentrated as previously described (Foxwell et al, 1998).  
 
MSCs were plated at 1x104 cells/well in a 96-well plate, or 3x105 cells in a small petri dish 
and left overnight to adhere. The next day serum containing media was removed and virus 
suspensions, in serum free media, were added to the cells at multiplicity of infection (M.O.I.) 
50 for the STAT3 CA construct and at M.O.I. 100 for the STAT3 DN and AdGFP control virus. 
The cultures were left to incubate with the adenoviruses for 2h at 37°C after which the viral 
suspensions were removed, cultures washed and media replaced with complete DMEM 
media or osteogenic media. The transgene is produced after overnight incubation and can 
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be detected either by visualising the cultures under UV light for the GFP construct or WB to 
detect pSTAT3. 
 
 2.2.14 RNA isolation and Real Time RT-PCR 
Total RNA was isolated from 1x105 MSC or 1x106 monocytes using QIAamp RNA Blood Mini 
Kit (Qiagen Ltd, Crawley, West Sussex, UK) according to manufacturer’s instructions. RT-PCR 
reactions were set up using QuantiFastTM SYBR® Green RT-PCR (Qiagen Ltd, Crawley, West 
Sussex, UK) to 10µl reaction volume adding 50-100ng/ml RNA and primer pairs. Primers 
used were ALP forward 5’ACTGGTACTCAGACAACGAG3’ and ALP reverse 
5’AAGCTCTTCCAGGTGTCAAC3’ and as housekeeping gene acidic ribosomal protein (ARP) 
forward 5’CGACCTGGAAGTCCAACTAC3’, ARP reverse 5’ATCTGCTGCATCTGCTTG3’. Reactions 
were run on a Rotor Gene 6000 (Corbett Research UK, Ltd., Cambridge, UK) using the 
following settings: 50°C for 15min, 95°C for 5min, 95°C for 10sec and 60°C for 30sec 
repeated for 40 cycles. Data were analysed for delta delta CT analysis using Rotor Gene 
6000 software (Corbett Research UK, Ltd., Cambridge, UK).     
 
2.2.15 Microarray 
A microarray study was performed in collaboration with Dr Dilair Baban at the Welcome 
Trust Centre for Human Genetics, Oxford using the Illumina Whole-Genome Gene 
Expression analysis platform. The HumanHT-12 v3 expression BeadChips were used, which 
target more than 25,000 annotated genes with >48,000 probes derived from the National 
Center for Biotechnology Information Reference Sequence (NCBI) RefSeq (Build 36.2, Rel 
22) and the UniGene (Build 199) databases.  
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Two different studies were performed, to analyse the transcriptome of:  
1. MSCs that had been infected with STAT3 adenoviral constructs and virus control  
2. Monocytes that had been cultured in the absence or presence of MSCs or in co-
culture with MSCs and either PGE2, COX-2 inhibitor NS-398 or both PGE2 and NS-398.  
 
For the MSC study, 4x105 MSC were plated in small petri dishes and left overnight to adhere. 
The next day MSCs were infected with STAT3 CA, STAT3 DN and AdGFP adenoviral 
constructs as described in section 2.2.13. After 2h of infection, the viral suspension was 
removed, cultures washed twice and osteogenic media added to all cultures. After 24h, 
media was removed and cultures lysed for RNA extraction. Identical MSC cultures were set 
up in 96-well plate format to assess ALP after 7 days of culture as a validation of the 
biological effect. The experiment was repeated five times and the MSCs used were from five 
different donors and varying passage (P4, P5 and P6). For the monocyte study, 3x106 
moncytes were added to small petri dishes either alone or where 3x105 MSC had already 
been plated. Monocyte/MSC co-cultures were also set up with the addition of either PGE2, 
COX-2 inhibitor NS-398 or both PGE2 and NS-398. All cultures were kept in osteogenic 
media. At 2h and 8h monocytes were collected from the cultures and lysed for RNA 
extraction. Identical cultures were set up in 96-well plate format to assess ALP after 7 days 
of culture as a validation of the effect on MSC differentiation. The study included five 
biological replicates and monocytes from five different donors were used.  
 
Total RNA was extracted from each sample using the QIAamp RNA Blood Mini Kit (Qiagen Ltd, 
Crawley, West Sussex, UK) according to manufacturer’s instructions. Isolated RNA was 
CHAPTER 2                                                                                                                MATERIALS AND METHODS 
127 
 
quantified and RNA quality assessed using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE). The ratio of absorbance at 260nm and 280nm is 
used to assess the purity of RNA. A ratio of ~2 is accepted as pure RNA while a lower 260/280 
ratio may indicate contamination by protein or phenol. All samples included in the microarray 
study exhibited the expected effect on MSC differentiation and had a 260/280 ratio of ≥1.8. 
RNA quality was further validated using RNA6000 Nano Assay on Agilent BioAnalyzer 2100 
(Agilent Technologies, Santa Clara, CA). 
 
The microarray and data analysis were performed by Dr Dilair Baban at the Welcome Trust 
Centre for Human Genetics, Oxford. Briefly, commercially available high-density 
oligonucleotide, from Illumina whole genome gene expression BeadChips (Human 
HT12_V3_0_R3_11283641, Illumina Inc, San Diego, California, USA), were used with 48803 
probes representing 37879 human transcripts. In brief, 500ng of total RNAs were reverse 
transcribed to synthesize first- and second- strand complementary DNA (cDNA), followed by 
in vitro transcription to synthesize biotin-labeled complementary RNA (cRNA) using 
TotalPrep-96 RNA amplification kit from Ambion. A total of 750ng of biotin-labeled cRNA 
from each sample was hybridised to the HT12 BeadChip (Illumina Inc., San Diego, CA) at 58C 
for 18 h. The hybridised BeadChip was washed and labeled with streptavidin-Cy3 according 
to the manufacturer’s protocols. Chips were scanned with Illumina BeadScan and scanned 
image was imported into GenomeStudioV2010.1 (Illumina Inc) for data extraction.  
 
Data were normalised and analysed using GeneSpring 11.5 (Agilent Technologies, Santa 
Clara, CA). Microarray data were normalised by percentile shift to the 75th percentile with 
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the baseline set to the median of all samples. Genes with low expression (20% or less above 
background noise) were filtered out from further analysis. Genes with significantly altered 
expressions were identified by one way ANOVA with Benjamini-Hochberg multiple testing 
correction, with p<0.01. The entities satisfying the significance analysis were passed on for 
the fold change analysis. For a given gene its change in expression was calculated by dividing 
its average normalised intensity in treated samples from the respective control values. 
Significantly differentially expressed genes were identified with functional classifications, 
pathways analysis and gene set enrichment determined. 
 
2.2.16 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5 (GraphPad software, San 
Diego, CA). Human MSCs were from ten different donors and human PBMCs and monocytes 
were from a different donor each time. Each experiment was performed in triplicate, or 
duplicate for bone nodule assays and migration assays, at least three times, with the mean 
and standard error of the mean (S.E.M.) or standard deviation (SD) calculated in each case. 
Statistical analyses were performed using one way analysis of variance (ANOVA) with 
Bonferroni’s correction for multiple comparisons. Where multiple results were compared 
against a standard or control series, Dunnett’s post test correction was performed. Results 
are expressed as mean ± S.E.M. were cumulative data from multiple experiments are shown 
or as mean ± S.D. were results from a representative experiment are presented. Results 
were considered statistically significant when P<0.05. Significant results were depicted using 
asterisks, where *: P<0.05, **: P<0.01, ***: P<0.001. This convention was used throughout. 
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CHAPTER THREE 
Monocytes Promote Osteoblast Differentiation 
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3.1 Introduction 
The ability to direct stem cell differentiation represents the holy grail of regenerative 
medicine. Directing the formation of new bone would be favourable not only in genetic 
diseases such as osteogenesis imperfecta (Horwitz et al, 2002; Horwitz et al, 1999) but also 
replacing bone in bone fractures, osteoporosis, osteolytic bone tumours and inflammatory 
diseases such as rheumatoid arthritis. In recent decades a population of adult stem cells, 
known as Mesenchymal Stem Cells (MSCs), has emerged as a valuable therapeutic agent for 
regeneration of lost tissue and particularly bone (Bianco & Robey, 2001; Dazzi & Horwood, 
2007; Jethva et al, 2009; Niklason, 2000; Parekkadan & Milwid, 2010; Petite et al, 2000; 
Undale et al, 2009) since MSC are the progenitors of OBs.  
 
The fact that bone loss is a major characteristic of inflammatory disease led to the early 
realisation that the immune system can direct bone turnover. It is now well established that 
multiple immune components regulate the OCs and OBs (Lorenzo et al, 2008; Takayanagi, 
2009; Walsh et al, 2006), however the majority of investigations have focused on the 
regulation of OC differentiation and function due to the implications for bone loss in 
disease. Understanding the complex mechanisms that govern the differentiation of MSCs to 
OBs and how this is affected by the immune system could ultimately allow directing 
osteogenic differentiation in order to replace bone once it is lost. This study aimed to 
investigate the interactions between immune cells and MSCs and the effect on osteogenic 
differentiation. Furthermore, to elucidate the mediators and pathways involved with a view 
to the possible identification of targets for the development of new therapeutic 
interventions. 
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3.2 Trilineage Differentiation of hMSC 
A fundamental property of MSCs is the ability to differentiate to cells of the mesenchymal 
lineage (Dominici et al, 2006). Human MSCs used were assessed for their differentiation 
potential towards the osteogenic, adipogenic and chondrogenic lineages in the presence of 
appropriate stimuli.  
 
For differentiation experiments 1x104 MSCs were plated in 24-well plates and left overnight 
to adhere. The following day media was replaced with either control or differentiation 
media as described in section 2.2.2. Trilineage differentiation of hMSCs is depicted in Figure 
3.1. In the presence of osteogenic differentiation media (Figure 3.1A&B), MSCs gave rise to 
OBs that stained positively for ALP, a marker for osteogenic differentiation, (Figure 3.1A) 
and formed mineralised nodules as visualized by Alizarin Red S staining (Figure 3.1B). MSC 
cultures kept in adipogenic differentiation media were stained with Oil Red O and showed 
differentiated adipocytes containing cytoplasmic lipid droplets (Figure 3.1C). Finally, a pellet 
of MSC cultured in chondrogenic differentiation media then fixed, paraffin embedded, 
sectioned and stained with Alcian Blue demonstrated focal areas of cartilage formation 
(Figure 3.1D). Thus, verifying that hMSC used in this study exhibit mesenchymal tri-lineage 
differentiation potential. 
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Figure 3.1 Trilineage differentiation potential of hMSCs. 
   
   
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Bone marrow derived MSC were plated at 1x104 cells per well of a 24-well plate and 
differentiation media added.  Osteogenic differentiation was assessed by ALP staining after 7 days 
(A) and by Alizarin Red staining for bone nodules after 21 days (B). Adipogenic differentiation was 
assessed after 21 days by Oil Red O staining for cytoplasmic lipid vesicles of adipocytes (C). For 
chondrogenic differentiation a pellet of MSC was kept in chondrogenic diffrentiation media for 21 
days, when pellets were fixed, paraffin embedded and sectioned and differentiation determined by 
staining of sections with Alcian blue for glycosaminoglycans produced by chondrocytes (D). 
 
A B 
C D 
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3.3 Peripheral Blood Mononuclear Cells Can Induce Osteogenic 
Differentiation of MSC 
To investigate the effect of peripheral blood mononuclear cells (PBMC) on the 
differentiation of MSCs to OBs, 1x104 hMSCs were co-cultured with PBMCs isolated from 
healthy donors in increasing ratios of PBMCs; 1:1 (104 PBMCs), 2:1 (2x104 PBMCs), 5:1 (5x104 
PBMCs) and 10:1 (105 PBMCs) for 7 days when co-cultures were assessed for OB 
differentiation. ALP activity was chosen as an early marker for the progression of MSC 
differentiation to OBs, which reaches a peak value at day 7 of differentiation. Although ALP 
expression is not the most specific marker for OBs since it is also expressed by other cell 
types, it is routinely used in the literature since ALP expression is increased during 
osteogenic differentiation and OBs produce much higher levels of ALP as compared to other 
cell types (Golub & Boesze-Battaglia, 2007). Additionally, the formation of bone nodules is 
the ultimate indication of the differentiation of fully functional OBs with the ability to 
synthesise matrix proteins and promote mineralisation. This was assessed after 21 days by 
staining the calcium deposits with Alizarin Red S.  
 
ALP staining revealed that in the presence of increasing ratios of PBMCs there was a dose 
dependent increase in MSC-ALP expression as compared to MSC alone cultures (Figure 
3.2A). To eliminate the possibility that PBMCs might also express ALP, PBMCs were cultured 
alone and after 7 days were shown not to stain for ALP indicating that ALP staining is 
attributable to the MSCs (data not shown). Quantification of ALP (Figure 3.2B) also showed 
that a dose dependent increase occurs with increasing ratios of added PBMCs both in the 
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presence and absence of osteogenic media suggesting that PBMCs might be sufficient to 
drive osteogenic differentiation without the exogenous addition of supplementary 
differentiation factors.   
 
Figure 3.2 PBMCs can increase osteogenic differentiation of MSCs 
 
     
     
 
 
 
 
 
 
Figure 3.2 1x104 MSC per well were plated in 24-well or 96-well plates either alone or with 
increasing ratios of PBMCs (1x104, 2x104, 5x104, 1x105) both in the presence and absence of 
osteogenic stimuli. After 7 days, cultures were stained for ALP (A) and ALP activity was also 
quantified (B).Graph represents combined data of three independent experiments performed in 
triplicate * P<0.05, ** P<0.01, *** P<0.001 one-way ANOVA with Dunnett’s post-test comparison to 
MSC alone. After 21 days, cultures were stained with Alizarin Red S to visualize bone nodules (C) 
bone nodule formation was quantified by eluting and spectrophotometrically quantifying the dye 
(D). Graph represents combined data of two independent experiments performed in triplicate. Data 
are represented as mean ± S.E.M. Pictures are representative of three independent experiments 
performed in duplicate. 
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To assess bone nodule formation, after 21 days cultures were stained with Alizarin Red S 
and the stain was also eluted and quantified (Figure 3.2C & D). In the presence of increasing 
ratios of PBMCs and osteogenic media there was an increase in bone nodule formation 
proving that PBMCs can enhance MSC-OB differentiation and that these OBs are able to 
synthesise and deposit extracellular matrix. However, although co-culture in control media 
with PBMCs caused an increase in ALP activity there was no increase in bone nodule 
formation (Figure 3.2C & D). It is possible that, although sufficient to cause an increase in 
ALP activity, PBMCs alone cannot drive differentiation to OBs with the ability to form and 
mineralise bone nodules without additional osteogenic factors. Subsequent experiments 
using higher ratios of PBMCs did not cause a further increase in ALP activity (data not 
shown), thus the 10:1 ratio was selected as optimal in promoting ALP activity and bone 
nodule formation of MSCs. This ratio was used in subsequent experiments. 
 
3.4 Monocytes are the Population Responsible for Increasing MSC-OB 
Differentiation 
To determine the specific cell type responsible for promoting MSC-OB differentiation, 
PBMCs were separated into discrete cells types. Following blood separation using 
Lympholyte® density gradient centrifugation as described in section 2.2.3, isolated PBMCs 
consist of primarily T cells (~70%), B cells (1-5%) and monocytes (~10%) with a lower 
representation of granulocytes and neutrophils. The latter, although they represent a large 
proportion of the cells in the peripheral blood, are mostly removed with density gradient 
centrifugation and also do not persist in cultures as they have a short half life. 
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3.4.1 Depletion and Enrichment of T cell, B cell and Monocyte Populations in PBMC 
Using magnetic separation based on cell surface antigens, T cells, B cells and monocytes 
were depleted from total PBMCs. The efficiency of the depletions was confirmed using flow 
cytometry of total and depleted populations where T cells were identified as CD3+ cells, B 
cells as CD19+ and monocytes as CD14+ (Figure 3.3A). Co–cultures of the PBMCs depleted of 
either T cells, B cells or monocytes were established with MSCs at a ratio of 10:1 in control 
or osteogenic media and monocultures of MSCs were included as control. Since the 
abundance of T cells, B cells and monocytes differs in PBMCs, depleting the different 
populations resulted in the removal of different amounts of cells. In order to add equal 
number of cells (1x105) and keep the 10:1 ratio constant, the depleted populations were 
recounted after depletion and prior to addition in MSC cultures. Depletion of monocytes 
gave a striking decrease in MSC ALP activity (Figure 3.3B) indicating that this was the 
population responsible for causing the increase in MSC-ALP activity. ALP levels were lower 
than basal expression in MSC alone cultures suggesting that increased numbers of T cells 
and B cells in the PBMC-M population could be inhibitory of ALP expression. Conversely, 
depletion of T cells and B cells resulted in an increase in ALP activity comparing to the effect 
of whole PBMCs. This increase could be justified by the fact that T and B cell depleted 
populations corrected for cell number will contain an increased proportion of monocytes, a 
further indication that monocytes are the inducers of ALP in MSCs.  
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Figure 3.3 Depletion of monocytes within PBMCs abrogates their osteogenic effect 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
Figure 3.3 PBMC populations were depleted of T cells, B cells and monocytes using Dynabeads® 
(Invitrogen Dynal) as described in section 2.2.3.1. Efficient depletion was validated by FACS where 
total or depleted populations were assessed for the presence of CD3, CD19 or CD14 positive cells 
(A). Total PBMCs or the PBMC-M, PBMC-T and B PBMC-B populations were cultured with MSC at 
10:1 ratio. After 7 days of culture in the presence or absence of osteogenic media, ALP quantification 
was performed (B). Graph represents combined data of three independent experiments performed 
in triplicates shown as means ± S.E.M. * P<0.05, *** P<0.001 one-way ANOVA with Bonferroni’s 
post-test comparison.  
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The contribution of monocytes in increasing MSC-ALP activity was further verified when 
enriched populations were added in MSC cultures. Populations enriched for T cells, B cells or 
monocytes were isolated as untouched populations meaning that the CD3, CD19 and CD14 
receptors on T cells, B cells and monocytes respectively, usually used in selection processes, 
were not engaged prior to addition to MSCs thus avoiding possible target cell activation. 
Enrichment efficiency was verified using flow cytometry and cell surface markers CD3, CD19 
and CD14 as previously. FACS plots in Figure 3.4A demonstrate that populations used 
comprised of at least 80% of the target cell type identified by CD3, CD19 or CD14 
expression. Enriched populations were added at a ratio of 10:1 to MSC cultures both in the 
presence and absence of osteogenic media.  
 
As depicted in Figure 3.4B, addition of the enriched T cell and B cell populations to MSC 
cultures did not have any effect on basal mesenchymal ALP activity as compared to the 
values of the MSC alone control. This indicated that T cells and B cells neither promote nor 
inhibit MSC differentiation at least in their resting state. In contrast, in the presence of 
monocyte-enriched populations there was a significant increase in MSC ALP activity (3-fold 
as compared to control); this effect was even greater than total PBMCs. This is consistent 
considering that within PBMC populations monocytes account for only 5-10% leading to the 
assumption that if they indeed can cause increase in ALP activity that should be in higher 
levels in enriched population rather than whole PBMCs. 
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  Figure 3.4 Enrichment of monocytes within PBMCs enhances their osteogenic effect 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Enriched populations of T cells, B cells and monocytes were isolated from PBMC using 
negative isolation kits from Dynal Invitrogen as described in section 2.2.3.1. The purity of isolated 
populations was validated by FACS (A). Total PBMCs or enriched populations were added to MSC 
cultures at a ratio of 10:1 in control or osteogenic media. After 7 days of culture ALP quantification 
was performed (B). Graph represents combined data of three independent experiments performed 
in triplicates shown as means ± S.E.M. *** P<0.001 one-way ANOVA with Dunnet’s post-test 
comparison to MSC alone. After 21 days cultures were stained for bone nodule formation with 
Alizarin Red S and dye eluted and quantified (C). Graph represents combined data of two 
independent experiments performed in triplicate and shown as means ± S.E.M.  
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In the presence of monocyte enriched populations, increased bone nodule formation was 
also observed in MSC cultures, as shown by the increased amount of Alizarin Red S stain 
quantified in MSC-monocyte co-cultures (Figure 3.4C). This increase was considerably more 
pronounced comparing with the effect of total PBMC populations. Increased bone nodule 
formation was verified in further MSC-monocytes co-cultures repeated using monocytes 
from at least three different donors, stained using Alizarin Red S stain and depicted in 
representative microphotographs (Figure 3.5). These marked differences in MSC-ALP 
activity and bone nodule formation in the presence of monocytes confirmed that 
monocytes are potent inducers of MSC-OB differentiation. 
 
Figure 3.5 Addition of monocytes increases bone nodule formation in MSC cultures 
 
 
 
 
 
 
Figure 3.5 1x104 MSC were plated in 24-well plate and left overnight to adhere. Culture media was 
then replaced to osteogenic media or osteogenic media and monocyte at a ratio of 10:1 (1x105). 
Cultures were kept for 21 days with media change every 3 days. Bone nodule formation was 
visualised using Alizarin Red staining. Pictures are representative of at least three experiments 
performed in duplicate using monocytes from different donors each time. 
       MSC alone                                                    10:1 Monocyte-MSC co-culture 
                                                                    In osteogenic media 
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3.4.2 The Increase in MSC ALP Activity in the Presence of PBMC or Monocytes is Due to 
Differentiation and not Proliferation 
It can be argued that the overall increase in ALP activity in MSC-PBMC or MSC-monocyte co-
cultures can be due to an increase in the cell number of MSCs rather than an increase in ALP 
expression. To examine whether the increase in ALP activity should be attributed to 
differentiation or proliferation, MSC proliferation in co-cultures with increasing ratios of 
PBMCs or monocytes was assessed.  
 
Figure 3.6 Co-cultures with PBMCs or monocytes do not influence MSC proliferation  
 
 
 
 
 
 
 
Figure 3.6 1x104 MSCs were plated in 96-well plates either alone or with increasing ratios (1:1, 2:1, 
5:1, 10:1) of PBMC (A) or monocytes (B) as previously. After 7 days, cultures were washed to remove 
the majority of PBMC or monocytes, detached using trypsin-EDTA and counted using 
haemocytometer. Viability assay, by trypan blue staining, was also performed at the same time of 
counting. Graphs represent combined data of three independent experiments performed in 
triplicate shown as means ± S.E.M. 
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Cell counts were performed using a haemocytometer as described in section 2.2.6. Mean 
values for each condition were plotted as number of cells x104/ml. As depicted in Figure 3.6, 
in the presence of osteogenic media there was an increase in cell number as compared to 
control media, which is expected as the first phase of osteogenic differentiation during week 
1 is the proliferative phase (Quarles et al, 1992). Co-culturing MSC with PBMCs (Figure 3.6A) 
or monocytes (Figure 3.6B) did not cause a further increase in the cell number of MSC as 
compared to MSC alone cultures, thus the increase in ALP activity can be attributed solely to 
differentiation and not proliferation. The co-culture with PBMC or monocytes or the fact 
that there was increasing number of cells with increasing ratios did not affected MSC 
viability as assessed by trypan blue while performing the cell count.  
 
3.4.3 M-CSF and GM-CSF Mφ Promote Osteoblast Differentiation 
In connection to the findings presented so far showing a role for monocytes in OB 
differentiation, a recent study by Chang and colleagues showed that Mφs are important 
regulators of bone tissue both in vivo and in vitro (Chang et al, 2008). More specifically, in 
vitro they showed that Mφs are important for efficient mineralisation of mature OBs. To 
investigate whether Mφs also influence OB differentiation from MSCs, Mφs/MSC co-
cultures were established as previously. Human monocytes can be differentiated in vitro 
into Mφs in the presence of GM-CSF or M-CSF (Burgess & Metcalf, 1980; Verreck et al, 
2006). Similarly to the effect seen in monocyte cultures, Mφs were able to enhance ALP 
activity of MSCs and irrespective of the differentiation signal, M-CSF and GM-CSF Mφs 
induced ALP activity equally (Figure 3.7). 
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 Figure 3.7 M-CSF and GM-CSF Mφs increase ALP activity of MSCs 
 
 
 
 
 
 
 
Figure 3.7 Monocyte-derived Mφ were differentiated with either 100ng/ml M-CSF or 100ng/ml GM-
CSF for 3-5 days.. Equal numbers (1x105) of the differentiated Mφ were added on top of 1x104 MSC 
in control or osteogenic media. ALP activity was quantified after 7 days. Graphs represent 
cumulative data of 5 independent experiments performed in triplicate and shown as means ± S.E.M. 
* P<0.05 one-way ANOVA with Dunnet’s post-test comparison to MSC alone.  
 
3.4.4 MSC Migrate Towards Monocytes 
The previous experiments identified that in co-culture monocytes can promote osteogenic 
differentiation of MSCs. However, osteogenic differentiation for bone repair in vivo requires 
the recruitment of MSCs which respond to chemoattractant signals and migrate. MSC have 
been shown to migrate to sites of injury and to have beneficial contributions in tissue repair 
in neuronal tissue after stroke (Chen et al, 2001), in the ischemic myocardium after 
myocardial infarction (Barbash et al, 2003; Kawada et al, 2004), in damage meniscus and 
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cartilage in the knee joint (Murphy et al, 2003), as well as following bone fractures which 
lead to MSC migration to the injured site and subsequent repair (Niedzwiedzki et al, 1993; 
Steadman et al, 2001). MSC migrate under the influence of chemotactic signals that are 
primarily produced by monocytes/Mφ which are themselves quickly recruited at sites of 
injury. Since monocytes can influence MSC differentiation it was interesting to investigate 
whether they may also have a role in inducing MSC migration.  
 
The role of monocytes on MSC migration was investigated using an in vitro transwell system 
as described in section 2.2.7, where MSCs migrate through an 8µm pore membrane from an 
upper chamber towards monocytes or serum containing media located in the lower 
chamber (see schematic in Figure 3.8A). The 8µm pore membrane transwell system was 
previously used to study migration of MSCs in response to chemoattractant gradients 
(Ponte et al, 2007; Ringe et al, 2007). Similarly to these studies, experiments were 
performed in serum free (SF) media, SF media alone represented migration baseline and 
20% serum containing media was used as a positive control for migration (Ponte et al, 2007; 
Ringe et al, 2007). As shown in representative microphotographs (Figure 3.8A) as well as by 
quantification of migrated cells (Figure 3.8B), monocytes caused migration of MSCs similar 
to that induced by the 20% serum containing positive control. These data indicated that in 
addition to promoting osteogenic differentiation of MSCs, monocytes can also induce 
migration of MSCs possibly through the production of soluble factors such as chemokines. It 
can be speculated that in vivo monocytes could be acting to recruit MSCs prior to exerting 
their enhancing effects on osteogenic differentiation.  
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Figure 3.8 MSCs migrate towards monocytes 
           
 
 
                            
 
 
 
 
 
 
 
 
Figure 3.8 1x104 MSC were seeded in 8.0 μM transwells suspended in the wells of a 24-well plate 
which contained either serum free media (to measure baseline migration), 20% serum containing 
media (serving as positive control) or 1x105 monocytes. After overnight incubation at 37°C, migrated 
cells found on the underside of the transwell membrane, were fixed and stained as described in 
section 2.2.7 and visualized under light microscope (A). Pictures are representative of three 
independent experiments performed in duplicate (20x magnification). Migration was quantified by 
counting migrated cells in nine random fields of view at 20x magnification and plotted as 
chemokinetic index (number of cells/field of view) (B). Graph is combined data of three independent 
experiments performed in duplicate shown as means ± S.E.M.  *** P<0.001 one-way ANOVA with 
Dunnett’s post-test comparison using the SF condition as control.  
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3.4.5 The Ability of Monocytes to Promote MSC Differentiation Depends on Cell Contact 
and Monocyte-Derived Soluble Factors. 
As shown above monocytes can stimulate MSC migration most probably through the 
production of soluble mediators such as various chemokines. Indeed MSCs are known to 
express receptors for a great variety of chemokines on their cell surface and have also been 
shown to migrate to various chemokines (Ponte et al, 2007; Ringe et al, 2007) (also Table 
1.2). The ability of monocytes to attract MSCs could be indicative of cell to cell interactions 
that could be required for monocyte to influence MSC differentiation. Alternatively, soluble 
factors that promote migration could also be responsible for the enhancement of MSC 
differentiation. Hence, a question stemming from the observation that monocytes can 
induce MSC differentiation is whether this is mediated by soluble factors or whether it may 
require direct cell contact between the MSCs and monocytes.  
 
Co-cultures of MSCs and monocytes were repeated using transwells whereby the two 
populations are separated by a semi-permeable membrane (0.4µM pore size) which allows 
soluble factors to permeate the entire well. The schematic in Figure 3.9A helps explain the 
experimental design. Firstly, MSCs were cultured either alone or in contact with 10:1 ratio of 
monocytes. Additionally, MSCs in the lower chamber were separated from monocytes in the 
upper chamber of the transwells or both MSCs and monocytes (10:1 ratio) were added to 
the upper chamber of the transwells. At day 7 the transwells were removed and MSC 
differentiation was assessed in the lower chamber by ALP expression. 
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Figure 3.9 Monocyte-induced ALP activity in MSCs requires cell contact and soluble factors 
 
 
 
 
 
    
 
    
 
 
 
 
 
 
 
Figure 3.9 Co-cultures of monocytes and MSCs were established at a ratio of 10:1, either in contact 
or separated through a 0.4μM semi permeable membrane, with the monocytes on the upper 
chamber and the MSC on the lower chamber. In the last condition both MSCs and monocytes were 
present in the transwell at the ratio of 10:1. MSC alone culture was also included as control. After 7 
days, ALP expression was assessed on the MSC cultures in the lower chamber of the wells either by 
staining (A) or quantification of activity (B). Pictures are representative of three independent 
experiments performed in duplicate. Graph is cumulative data of three independent experiments 
performed in duplicate. Error bars represent means ± S.E.M. * P< 0.05 ** P<0.01 one-way ANOVA 
with Dunnett’s post-test comparison. 
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Consistent with previous experiments, when MSCs and monocytes were in contact, an 
increase in ALP staining (Figure 3.9A) and activity (Figure 3.9B) was observed. Conversely, 
when the two populations were separated the effect was lost indicating that there is a 
requirement for cell contact between the two populations that leads to increased ALP 
activity and hence osteogenic differentiation of MSCs. Interestingly, when MSCs and 
monocytes were both present in the upper chamber of the transwells, the MSCs below 
showed an increase in ALP activity. This strongly suggests that cell contact results in the 
production of a soluble factor, or factors, that permeate the well and cause the 
differentiation of MSCs in the lower chamber. Cell contact might be the first step in a 
mechanism that involves multiple steps with the production of soluble factors that promote 
MSC differentiation. These findings suggest that both cell-contact and soluble factors are 
required for monocytes to drive MSC-OB differentiation. 
 
3.4.6 The Ability of Monocytes to Promote MSC-OB Differentiation is Mediated by Soluble 
Osteogenic Factor(s) that are Monocyte-Derived. 
Data from the transwell experiments suggested that both cell contact and soluble factors 
contribute to the ability of monocytes to increase MSC-OB differentiation. In order to 
investigate whether these soluble factors are produced by the monocytes, co-cultures of 
MSCs and fixed monocytes were established as described in section 2.2.5.2. Using cell 
fixation, the receptors present on the cell surface are retained and are able to interact but 
secretion of any new molecules is not possible. 
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Non-fixed monocytes induced osteogenesis as indicated by the increase in MSC-ALP activity 
both in control (green bars) and osteogenic media (red bars) (Figure 3.10). In contrast, fixed 
monocytes did not have any effect on ALP activity in either the control (green checked bars) 
or osteogenic media (red checked bars); i.e. ALP activity was the same as MSC alone 
cultures. This experiment shows that in the co-culture system cell contact alone is not 
enough but soluble factor(s) produced by monocytes are required to induce osteogenic 
differentiation of MSCs. 
 
Figure 3.10 Osteogenic soluble factor(s) are monocyte-derived 
 
 
 
 
 
 
 
Figure 3.10 Monocyte and MSC co-cultures were repeated with 1x105 fresh or fixed monocytes in a 
96-well plate with or without osteogenic media. Monocyte fixation was performed by 1 minute 
incubation in 2ml of 0.05% glutaraldehyde followed by a 1 minute incubation in 0.2M glycine. 
Monocytes were then washed twice using culture medium, counted and added onto MSC cultures. 
After 7 days ALP quantification was performed. Graph represents combined data of three 
independent experiments performed in triplicate shown as means ± S.E.M. ** P<0.01 one-way 
ANOVA with Dunnett’s post-test comparison. 
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3.4.7 Co-culture Supernatants can Induce ALP activity and Bone Nodule Formation. 
To confirm that the soluble factor(s) resulting from the interactions between MSCs and 
monocytes have osteogenic activity, 24h supernatants were obtained from 10:1 
monocyte/MSC co-cultures. The supernatants were filtered to eliminate cellular 
components and added on top of MSC cultures that were then assessed for ALP activity 
after 7 days or bone nodule formation after 21 days. In separate wells monocytes were 
added to MSC cultures to allow for a direct comparison of the osteogenic activity of the co-
culture supernatants versus the monocytes in contact. ALP quantification showed an 
increase in the MSC cultures treated with the 10:1 co-culture supernatant as compared to 
MSC alone (Figure 3.11A); although it should be noted that this increase was lower than 
that induced by the direct contact with monocytes. Similarly, the co-culture supernatants 
also had the ability to enhance the formation of mineralised bone nodules in the MSC 
cultures compared to MSC cultured just in osteogenic media (Figure 3.11B), but again this 
increase in bone nodule formation was lesser than that observed in the presence of 
monocytes in the MSC cultures.  
 
 
 
 
 
 
CHAPTER 3                                                            MONOCYTES PROMOTE OSTEOBLAST DIFFERENTIATION 
151 
 
Figure 3.11 Supernatants from 10:1 monocyte/MSC co-cultures can induce OB 
differentiation 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Supernatant from 10:1 monocyte/MSC co-cultures in control or osteogenic media was 
collected after 24h of incubation and added on top of MSC. In separate wells monocytes were added 
to and MSC monocultures were also included as control. After 7 days ALP activity was quantified (A). 
MSC cultures either alone, with the addition of monocytes or 10:1 co-culture supernatant in 
osteogenic media were also set up in 24-well plates and kept for 21 days when bone nodule 
formation was assessed with Alizarin Red staining (B). Graph represents cumulative data of three 
independent experiments performed in triplicate shown as means ± S.E.M. Pictures are 
representative of three independent experiments performed in duplicate. *** P<0.001 one-way 
ANOVA with Dunnett’s post-test comparison. 
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3.5 Proteomic Analysis of MSC/Monocyte Co-culture Supernatants. 
The identification of a soluble mediator with the ability to induce osteogenic differentiation 
has major potential as a therapeutic tool for the promotion of new bone formation. In an 
effort to identify the soluble factor(s) a proteomic approach was investigated with the 
assistance of Dr Robin Wait, at the Kennedy Institute of Rheumatology. 
 
3.5.1 Supernatant osteogenic activity declined with exposure to heat.  
To verify that the osteogenic factor(s) were in fact proteins, co-cultures of monocytes and 
MSC were set up at a 10:1 ratio as before but scaled up to include 1x106 monocytes:1x105 
MSC /ml of media in a 6 well plate or small petri dish. The cultures were left for 24h and 
then the supernatant was collected, filtered to remove any cells and separated into two 
aliquots. One aliquot was heated at 95°C on a dry heat block for 20min to denature its 
protein constituents, while the second aliquot was kept on ice.  The heated aliquot was then 
cooled to room temperature and supplemented with serum to 10% to replenish the serum 
proteins denatured with heat. Both heated and control 10:1 co-culture supernatants were 
then added on top of MSC cultures and after 7 days ALP activity levels assessed. In MSC 
cultures that received the control supernatant ALP activity was increased as expected 
(Figure 3.12). Conversely the osteogenic activity of the heated 10:1 co-culture supernatant 
declined suggesting that the factor(s) responsible for the osteoinductive properties is 
proteinaceous in nature. 
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Figure 3.12 Osteogenic activity of 10:1 co-culture supernatant is attenuated by heat  
 
 
 
 
 
 
Figure 3.12 Supernatant from 10:1 monocyte to MSC co-cultures in control or osteogenic media was 
collected after 24h of incubation and separated into two aliquots. One aliquot was heated at 95°C on 
a dry heat block for 20min to denature its protein constituents while the second aliquot was kept on 
ice.  The heated aliquot was cooled to room temperature, supplemented with serum to 10% and 
then both s/n aliquots- heated and not heated- were added separately on top of MSC cultures in 96-
well plates. Wells where monocytes were added as positive control and MSC monocultures for 
baseline differentiation were also included. After 7 days ALP activity was quantified. Graph 
represents cumulative data of three independent experiments performed in triplicate and shown as 
means ± S.E.M. * P<0.05 one-way ANOVA with Bonferroni’s post-test comparison. 
 
3.5.2 Osteogenic Activity was Lost Following Fractionation 
Supernatants from monocyte and MSC co-cultures contained the osteogenic factor(s) which 
were of proteinaceous nature. In an attempt to isolate and identify this factor(s), a 
chromatographic purification technique was utilised. This approach involves the separation 
of the supernatant protein constituents according to their size by a process of gel filtration 
chromatography. The aim of this approach was to investigate if the osteogenic activity of 
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the 10:1 co-culture supernatant can be attributed to a specific fraction of proteins that can 
be then further analysed using mass spectrometry.  
 
The 10:1 co-culture supernatant was applied to a gel filtration column made of porous gel 
beads of highly cross-linked polymers that effectively act as a molecular sieve. This process 
results in the separation of the protein constituents in fractions of decreasing size. The 
principle of the gel filtration chromatography is detailed in section 2.2.9. The gel filtration 
column was connected to an FPLC machine with a UV spectrophotometer that detects the 
proteins as they exit the column and registers readings on a trace plotted against the 
volume of the flowthrough. The flow through was collected in 1ml aliquots and was divided 
into four arbitrary fractions using the trace (Figure 3.13A). Aliquots corresponding to each 
fraction were pooled and concentrated. A small aliquot from each concentrated fraction as 
well as an aliquot of the unfractionated supernatant were run on sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS PAGE) and the constituent proteins were visualized 
using silver staining (Figure 3.13B). The unfractionated supernatant consisted of many 
different proteins of varying molecular sizes. The strongest band for the unfractionated 
supernatant and all fractions was at the position where albumin is usually found when 
performing spectrophotometric analysis. This is not surprising as albumin represents the 
most abundant serum protein. The different fractions had some differences in the bands 
present but overall the separation according to size was not very efficient since there wasn’t 
a decrease in the size of the proteins from fractions 1-4.  
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Figure 3.13 Osteogenic activity of 10:1 co-culture supernatant is lost following fractionation 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 10:1 co-culture supernatant was run through a XK 16/100 column, packed with 750ml 
Sephacryl TM S200 HR (GE Healthcare, UK) using the Amersham Akta fast protein liquid 
chromatography (FPLC) system as described in section 2.2.9. The flow through was collected into 1 
ml aliquots. Using the spectorphotometric wave (A) the gel filtration flow through was divided into 4 
arbitrary fractions and concentrated. A small aliquot from each concentrated fraction as well as the 
unfractionated supernatant, were analysed on an SDS PAGE gel and protein visualized using silver 
staining as described in section 2.2.10 (B). The concentrated fractions were reconstituted with cell 
culture media and added to MSC cultures to assess ALP activity after 7 days (C). Pictures are 
representative of three separate experiments each one using 10:1 co-culture supernatant from 
different donor monocytes. Graph is cumulative data from three independent experiments 
performed in triplicate shown as means ± S.E.M. 
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The osteogenic activity of the four fractions was assessed after 7 days of culture with MSCs. 
ALP quantification showed that although the unfractionated co-culture supernatant caused 
an increase in ALP activity as shown previously, none of the fractions had a similar effect. 
This suggested that the osteogenic factor(s) were either retained on the gel filtration 
column or removed in the process of concentrating if their size is smaller than the 
concentration column cut-off (100kDa). Alternatively the factor(s) could have been 
denatured by the process of gel filtration and the various manipulations.  
 
In summary, the attempt to isolate and identify the osteogenic factor(s) contained in the 
10:1 co-culture supernatant by chromatographic purification techniques led to loss of 
activity of the supernatant fractions. For this reason further spectrophotometric analysis for 
the identification of individual proteins in the fractions was not undertaken. 
 
3.6 Investigation of 10:1 Monocyte/MSC co-culture supernatants using ELISAs 
It was previously shown that supernatants derived from co-culturing monocytes and MSCs 
had the ability to induce ALP activity and the formation of mineralised bone nodules in MSC 
cultures. The osteogenic factor(s) was shown to be a protein but as described in the 
previous section chromatographic purification techniques employed failed to identify the 
osteogenic factor(s) in these supernatants. A more targeted approach was to investigate co-
culture supernatants for the presence of soluble factors known to be involved in osteogenic 
differentiation such as the BMPs and TGF-β using enzyme-linked immunosorbent assays 
(ELISAs).  
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3.6.1 ELISAs of TGF-β super family members revealed that co-culture supernatants 
contained very low concentrations of BMPs 2, 4 and 7  
Key initiators of differentiation along the osteogenic lineage are the BMPs, members of the 
TGF superfamily, which have been studied extensively in relation to osteogenic 
differentiation of MSCs (Bandyopadhyay et al, 2006; Urist, 1965; Urist & Strates, 1971; 
Yamaguchi et al, 2000). BMPs 2, 4 and 7 are the most commonly studied pro-osteogenic 
BMPs in vitro and in vivo. TGFβ1 is also essential for osteogenic commitment of bone 
marrow cells (Devescovi et al, 2008; Harris et al, 1994; Joyce et al, 1990b; Marcelli et al, 
1990). To determine if these BMPs and TGFβ1 were the mediators implicated in driving OB 
differentiation by monocytes, the levels in the supernatants from MSCs and MSC/monocyte 
co-cultures were measured using enzyme-linked immunosorbent assay (ELISAs).  
 
Table 3.1 BMP and TGFβ1 concentration in MSC and 10:1 monocyte/MSC culture supernatants 
Growth Factor MSC alone 10:1 monocytes:MSC 
BMP2 14.965 8.515 
BMP4 2.555 2.28 
BMP7 <5 <5 
TGFβ1 1049.26 957.235 
Table 3.1 Supernatant from MSC alone cultures and 10:1 monocyte/MSC co-culture were tested for 
the presence of BMP2, BMP4, BMP7 and TGFβ1 using individual, commercially available enzyme-
linked immunosorbent assays (all from R&D systems, Abington, UK) according to manufacturer’s 
instructions. Assay sensitivity was defined as the lowest standard for each assays’ standard curve 
and expressed as ‘less than’ value at, or beyond the limit of sensitivity.  
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Table 3.1 shows that there were no differences in the levels of BMPs 2, 4 and 7 or TGFβ1 
between the culture supernatants from either MSC alone or 10:1 monocytes/MSC co-
cultures. All BMP2, BMP4 and BMP7 were detected the very low levels. The concentration 
of BMP7 was lower than the least concentrated standard and therefore out of the assay 
limit. TGFβ1 was detected at higher levels but there was again no difference when MSCs 
were cultured in the presence of monocytes. 
 
3.6.2 Cytokines and chemokines are upregulated in Monocyte-MSC co-culture 
supernatants 
ELISAs for BMP and TGFβ1 showed that these were not present in higher concentrations in 
the osteogenic 10:1 monocyte/MSC supernatants; hence they are not the mediators of the 
increased MSC OB differentiation. The investigation into the identity of the osteogenic 
mediators turned to other possible factors of soluble nature. All evidence so far suggest that 
the mediator(s) with osteogenic activity contained in the co-culture supernatants are 
soluble proteins that are produced by monocytes following MSC/monocyte interactions and 
are probably small in size and act in small concentrations. It can be hypothesised that such 
mediators could be cytokines and chemokines, immune mediators that are abundantly 
produced by monocyte/Mφs following activation or cellular interactions. A number of 
studies have shown upregulation or downregulation of cytokine production by 
monocytes/Mφ when co-cultured with MSC; for example production of IL-10 and IL-6 was 
increased whereas production of IL-12 and TNFα was inhibited (Beyth et al, 2005; Groh et al, 
2005; Kim & Hematti, 2009; Nemeth et al, 2009). Using a commercially available 30-plex 
immunoassay and the Luminex xMAP® system, the protein levels of 30 different cytokines, 
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chemokines and growth factors were measured in MSC alone, monocyte alone or 10:1 
monocyte/MSC culture supernatants.  
 
The results of this assay are summarized in Table 3.2. Of the 30 molecules included in this 
assay nine (IL-2, IL-5, IL-13, IL-15, IL-17, VEGF, Eotaxin, EGF, FGF2) were at undetectable 
levels (lower than the assay sensitivity) and were thus excluded from Table 3.2. A number of 
cytokines were found to have increased levels in the co-culture supernatant as compared to 
MSC or monocyte alone supernatants. Pro-inflammatory cytokines IL-1β, IL-6, TNFα and 
IFNα were all upregulated in co-culture supernatants. More specifically the amount of IL-6 in 
the co-culture supernatant was higher than the highest standard of the assay. The IL-1 
receptor agonist (IL-1RA) and IL-2 receptor (IL-2R) were also detected at higher levels in the 
10:1 co-culture supernatants as compared to MSC or monocyte alone supernatants. In 
agreement with previous reports (Beyth et al, 2005; Groh et al, 2005; Kim & Hematti, 2009; 
Nemeth et al, 2009), the anti-inflammatory cytokine IL-10 was also found to be upregulated 
in the monocyte/MSC co-culture supernatant. Most notably the majority of chemokines 
included in the assay, MIP-1α, MIP-1β, IP-10, MIG, RANTES, MCP-1, were found to be 
upregulated as compared to MSC or monocyte alone supernatants (Table 3.2). Finally, 
granulocyte colony stimulating factor (G-CSF) and hepatocyte-stimulating factor (HSF) were 
found at higher levels in co-culture supernatants.  
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Table 3.2 Cytokines and chemokines elevated in 10:1 monocyte/MSC co-culture 
supernatants. 
Molecule  MSC alone monocytes alone 10:1 monocytes:MSC 
IL-1β <15 <15 323±44 
IL-1RA 187±57 3503±756 8246±1029 
IL-2R 74±1 132±54 683±87 
IL-4 28±1 31±1 64±7 
IL-6 707±152 <3 >6900 
IL-7 <10 <10 71±17 
IL-8 200±64 12153±7327 126119±5263 
IL-10 <1 <1 115.64±22.2 
IL-12 45±1 79±7 1270.93±688.65 
TNFα 14±0 15±1 46±3 
IFNα <15 <15 111±18 
IFNγ 37±1 41±1 54±4 
GM-CSF 117±1 118±2 139±3 
MIP-1α <10 <10 9282±937 
MIP-1β 30±0 112±32 12400±5847 
IP-10 <5 <5 2514±307 
MIG <4 <4 24±0 
RANTES 19±1 19±1 280±47 
MCP1 270±23 848±142 39990±7994 
G-CSF 50±1 67±0 2288±353 
HGF <5 <5 103±45 
 
Table 3.2 Supernatant or standard (50µl) was added to wells of a 96-well micro plate in duplicate. 
Polystere microspheres pre-coated with antibodies specific to the molecules being tested were then 
added and incubated for 2 hours. After washing, a solution containing a mixture of biotinylated, 
analyte-specific antibodies was added and incubated for a further 1 hour. After washing, streptavidin 
conjugated to R-Phycoerythrin was added and incubated for a further 30 minutes. After repeated 
washing the plate was read using a Luminex 100TM instrument. This system permits beads to be read 
individually and concentration values are generated using the Luminex software. All values represent 
mean concentration (pg/ml) ± SD. Assay limits were defined by the standard curve and expressed as 
‘less than’ or ‘more than’ value where the limit of sensitivity was reached. The limit of sensitivity 
varied between factors tested.   
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Since the 30-plex immunoassay was performed only on the supernatants from one 
experiment, further ELISAs for selected molecules that were shown to be upregulated in the 
10:1 co-culture supernatants were perform to verify the findings. The levels of IL-1β, IL-6, IL-
6R, IL-8, IL-10 and TNFα were measured in supernatants from three different experiments 
and are depicted in Figure 3.14. 
 
Figure 3.14 IL-1β, IL-10, TNFα, IL-6 and IL-8 levels are increased in 10:1 co-culture 
supernatants  
 
 
 
 
Figure 3.14 The levels of IL-1β, IL-10, TNFα, IL-6 and IL-8 were measured in MSC alone, monocyte 
alone or 10:1 co-culture supernatants using Luminex technology on a Luminex 100TM instrument 
(Luminex Corp, Austin Tx) as described in section 2.2.11.1. (A) Concentration of IL-1β, IL-10, TNFα 
and IL-6Rs at pg/ml (B) Concentration of IL-6 and IL-8 which were detected at higher levels at ng/ml. 
Graphs represent cumulative data of three independent experiments performed in triplicate and 
shown as mean ± S.E.M.  
 
These further assays confirmed the results of the 30-plex immunoassay; all cytokines were 
found to be upregulated in the 10:1 co-culture supernatants (Figure 3.14). IL-1β and IL-10 
were detected in monocyte alone supernatants but their levels were increased in the 10:1 
co-culture supernatnants (Figure 3.14A). MSC or monocytes cultured alone did not produce 
any detectable TNFα but in 10:1 monocyte/MSC co-cultures TNFα levels were increased 
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(Figure 3.14A). MSC alone cultures produced a high amount of IL-6 but these levels were 
even higher in the co-cultures (Figure 3.14B). Finally, IL-8 was present at high concentration 
in 10:1 co-culture supernatant but it was similar to levels produced in monocyte alone 
culture (Figure 3.14B).  
 
3.6.3 Exogenous addition of recombinant proteins and antibody neutralisation of various 
cytokines elevated in Monocyte/MSC co-cultures.  
As shown above in the co-cultures of monocytes and MSC a number of cytokines were up-
regulated when compared to the levels in monocyte or MSC monocultures. The increased 
levels of these molecules could indicate that they are the possible mediators of the 
osteogenic activity of the 10:1 co-culture supernatant. To investigate their involvement, 
recombinant proteins were exogenously added to MSC alone cultures to assess their effect 
on ALP activity. Additionally, neutralising antibodies where used to inhibit these cytokines in 
the monocyte/MSC 10:1 co-cultures and thus decipher whether neutralising these would 
also lead to the inhibition of the monocyte-induced ALP activity. Table 3.3 summarises the 
results of the addition of recombinant proteins as well as their respective neutralising 
antibodies.  
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Table 3.3 Effect of recombinant proteins and antibody neutralisation in monocyte/MSC co-
cultures 
Cytokine Addition of 
recombinant 
cytokines 
Neutralisation of 
endogenous 
cytokines 
Known Effects on Osteogenic 
Differentiation 
Inflammatory Cytokines  
IL-1β ↑ no effect ↑ALP activity ↑mineralisation 
↓Runx2, collagen I expression  
IL-6 no effect no effect ↑ OB differentiation in 
combination with sIL-6R 
IL-8 no effect n/d --- 
TNFα ↓ no effect ↓OB differentiation, collagen I 
synthesis and mineralisation 
↑apoptosis 
IL10 and IL10 family members  
IL-10 no effect no effect ↓ALP, collagen I, osteocalcin 
and mineralisation 
IL-19 no effect n/d --- 
IL-20 no effect n/d --- 
IL-22 no effect no effect --- 
IL-28 no effect no effect --- 
IL-29 no effect no effect --- 
Interferons 
IFNα ↓ no effect ↓Proliferation and ALP 
IFNβ ↓ no effect --- 
IFNγ ↓ no effect ↓Proliferation and OB 
differentiation 
 
Table 3.3 Cultures of MSC were treated with recombinant proteins for IL-1β, IL-6, TNFα and IL-10 in 
dose response (0.1, 1, 10 and 100 ng/ml) or with a single dose (10ng/ml) of IL-22, IL-28, IL-29, IL-19, 
IL-20 and IL-25 in control or osteogenic media. Co-cultures of monocytes and MSCs at a ratio of 10:1 
were supplemented with inhibitory antibodies against IL-1β, IL-6, TNFα, IL-10, IL-22, IL-28, IL-29, 
IFNα, IFNβ and IFNγ at a concentration of 10μg/ml. ALP quantification was performed after 7 days of 
culture. Table depicts the effect of recombinant protein addition or antibody inhibition on MSC 
osteogenic differentiation. ↑ : increase in ALP activity compared to MSC alone culture, ↓ : decrease 
in ALP activity as compared to MSC alone culture, n/d: not investigated   
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MSCs were treated in dose response (0.1, 1, 10 and 100 ng/ml) of IL-1β, IL-6, TNFα, IL-8 and 
IL-10 or with a single dose (10ng/ml) of IL-10 family cytokines IL-19, IL-20, IL-22, IL-28 or IL-
29 and IFNs α, β and γ in control or osteogenic media to assess their direct effect on 
osteogenic differentiation. Additionally, co-cultures of monocytes and MSCs were 
supplemented with inhibitory antibodies against IL-1β, IL-6, TNFα, IL-10, IL-22, IL-28, IL-29, 
IFNα, IFNβ and IFNγ at a concentration of 10μg/ml. In agreement with previous reports 
(Ding et al, 2009), addition of recombinant IL-1β induced levels of ALP in MSCs indicating a 
possible role for this cytokine in mediating the monocyte effect on MSCs. However, 
neutralisation of IL-1β in monocyte/MSC co-cultures did not inhibit the ability of monocytes 
to induce ALP activity in MSC thus invalidating a role for IL-1β. Addition of recombinant 
TNFα inhibited ALP activity in MSC which is in agreement with literature (Abbas et al, 2003; 
Gilbert et al, 2005), but inhibitory antibodies against TNFα did not alter the ability of 
monocytes to induce ALP in co-cultures with MSCs. Finally, IFNs α, β and γ had an inhibitory 
effect on MSC ALP activity but their neutralisation in monocyte/MSC co-cultures did not 
affect MSC ALP activity levels. None of the other recombinant molecules or inhibitory 
antibodies had an effect on MSC cultures or co-cultures respectively. Overall, in spite 
identifying a number of soluble factors upregulated in monocyte/MSC co-cultures, the 
ostegenic activity could not be attributed to any of those tested. 
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3.7 Monocyte and MSC co-culture supernatants can induce signaling in MSC 
So far it was shown that supernatants from co-cultures of monocytes and MSCs have the 
ability to induce ALP activity (Figure 3.11A) and bone nodule formation (Figure 3.11B), 
therefore concluding that these supernatants have osteogenic activity. In an effort to 
identify the soluble mediator(s) with osteogenic activity a proteomic approach and ELISA 
analysis were attempted. A number of cytokines were found to be upregulated in 
monocyte/MSC co-cultures and then exogenously added or neutralised in MSC cultures or 
co-cultures with monocytes. Unfortunately both approaches did not result in uncovering the 
identity of the osteogenic mediator(s) involved in our system. Thus further investigations 
are required. Investigation of MSC signalling as a way of possibly delineating the osteogenic 
effects of the 10:1 supernatant was pursued. Co-culture supernatants from 10:1 
monocyte/MSC cultures, shown previously to have osteogenic activity, were used to treat 
MSC in a timecourse and then cellular lysates were analysed for the activation of various 
signalling pathways, more specifically NFκB, MAPKs p38, JNKs and ERKs and STAT3. 
 
As depicted in Figure 3.15 supernatant from 10:1 monocyte/MSC co-cultures can induce 
signaling in MSCs. All signaling pathways tested were activated in a timecourse of MSC 
treatment with 10:1 co-culture supernatant. STAT3, JNK and p38 phosphorylation as well as 
IκBa degradation, that indicates activation of NFκB pathway, were induced with a maximum 
at 30min. ERK phosphorylation was also induced but to a lesser extend because MSCs 
already expressed constitutive levels of pERKs. Since all pathways tested were activated in 
MSCs treated with co-culture supernatant a specific response to the osteogenic activity of 
the co-culture supernatant could not be correlated.  
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Figure 3.15 10:1 monocyte/MSC co-culture supernatant induces signalling in MSCs 
 
     
     
     
    
    
     
 
Figure 3.15 Supernatants from 10:1 monocyte to MSC co-cultures were collected after 24h of 
incubation and used to treat 2x105 MSC for 5, 10, 20, 30 and 60 minutes. Treated MSC as well as 
untreated control were subsequently lysed and 10μg of protein per condition was subjected to 
Western Blotting analysis for the detection of specific proteins using anti-human antibodies for 
phospho-STAT3 (Tyr 705), total STAT3, IκBα and phosphorylated forms of MAPKs JNKs, p38 and 
ERKs. Levels of β-tubulin determined using anti-β-tubulin antibody were used as loading control. 
Blots are representative of three independent experiments.   
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The activation of all the various pathways is not surprising considering the number of 
molecules that are present in the co-culture supernatant that is probably even greater than 
the ones identified using ELISAs. For example, the presence of IL-6 and IL-10 could be 
responsible for the activation STAT3 signalling and TNFα for the activation of the NFκB 
pathway. It is also known that the MAPKs are activated by many cytokines, growth factors 
and chemokines. 
 
It was shown previously that the osteogenic factor are monocyte-derived, since in co-
cultures of MSC with fixed monocytes, the latter lose the ability to induce MSC ALP activity 
(Figure 3.10). Co-culture supernatants from these experiments were used to treat MSCs and 
determine the activation of the same signalling pathways. As depicted in Figure 3.16, the 
ability of 10:1 monocyte/MSC co-culture supernatant to induce signalling was validated. 
Interestingly, there was a difference when MSC were treated with 10:1 supernatant where 
the MSC or alternatively the monocytes had been fixed. While the former retained the 
ability to induce phosphorylation of STAT3, MAPKs as well as IκBa degradation, co-culture 
supernatant from fixed monocytes failed to induce activation of any of the pathways tested. 
This indicated that activation of these pathways in MSCs sytem is depended on monocyte-
derived factors. 
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Figure 3.16 Supernatants from co-cultures with fixed monocytes fail to induce signaling in 
MSCs 
 
    
    
    
    
    
   
    
Figure 3.16 Supernatants from 10:1 monocyte/MSC co-cultures or from 10:1 monocyte/MSC co-
cultures where the MSC or monocytes were fixed prior to culturing were collected after 24h of 
incubation in control (CM) or osteogenic media (OM) and used to treat 2x105 MSC for 30 minutes. 
Treated MSC as well as untreated controls, in control and osteogenic media, were subsequently 
lysed and 10μg of protein per condition was subjected to Western Blotting analysis for the detection 
of specific proteins using anti-human antibodies for phospho-STAT3 (Tyr 705), total STAT3, IκBα and 
phosphorylated forms of MAPKs JNKs, p38 and ERKs. Levels of β-tubulin determined using anti-β-
tubulin antibody were used as loading control. Blots are representative of three independent 
experiments. 
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Since in the previous experiments it was found that 10:1 supernatant could activate all 
signalling pathways tested in MSCs, the effect of 10:1 supernatant was compared to MSC 
alone and monocyte alone culture supernatants since the latter two do not exhibit 
osteogenic activity. Figure 3.17 shows that STAT3 and p38 MAPK phosphorylation as well as 
IκBa degradation were only detected in the MSCs treated with 10:1 co-culture supernatants 
and not with the MSC or monocyte alone supernatants. Conversely, JNK and ERK MAPK 
phophorylation was also induced by the monocyte alone supernatant as well the 10:1 co-
culture supernatant. Since the monocyte alone supernatant cannot induce ALP acivity this 
indicates that JNK and ERK signaling cannot be correlated with the osteogenic activity of the 
10:1 co-culture supernatant. Even though these studies provided some evidence of the 
regulation of MSC signalling by monocyte-derived factors it was not possible to attribute the 
monocyte osteogenic effects to a single pathway. 
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Figure 3.17 STAT3, NFκB and p38 MAPK pathways are specifically induced by co-culture 
supernatant 
 
     
     
    
    
     
     
     
Figure 3.17 Supernatants either from MSC alone cultures, monocyte alone cultures or 10:1 
monocyte- MSC co-cultures in control (CM) or osteogenic media (OM) were collected after 24h of 
incubation and used to treat 2x105 MSC for 30 minutes. Treated MSC as well as untreated controls, 
in control or osteogenic media, were subsequently lysed and 10μg of protein per condition was 
subjected to Western Blotting analysis for the detection of specific proteins using anti-human 
antibodies for phospho-STAT3 (Tyr 705), total STAT3, IκBα and phosphorylated forms of MAPKs 
JNKs, p38 and ERKs. Levels of β-tubulin were used as loading control. Blots are representative of 
three independent experiments. 
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3.8 Discussion 
For about the last decade it has become quite prominent that there exist strong interactions 
between the immune and skeletal systems (Arron & Choi, 2000; Lorenzo et al, 2008). This 
was supported by the continuous accumulation of strong evidence for the direct regulation 
of bone cells’ differentiation and function by immune cells and immune mediators, with the 
most important finding being the identification of RANKL as the key differentiation signal for 
osteoclastogenesis (Anderson et al, 1997; Lacey et al, 1998; Wong et al, 1997; Yasuda et al, 
1998b). Indeed the majority of investigations in the field of osteoimmunology have since 
focused on the regulation of OCs due to the direct implications with increased bone loss in 
inflammatory disease (Goldring & Gravallese, 2000; Gough et al, 1998; O'Gradaigh & 
Compston, 2004). However, OC and OB functions are closely coupled and increased OC 
bone resorption should lead to increased OB bone formation (Datta et al, 2008; Hartmann, 
2009; Itoh et al, 2002; Rodan & Fleisch, 1996; Wronski et al, 1991). The fact that this is not 
the case in diseases such as RA where excessive resorption is not met by equivalent bone 
formation, leads to the assumption that OB differentiation and function could be directly 
influenced by the immune system. This study aimed to elucidate these interactions. 
 
This chapter started with the initial finding that PBMCs could promote the differentiation of 
MSCs to mature OBs with the ability to express increased levels of ALP (Figure 3.2A & B) and 
enhanced mineralisation in vitro (Figure 3.2C & D). The increase in ALP activity and bone 
nodule formation in the presence of PBMCs was not due to MSC proliferation because co-
culture with PBMCs did not increase the number of MSC compared with MSCs cultured 
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alone (Figure 3.6A). The idea that immune and bone cells regulate each other is not new. 
Stromal cells, including MSC and OBs, are important for the maintenance of the niche where 
haematopoetic progenitors reside and they are also critical regulators of haematopoeisis 
(Calvi et al, 2003; Dazzi et al, 2006). MSCs also have strong immunomodulatory abilities 
manifested in the induction of division arrest anergy in T cells thus inhibiting their 
proliferation (Glennie et al, 2005). Conversely, Haematopoietic Stem Cells (HSCs), the 
progenitors of all haematopoietic cells, themselves have been shown to increase MSC-OB 
differentiation thus regulating their own niche (Jung et al, 2008). In this study it was found 
that more mature haematopoietic cells, such as the mononuclear cells present in peripheral 
blood, have the ability to regulate OB differentiation. 
 
Although an increase in ALP activity was also observed in the absence of osteogenic media, 
the formation of bone nodules still required the osteogenic stimulus (Figure 3.2C & D). This 
suggested that the signal provided by the PBMCs can induce OB differentiation and 
upregulation of ALP, but that ultimately the formation of bone nodules requires further 
signals. It is also known that primary OBs in culture lose their ALP activity with passaging and 
require low doses of ascorbic acid in the media for maintenance, and high doses to allow for 
bone nodule formation. The requirement for extra stimuli is not unreasonable if considered 
in the context of the in vivo setting. It would not be physiologically favourable for OB 
differentiation and bone formation to occur whenever an MSC or an OB precursor 
encountered a mononuclear cell. In turn, regulation of MSC-OB differentiation by PBMCs in 
an in vivo setting will surely depend on many other factors present in the immediate 
environment that will amplify the PBMC signals and direct OB differentiation according to 
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local requirements. For example, the actions of bone resorbing OCs release osteogenic 
growth factors such as BMPs and TGFβ that are trapped in the bone matrix (Dallas et al, 
2002; Guise & Chirgwin, 2003; Oreffo et al, 1989). Also the inflammatory setting mediated 
by inflammatory immune cells and cytokines in the early stages of bone fracture repair 
seems to be favourable for increased MSC recruitment and differentiation contributing to 
bone repair (Glass et al, 2011; Xie et al, 2008). This represents a physiological checkpoint 
that ensures appropriate spatial and temporal responses for the formation of new tissue. 
 
Due to an abundance of data illustrating the close regulation of OC differentiation and 
activation by T cells (O'Gradaigh & Compston, 2004; Weitzmann & Pacifici, 2005), the latter 
seemed as good candidates to also have a role in regulating OB differentiation from their 
mesenchymal progenitors. It is known that activated T cells can promote OC formation and 
function (Horwood et al, 1999), whereas resting T cells have been shown to inhibit these 
processes (Shinoda et al, 2003). Additionally, it was recently shown that T cells are critical 
for the preservation of bone homeostasis and attainment of peak bone mass in vivo (Li et al, 
2007b). A limited number of studies have suggested a possible role for activated T cells in 
promoting OB differentiation and mineralization (Rifas, 2006; Rifas et al, 2003) but this role 
has not been definitively proven by further studies. Work by Tiana Corbachev, an MSc 
student in Dr. Nikki Horwood’s lab, showed that resting T cells did not influence MSC 
osteogenic differentiation but, contradictory to the previous studies, they were inhibitory if 
activated (unpublished data).  
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Surprisingly, further dissection of the original finding that PBMCs could promote MSC-OB 
differentiation illustrated that among the different immune cell populations present in the 
peripheral blood, monocytes, and not T cells, were the inducers of osteogenic 
differentiation (Figure 3.3. &  3.4). Whilst the addition of total PBMC populations caused an 
increase in MSC-ALP activity, this effect was lost when monocytes were depleted (Figure 
3.3). In turn, in the presence of purified monocyte populations there was a strong increase 
in ALP activity and bone nodule formation indicating that monocytes were providing 
differentiation signals (Figure 3.4 & 3.5). Subsequently, it was shown that M-CSF or GM-CSF 
Mφs could also enhance ALP activity in co-cultures with MSCs similarly to monocytes (Figure 
3.7). These findings were particularly interesting since at the time of this study a role for 
Mφs in bone homeostasis and turnover was suggested by Chang and colleagues (Chang et 
al, 2008). They were able to demonstrate a distinct resident Mφ population intercalated 
through murine and human bone tissues; these Mφs were shown to be in contact with bone 
lining OBs on bone surfaces and furthermore, depleting them in vivo resulted in loss of the 
OBs on bone remodelling sites. The investigators went further to show that Mφs were co-
isolated with calvarial OBs and were required for efficient mineralisation in in vitro co-
cultures. Even though this work proves a role for Mφs in bone homeostasis and thus 
supports our findings, researchers did not address or speculate about the influence of Mφs 
on the differentiation of OBs from their mesenchymal progenitors. The findings presented in 
this chapter show that monocytes and Mφs not only increase mineralization of mature OBs 
but also promote their differentiation from MSCs.  
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Interactions between MSC and monocytes have been previously reported with regards to 
MSC’s immunomodulatory abilities. Interestingly, Groh et al. have demonstrated that in 
order for MSCs to exert their immunosuppressive effect on T cells the presence of 
monocytes is also needed (Groh et al, 2005). The requirement for monocytes was also 
validated by Simon Jones (unpublished observation, PhD thesis) who showed that 
supernatants from co-cultures of stromal cells and CD3+ purified lymphocytes had poor 
inhibitory effect on PBMC proliferation assays. Only supernatants from cultures in which 
purified monocytes had been added induced anti-proliferative effects, illustrating that 
monocytes were required and that both cell-cell contact and soluble factors are mediating 
the ability of stromal cells to immunomodulate T cells. Similarly to this experiment, here it 
was also shown that the interactions between MSC and monocytes that lead to increased 
OB differentiation require both cell contact and soluble factors (Figure 3.9) and that these 
soluble factors are monocyte-derived (Figure 3.10). The same requirements were also 
identified by Jung and colleagues who showed that HSCs could promote MSC-OB 
differentiation (Jung et al, 2008).  
 
Identifying the monocyte-derived soluble factor(s) with osteogenic ability offers incredible 
potential for use as a therapeutic agent in regenerative medicine where it could be used to 
induce directed bone formation. Hence the investigation focused on uncovering the nature 
and identity of the soluble factor(s) produced after interactions between MSC and 
monocyte that are responsible for increasing ALP activity and bone nodule formation. 
Although it was established that the osteogenic stimulus from the 10:1 co-culture 
supernatant was heat-labile (Figure 3.12), an indication that it is a protein, a 
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chromatographic purification approach was unsuccessful. These efforts were hampered 
party due to the fact that this factor seemed to be present at very low concentration and 
was obscured by more abundant serum proteins (Figure 3.13B). More importantly, the 
methods used to purify and concentrate the fractions had deleterious effects on the 
osteogenic activity of the supernatants (Figure 3.13C). This could be possibly due to the fact 
that the osteogenic factor could be highly charged and thus be retained on the 
chromatography column or it could be of a very small size and thus pass through the 100kDa 
cutoff filter of the concentration columns. Additionally, the fact that the chromatographic 
purification process was performed in room temperature could have resulted in the loss of 
protein activity. 
 
A more targeted approach was to investigate whether known soluble factors with 
osteogenic potential such as BMPs and TGFβ1 were present in the co-culture supernatants. 
Using ELISAs it was shown that even though BMPs are well established osteogenic factors 
(Bandyopadhyay et al, 2006; Chen et al, 2004a; Urist, 1965; Urist & Strates, 1971; 
Yamaguchi et al, 2000), they were present at very low concentration in the cultures and 
furthermore they were not upregulated in the co-culture supernatants as compared to MSC 
only control supernatant (Table 3.1). Additionally, work by Dr Mei Mei Wong showed that 
neutralising antibodies to BMPs 2, 3, 4, 7 as well as TGFβ1 in Mφ/MSC co-cultures failed to 
abrogated the Mφ-induced increase in ALP activity (Dr Mei Mei Wong PhD thesis) further 
dismissing a role for BMPs and TGFβ1 in mediating the osteogenic ability of monocytes and 
Mφs. The investigation turned to other soluble factors such as cytokines, chemokines and 
growth factors known to be major products of monocytes and to affect cellular processes at 
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low concentrations. A number of cytokines such as IL-1β, IL-6, IL-8, IL-10 and TNFα, 
chemokines such as MIP-1α, MIP-1β and RANTES and growth factors G-CSF and HSF were 
found to be upregulated in 10:1 co-culture supernatants (Table 3.2 & Figure 3.14). 
Upregulation of IL-1β, IL-6, IL-8 and IL-10 as well as a number of chemokines following 
monocyte/Mφs interactions with MSC were also previously shown by a number of 
investigators (Beyth et al, 2005; Groh et al, 2005; Kim & Hematti, 2009; Nemeth et al, 2009) 
(Dr Mei Mei Wong PhD thesis). To validate a role for the identified soluble factors in 
mediating the monocyte osteogenic effects, recombinant cytokines were exogenously 
added in MSC cultures or neutralising antibodies in co-cultures with monocytes; none of the 
cytokines tested were not validated as the mediators for the monocyte effects on MSC 
differentiation (Table 3.3).  
 
Since proteomic and antibody approaches failed to identify the monocyte-derived 
osteogenic factor(s), the effect of the co-culture supernatants on MSC signalling was 
investigated since signalling pathways activated would suggest the soluble mediators acting 
on the MSCs. All pathways investigated (STAT3, NFκB and MAPKs pathways) were activated 
when MSCs were treated with the 10:1 co-culture supernatants (Figure 3.15). Monocyte-
derived factors were responsible for this activation since monocyte:MSC co-culture 
supernatants were monocytes had been fixed prior to co-culture failed to induce signalling 
in MSC (Figure 3.16). Comparing with the effect of monocyte alone culture supernatants 
that lack osteogenic activity, STAT3, NFκB and p38 MAPK signalling were specifically 
activated only by the 10:1 co-culture supernatant invalidating a role for the JNKs and ERKs 
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MAPKs (Figure 3.17). In spite of this, the osteogenic effect could not be attributed to a 
specific pathway.  
 
In summary, the results presented in this chapter demonstrated for the first time that 
monocytes and Mφs are potent inducers of the osteogenic differentiation of MSCs; this 
regulation proceeds through cell contact interactions but is ultimately mediated by soluble 
factor(s). The factor(s) exhibiting osteogenic activity was a protein but not a BMP commonly 
associated with osteogenic differentiation, nor any of the cytokines that were identified to 
be upregulated in monocyte-MSC co-culture supernatants. Investigations in MSC signalling 
revealed that the osteogenic co-culture supernatants induced activation of STAT3, NFκB and 
p38 MAPKs signaling pathways. In the search for a differential effect on osteogenic 
differentiation that would aid in delineating our mechanism, the contribution of monocyte 
subsets and monocyte activation was investigated and forms the basis of Chapter 4. 
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CHAPTER FOUR 
Monocytes Promote OB differentiation via STAT3 
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4.1 Introduction 
Experiments from the previous chapter showed that monocytes can promote the 
differentiation of MSCs to OBs leading to increased levels of ALP and bone nodule 
formation. The increased differentiation required contact between the two cell types but it 
was ultimately mediated by soluble factor(s) that were derived from the monocytes. Hence 
the study focused on the identification of the osteogenic factor(s) utilising firstly a 
chromatographic approach and secondly analysis of the osteogenic supernatants by ELISAs. 
Unfortunately, both approaches failed to identify possible mediators with osteogenic 
activity; however it was shown that the osteogenic supernatants could induce signalling in 
MSCs.  
 
To elucidate the signalling pathways and mediators involved it was sought to investigate 
whether monocyte subsets or activation of monocytes would have a different effect on MSC 
differentiation to the so far described promoting effect. For example, it is known that the 
regulation of OC differentiation by T cells depends on their activation state since resting T 
cells inhibit (Shinoda et al, 2003) but activated T cells promote osteoclastogenesis (Horwood 
et al, 1999; Kong et al, 1999a). Further studies have shown that whether activated T cell 
subsets will support osteoclastogenesis depends on their cytokine profiles (Takayanagi, 
2009) and have identified the TH17 subset (producing IL-17) as the major osteoclastogenic T 
cells as compared to the TH1 and TH2 (Sato et al, 2006). Such differential effects on MSC 
differentiation between monocyte subsets or activated monocytes would allow 
comparisons that would help to narrow down to possible mediators or pathways involved.   
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4.2 The effect of CD14++CD16- and CD14+CD16+ monocyte subsets on 
osteogenic differentiation of MSC 
4.2.1 Human monocyte subsets present in peripheral blood  
Similar to T cell subsets, monocytes populations can be analysed to distinct functional 
subpopulations. In humans, two major monocyte subsets have been reported in the 
literature on the basis of their expression of cell surface markers CD14 and CD16 (Gordon & 
Taylor, 2005; Grage-Griebenow et al, 2001; Passlick et al, 1989; Ziegler-Heitbrock et al, 
1988; Ziegler-Heitbrock et al, 2010). These subsets, namely CD14++CD16- and CD14+CD16+, 
have been shown by various investigators to have differential chemokine expression (Weber 
et al, 2000), migratory properties (Geissmann et al, 2003), as well as cytokine production 
upon activation (Belge et al, 2002; Frankenberger et al, 1996; Ziegler-Heitbrock et al, 1992). 
The CD14+CD16+ have also been implicated with several inflammatory diseases (Fingerle et 
al, 1993; Hakkinen et al, 2000; Ziegler-Heitbrock, 2007), and their numbers been found to be 
elevated in the blood and joints of RA patients (Baeten et al, 2000; Hepburn et al, 2004; 
Kawanaka et al, 2002; Wijngaarden et al, 2003). A wealth of data suggests that these 
subsets are functionally distinct. 
 
To investigate whether the increased MSC-OB differentiation seen in the presence of 
monocytes could be attributed to a particular monocyte subset, pure populations of the 
CD14++CD16- and CD14+CD16+ subsets were isolated using fluorescence-activated cell 
sorting. Pre-sort FACS plots illustrate the two populations according to their staining for 
markers CD14 and CD16 (Figure 4.1A). As previously shown by Zeigler-Heitbrock and 
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colleagues (Passlick et al, 1989; Ziegler-Heitbrock et al, 1988), the CD14++CD16- are the 
primary population representing ~90% of total monocytes in the peripheral blood (Figure 
4.1A Q3), while the CD14+CD16+ are less abundant making up just 5-10% of total 
populations (Figure 4.1A Q2). Post-sort FACS plots show that the subset populations 
CD14++CD16- (Figure 4.1B) and CD14+CD16+ (Figure 4.1C) were isolated to a high purity (97-
99%).  
 
Figure 4.1 Human peripheral blood monocytes sorted into CD16- and CD16+ populations 
 
 
 
 
 
 
Figure 4.1 FACS analysis of total monocytes and monocyte subsets. A: Total monocytes where 
stained with CD14-FITC and CD16-PE conjugated antibodies. FACS analysis reveals two distict 
populations according to CD14 and CD16 expression namely CD14++CD16- and CD14+CD16+. B-C: The 
two populations were sorted and re-run to validate efficiency of separation. Both CD14++CD16- (B) 
and CD14+CD16+ (C) subset populations were >95% pure. FACS plots are representative of seven 
different cell separations using monocytes from seven different donors. 
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4.2.2 CD14++CD16- and CD14+CD16+ monocyte subsets have differential effect on 
osteogenic differentiation when activated with LPS 
Equal numbers of total monocytes (pre-sort) (Figure 4.1A), as well as sorted CD14++CD16- 
(Figure 4.1B) and CD14+CD16+ monocytes (Figure 4.1C) were added at a ratio of 10:1 to MSC 
cultures and kept in culture with or without osteogenic media for 7 days when ALP activity 
was quantified. By including the total monocyte population, comparisons can be made with 
regards to the effect of each subset and their contribution to the overall effect of the total 
populations. For example, it is possible that although the CD14+CD16+ subset is less 
abundant in total populations it could have more potent effects in isolation and vica versa. 
As shown in Figure 4.2A, in the presence of monocytes there was an increase in ALP activity 
of MSC cultures irrespective of them being the total monocyte populations or the individual 
subsets; both CD14++CD16- and CD14+CD16+ monocytes were equally able to increase ALP 
activity with similar potency to each other and to the total monocyte population. This 
indicated that resting monocyte subsets have no differential effect onn MSC-OB 
differentiation but instead both have an equal ability to promote differentiation. 
 
Since unactivated monocyte subsets did not affect MSC OB differentiation differently, the 
possibility that activation of the different subsets could lead to differential effects was 
investigated. Similarly to this hypothesis, the regulation of OC differentiation by T cells 
depends on their activation state, where resting T cells are known to inhibit (Shinoda et al, 
2003), whilst activated T cells promote osteoclastogenesis (Horwood et al, 1999; Kong et al, 
1999a).  
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Figure 4.2 Monocyte subsets differentially affect MSC osteogenic differentiation when 
activated 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 A: Equal numbers (1x105) of the sorted CD14++CD16- and CD14+CD16+ monocyte subsets 
as well as total monocyte populations were added on top of 1x104 MSC in control or osteogenic 
media. B: The same experiment was also set up in the presence of 10ng/ml of LPS in all wells. ALP 
activity was quantified after 7 days. Graphs represent cumulative data of at least 4 independent 
experiments performed in triplicate and shown as means ± S.E.M. * P<0.05, *** P<0.001 one-way 
ANOVA with Bonferroni’s post-test comparison. 
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Additionally, it has been shown that following treatment with LPS, a characteristic feature of 
the CD14+CD16+ monocytes is the production of high levels of TNFα but undetectable IL-10 
while CD14++CD16- were described as mostly producing IL-10 and low levels of TNFα (Belge 
et al, 2002). As shown in Figure 4.2B, indeed in the presence of LPS the monocytes subsets 
had a different effect on MSC-OB differentiation. It should also be noted that the presence 
of LPS in the MSC alone cultures did not affect baseline differentiation as compared to 
Figure 4.2A. In the presence of LPS CD14++CD16- monocytes stimulated an increased 
differentiation response which was also significantly greater than the effect of total 
monocytes. Conversely, LPS activated CD14+CD16+ monocytes inhibited MSC-OB 
differentiation resulting in ALP levels that were lower than basal levels of MSC alone 
cultures. The effect of total monocyte populations was also decreased with LPS activation if 
compared to the MSC-ALP activity in the presence of the non-activated total monocytes 
(Figure 4.2A). This might indicate that while the CD14++CD16- monocytes make up 90-97% of 
total populations their effect seems to be greatly counter balanced by the CD14+CD16+ 
monocytes. The contribution of either subset to the effect of total populations could be 
assessed in additional experiments where different ratios of the stimulatory CD14++CD16- 
and the inhibitory CD14+CD16+ subsets combined could be added to MSC cultures, but this 
was not addressed in this study. The findings presented here suggest that under steady 
state situations monocytes subsets equally promote osteogenic differentiation of MSCs; in 
contrast in an inflammatory context CD14++CD16- further promote whereas the CD14+CD16+ 
monocytes, in addition to contributing to the pro-inflammatory milieu, inhibit MSC 
differentiation to OBs.  
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4.2.3 M-CSF and GM-CSF Mφ differentially affect MSC osteogenesis when activated 
Human Mφs can be differentiated in vitro in the presence of GM-CSF or M-CSF (Akagawa, 
2002; Burgess & Metcalf, 1980; Verreck et al, 2006). Similarly to the monocyte subsets 
described above, in response to LPS stimulation GM-CSF and M-CSF Mφs greatly differ in 
their cytokine production and based on these cytokine expression patterns have been 
termed M1 and M2 Mφs respectively (Fleetwood et al, 2007; Verreck et al, 2006). More 
specifically, GM-CSF Mφs exhibit a pro-inflammatory phenotype with secretion of IL12/IL23, 
IL1β, IL-6 and TNFα without detectable IL-10 while M-CSF Mφs produce anti-inflammatory 
IL-10 and low levels or pro-inflammatory cytokines (Fleetwood et al, 2007; Tadokoro & de 
Almeida Abrahamsohn, 2001; Verreck et al, 2006).  
 
As shown previously, irrespective of the differentiation signal, M-CSF and GM-CSF Mφs were 
equally able to induce ALP activity in MSC co-cultures (Figure 3.7). To investigate whether 
LPS activation would alter this effect, M-CSF or GM-CSF Mφ/MSC co-cultures were repeated 
in the presence of 10ng/ml of LPS. Firstly, it was validated that the M-CSF and GM-CSF Mφs 
generated showed the same responses to LPS polarisation as reported in literature, by 
measuring their expression of IL-10 and IL-12 following LPS activation (Figure 4.3). Indeed, 
M-CSF Mφs expressed 6x more IL-10 mRNA than GM-CSF Mφs (Figure 4.3A); conversely 
GM-CSF Mφ expressed very low levels of IL-10 mRNA as well as 40x more IL-12 mRNA than 
the M-CSF Mφs (Figure 4.3B). This indicated that the phenotype of polarised M-SCF and 
GM-CSF Mφs used in the Mφ/MSC co-cultures agreed with the reported phenotype in 
literature.  
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Figure 4.3 M-CSF Mφs produce more IL-10 but less IL-12 compared to GM-CSF Mφs 
 
 
 
 
 
Figure 4.3 Monocyte-derived Mφs were differentiated with either 100ng/ml M-CSF or 100ng/ml 
GM-CSF for 3-5 days. Subsequently, 1x106 cells of each were treated with 10ng/ml LPS overnight or 
cultured without LPS as controls. Cells were subsequently lysed, RNA extracted and levels of IL-10 
and IL-12 mRNA measured using real-time RT-PCR. mRNA levels were normalised to GAPDH and 
shown as fold induction compared to no LPS treatment. Real-time RT-PCR was kindly performed by 
Andrea Guerra.  
 
M-CSF or GM-CSF Mφs generated were then added to MSC cultures in the presence of 
10ng/ml of LPS. Quantification of ALP activity revealed that while non-activated M-CSF and 
GM-CSF Mφs could equally promote MSC differentiation, LPS activation greatly enhanced 
the effect of the M-CSF Mφs without altering the osteoinductive ability of the GM-CSF Mφs 
(Figure 4.4A). Additionally to activation with LPS, Mφs can be polarised in vitro to acquire 
either classical or alternative activation phenotypes under the influence of IFNγ and IL-4 
respectively (Gordon, 2003; Gordon & Taylor, 2005). Classical activation mediated by the 
priming stimulus of IFNγ followed by a microbial trigger such as LPS, leads to pro-
inflammatory cytokine production, nitric oxide production and is associated with microbial 
killing and tissue damage.  
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Figure 4.4 M-CSF and GM-CSF Mφs differentially affect OB differentiation when activated 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Monocyte-derived Mφs were differentiated with either 100ng/ml M-CSF or 100ng/ml 
GM-CSF for 3-5 days. On the last 24h of differentiation 20ng/ml of either IL-4 or IFNγ were added to 
half of the M-CSF or GM-CSF cultures respectively. A: Equal numbers (1x105) of the differentiated 
Mφ (M-CSF, GM-CSF, M-CSF+IL-4 and GM-CSF +IFNγ) were added on top of 1x104 MSC in control or 
osteogenic media. B: The same experiment was also set up in the presence of 10ng/ml of LPS in all 
wells. ALP activity was quantified after 7 days. Graphs represent cumulative data of 5 independent 
experiments performed in triplicate and shown as mean ± S.E.M. * P<0.05, ** P<0.01 one-way 
ANOVA with Bonferroni’s post-test comparison. 
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In contrast, alternative activation mediated by IL-4, which is associated with Th2 responses, 
leads to upregulation of arginase and has been linked to tissue repair (Gordon, 2003; 
Mantovani et al, 2005; Martinez et al, 2008). To further polarise GM-CSF Mφs, IFNγ was 
added for the last 24h of differentiation. Similarly, to induce an alternative activation 
phenotype IL-4 was added to M-CSF Mφs. Co-cultures with MSCs were established in the 
presence and absence of 10ng/ml LPS. As shown in Figure 4.4B, IL-4 treated M-CSF Mφs 
could increase ALP activity equally with the IFNγ treated GM-CSF Mφs. However, in the 
presence of LPS the effect on MSC differentiation differed; IL-4 treated M-CSF Mφs caused a 
further enhancement of MSC-ALP activity whereas IFNγ treated GM-CSF Mφs completely 
inhibited MSC ALP activity which was down to the levels of the MSC alone control. Similarly 
to monocyte subsets’ effects, polarising Mφs towards an anti-inflammatory phenotype 
favoured MSC osteogenesis by increasing ALP activity, whereas pro-inflammatory Mφs 
inhibited it.  
 
4.2.4 CD14++CD16- and CD14+CD16+ monocyte subsets have differential cytokine 
production when activated with LPS 
As reported in literature CD14++CD16- and CD14+CD16+ monocyte subsets differ in the 
production of cytokines when activated with LPS (Belge et al, 2002; Serbina et al, 2009; 
Szaflarska et al, 2004). To investigate whether this could justify their different effect on 
MSC-OB differentiation, it was first sought to investigate the cytokine profile of the two 
subsets following TLR4 activation with LPS. Monocytes (either total, CD14++CD16- or 
CD14+CD16+) were treated with the same concentration of LPS as that added to 
monocyte/MSC co-cultures (10ng/ml) and the levels of IL-10, TNFα, IL-1β, IL-6, IL-6R and IL-8 
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were measured in  the resulting supernatants using Luminex technology (as described in 
section 2.2.11.1). Control supernatants from cultures without LPS were included.  
 
As shown in Figure 4.5, following LPS activation IL-10 (except in total monocyte 
populations), TNFα, IL-1β and IL-6 were up-regulated compared to resting populations. 
Monocyte subsets CD14++CD16- and CD14+CD16+ as well as the total monocytes, produced 
equal levels of IL-1b (Figure 4.5C). Also, in the presence of 10ng/ml LPS IL-6 levels were 
elevated whilst IL-6R levels decreased in the two subsets as well as in total monocytes 
(Figure 4.5D  &  E). IL-8 levels were not affected by LPS activation in these cells (Figure 4.5 
F). It is known that LPS causes up-regulation of IL-8 in monocytes, but in this experiment 
monocytes already had constitutive levels of IL-8 that were not up-regulated further. Overall 
there were no differences in the responses of the CD14++CD16- and CD14+CD16+ subsets for 
IL-1 β, IL-6, IL-6R and IL-8. 
 
In contrast to the other cytokines investigated, IL-10 and TNFα showed subset-specific 
responses (Figure 4.5A and B). Although the CD14++CD16- monocytes also upregulated TNFα 
production after LPS activation, the CD14+CD16+ population were, as expected, the main 
producers of this cytokine (Figure 4.5B). IL-10 was upregulated in CD14++CD16- monocytes, 
whilst CD14+CD16+ failed to produce IL-10 upon LPS stimulation (Figure 4.5A). These findings 
are agreement with the reported literature (Belge et al, 2002).  
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Figure 4.5 CD14++CD16- and CD14+CD16+ monocyte subsets have differential cytokine 
production when activated with LPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 2x105 monocytes were treated with 10ng/ml LPS overnight, supernatants collected and 
spun down to eliminate cell debri. Culture supernatants where LPS was not added were used as 
controls. The levels of IL-10, TNFα, IL-1β, IL-6, IL-6R and IL-8 in culture supernatants were 
determined using Luminex methodology as described in section 2.2.11.1.  
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4.2.5 IL-10 does not directly affect osteogenic differentiation of MSCs whilst TNFα inhibits 
at high concentrations  
The differential cytokine profile of the monocyte subsets could be a possible justification for 
their differential effect on MSC-OB differentiation. For example, TNFα shown here to be 
produced by the CD14+CD16+ monocytes, has been suggested to strongly inhibit the 
osteogenic differentiation of MSCs (Abbas et al, 2003; Belge et al, 2002; Gilbert et al, 2005). 
Conversely, IL-10, produced by the CD14++CD16- monocytes, could positively affect MSC 
osteogenic differentiation by directly promoting it or by indirectly counterbalancing the 
TNFα inhibiting effect. With regards to IL-10 effects on OB differentiation there is conflicting 
evidence in the literature; IL-10 was shown to be inhibiting the production of bone proteins 
including ALP, collagen type I and osteocalcin as well as the formation of mineralised 
extracellular matrix in cultures of mouse bone marrow (Van Vlasselaer et al, 1993). 
Surprisingly, the IL-10-/- mouse has been shown to be osteoporotic and have a decreased 
osteoprogenitor pool as well as decreased ALP activity and mineralisation of mature OBs 
(Dresner-Pollak et al, 2004). 
 
As shown in Chapter 3 addition of IL-10 in MSC cultures did not have any effect on ALP 
activity whereas TNFα inhbited it (Table 3.3). Indeed as shown in Figure 4.6A, exogenous 
addition of IL-10 did not have any effect on the ALP activity of the MSC in any of the 
concentrations tested.  However, addition of TNFα resulted in a decrease in ALP activity 
which was not statistically significant at 10ng/ml, but at 100ng/ml of TNFα significantly 
inhibited ALP activity (Figure 4.6B).  
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Figure 4.6 IL-10 does not affect, but TNFα inhibits MSC differentiation to OBs 
 
 
 
 
 
 
 
Figure 4.6 Increasing concentrations (0.1, 1, 10 and 100 ng/ml) of IL-10 (A) and TNFa (B) were added 
on top of MSC seeded at 1x104/ well of a 96-well plate in control or osteogenic media. After 7 days 
of culture and ALP was quantified. Graphs represent cumulative data of 3 independent experiments 
performed in triplicate and shown as means ± S.E.M. * P<0.05 one-way ANOVA with Dunnett’s post-
test comparison to 0ng/ml. 
 
4.3 Monocytes Promote Osteoblast Differentiation via STAT3  
As shown above, TNFα could be the mediator of the inhibitory effects of the CD14+CD16+ 
monocytes on MSC differentiation; conversely IL-10 did not have any effects on MSC ALP 
activity indicating that the ability of CD14++CD16- to promote MSC differentiation cannot be 
attributed to IL-10. To further the investigations for the identification of the monocyte-
derived osteogenic factors, the influence of monocyte subsets on MSC signalling was 
investigated. As shown in chapter 3, supernatants from 10:1 monocyte/MSC co-cultures 
have osteogenic activity since they cause an increase in ALP (Figure 3.11A) and bone 
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nodules (Figure 3.11B) in MSC cultures. These supernatants were also shown to activate a 
number of signalling pathways in MSC including STAT3, p38 MAPK and NFκB (Figure 3.15). It 
was hypothesised that the differential effect of activated monocyte subsets on MSC 
osteogenesis; namely that CD14++CD16- monocytes promoted, whilst CD14+CD16+ inhibited 
differentiation, might correlate with differential effects on MSC signalling. 
 
4.3.1 CD14++CD16- and CD14+CD16+ monocyte subsets differentially induce STAT3 
phosphorylation in MSC 
Treatment of MSC cultures with supernatants from 10:1 co-cultures of either the monocyte 
subsets or total monocytes and MSC showed that all the pathways investigated, except 
STAT3, were activated equally by both monocyte subsets’ supernatants as well as from the 
total monocyte co-culture supernatant (Figure 4.7). This indicated that signalling via these 
pathways could not be correlated with the monocyte subsets’ effects of MSC osteogenic 
differentiation.  Conversely, STAT3 was activated in MSC treated with supernatants from co-
cultures with CD14++CD16- were MSC-ALP was increased whereas supernatants form 
CD14+CD16+ co-cultures where MSC-ALP activity was inhibited failed to induce STAT3 
activation in MSCs. This highlighted a possible role for STAT3 signalling as the mechanism by 
which monocytes regulate of MSC-OB differentiation. 
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Figure 4.7 CD14++CD16- and CD14+CD16+ monocyte subsets differentially induce STAT3 
phosphorylation in MSCs 
 
        
        
        
        
         
         
          
 
Figure 4.7 Supernatants from MSC co-cultures with total monocytes, CD16- or CD16+ monocyte 
subsets were collected after 24h of culture and used to treat 2x105 MSC for 30min as previously. 
Treated MSCs as well as untreated controls, were subsequently lysed and 10μg of protein per 
condition was subjected to Western Blotting analysis using anti-human antibodies for phospho-
STAT3 (Tyr 705), total STAT3, IκBα and phosphorylated forms of MAPKs JNKs, p38 and ERKs. β-
tubulin were used as loading control. Blots are representative of three independent experiments. 
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4.3.2 Neither IL-10 nor IL-6 induce STAT3 phosphorylation in MSC 
Analysis of monocyte/MSC co-cultures supernatants in Chapter 3 demonstrated that IL-10 
and IL-6 were strongly upregulated following monocyte/MSC interactions (Table 3.2 and 
Figure 3.14); these are known to be potent inducers of STAT3 signalling (Lai et al, 1996; 
Wehinger et al, 1996). Even though as shown above STAT3 signalling is a possible pathway 
mediating the monocyte-induce osteogenesis, treatment of MSCs with IL-10 and IL-6 did not 
affect ALP activity levels thus osteogenic effects could not be attributed to either cytokine 
(Table 3.3). Additionally, neutralisation of IL-6 and IL-10 in monocyte/MSC co-cultures did 
not inhibit the enhancement in ALP activity further discounting a role for IL-10 and IL-6 
(Table 3.3). It was therefore interesting to investigate whether IL-10 and IL-6 could induce 
STAT3 signalling in MSCs. 
 
MSCs were treated with both IL-10 and IL-6 in a time course and also with various doses and 
then analysed using Western Blot for STAT3 phosphorylation. Neither treatment resulted in 
activation of STAT3 (Figure 4.8A and B). In both cases monocytes treated either with IL-10 
or IL-6 served as a positive control for STAT3 activation. The lack of STAT3 activation 
indicated that MSCs were unresponsive to IL-10 or IL-6, therefore STAT3 activation in MSCs 
treated with the monocyte/MSC co-culture supernatants cannot be attributed to the 
upregulation of these cytokines in the co-cultures. Additionally, this may explain why both 
IL-10 and IL-6 failed to have any effects on MSC differentiation. 
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Figure 4.8 Neither IL-10 nor IL-6 induce STAT3 phosphorylation in MSCs 
 
 
      
      
 
 
 
       
       
 
Figure 4.8 A: 2x105 MSC were treated with 5ng/ml of IL-10 for 10, 15 and 20 min or with 1, 5 and 
10ng/ml of IL-10 for 15min.  B: 2x105 MSC were treated with 10 ng/ml of IL-6 for 10, 20 and 30 min 
or with 5, 10 and 20ng/ml of IL-6 for 15min. Monocytes treated with 5ng/ml of IL-10 or IL-6 for 15 
min were used as positive controls. Positive monocyte controls, untreated MSC controls and treated 
MSCs were lysed and 10μg of protein per condition was subjected to Western Blotting analysis for 
the detection of phospho-STAT3 (Tyr 705) and total STAT3. Levels of β-tubulin were used as loading 
control. Blots are representative of three independent experiments. 
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4.3.3 Activation of STAT3 in MSCs increases osteogenic differentiation 
The previous experiments suggested a role for STAT3 signalling in the monocyte-induced 
MSC osteogenesis. To further investigate this adenoviral constructs were used to 
overexpress a constitutively active (CA) or a dominant negative (DN) form of STAT3. An 
adenoviral construct expressing GFP was used as control virus and to also assess infection 
efficiency. The adenoviral constructs as well as the methodology used as described in detail 
in section 2.2.13. 
 
MSC were infected with good efficiency as shown by the expression of GFP when cultures 
were visualised under UV light (Figure 4.9A). To verify the expression of the STAT3 mutant 
forms, WB analysis of lysates of infected MSCs after 24h of infection was performed. As 
depicted in Figure 4.9B MSCs infected with the STAT3CA form constitutively expressed 
phosphorylated STAT3. Subsequently, STAT3CA and STAT3DN as well as AdGFP infected 
MSCs were cultured for 7 days in osteogenic media and ALP activity assessed. The 
expression of the STAT3CA in MSCs induced a significant increase in ALP activity (Figure 
4.10A) compared to non-infected MSCs or virus control. Although there was a slight 
decrease in ALP activity in the STAT3DN infected MSCs, this was not statistically significant. 
The ability of STAT3 to induce MSC osteogenesis was further validated in STAT3CA MSC 
cultures where after 21 days there was an increase in the number and size of bone nodules 
formed in osteogenic media (Figure 4.10C) as compared to virus control infected cultures 
(Figure 4.10B). These findings indicated that STAT3 activation is a potent inducer of MSC 
osteogenesis and could therefore represent the mechanism by which monocytes and Mφs 
induce enhanced OB differentiation. 
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Figure 4.9 Adenoviral infection of MSCs with viruses encoding for STAT3CA and STAT3DN 
forms 
 
          
 
 
 
 
 
 
 
 
 
 
Figure 4.9 MSCs were infected with adenoviral constructs expressing mutant forms of STAT3; STAT3 
CA (M.O.I. 50) and STAT3 DN (M.O.I. 100) as well as AdGFP (M.O.I. 100) as control virus overnight. A: 
MSCs infected with the AdGFP virus were observed under UV after 24h of infection to assess 
infection efficiency. B: To assess protein expression, infected MSCs were lysed after 24h of infection 
and 10μg of protein per condition was subjected to Western Blotting analysis for the detection of 
phospho-STAT3 (Tyr 705) and total STAT3. Blots and microphotographs are representative of three 
independent experiments. 
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Figure 4.10 STAT3 constitutive signalling increases osteogenic differentiation in MSCs 
 
 
 
 
 
 
 
         
 
 
 
 
 
Figure 4.10 MSCs were infected with adenoviral constructs expressing mutant forms of STAT3; 
STAT3 CA and STAT3 DN as well as AdGFP as control virus. A: Infected MSCs were cultured in 
osteogenic media for 7 days when ALP activity was quantified. Graphs represent cumulative data of 
5 independent experiments performed in triplicate and shown as means ± S.E.M. *** P<0.001 one-
way ANOVA with Dunnett’s post-test comparison to GFP infected MSCs. B-C: MSCs infected with 
AdGFP virus control or STAT3CA virus respectively were cultured in osteogenic media for 21 days 
when bone nodule formation was assessed using Alizarin Red staining. Microphotographs of bone 
nodules are representative of three independent experiments. 
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4.3.4 STAT3 signalling in MSC is required for the monocyte-induced osteogenesis 
STAT3 constitutive activation in MSCs was sufficient to cause increased osteogenesis in the 
absence of monocytes. This suggested that activation of STAT3 signalling in MSCs could be a 
mechanism by which monocytes induce the increased osteogenic differentiation. To 
validate this, the effect of 10:1 osteogenic co-culture supernatants on the ALP activity of 
STAT3DN infected MSCs (where STAT3 signalling is abrogated) was assessed. STAT3 DN virus 
suppressed ALP induction in MSC cultured with co-culture supernatants (Figure 4.11) 
indicating that the activation of STAT3 in MSCs is required for the osteogenic effect of the 
co-culture supernatants. Interestingly, the combination of STAT3 constitutive activation in 
MSCs and treatment with 10:1 co-culture supernatant caused a super induction of ALP 
activity (Figure 4.11). This might suggest that co-culture supernatants can further activate 
STAT3 and cause increased differentiation. Alternatively, additional factors contained in the 
co-culture supernatants can activate other pathways that further enhance the osteogenic 
effect of STAT3 activation. These possibilities were not addressed presently. 
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Figure 4.11 STAT3 activation is required in the MSCs for monocyte-induced osteogenesis 
 
 
 
 
 
 
 
 
Figure 4.11 MSC were infected with adenoviral constructs expressing mutant forms of STAT3; 
STAT3CA and STAT3DN as well as AdGFP control virus. Infected MSC were then cultured in 
osteogenic media or osteogenic media from 10:1 monocyte- MSC co-cultures prepared 24h earlier. 
ALP was quantified after 7 days of culture. Graphs are representative of three independent 
experiments performed in triplicate and shown as means ± S.E.M. *P<0.05, *** P<0.001 one-way 
ANOVA with Dunnett’s post-test comparison to GFP infected MSC. 
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4.4 Gene array analysis of MSC expressing STAT3CA and STAT3DN 
STAT3 activation was identified as a mechanism by which monocytes induce osteogenic 
differentiation of MSCs and furthermore, MSCs overexpressing a CA form of STAT3 showed 
enhanced osteogenesis. To investigate the mechanisms by which STAT3 activation leads to 
enhanced osteogenesis in MSCs a microarray approach was employed. The transcriptome of 
MSCs overexpressing STAT3 mutant forms, STAT3CA and STAT3DN was compared with 
MSCs infected with control virus AdGFP. MSCs from five different donors were infected with 
the adenoviral constructs as detailed in section 2.2.13 and cultured for 24h after which RNA 
was isolated.  
 
Figure 4.12 ALP mRNA is upregulated in MSCs expressing STAT3CA  
 
 
 
 
 
Figure 4.12 MSC were infected with AdGFP control virus, STAT3DN or STAT3CA adenoviral contructs 
as described in section 2.2.13. After 24h of culture RNA was isolated using the QIAamp RNA Blood 
Mini Kit (Qiagen Ltd, Crawley, West Sussex, UK) according to manufacturer’s instructions and levels 
of ALP were assessed using real-time RT-PCR as described in section 2.2.14. Values are fold increase 
of ALP normalised to MSCs with no virus. 
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Prior to the microarray analysis, it was verified by real time RT-PCR that 24h after infection 
with STAT3CA was sufficient to cause a two-fold upregulation of ALP mRNA in MSCs (Figure 
4.12). Furthermore, to validate the biological activity of the MSC samples before including 
them in the microarray analysis, identical cultures were set up to assess ALP activity. As 
depicted in Figure 4.13A-E, MSCs from all five donors responded in the expected way; i.e. 
STAT3CA induced an increase in ALP activity in the MSCs albeit to different magnitudes. The 
magnitude of the ALP response differed between the MSC donors and was also dependent 
on the passage of the MSCs, however the STAT3CA superinduced ALP activity in all MSC 
cultures.   
 
Isolated RNA was quantified and RNA quality assessed using a NanoDrop 
spectrophotometer and the ratio of absorbance at 260nm and 280nm used to assess RNA 
purity as described in section 2.2.15. Table 4.1 shows RNA quantification and purity of all 
samples used in this study. The subsequent steps including analysis of differentially 
expressed genes and pathway analysis was performed by the Genomic Services at the 
Welcome Trust Centre for Human Genetics in collaboration with Dr. Dilair Baban. Further 
validation of RNA quality was performed using the Agilent Bioanalyser, prior to labeled 
cDNA synthesis and hybridization on Illumina Human HT-12 v3.0 Expression BeadChip 
microarray chips. The hybridized and washed chips were scanned using the Illumina 
BeadScan. Raw data normalization, filtering and analysis were performed using GeneSpring 
11.5 as described in section 2.2.15. 
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Figure 4.13 STAT3CA induced ALP activity in all MSC donors used in the microarray study 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Prior to using in the microarray study, ALP was assessed in the MSC from 5 different 
donors either not infected or infected with STAT3CA, STAT3DN or AdGFP control virus after 7 days of 
culture in osteogenic media. Each graph A-E represents data of a single experiment performed in 
triplicate shown as means ± S.E.M. Graph F shows the cumulative data of graphs A-E shown as 
means± S.E.M. *** P<0.001 one-way ANOVA with Dunnett’s post test to MSC no virus. 
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Table 4.1 Quantification and purity of MSC RNA samples used the microarray study  
Sample ID RNA C ng/µl A260 A280 260/280 260/230 
Donor 1 P4 
MSC STAT3CA 133.7 3.344 1.563 2.14 2.11 
MSC STAT3DN 129.7 3.243 1.52 2.13 2.1 
MSC AdGFP 131.2 3.279 1.536 2.13 2.14 
Donor 2 P5 
MSC STAT3CA 223.46 5.586 2.619 2.13 2.21 
MSC STAT3DN 186.22 4.656 2.199 2.12 2.15 
MSC AdGFP 198.7 4.968 2.391 2.08 2.21 
Donor 3 P6 
MSC STAT3CA 172.7 4.318 2.043 2.11 2.14 
MSC STAT3DN 164.6 4.115 1.931 2.13 2.08 
MSC AdGFP 134.7 3.369 1.581 2.13 2.09 
Donor 4 
MSC STAT3CA 196 4.9 2.309 2.12 2.1 
MSC STAT3DN 179.4 4.484 2.138 2.1 2.11 
MSC AdGFP 168.5 4.212 1.996 2.11 2.23 
Donor 5 
MSC STAT3CA 119.6 2.99 1.408 2.12 2.12 
MSC STAT3DN 109.1 2.728 1.27 2.15 2.08 
MSC AdGFP 119.3 2.981 1.391 2.14 2.1 
Table 4.1 RNA from MSC infected with STAT3CA, STAT3DN or AdGFP control virus was isolated after 
24h of infection, using the QIAamp RNA Blood Mini Kit (Qiagen Ltd, Crawley, West Sussex, UK) 
according to manufacturer’s instructions. To ascertain concentration and quality of the RNA a 
NanoDrop spectrophotometer was used.  
 
Genes with significantly altered expressions were identified by one way ANOVA with 
Benjamini-Hochberg multiple testing correction, with p<0.01. The entities satisfying the 
significance analysis were passed on for the fold change analysis. For a given gene its change 
in expression was calculated by dividing its average normalised intensity in treated samples 
from the respective control values. Analysis resulted in 569 probe sets representing 377 
genes that were differentially expressed between STAT3CA MSC and AdGFP MSC. According 
to highest fold changes, the 40 most differentially regulated genes are listed in Table 4.2.  
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Table 4.2 The 40 genes with highest fold change in expression in MSC STAT3CA v MSCAdGFP 
Symbol Definition Fold change 
STAT3CA v 
AdGFP 
LBP Lipopolysaccharide binding protein  10.31 
IL1RL1 Interleukin 1 receptor-like 1 9.95 
SAA2 Serum amyloid A2 8.37 
CCL8 Chemokine (C-C motif) ligand 8 7.98 
NFE2 Nuclear factor (erythroid-derived 2) 6.67 
SERPINB4 Serpin peptidase inhibitor clade B (ovalbumin), member 4 5.99 
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 5.67 
F3 Coagulation factor III (thromboplastin, tissue factor) 5.18 
EFNA1 Ephrin A1 4.96 
IL6 Interleukin 6 (interferon, beta 2) 4.92 
CHI3L2 Chitinase 3-like 2 4.55 
SOCS3 Suppressor of cytokine signaling 3 4.55 
SAA1 Serum amyloid A1 4.43 
FLJ22447 PREDICTED: hypothetical gene supported by AK026100 4.42 
WWC1 WW and C2 domain containing 1 4.33 
SERPINB3 Serpin peptidase inhibitor clade B (ovalbumin), member 3 4.27 
NAMPT Nicotinamide phosphoribosyltransferase 4.25 
MT1M Metallothionein 1M 4.22 
CH25H Cholesterol 25-hydroxylase 4.08 
PIM1 pim-1 oncogene 4.07 
STEAP4 STEAP family member 4 3.76 
KIAA1199 KIAA1199 3.68 
CA2 Carbonic anhydrase II 3.65 
TNC Tenascin C 3.58 
ANGPTL4 Angiopoietin-like 4 3.39 
RCAN1 Regulator of calcineurin 1 3.39 
ACHE Acetylcholinesterase 3.38 
HP Haptoglobin 3.33 
GSDMC Gasdermin C 3.27 
IL1R2 Interleukin 1 receptor, type II 3.22 
BCL3 B-cell CLL/lymphoma 3 3.18 
IL1R1 Interleukin 1 receptor, type I 3.03 
RGS16 Regulator of G-protein signaling 16 3 
MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 2.99 
TDO2 Tryptophan 2,3-dioxygenase (TDO2) 2.93 
KRTAP1-5 Keratin associated protein 1-5 2.92 
SLC2A3 Solute carrier family 2 (facilitated glucose transporter), member 3 2.92 
PLAU Plasminogen activator, urokinase 2.90 
C10orf10 Chromosome 10 open reading frame 10 2.90 
IGF1 Insulin-like growth factor 1 (somatomedin C) 2.87 
Table 4.2 The table lists the 40 most highly significantly regulated transcripts in MSC STAT3CA 
compared to MSC AdGFP (with p<0.01 cutoff using one way ANOVA with Benjamini-Hochberg 
multiple testing correction). Values shown are the medians from the five donors.  
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A variety of genes were found to be regulated in the STAT3CA MSCs including cytokines, 
chemokines and cell surface molecules (Table 4.2). Of interest, IL-6 was highly upregulated, 
which agrees with high IL-6 production found in monocyte/MSC co-cultures (Figure 3.14B). 
Also of interest was the upregulation of IGF1, which is known to promote osteogenic 
differentiation (Levi et al, 2010a). Furthermore, Table 4.4 lists a number of additional genes 
of interest found to be differentially regulated in STAT3CA MSC v AdGFP MSCs.  
 
Table 4.4 Other selected genes differentially regulated in MSC STAT3CA v MSC AdGFP 
Symbol Definition Fold change 
STAT3CA v AdGFP 
CXCL5 Chemokine (C-X-C motif) ligand 5 2.76 
CCL7 Chemokine (C-C) motif ligand 7 2.69 
ALPL Alkaline phosphatase, liver/bone/kidney 2.6 
CXCL12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor1) 2.59 
CCL20 Chemokine (C-C motif) ligand 20 2.29 
DKK1 Dickkopf homolog 1 (Xenopus laevis) -2.28 
IGFBP1 Insulin-like growth factor binding protein 1  2.27 
OSMR Oncostatin M receptor  2.05 
RUNX2 Runt-related transcription factor 2 1.95 
LIFR Leukemia inhibitory factor receptor alpha 1.66 
Table 4.4 The table lists additional differentially regulated transcripts of interest in MSC STAT3 
compared to MSC AdGFP. These were selected because they represent chemokines, are associated 
with osteogenic differentiation (ALP, DKK1 and RUNX2) or include receptors IGF1 and IL-6 family 
member OSM.  
 
These included genes associated with osteogenic differentiation such as ALP, which showed 
a 2.6 fold change in MSC STAT3CA compared to MSC AdGFP. This agreed with the 
preliminary data depicted in Figure 4.12, where using real-time RT-PCR it was shown that 
STAT3CA overexpression caused a 2.4 fold change in the levels of ALP mRNA. Table 4.4 also 
shows that expression of DKK1, a negative regulator of osteogenic differentiation, was 
downregulated by 2.28 fold. Furthermore, there was a 1.95 fold upregulation of bone-
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specific transcription factor Runx2 in the STAT3CA MSCs. In association with IGF1, IGF 
binding protein 1 (IGFBP1) showed 2.27 fold change in expression. Finally, although the IL-6 
receptor was not found to be expressed in the STAT3CA MSCs, there was 2 fold induction of 
the receptor for Oncostatin M (OSMR) and 1.66 fold upregulation of the receptor for 
Leukemia Inhibitory factor (LIFR), which both belong to the IL-6 family of cytokines.   
 
Table 4.5 Pathways identified by ontological analysis to be overrepresented in MSC 
STAT3CA v MSC AdGFP  
Pathways Homo 
sapiens 
genes 
Regulated genes 
1.5 fold STAT3CA v 
AdGFP 
Expected P value 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway 
283 23 6.21 1.33E-07 
Angiogenesis 191 12 4.19 1.27E-03 
Interleukin signaling pathway 161 9 3.53 1.01E-02 
Heteromeric G-protein signaling 
pathway-Gq alpha Go alpha 
mediated 
134 7 2.94 3.01E-02 
TGF-β signaling pathway 145 7 3.18 4.29E-02 
Cytoskeletal regulation by Rho 
GTPase 
98 6 2.15 2.23E-02 
Toll receptor signaling pathway 62 4 1.36 4.91E-02 
Insulin/IGF pathway-
MAPKK/MAPK pathway 
35 4 0.77 7.84E-03 
Table 4.5 Table lists the pathways together with significance values identified by ontological analysis 
to be significantly overrepresented in the differentially regulated genes of the STAT3CA MSCs v 
AdGFP MSCs analysis in comparison to the number expected relating to the abundance of genes in 
these pathways in Homo sapiens.  
 
The genes differentially regulated in STAT3CA MSCs v AdGFP MSCs were classified 
ontologically and shown to be significantly overrepresented in the STAT3CA MSCs as 
compared to the all the genes associated with each pathway in humans (Table 4.5). The 
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majority of regulated genes were found to be associated with inflammation mediated by 
chemokine and cytokine signalling pathway, angiogenesis and interleukin signalling 
pathway. Other represented pathways were TGF-beta signalling pathway, cytoskeletal 
regulation by Rho GTPase and Toll receptor signalling pathway as shown in Table 4.5.   
 
Finally, in contrast to the 377 genes differentially expressed in STAT3CA MSCs v AdGFP, gene 
expression analysis identified only five genes that were differentially expressed between 
STAT3DN MSCs and AdGFP MSCs. These are listed in Table 4.6. Interestingly, serum amyloid 
A2 (SSA2) which was the third most upregulated gene in STAT3CA MSCs (8.37 fold 
upregulated compared to AdGFP MSCs) (Table 4.2) was found to be downregulated in 
STAT3DN MSCs. 
 
Table 4.6 All differentially regulated genes in MSC STAT3DN v MSC AdGFP 
Symbol Definition Fold change  
STAT3DN v AdGFP 
HBD Hemoglobin, delta  4.94 
C10orf10 Chromosome 10 open reading frame 10 -2.02 
DDIT4L DNA-damage-inducible transcript 4-like -1.59 
SAA2 Serum amyloid A2 -1.56 
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 1.53 
Table 4.6 The table lists all significantly regulated transcripts in MSC STAT3DN compared to MSC 
AdGFP (with p<0.01 cutoff using one way ANOVA with Benjamini-Hochberg multiple testing 
correction). Values shown are the medians from the five donors.  
 
Although this microarray data can offer valuable information for the mechanism of STAT3-
induced osteogenesis, further analysis and verification of the microarray data was not 
pursued; instead this study focused on the identification of monocyte-derived osteogenic 
factors.  
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4.5 Discussion 
The results described in this section demonstrated that CD14++CD16- and CD14+CD16+ 
monocyte subsets had a differential effect on MSC differentiation when they were activated 
with LPS (Figure 4.2). While in the resting state both subsets were equally able to drive 
osteogenic differentiation (Figure 4.2A), when activated, the CD14++CD16- monocytes 
promoted but the CD14+CD16+ monocytes inhibited osteogenic differentiation (Figure 4.2B). 
The two major human monocytes subsets CD14++CD16- and CD14+CD16+ have been shown 
to represent functionally distinct subsets, with differential migration and differentiation 
potential, chemokine receptor expression, and cytokine repertoire (Geissmann et al, 2003; 
Weber et al, 2000; Ziegler-Heitbrock et al, 1992). Interestingly, the CD14+CD16+ subset that 
inhibited MSC differentiation has been shown to have a pro-inflammatory phenotype and to 
accumulate in many inflammatory diseases (Fingerle et al, 1993; Hakkinen et al, 2000; 
Thieblemont et al, 1995; Ziegler-Heitbrock, 2007). For example, CD14+CD16+ monocytes 
have been shown to accumulate in the joints and blood of patients suffering from RA where 
their numbers have been shown to correlate with disease activity (Baeten et al, 2000; 
Hepburn et al, 2004; Kawanaka et al, 2002; Wijngaarden et al, 2003) and decrease in 
response to therapy (Fingerle-Rowson et al, 1998). The CD14+CD16+ monocytes are thought 
to be contributing to the inflammatory milieu since they have been shown to be a major 
source of TNFα but produce very little IL-10 in comparison to the CD14++CD16- monocytes 
(Belge et al, 2002), which probably mediate their role in the pathogenesis of disease.   
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Indeed, many of the immune processes associated with the pathogenesis of RA are 
mediated by an imbalance between pro-inflammatory and anti-inflammatory cytokines in 
the RA synovium. The continuous cytokine imbalance favours OC differentiation and 
increased bone resorption, which under physiological conditions is closely followed by 
increased bone formation. The finding that CD14+CD16+ monocytes are inhibitory of MSC 
osteogenic differentiation suggest that, in addition to contributing to the pro-inflammatory 
milieu, CD14+CD16+ monocytes also participate in the pathogenesis of disease through the 
inhibition of MSC-OB differentiation; this inhibition of OB differentiation, that would 
otherwise be favourable for joint repair, also provides an aetiology for the lack of repair in 
the RA joint.  
 
Similarly to the CD14++CD16- monocytes promoting and CD14+CD16+ monocytes inhibiting 
MSC differentiation, polarising Mφs towards anti-inflammatory or pro-inflammatory 
phenotypes resulted in enhancement or inhibition of MSC differentiation respectively 
(Figure 4.4). Mφs differentiated under the influence of GM-CSF or M-CSF are considered to 
acquire a pro-inflammatory or anti-inflammatory phenotype respectively similar to the 
classical or M1 (associated with IFNγ and LPS) or alternative or M2 (associated with IL-4 and 
IL-13) Mφ activation (Verreck et al, 2006). M1 Mφs which produce pro-inflammatory 
cytokines, mediate resistance to pathogens and contribute to tissue destruction whilst M2 
Mφs which produce anti-inflammatory cytokines are associated with phagocytic activity, 
immunoregulation and tissue repair (Gordon, 2003; Martinez et al, 2008). In this chapter it 
was shown that when resting, M-CSF (M2) Mφ promoted MSC osteogenic differentiation 
equally to GM-CSF (M1) Mφ and in the presence of LPS the M-CSF (M2) Mφ-induced 
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osteogenesis was enhanced (Figure 4.4A). Further polarization of GM-CSF (M1) Mφ towards 
pro-inflammatory classically activated phenotype resulted in a significant inhibition of MSC 
differentiation whilst the alternatively activated anti-inflammatory M-CSF (M2) Mφ 
promoted MSC osteogenic differentiation (Figure 4.4B).  
 
It was interesting to observe that, the differentiation signal used to generate Mφs affected 
their ability to influence MSC differentiation. M-CSF is constitutively expressed by several 
cell types including fibroblasts, endothelial cells, stromal cells and OBs (Bartocci et al, 1987; 
Metcalf & Nicola, 1995). Therefore it is likely that under steady-state situations M-CSF will 
drive Mφ differentiation to a M2 phenotype. The findings presented in this chapter suggest 
that Mφs actively contribute in regulating bone by promoting the differentiation of OBs 
from their mesenchymal progenitors. Indeed, resident tissue Mφs are present in most 
tissues and their existence closely associated with bone surfaces has already been reported 
(Hume et al, 1984). Furthermore, these Mφs have recently been identified to have 
important roles in regulating bone homeostasis (Chang et al, 2008). On the other hand GM-
CSF is produced at sites of inflammation and infection, which is also characterised by large 
amounts of IFNγ (Bartocci et al, 1987; Metcalf & Nicola, 1995). Consistent with a pro-
inflammatory function for GM-CSF on Mφs at sites of inflammation where its levels are 
elevated, and according to data presented in this chapter, it is likely that during these 
conditions MSC osteogenic differentiation is inhibited.  
 
The resolution of inflammation that coincides with the downregulation of GM-CSF and 
predominance of M-CSF will again promote the M2 Mφ phenotype favouring tissue repair 
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(Chen et al, 2008; Kim & Hematti, 2009) and MSC OB differentiation. Mφs are important for 
homing to the sites of injury and inflammation and mediating important events that 
promote resolution and healing. It has been suggested that such important resolution 
events, for example the clearance of apoptotic cells, are mostly confined to a specialized 
subset of phagocytes with anti-inflammatory properties (Xu et al, 2006a) such as the MCSF 
Mφs. Interestingly, MCSF Mφs also express considerable levels of various chemokine 
molecules including monocyte chemoattractant protein-1 (MCP-1), Mφ inflammatory 
protein-1β (MIP-1β) and regulated on activation normal T expressed and secreted (RANTES) 
(Verreck et al, 2006). Hence, the anti-inflammatory MCSF Mφs possibly have multiple roles 
in inflammatory resolution and repair including, which in addition to phagocytic activity and 
immunoregulation, includes attracting MSCs to sites of injury and promoting their 
differentiation contributing to tissue repair.  
 
The identification of an inhibitory effect on MSC osteogenic differentiation by CD14+CD16+ 
monocytes allowed for further investigation of MSC signalling in an attempt to identify 
pathways involved in the monocyte-induced MSC osteogenesis. These studies identified the 
STAT3 signalling pathway to be specifically activated by CD14++CD16- monocytes, which 
promoted osteogenic differentiation, but not by CD14+CD16+ monocytes, which inhibited 
differentiation (Figure 4.7). Monocyte subsets did not differentially regulate any of the 
other pathways tested. STAT3 activation in MSCs was not attributed to either IL-10 or IL-6 
(Figure 4.8) even though these two cytokines were previously shown to be upregulated in 
co-cultures of MSC with monocytes (Figure 3.14B). This is probably due to a lack of IL-10R 
and IL-6R expressed on MSCs, thus making them unresponsive to IL-10 or IL-6 induced 
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STAT3 signalling. This also agrees with the fact that neither IL-10 nor IL-6 did affect 
osteogenic differentiation of MSC, previously shown in Chapter 3 (Table 3.3).  
 
Further validation for the role of STAT3 as a mechanism of the monocyte-induced 
osteogenesis was the observation that overexpression of constitutively active STAT3 using 
adenoviral infection led to enhanced osteogenesis of MSCs. This was characterised by 
increased ALP activity (Figure 4.10A) and increased mineralisation (Figure 4.10B). 
Furthermore, the STAT3 DN virus suppressed MSC ALP activity induced by the osteogenic 
10:1 co-culture supernatants suggesting that signalling through the STAT3 pathway is indeed 
a mechanism by which monocytes, and possibly also Mφs, induce MSC osteogenesis (Figure 
4.11). Conversely, overexepression of STAT3 CA in MSCs greatly enhanced the osteogenic 
activity of the 10:1 co-culture supernatant. This could be due to the greater enhancement of 
the STAT3 activation or it could indicate that STAT3 activation in MSCs makes them more 
responsive to other osteoinductive signals present in the 10:1 supernatant.    
 
In support of the findings in this chapter, signalling through the JAK/STAT pathway has been 
extensively implicated with OB differentiation. Even though a number of studies have 
identified a role for IL-6 in directly promoting osteogenic differentiation (Bellido et al, 1997; 
Nishimura et al, 1998) these were conducted on osteoblastic cell lines such as MG-63 or 
calvarial osteoblast. In support of the findings in Chapter 3 (Table 3.3), studies in human 
bone marrow-derived MSCs showed that IL-6 could not induce osteogenic differentiation 
since the cells lack the IL-6R, but osteocommittment with dexamethasone made them 
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responsive to IL-6 or sIL-6R/IL-6. In contrast, in the present study MSCs did not respond to 
IL-6 neither in control nor in dexamethasone-containing osteogenic media (Table 3.3).  
 
Further studies have shown that members of the IL-6 family such as IL-11, oncostatin M 
(OSM) and Leukemia Inhibitory Factor (LIF) could increase osteogenic differentiation in vitro 
and in vivo when either injected or overexpressed in mice (Cornish et al, 1993; Malik et al, 
1995; Metcalf & Gearing, 1989; Takeuchi et al, 2002) suggesting a central role for STAT3 
signalling in osteogenic differentiation. Indeed osteoblast-specific disruption of the Stat3 
gene via the Cre-LoxP recombination system using α1(I)-collagen promoter Cre transgenic 
mice resulted in an osteoporotic phenotype because of reduced bone formation rate (Itoh 
et al, 2006). In the same study, glycoprotein 130 (gp130) knock-in mice, in which STAT3 
activation is enhanced through this common signal-transducer of the IL-6 family, showed an 
osteosclerotic phenotype. Thus the STAT3 signal in OBs plays a pivotal role in bone 
formation in vivo.  
 
The data presented in this chapter also correlate with a recent study by Mikami et al., who 
showed that the siRNA knockdown of STAT3 results in a significant reduction of MSC ALP 
activity following treatment with dexamethasone and BMP-2 (Mikami et al, 2010). 
Contradictory to this and to the findings in this chapter, Levy et al. have shown that 
eradication of STAT3 signaling also using siRNA resulted in highly efficient osteogenic 
differentiation induced by BMP-2 despite also showing that BMP2/4 induced STAT3 tyrosine 
phosphorylation (Levy et al, 2010). In spite of this contradictory report, the in vivo studies by 
Itoh et al. (Itoh et al, 2006) as well as the strong induction in osteogenesis observed in MSCs 
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where STAT3 was constitutively activated (Figure 4.10) stipulate an important role for STAT3 
signalling positively influencing MSC osteogenic differentiation.  
 
The striking enhancement in MSC osteogenesis caused by the constitutive activation of 
STAT3 provided an interesting system to study in an attempt to identify the mechanism or 
mediators for the increased osteogenic differentiation using a whole genome expression 
approach. Gene expression profiling using microarray analysis resulted in 377 genes that 
were differentially expressed between MSC overexpressing STAT3CA and virus control. 
Importantly, genes that have been previously reported as STAT3 targets in the literature, 
such as lipopolysaccharide-binding protein (LBP), SOCS3, JunB and Myc (Duan & Simpson-
Haidaris, 2003; He et al, 2003; Hutt et al, 2000; Schumann et al, 1996), were identified in the 
STAT3CA MSCs (Table 4.2). Furthermore a significant number of genes found to be 
upregulated (such as LBP, SLC2A3, IGFBP1, CCL2, EFNA1 and others) or downregulated 
(IFIT1, MX1, OAS1) by STAT3CA were the same with those found in another study also 
investigating the gene expression profile of constitutive activation of STAT3 in lung epithelial 
cells (Dauer et al, 2005). This might indicate that these genes are not specifically related to 
OB differentiation. In contrast, specific to OB differentiation and further validating the role 
of STAT3 signalling in MSC OB differentiation, in STAT3CA MSCs there was upregulation of 
ALP and RUNX2 as well as downregulation of Dikkopf homolog 1 (DDK1), a negative 
regulator of Wnt signalling and osteogenic differentiation (Li et al, 2006a; Niida et al, 2004) 
(Table 4.4).  
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Pathway analysis of the differentially expressed genes in STAT3CA MSCs revealed relations 
to inflammation mediated by chemokine and cytokine signalling pathways, angiogenesis, 
interleukin signalling pathway, Gq alpha and Go alpha mediated G-protein signalling 
pathway, cytoskeletal regulation by Rho-GTPase, TGFβ regulation and toll receptor signalling 
pathway (Table 4.5). The high number of regulated genes identified in this study associated 
with inflammation, chemokine and cytokine signalling as well as interleukin signalling 
pathways supports the idea that OB differentiation is strongly regulated by the immune 
system and its mediators. Furthermore, in the study mentioned above, Dauer et al. also 
found that the identified genes in lung epithelial cells expressing constitutively active STAT3 
were associated with inflammation, angiogenesis, blood coagulation, cell migration and 
remodeling of extracellular matrix, and suggested that this is a phenotype related to wound 
healing (Dauer et al, 2005).   
 
From differentially regulated genes (Tables 4.2) a number of interesting candidates with 
potential role in influencing osteogenic differentiation can be identified. Lipopolysaccharide 
binding protein (LBP) was the most upregulated transcript induced in MSC overexpressing 
STAT3CA. LBP forms high-affinity complexes with LPS and delivers it to cell surface CD14 
which then forms a complex with TLR4 and MD2. LBP has been shown to be a STAT3 target 
gene and its expression was upregulated in MSC treated with CXCL7 (Kalwitz et al, 2009). 
Upregulation of LBP might make MSCs more responsive to LPS but there is no evidence of 
whether it influences osteogenic differentiation.  
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STAT3CA induced the expression of IL-6 and interestingly the Oncostatin M receptor (OSMR) 
and Leukemia Inhibitory Factor receptor (LIFR). Together with IL-6, OSM and LIF belong to 
the IL-6 family of cytokines that activate STAT3 signalling through gp130. The possibility that 
IL-6 has a direct effect in promoting MSC osteogenesis was discounted in the previous 
chapter (Table 3.3). However, the in vivo evidence describing bone phenotypes for the OB-
specific disruption of the Stat3 gene and also gp130 knock-in in mice (Itoh et al, 2006), 
points to a role for other members of the IL-6 family such as OSM and LIF, which also use 
the gp130 adaptor and lead to STAT3 activation. Indeed, it has been shown that OSM and 
LIF could increase osteogenic differentiation in vitro and in vivo when either injected or 
overexpressed in mice (Cornish et al, 1993; Malik et al, 1995; Metcalf & Gearing, 1989; 
Takeuchi et al, 2002). The upregulation of the receptors for OSM and LIF in STAT3CA MSC is 
an interesting indication for the regulation of differentiation by these two ligands.   
 
Serum amyloid A2 and A1 were found to be upregulated in the STAT3CA MSC and 
interestingly SAA2 was downregulated 1.56 fold in the STAT3DN MSC. Serum amyloid A 
(SAA) proteins are a family of cytokine-induced acute-phase proteins. In humans, SAA1 and 
SAA2 genes encode for non-glycosylated acute-phase SAA proteins SAA1 and SAA2. Acute-
phase SAAs are secreted during the acute phase of inflammation and have several roles 
including the recruitment of immune cells to inflammatory sites and the induction of 
enzymes that degrade extracellular matrix. Even though SAA are synthesized primarily by 
the liver their production by human bone tissues has been reported previously. Kovacevic et 
al. have demonstrated SAA1/2 expression in non-differerentiated MSC with the levels of 
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SAA1/2 significantly increasing under osteogenic differentiation conditions (Kovacevic et al, 
2008). The role of SAA in bone cells and osteogenic differentiation remains unknown.  
 
Another interesting candidate found to be upregulated in STAT3CA expressing MSCs was 
ephrinA1. Ephrin A1 belongs to a family comprising of 14 Eph membrane bound receptor 
tyrosine kinases and their 8 eprhin ligands (Holder & Klein, 1999). Ephrin A1 is the ligand 
receptor for EphA2. They predominantly function by inhibitory or repulsive cellular 
responses via cell-cell contact meaning that the responses can be mediated through the 
receptor (forward signalling) and/or the ligand (reverse signalling) (Cooke & Moens, 2002; 
Mellitzer et al, 1999; Pasquale, 2008). The Eph/ephrins have been intensely studied for their 
roles during embryonic development particularly within the central nervous system but 
recent studies suggest that Eph/eprhin molecules of both subclasses also regulate bone 
homeostasis mediating the crosstalk between OB and OCL (Allan et al, 2008; Irie et al, 2009; 
Lorenzo, 2008; Mundy & Elefteriou, 2006; Zhao et al, 2006). More specifically Irie et al. 
showed that bidirectional signalling through ephrin A2-EphA2 enhances osteoclastogenesis 
while suppressing osteoblastogenesis (Irie et al, 2009), while recently ephrin B was shown to 
mediate human MSC attachment, migration and endochondral ossification (Arthur et al, 
2011). These findings may suggest a role for ephrinA1 in regulating osteogenesis.  
 
In summary, in this chapter differential effects were identified for CD14++CD16- and 
CD14+CD16+ monocyte subsets as well as M-CSF and GM-CSF Mφs, in their ability to 
influence MSC OB differentiation. These findings provide an insight into the regulation of 
MSC osteogenic differentiation both in homeostasis and disease settings. Furthermore, 
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STAT3 was identified as a mechanism by which monocyte/Mφs promote osteogenic 
differentiation of MSCs. A microarray study identified differentially regulated genes in 
STAT3CA MSCs and offered interesting information for the mechanism of STAT3-induced 
osteogenesis. However, further analysis and verification of the microarray data was not 
pursued; instead this study focused on the identification of the monocyte-derived 
osteogenic factors. 
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CHAPTER FIVE 
Monocytes Promote OB Differentiation Via COX2 
and OSM 
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5.1 Introduction 
Based on the different effect of the CD14++CD16- and CD14+CD16+ monocytes on MSC OB 
differentiation, it was identified that STAT3 is a mechanism by which monocytes promote 
MSC osteogenesis. Indeed, constitutive activation of STAT3 in MSCs resulted in increased 
ALP activity and mineralisation, whereas abrogation of STAT3 signalling using a STAT3DN 
form inhibited the osteogenic effect of monocyte/MSC co-culture supernatants. These 
findings stipulated a critical role for STAT3 in the crosstalk between monocytes and MSCs, 
however the identity of the soluble factor(s) mediating the monocytes’ osteogenic ability 
remained elusive.  
 
Interactions between MSCs and Mφs previously reported that cell-cell interactions led to 
upregulation of IL-10, a STAT3 activator in monocytes/Mφs, but also upregulation of 
cyclooxygenase 2 (COX2) expression in the MSCs (Nemeth et al, 2009). COX2 enzyme 
catalyses the biosynthesis of PGE2; indeed it was shown that in the Mφ/MSC co-cultures 
there was an increase in PGE2 production (Nemeth et al, 2009). Interestingly, PGE2 was 
previously identified as a mediator of the immunosuppressive effects that MSCs exert on 
immune cells including T cells but also DC and monocyte/Mφ (Aggarwal & Pittenger, 2005). 
Other than being a regulator of immunity and inflammation (Harris et al, 2002), PGE2 has 
also been shown to be stimulatory of bone formation and bone resorption (Lader & 
Flanagan, 1998; Ono et al, 1998; Raisz, 1999; Woodiel et al, 1996) and OBs are major 
producers of PGE2. The involvement of COX2 and PGE2 in monocyte mediated MSC 
osteogenic differentiation was investigated. 
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5.2 Cyclooxygenase 2 (COX2) is required for monocyte-induced MSC 
osteogenesis 
Cyxloxygenase (COX) enzymes catalyze the biosynthesis of prostaglandins (PGs). There are 
three isoforms of the COX enzymes; COX1, COX2 and the less investigated COX3. COX1 is 
constitutively expressed in tissues such as the stomach and kidney whereas COX2 is an 
inducible enzyme induced by mitogens or inflammatory mediators (Rouzer & Marnett, 
2009). Despite being an inducible isoform elsewhere in the body, COX2 seems to have 
constitutive actions in the skeleton. This is supported by findings showing that mouse 
primary bone tissue cultured in vitro (Pilbeam et al, 1997) as well as primary bone cells 
(Chikazu et al, 2002; Joldersma et al, 2000; Klein-Nulend et al, 1997; Secreto et al, 2003) and 
OBs lining the bone surfaces in vivo (Forwood et al, 1998) express COX2 in the unstimulated 
state. In spite of the presence of constitutive levels in bone, COX2 expression can be further 
induced and has been shown to mediate important process such as bone resorption, 
mechanotrasduction and fracture repair (Li et al, 2006b). Mice lacking COX2 have altered 
bone architecture and mechanical properties (Alam et al, 2005; Chen et al, 2003b; 
Robertson et al, 2006) and also have delayed fracture repair due to a persistence of 
undifferentiated mesenchyme (Zhang et al, 2002a). The role of PGE2 and COX2 as the 
mediators of monocyte-induced MSC osteogenesis was investigated. 
 
5.2.1 PGE2 is upregulated in 10:1 monocyte to MSC co-cultures 
The levels of PGE2 were assessed using ELISA in supernatants from either MSC alone 
cultures, monocyte alone cultures or co-cultures of 10:1 monocyte/MSC that were 
incubated for 4h, 8h, 24h and 48. Low levels of PGE2 were constitutively produced by 
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unstimulated MSCs in agreement with previous reports (Aggarwal & Pittenger, 2005), but 
not by monocytes when cultured alone (Figure 5.1). Co-culturing MSCs and monocytes 
resulted in an upregulation of PGE2 production that increased with time (Figure 5.1). This 
finding correlates with published data showing that PGE2 levels are increased in co-cultures 
of murine bone marrow MSCs and Mφs (Nemeth et al, 2009).  
 
Figure 5.1 PGE2 is upregulated in monocyte/MSC co-cultures 
 
 
 
 
 
 
Figure 5.1 MSCs and monocytes were cultured either alone or together at a ratio of 10:1. Co-culture 
supernatants were collected at 4, 8, 24 and 48h and PGE2 levels detected by ELISA according to 
manufacturer’s instructions (R&D). MSC and monocyte alone supernatants were only from the 4h 
timepoint. Graph represents cumulative data of PGE2 concentration from supernatants of three 
separate experiments analysed on the same ELISA plate in duplicate using PGE2 Parameter
TM Assay 
Kit from R&D Systems, Abington, UK according to manufacturer’s instructions. Data shown as mean 
± S.E.M.   * P<0.05, *** P<0.001 one-way ANOVA with Dunnett’s post-test comparison to MSC. 
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5.2.2 COX2 is upregulated in both MSC and monocytes in co-cultures 
The presence of PGE2 in monocyte/MSC co-culture supernatants suggested that COX2 
expression would be upregulated in this setting. Similarly, in addition to increased PGE2 
levels, Nemeth and colleagues also showed increased COX2 expression in the co-cultures of 
murine bone marrow MSCs and Mφs (Nemeth et al, 2009). Indeed COX2 expression 
increased over time in MSCs treated with 10:1 monocyte/MSC co-culture supernatants for 
1, 2 or 4 hours (Figure 5.2) indicating that MSCs could be responsible for the production of 
PGE2 in the monocyte:MSC co-cultures.  
 
Figure 5.2 COX2 is upregulated in MSCs treated with 10:1 co-culture supernatant 
 
 
  
 
Figure 5.2 MSCs were treated with supernatants from 10:1 Monocyte/MSC co-culture for 1h, 2h and 
4h and protein extracted was immunoblotted for COX2 as described in section 2.2.12. Top panel is 
showing induction of COX2 in MSCs. Bottom panel shows β-tubulin used as control to verify equal 
loading. Blots are representative of three experiments performed.   
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However, PGE2 production could also be attributed to the monocytes (James et al, 2001). 
Investigation of COX2 expression in monocytes was performed using intracellular staining 
and flow cytometry so that monocyte populations could be assessed separately (gated for 
CD45+ cells) from the MSCs in the co-culture. As expected, resting monocytes did not 
express COX2 (Figure 5.3A), consistent with the fact that they did not produce any PGE2 
(Figure 5.1), while activation with 10ng/ml of LPS for 4h, used as positive control (Dean et al, 
1999), induced expression of COX2 (Figure 5.3B).  
 
Figure 5.3 COX2 is upregulated in monocytes co-cultured with MSCs 
 
 
 
 
 
Figure 5.3 Monocytes were cultured either alone (A), with 10ng/ml LPS (B) or with MSCs at a ratio of 
10:1 (C) for 4h; cells were first stained for surface marker CD45 and then permeabilised for 
intracellular staining for COX-2 as described in section 2.2.4. Intracellular COX-2 expression was 
assessed using flow cytometer. Populations were gated on monocytes based on size, granularity and 
CD45 expression. FACS plots shown are representative of three separate experiments.  
 
Interestingly, monocytes that had been in co-culture with MSCs for the same amount of 
time also upregulated expression of COX2 that was even higher than that caused in the 
presence of LPS (Figure 5.3C); 69.5 % monocytes from co-cultures were CD45+COX2+ (Figure 
Monocytes alone                             +10ng/ml LPS 4h                                 +MSC for 4h A B C 
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5.3C Q2) v 21.4% CD45+COX2+ monocytes following LPS activation (Figure 5.3B Q2). This 
indicates that monocyte/MSC interactions strongly induce COX2 in the monocytes which 
could also be the source of PGE2 in the MSC-monocyte co-cultures. It is possible that the 
baseline levels of PGE2 produced by the MSCs (Figure 5.1) can induce COX2 activation and 
PGE2 production by the monocytes in the co-cultures, since it is known that PGE2 can 
enhance its own production by inducing COX2 expression (Kawaguchi et al, 1994; Pilbeam et 
al, 1993; Pilbeam et al, 1995; Suda et al, 1998). Furthermore, the increased levels of PGE2 
could also act on the MSCs to further enhance COX2 expression and PGE2 production. 
 
5.2.3 COX2 inhibition abrogates monocyte osteogenic effect 
The upregulation of COX2 expression and PGE2 production in monocyte/MSC co-cultures 
was particularly interesting as they have been described to regulate bone formation 
(Kawaguchi et al, 1995; Kawaguchi et al, 1994; Raisz, 1995). A number of studies have 
suggested that PGE2 and COX2 directly influence OB differentiation by regulating the 
expression of bone specific transcription factors RUNX2 and Osterix (Ninomiya et al, 2011; 
Yoon et al, 2010; Zhang et al, 2002a). Systemic or local injection of PGE2 stimulates bone 
formation (Suponitzky & Weinreb, 1998; Weinreb et al, 1997) whilst increased lamellar bone 
formation in response to mechanical loading is mediated by COX2 and can be completely 
inhibited by COX inhibitors indomethacin and NS-398 (Duncan & Turner, 1995; Forwood, 
1996).  
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To investigate the implication of COX enzymes in the osteogenic ability of monocytes in 
monocyte/MSC co-cultures, the COX inhibitors indomethacin and NS-398 were used. 
Indomethacin is a non-selective COX inhibitor which targets both COX1 and COX2 isoforms 
whilst NS-398 is COX2 specific inhibitor. DMSO was used as vehicle control since both 
inhibitors are diluted in this carrier. Firstly, as depicted in Figure 5.4 in the presence of 
indomethacin the ability of monocytes to increase MSC ALP activity in monocyte/MSC co-
cultures was significantly abrogated suggesting a role for the COX enzymes as mediators of 
the monocyte osteogenic effect.  
 
Figure 5.4 COX inhibition abolishes monocyte-induced MSC ALP increase 
 
 
 
 
 
 
Figure 5.4 1x104 MSC cultured either alone or with 1x105 monocytes were treated with COX inhibitor 
indomethacin at a concentration of 5μM as well as DMSO as vehicle control added to cultures at an 
equivalent amount to indomethacin. ALP activity was assessed after 7 days. Data shown are 
cumulative of three independent experiments performed in triplicate and represented as mean ± 
S.E.M. * P<0.05 one-way ANOVA with Bonferroni’s post-test comparison.  
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Since indomethacin is a non-selective COX inhibitor, to specifically target COX2 the effect of 
COX2 specific inhibitor NS-398 was also investigated. NS-398 inhibits COX2 enzymatic 
activity by tightly binding to its cyclooxygenase active site thus blocking the conversion of 
arachidonate to PGH2 which represents the common intermediate in PGE2 synthesis 
(DeWitt, 1999). In the presence of NS-398 there was a similar effect as with indomethacin; 
monocytes could no longer super induce ALP activity in MSCs (Figure 5.5A).  
 
Figure 5.5 COX2 inhibition abolishes monocyte-induced MSC ALP increase 
 
 
 
 
 
 
Figure 5.5 A: 1x104 MSC cultured either alone or with 1x105 monocytes were treated with COX2 
specific inhibitor NS-398 at a concentration of 5μM as well as DMSO as vehicle control added to 
cultures at an equivalent amount to NS-398. ALP activity was assessed after 7 days. Data shown are 
cumulative of five independent experiments performed in triplicate and represented as mean ± 
S.E.M. *** P<0.001 one-way ANOVA with Bonferroni’s post-test comparison. B: Inhibition of ALP 
activity in MSCs is not due to toxic effect of NS-398 as shown by MTT assay. DMSO was used as 
vehicle control. Data shown are absorbance values relative to those of MSC alone cultures set as 1 
(dash line) and are cumulative of three independent experiments performed in triplicate and 
represented as mean ± S.E.M.  
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The inhibition of ALP activity of MSCs in the presence of the inhibitor NS-398 was not due to 
toxic effect because it did not affected baseline ALP in MSCs cultured alone. Furthermore, 
NS-398 treatment did not decrease values of MTT assay indicating no effect on viability and 
metabolic activity of MSCs (Figure 5.5B). These findings indicate that COX, and more 
specifically COX2 activity has an important role in the ability of monocytes to enhance MSC 
differentiation to OBs. 
 
5.2.4 Inhibition of monocyte-induced MSC ALP by NS-398 is rescued by PGE2 or EP2/4 
receptor agonists 
COX2 mediates the synthesis of PGE2, and as shown previously, PGE2 production is induced 
in monocyte/MSC co-cultures (Figure 5.1). The abrogation of monocyte-induced ALP activity 
in MSCs by NS-398 is therefore most likely due to the inhibition of PGE2 production. To 
investigate this, monocyte/MSC co-cultures were repeated in the presence of NS-398 as 
well as in the presence of both NS-398 and PGE2. As depicted in Figure 5.6, whilst NS-398 
inhibited the increase in ALP activity of MSCs in co-culture with monocytes, the 
simultaneous addition of NS-398 and PGE2 rescued this effect; PGE2 addition restored MSC 
ALP activity levels to those induced by the co-culture with monocytes. This indicates that 
the inhibition of the monocyte osteogenic activity by NS-398 is indeed due to the inhibition 
of PGE2 production. Furthermore, it suggests that PGE2 could be the mediator of the 
monocyte-induced osteogenesis.    
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Figure 5.6 COX2 inhibition by NS-398 is rescued by exogenous PGE2  
 
 
 
 
 
 
 
 
Figure 5.6 1x104 MSC cultured either alone or with 1x105 monocytes were treated with COX-2 
specific inhibitor NS-398 at 5µM or both NS-398 and PGE2 at 1μM for 7 days when MSC ALP activity 
was quantified. Graph shows cumulative data of three independent experiments performed in 
triplicate and represented as mean ± S.E.M. * P<0.05 ** P<0.01 one-way ANOVA with Bonferroni’s 
post-test comparison. 
 
PGE2 exerts its actions by binding to one of its four subtypes of receptors EP1, EP2, EP3 and 
EP4 (Sugimoto & Narumiya, 2007). Interestingly, the effects of PGE2 on bone have been 
shown to be specifically mediated through the EP2 and EP4 receptors (Gao et al, 2009; Li et 
al, 2007a; Ninomiya et al, 2011; Paralkar et al, 2003; Xie et al, 2009; Yoshida et al, 2002b). To 
investigate this in the monocyte/MSC co-culture system, specific agonists to the different 
receptor subtypes were used. As shown in Figure 5.7, exogenous addition of EP2 and EP4 
receptor agonists butaprost and misoprostol, but not EP1/3 receptor agonist sulprostone, 
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rescued the blocking effect of NS-398 in monocyte-induced MSC differentiation. Addition of 
either butaprost or misoprostol restored ALP activity levels to those of 10:1 monocyte/MSC 
co-cultures, whereas sulprostone addition failed to restore ALP activity levels. These data 
point to a role for the EP2 and EP4 receptors mediating the actions of PGE2 in the 
monocyte/MSC co-cultures.  
 
Figure 5.7 COX2 inhibition by NS-398 is rescued by EP2/EP4 receptor agonists  
 
 
 
 
 
 
 
 
Figure 5.7 1x104 MSC cultured either alone or with 1x105 monocytes were treated with COX-2 
specific inhibitor NS-398 at 5µM, NS-398 and PGE2 at 1μM or NS-398 and PGE2 receptor agonists 
Butaprost (10μM), Misoprostol (1μM) or Sulprostone (1μM) for 7 days. ALP activity was quantified. * 
Graph shows cumulative data of three independent experiments performed in triplicate and 
represented as mean ± S.E.M. * P<0.05 ** P<0.01 one-way ANOVA with Dunnett’s post-test 
comparison to MSC. Butaprost: EP2 receptor agonist, Misoprostol: EP2/3/4 receptor agonist, 
Sulprostone: EP1/3 receptor agonist  
M
S
C
+N
S-
39
8
+N
S&
B
ut
ap
ro
st
+N
S&
m
is
op
ro
st
ol
+N
S&
su
lp
ro
st
on
e
10
:1
+N
S-
39
8
+N
S&
B
ut
ap
ro
st
+N
S&
m
is
op
ro
st
ol
+N
S&
su
lp
ro
st
on
e
0
1
2
3
4
5
6
-------------------10
4
MSC------------------- -------------10
5
mono:10
4
 MSC-------------
**
**
*
nsnsA
L
P
 a
c
ti
vi
ty
(p
-N
it
ro
p
h
e
n
o
l 
m
m
o
l/
L
)
CHAPTER 5                                         MONOCYTES PROMOTE OB DIFFERENTIATION VIA COX2 AND OSM 
234 
 
5.2.4 Direct addition of PGE2 in MSC cultures does not increase ALP activity 
As shown previously, PGE2 was upregulated in monocyte/MSC co-cultures (Figure 5.1) and 
could rescue the inhibition of monocyte-induced MSC ALP activity by NS-398 (Figure 5.6). 
Previous studies have reported that PGE2 increased ALP and osteocalcin expression as well 
as bone nodule formation in cultures of rat calvaria OB or rat bone marrow stromal cells 
(Minamizaki et al, 2009; Nagata et al, 1994; Weinreb et al, 1999). Other investigators have 
reported that PGE2 is necessary for MSC differentiation to OBs in COX2-/- mice and 
furthermore, exogenous PGE2 enhanced Runx2 and Osterix expression (Zhang et al, 2002a). 
To investigate a direct role of PGE2 in inducing OB differentiation, increasing concentrations 
of PGE2 were added to MSC cultures and the effect on ALP activity was assessed.  
 
As depicted in Figure 5.8, 0.1 µM PGE2 caused a small but not significant increase in MSC 
ALP activity; this effect was markedly weaker than the increase in ALP activity induced by 
co-culture with monocytes. Hence, an osteogenic effect could not be attributed to PGE2 in 
this system and thus it does not represent the mediator of the monocyte-osteogenic effect. 
However, the effect of NS-398 in monocyte/MSC co-cultures (Figure 5.5A) as well as the 
ability of PGE2 to rescue ALP activity inhibited by NS-398 (Figure 5.6) supports that COX2 
and PGE2 are important mediators in this system, albeit not directly driving MSC 
osteogenesis.      
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Figure 5.8 PGE2 does not induce significant increase in MSC ALP activity  
 
 
 
 
 
 
Figure 5.8 1x104 MSC were treated with 0.1, 1 or 10 µM of PGE2 whilst in other wells 1x10
5 
monocytes were added to the MSCs. An equal amount to the highest dilution of PGE2 of 100% EtOH 
was added as vehicle control. MSC ALP activity was assessed after 7 days of culture. Data shown are 
representative of three independent experiments and represented as mean ± S.E.M.*** P<0.001 
one-way ANOVA with Dunnett’s post-test comparison to MSC.  
 
5.3 Lipoxygenases (LOX) are required for monocyte-induced MSC 
osteogenesis 
Since PGE2 had no direct effect on MSC osteogenic differentiation, it is possible that it is 
acting in an indirect manner in the regulation of monocyte-induced osteogenesis; for 
example PGE2 could be acting on the monocytes leading to the production of soluble factors 
with osteogenic properties. In the study by Nemeth and colleagues, increased production of 
PGE2 in murine MSC and Mφ co-cultures was shown to be responsible for reprogramming 
the Mφs into a phenotype that favoured attenuation of inflammation and tissue destruction 
in a sepsis model through upregulation of anti-inflammatory IL-10 (Nemeth et al, 2009). 
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These Mφs resemble those isolated from the resolution phase of an inflammatory response 
that are characterised by enhanced anti-inflammatory cytokine production, such as IL-10, as 
well as high expression of COX2 (Bystrom et al, 2008). COX2 is critical for the resolution 
phenotype since, other than prostaglandin production, is required for the biosynthesis of 
the lipoxins, resolvins and protectins; mediators with anti-inflammatory and pro-resolution 
properties that are critical for the resolution of inflammation. The production of these 
molecules also requires the activity of enzymes known as lipoxygenases (LOX), 5-LOX, 12-
LOX and 15-LOX (Figure 5.9). During an inflammatory response, switching from the 
production of pro-inflammatory mediators to ones with pro-resolution properties is due to 
PGE2 inducing expression of the LOX enzymes and is important for the inflammatory 
responses to resolve in a timely and controlled manner (Levy et al, 2001). 
 
Figure 5.9 COX2 participates with LOX in the biosynthesis of resolution mediators 
 
 
 
 
 
 
Figure 5.9 COX2 is required together with LOX enzymes in the production of many lipid mediators 
important for inflammation and resolution such as the leukotrienes, lipoxins, resolvins and 
protectins. 
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Most interestingly, LOX enzymes have recently been implicated with regulation of bone. 
Studies of single nucleotide polymorphisms (SNPs) in LOX genes, ALOX12 and ALOX15, have 
shown an association with bone mineral content (Ichikawa et al, 2006; Urano et al, 2005), 
whilst LOX metabolites have been shown to regulate differentiation and resorbing activity of 
OCs (Herrera et al, 2008), as well as PTH-dependent OB growth (Somjen et al, 2008).  
 
5.3.1 LOX inhibition abrogates monocyte osteogenic effect 
To investigate the role of LOX enzymes in the ability of monocytes to enhance MSC 
osteogenesis, LOX inhibitor baicalein was added in monocyte/MSC co-cultures. DMSO was 
again used as vehicle control as baicalein is not soluble in water. As depicted in Figure 5.10A 
LOX inhibition in the presence of baicalein significantly inhibited the monocyte-induced 
increase in ALP activity of MSCs. Inhibition of ALP activity was not due to the inhibitor 
affecting cell viability or metabolism as shown by MTT assay (Figure 5.10B). LOX inhibition 
by baicalein also had an inhibitory effect on baseline differentiation in MSC alone cultures 
but this effect was not significant (Figure 5.10A). These findings suggest a role for LOX 
enzymes and their products in the regulation of OB differentiation by monocytes. 
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Figure 5.10 LOX inhibition by baicalein abolishes monocyte-induced ALP increase in MSCs  
 
 
 
 
 
 
Figure 5.10 A: 1x104 MSC cultured either alone or with 1x105 monocytes were treated with LOX 
specific inhibitor Baicalein at a concentration of 10μM as well as DMSO as vehicle control added to 
cultures at an equivalent amount to Baicalein. ALP activity was assessed after 7 days. Data shown 
are cumulative of five independent experiments performed in triplicate and represented as mean ± 
S.E.M. * P<0.05, ** P<0.01 one-way ANOVA with Bonferroni’s post-test comparison. B: The same 
cultures were set up to perform MTT assay in the presence of 10µM and DMSO as described in 
section 2.2.8. Data shown are absorbance values relative to those of MSC alone cultures set as 1 
(dash line) and are cumulative of three independent experiments performed in triplicate and 
represented as mean ± S.E.M.  
 
To investigate the involvement of specific LOX isoforms, in addition to baicalein, other 
specific inhibitors of LOX enzymes were also tested and are shown in Figure 5.11. In the 
presence of increasing concentrations of baicalein (Figure 5.11A), AA-861 (Figure 5.11B) and 
PD146176 (Figure 5.11C) which are 5-LOX specific inhibitors, or BW B70C (Figure 5.11D), a 
15/12-LOX inhibitor, there was a dose dependent decrease in MSC ALP activity induced by 
co-culturing with monocytes and osteogenic media (shown by the red lines). Unexpectedly, 
LOX inhibitors also had effects on baseline ALP activity of MSCs cultured alone in osteogenic 
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media (Figure 5.11 shown by the green lines); at the higher concentrations all LOX inhibitors 
(baicalein, AA-861, BW B70C and PD146176) inhibited ALP activity induced by osteogenic 
media suggesting a direct role for LOX products in regulating osteogenic differentiation of 
MSCs. 
 
Figure 5.11 Inhibition of 5/12/15-LOX abolishes monocyte-induced ALP increase in MSCs  
 
 
 
 
 
 
 
 
 
Figure 5.11 LOX inhibitor Bacicailein, 5-LOX inhibitors AA861 and BW B70C  (at 0.1, 1, 10 and 100µM) 
as well as 12/15-LOX inhibitor PD 146176 (at 0.01, 0.1, 1 and 10µM) were added in increasing 
concentrations in MSC cultures in the absence or presence of monocytes at a ratio of 10:1. DMSO 
was the vehicle control since all inhibitors were diluted in DMSO and equivalent amount to the 
highest concentration of each inhibitor was added. Graphs show data representative of three 
experiments performed in triplicate and represented as mean ± S.D. ** P<0.01, *** P<0.001 one-
way ANOVA with Dunnett’s post-test comparison to 0µM. 
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5.3.1 LOX products do not affect MSC osteogenic differentiation 
The findings shown above indicate that all LOX enzymes investigated, 5-LOX, 12-LOX and 15-
LOX have a role in mediating the monocyte osteogenic effect on MSCs, and possibly also in 
directly inducing osteogenic differentiation. LOX enzymes are responsible for the 
biosynthesis of leukotrienes, lipoxins and resolvins (Figure 5.9). Since inhibition of all LOX 
isoforms resulted in abrogation of the osteogenic effects, this pointed out to Lipoxins as the 
most likely candidates since their biosynthesis requires the action of all three isoforms 
(Figure 5.9). Commercially available 5(S)6(R)15(R)-Lipoxin A4, 5(S)6(R)-Lipoxin A4, 
Leukotriene B4, 17(R)-Resolvin D1, 17(S)-HpDoHE, Resolvin D2 and Resolvin E1 (listed in 
Table 5.1 together with their known actions and use in animal disease models) were tested 
for their ability to directly influence MSC ALP activity in control or osteogenic media. 
Surprisingly, none of these compounds had any effect on ALP activity in MSCs when directly 
added in culture for 7 days (Table 5.1). Hence an osteogenic effect could not be attributed 
to any of the LOX products tested.  
 
Of course this investigation only included a small number of these molecules that are 
commercially available. Furthermore, these compounds are extremely susceptible to 
oxidisation and might lose their properties very quickly in this culture system which might 
not be suitable for their study. Ideally a functional test to assure their activity should be 
included every time. Finally, the LOX enzymes probably catalyse the biosynthesis of many 
more lipid mediators that are not yet known or have just been identified such the recently 
identified maresins that are produced by Mφs by the action of 5/12/15-LOX enzymes and 
have similar anti-inflammatory and pro-resolution properties (Serhan et al, 2009). 
CHAPTER 5                                         MONOCYTES PROMOTE OB DIFFERENTIATION VIA COX2 AND OSM 
241 
 
Table 5.1 Products of LOX enzymes tested for their ability to influence osteogenic 
differentiation of MSCs 
Eicosanoids tested Effect of direct 
addition on 
MSC ALP 
Specific Actions Use in in vivo 
disease models 
Leukotriene B4 no effect ↑adhesion & activation of 
leukocytes on the endothelium, 
transmigration ↑PMN migration 
& ROS production 
 
5(S)6(R)15(R)-
Lipoxin A4 
no effect ↓PMN-mediated tissue damage 
↓Angiogenesis and cell 
proliferation ↓ROS extracellular 
release ↓pro-inflammatory 
cytokines (TNFα, IL-12) ↓DC-
lymphocyte interactions 
↑Phagocytosis and IL-10 
production  
Periodontitis, 
Peritonits, Dorsal Air 
Pounch, Colitis, 
Asthma, Cystic 
Fibrosis, 
Glomerulonephritis, 
Pleuritis, Bone 
Marrow transplant 
5(S)6(R)-Lipoxin A4 no effect 
17(S)-HpDoHE no effect   
17(R)-Resolvin D1 no effect ↓Adhesion receptors ↓ROS 
generation & pro-inflammatory 
cytokines (TNFα, IL-8) ↓PMN 
transmigration ↓PGE2 
production 
Peritonitis, Skin, 
Kidney ischemia-
reperfusion, Ocular 
Resolvin D2 no effect ↓PMN adhesion to endothelial 
cells ↑NO and Prostacyclin in 
endothelial cells ↑Microbial 
cleaning and clearance  
Peritonitis, Sepsis 
Resolvin E1 no effect ↓DC IL-12 production ↓DC 
migration ↓PMN chemotaxis 
↑Mucosal clearance of PMN by 
CD55 ↑PMN detachment ↑LX4 
production ↑ROS intracellular & 
microbial killing  
Skin, Periodontitis, 
Peritonitis, Asthma, 
Ocular, Colitis 
 
Table 5.1 Lipid mediators that are products of LOX enzymes biosynthesis pathways, their specific 
actions in inflammation and use in in vivo disease models of inflammation and inflammatory disease. 
Of notable interest Lipoxin A4 and Resolvin E1 which prevented loss of connective tissue and bone 
and promoted healing and tissue regeneration in a rabbit model of periodontitis. Compounds were 
added at concentrations of 10µM and 100µM in MSC cultures and incubated for 7 days in presence 
or absence of osteogenic media. ALP quantification showed that none of the compounds tested had 
an effect on MSC ALP activity. Compounds were tested on at least 2 different MSC donors. 5(S)6(R)-
Lipoxin A4 and 5(S)6(R)15(R)-Lipoxin A4 are two different forms of Lipoxin A4. The latter is derived 
from the aspirin-triggered formation of 15(R)-HETE intermediates from arachidonic acid. 17(S)-
HpDoHE is a precursor to 17(S)-Resolvins.  
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5.3.2 COX2 and LOX regulation of the osteogenic activity of monocyte:MSC co-culture 
supernatants 
The investigations detailed above indicated that the COX2 and LOX enzymes have a role in 
mediating the effect of monocytes in increasing ALP activity in MSCs. To delineate the 
possible mechanism by which COX2 and LOX enzymes mediate monocyte regulation of MSC 
differentiation, the effect of COX2 and LOX inhibitors was tested on MSC cultures treated 
with monocyte/MSC co-culture supernatants. In this way the direct effect on MSCs could be 
assessed in a system excluding the monocytes. Monocyte/MSC co-culture supernatants 
were previously shown to have the ability to induce ALP activity (Figure 3.11A) and bone 
nodule formation (Figure 3.11B) in MSC cultures. As shown in Figure 5.12, 10:1 
monocyte/MSC co-culture supernatants could significantly induce ALP activity of MSCs. 
Furthermore, in the presence of the COX2 inhibitor NS-398, the osteogenic activity of the 
monocyte/MSC co-culture supernatants was not affected; co-culture supernatants could still 
induce ALP activity. Conversely, the LOX inhibitor baicalein inhibited ALP induction by the 
co-culture supernatants (Figure 5.12). Collectively, these findings indicate that PGE2 
production in the co-cultures is required for the monocyte osteogenic effect and since it is 
already present in the monocyte/MSC co-culture supernatants its actions are not inhibited 
by NS-398. However, the osteogenic effect of co-culture supernatants was inhibited by 
baicalein indicating that PGE2 action and induction of ALP requires LOX enzyme activity in 
the MSCs.  
 
 
CHAPTER 5                                         MONOCYTES PROMOTE OB DIFFERENTIATION VIA COX2 AND OSM 
243 
 
Figure 5.12 LOX inhibition but not COX2 inhibition abolishes the osteogenic activity of 10:1 
monocyte/MSC co-culture supernatant  
 
 
 
 
 
 
Figure 5.12 1x104 MSC either cultured alone or with 10:1 monocyte:MSC co-culture supernatants 
were treated with 5µM COX-2 inhibitor NS-398 or 10µM LOX inhibitor Baicalein. DMSO as vehicle 
control was added in an equivalent amount as the highest concentration of inhibitors. After 7 days of 
culture ALP activity was quantified. Graph shows data representative of three independent 
experiments performed in triplicate and represented as means ± S.D. *** P<0.001 one-way ANOVA 
with Dunnett’s post-test comparison to MSC. 
 
Inhibition of osteogenic differentiation by LOX inhibitors strongly suggests a role for these 
enzymes in regulating OB differentiation. However, this role is not clear since osteo-
inductive properties could not be attributed to any of the LOX products tested. Additionally, 
though they may have a role in OB differentiation, it is unlikely that LOX products constitute 
the mediators of monocyte-induced osteogenesis since they are lipids, in contrast with the 
finding that the monocyte-derived factors with osteogenic activity were heat-labile, an 
indication that they are proteins. The involvement of LOX in regulating MSC OB 
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differentiation was not investigated further. Instead, the next part of this study focused on 
investigating the gene expression profile of monocytes regulated by NS-398 and PGE2.  
 
5.4 Gene array analysis of co-culture Monocytes and regulation by NS-398 
and PGE2 
COX2 activity and PGE2 were identified to be mediating the ability of monocytes to induce 
osteogenic differentiation of MSCs, since in the presence of COX2 specific inhibitor NS-398 
this ability was abrogated (Figure 5.5A) and NS-398 inhibitory effect was rescued by 
exogenously added PGE2 (Figure 5.6). This regulation by NS-398 and PGE2 represented a 
good model to investigate the trascriptome of monocytes in these co-cultures using a 
microarray approach with a view to identifying the monocyte-derived factors with 
osteogenic ability.  
 
Monocytes from five separate donors were isolated from buffy coats of healthy individuals 
as detailed in section 2.2.3.2. Monocytes were either cultured alone or in contact with MSC 
at a ratio of 10:1 for 2 hours or 8 hours. These timepoints were chosen based on 
observations that the osteoinductive factors are present in co-culture supernatants within 
6-12 hours (data not shown). In monocyte/MSC co-cultures either NS-398, PGE2 or both NS-
398 and PGE2 were added. Monocytes were collected from cultures by washing carefully, so 
as to retrieve as many monocytes without carrying over any of the adherent MSCs. 
Monocyte samples were lysed and RNA isolated using the QIAamp RNA Blood Mini Kit 
(Qiagen Ltd, Crawley, West Sussex, UK) according to manufacturer’s instructions.  
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Figure 5.13 Monocytes from all donors exhibited the same pattern in regulating MSC ALP 
activity in the presence of NS-398 and PGE2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Prior to using in the microarray study, monocytes from the five different donors were 
verified to be regulating MSC ALP in the same way. Each graph A-E represents data of a single 
experiment performed in triplicate shown as means ± S.D. Graph F shows the cumulative data of 
graphs A-E shown as mean ± S.E.M. * P<0.05, ** P<0.01, *** P<0.001 one-way ANOVA with 
Dunnett’s post-test comparison to MSC. 
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To validate that monocytes from each separate donor regulated MSC ALP activity as 
expected prior to microarray analysis, identical cultures were set up to assess ALP activity. 
As depicted in Figure 5.13A-E monocytes from all five donors responded in the expected 
way; 10:1 monocytes induced increase in ALP which was abrogated in the presence of NS-
398 but rescued with exogenous addition of PGE2. The variability in the magnitude of the 
response is due to monocyte and MSC donor variability and also depends on the passage of 
the MSCs but the pattern of regulation was always consistent.   
 
Isolated RNA was quantified and RNA quality assessed using a NanoDrop 
spectrophotometer. The 260/280 and 260/230 ratio of the samples used in this study is 
shown in Table 5.2. All samples had a 260/280 and 260/230 ratio close to 2 indicating RNA 
of good quality and purity. The subsequent steps of the microarray study including analysis 
of differentially expressed genes and pathway analysis was performed by the Genomic 
Services at the Welcome Trust Centre for Human Genetics in collaboration with Dr. Dilair 
Baban. Further validation of RNA quality was performed using the Agilent Bioanalyser, prior 
to labeled cDNA synthesis and hybridisation on Illumina Human HT-12 v3.0 Expression 
BeadChip microarray chips. The hybridized and washed chips were scanned using the 
Illumina BeadScan. Raw data normalization, filtering and analysis were performed using 
GeneSpring 11.5 as described in section 2.2.15.  
 
Legend for Table 5.2 (page 247) RNA from monocytes was isolated using the QIAamp RNA Blood 
Mini Kit (Qiagen Ltd, Crawley, West Sussex, UK) according to manufacturer’s instructions. To 
ascertain concentration and quality of the RNA a NanoDrop spectrophotometer was used.  
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Table 5.2 Quantification and purity of monocyte RNA samples used in the microarray study 
Sample ID  RNA C ng/µl A260 A280 260/280 260/230 
Donor 1 
Monocytes alone - 158.99 3.975 1.93 2.06 2.22 
10:1 Monocytes 
2h 
130.35 3.259 1.589 2.05 2.32 
10:1 Monocytes NS-398  114.23 2.856 1.388 2.06 2.35 
10:1 Monocytes PGE2 152.58 3.815 1.849 2.06 2.26 
10:1 Monocytes NS-398/PGE2 151.7 3.796 1.854 2.05 2.34 
10:1 Monocytes  
8h 
151.77 3.794 1.836 2.07 2.16 
10:1 Monocytes NS-398 129.76 3.244 1.581 2.05 2.26 
10:1 Monocytes PGE2 132.59 3.315 1.593 2.08 2.09 
10:1 Monocytes NS-398/PGE2 131.74 3.293 1.617 2.04 2.15 
Donor 2 
Monocytes alone - 159.11 3.978 1.962 2.03 2.15 
10:1 Monocytes 
2h 
150.95 3.774 1.852 2.04 2.2 
10:1 Monocytes NS-398 144.71 3.618 1.747 2.07 2.11 
10:1 Monocytes PGE2 162.75 4.069 2.015 2.02 1.95 
10:1 Monocytes NS-398/PGE2 146.32 3.658 1.798 2.03 1.4 
10:1 Monocytes 
8h 
143.3 3.583 1.76 2.04 2.06 
10:1 Monocytes NS-398 140.41 3.51 1.722 2.04 2.12 
10:1 Monocytes PGE2 149.68 3.742 1.857 2.02 1.56 
10:1 Monocytes NS-398/PGE2 136.93 3.423 1.679 2.04 2.03 
Donor 3 
Monocytes alone - 169.03 4.226 2.051 2.06 2.2 
10:1 Monocytes 
2h 
134.5 3.362 1.674 2.01 2.03 
10:1 Monocytes NS-398 142.52 3.563 1.792 1.99 2.13 
10:1 Monocytes PGE2 178.23 4.456 2.188 2.04 2.11 
10:1 Monocytes NS-398/PGE2 184.63 4.616 2.287 2.02 2.13 
10:1 Monocytes 
8h 
178.9 4.473 2.267 1.97 1.9 
10:1 Monocytes NS-398 161.04 4.026 1.972 2.04 2.08 
10:1 Monocytes PGE2 172.89 4.322 2.146 2.01 2.02 
10:1 Monocytes NS-398/PGE2 175.56 4.389 2.177 2.02 2.11 
Donor 4 
Monocytes alone - 169.98 4.249 2.115 2.01 2.16 
10:1 Monocytes 
2h 
142.79 3.57 1.771 2.02 2.11 
10:1 Monocytes NS-398 145.54 3.638 1.796 2.03 2.12 
10:1 Monocytes PGE2 162.34 4.058 2.008 2.02 2.14 
10:1 Monocytes NS-398/PGE2 168.62 4.216 2.103 2 2.15 
10:1 Monocytes 
8h 
150.17 3.754 1.873 2 1.46 
10:1 Monocytes NS-398 150.87 3.772 1.859 2.03 2.15 
10:1 Monocytes PGE2 158.46 3.961 1.963 2.02 2.13 
10:1 Monocytes NS-398/PGE2 155.81 3.895 1.922 2.03 2.1 
Donor 5 
Monocytes alone - 146.75 3.669 1.82 2.02 2.16 
10:1 Monocytes 
2h 
107.07 2.677 1.327 2.02 2.15 
10:1 Monocytes NS-398 121.74 3.043 1.498 2.03 2.16 
10:1 Monocytes PGE2 163.57 4.089 2.01 2.03 2.14 
10:1 Monocytes NS-398/PGE2 156.59 3.915 1.945 2.01 1.74 
10:1 Monocytes 
8h 
167.75 4.194 2.066 2.03 1.93 
10:1 Monocytes NS-398 159.94 3.999 1.965 2.03 2.17 
10:1 Monocytes PGE2 173.84 4.346 2.135 2.04 1.94 
10:1 Monocytes NS-398/PGE2 175.58 4.39 2.179 2.01 2.05 
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Genes with significantly altered expressions were identified by one way ANOVA with 
Benjamini-Hochberg multiple testing correction, with p<0.01. The entities satisfying the 
significance analysis were passed on for the fold change analysis. Firstly, gene expression of 
monocytes co-cultured with MSC for 2h and 8h was compared to monocytes that had been 
cultured alone.For a given gene its change in expression was calculated by dividing its 
average normalised intensity in treated samples from the respective control values. There 
were 1268 differentially expressed genes between monocytes co-cultured with MSC for 2h 
or 8h and monocytes cultured alone. Of these 812 were down-regulated and 456 were up-
regulated. The 20 most down-regulated genes are listed in Table 5.3 and the 50 most 
upregulated genes are listed in Table 5.4.  
 
Table 5.3 The 20 most down-regulated genes in monocytes from MSC co-cultures (2h and 
8h) compared to monocytes alone 
Symbol Definition Fold change 2h Fold change 8h 
CCR2 Chemokine (C-C motif) receptor 2  19.11 20.07 
CCR2 Chemokine (C-C motif) receptor 2 18.73 19.23 
TLR1 Toll-like receptor 1 11.88 7.59 
CEBPA CCAAT/enhancer binding protein (C/EBP) alpha 10.38 14.07 
PDK4 Pyruvate dehydrogenase kinase isozyme 4 9.76 10.74 
LOC646849 PREDICTED: hypothetical protein LOC646849 9.05 9.96 
CCR2 Chemokine Receptor (C-C motif) receptor 2 8.84 8.56 
PALLD Palladin cytoskeletal associated protein  8.07 8.92 
TLR6 Toll-like receptor 6 7.88 6.38 
DHRS9 Dehydrogenase/reductase (SRD family) member 9 7.11 20.86 
FUCA1 Fucosidase alpha-L-1 tissue 7.01 40.56 
FRAT2 Frequently rearranged in advanced T-cell lymphomas 2 6.96 3.68 
HHEX Hematopoietically expressed homeobox  6.66 10.50 
NFXL1 Nuclear transcription factor X-box binding-like 1 6.65 9.21 
DHRS9 Dehydrogenase/reductase (SRD family) member 9 6.57 28.89 
HMOX1 Heme oxygenase (decycling) 1 6.43 9.04 
MARCH1 Membrane-associated ring finger (C3HC4) 1 6.24 9.59 
NLRP12 NLR family pyrin domain containing 12 6.15 10.51 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 5.97 7.58 
CCR2 Chemokine (C-C motif) receptor 2 5.91 6.24 
Table 5.3 Fold change in expression was calculated by dividing the average normalised intensity in of 
genes with significantly down-regulated expression (with p<0.01 cutoff using one way ANOVA with 
Benjamini-Hochberg multiple testing correction) in monocytes co-cultured with MSC for 2h or 8h vs 
monocytes alone. Values shown are the medians from the five donors. 
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The most downregulated genes in monocytes co-cultured with MSCs vs monocytes alone 
were chemokine receptor 2 (CCR2), toll-like receptor 1 (TLR1) and TLR6, CCAAT/enhancer 
binding protein (C/EBP) alpha (CEBPA) and Pyruvate dehydrogenase kinase isozyme 4 
(PDK4) amongst others. As depicted in Table 5.4, the most upregulated genes in monocytes 
co-cultured with MSCs vs monocytes alone were mostly cytokines such as IL-6, IL-1A, TNF, 
IL-1B (highlighted in blue) and chemokines such as CCL20, CXCL2, CCL3L1, CCL4L2, CXCL1, 
CCL4, CCL3 and CXCL5 (highlighted in green). There was up-regulation of COX2 in monocytes 
following co-culture with MSCs consistent with FACS data showing that COX2 is induced in 
monocytes co-cultured with MSCs (Figure 5.3). COX2 upregulation is also consistent with 
the observation that blocking COX2 using specific inhibitor NS-398 inhibits the osteogenic 
capacity of monocytes. The most upregulated transcript was IL-6, and also highly 
upregulated were IL-1 and TNFα, all of which were previously identified to be upregulated in 
monocyte/MSC co-culture supernatants using ELISAs (Table 3.2 and Figure 3.14). However, 
these cytokines are not the mediators of monocyte osteogenic activity because their 
inhibition in monocyte/MSC co-cultures using neutralising antibodies did not ablate the 
osteogenic signal (Table 3.3). Other upregulated genes that are of particular interest are 
Tumour necrosis factor alpha-induced protein 6 (TNFAIP6 also known as TSG-6) as well as 
Oncostatin M (OSM). TSG-6 is regulator of OCs known to inhibit their differentiation and 
activity (Mahoney et al, 2008); the same investigators also provided some evidence that 
TSG-6 also inhibits BMP2-induced OB differentiation. OSM is the ligand for OSMR which was 
identified in Chapter 4 to be upregulated in the MSC overexpressing STAT3CA (Table 4.4). 
Interestingly, OSM signalling through OSMR and gp130 has been linked to OB differentiation 
(Itoh et al, 2006; Jay et al, 1996; Malaval et al, 2005; Song et al, 2007; Taguchi et al, 1998).  
CHAPTER 5                                         MONOCYTES PROMOTE OB DIFFERENTIATION VIA COX2 AND OSM 
250 
 
Table 5.4 The 50 most up-regulated genes in monocytes from co-cultures compared to 
monocytes alone 
Symbol Definition Fold change 2h Fold change 8h 
IL-6 Interleukin 6 (interferon, beta 2)  52.47 96.41 
CCL20 Chemokine (C-C motif) ligand 20 47.99 36.31 
PTGS2 Prostaglandin-endoperoxide synthase 2 (COX2) 47.14 39.04 
IL-1A Interleukin 1 alpha 47.00 42.72 
F3 Coagulation factor III (thromboplastin tissue factor) 39.70 30.10 
CXCL2 Chemokine (C-X-C motif) ligand 2 37.31 25.23 
G0S2 G0/G1 switch 2 36.56 23.55 
GJB2 Gap junction protein beta 2 26kDa 35.89 53.45 
CCL3L1 Chemokine (C-C motif) ligand 3-like 1 35.64 32.25 
LOC730249 PREDICTED: similar to immune-responsive protein 1 33.75 16.05 
TNF Tumour necrosis factor 31.82 30.24 
CCL3L1 Chemokine (C-C motif) ligand 3-like 1 31.52 27.42 
CCL4L2 Chemokine (C-C motif) ligand 4-like 2 27.32 22.27 
CCL3L1 Chemokine (C-C motif) ligand 3-like 1 25.87 23.94 
SERPINE2 Serpin peptidase inhibitor, clade E 25.65 26.02 
CXCL1 Chemokine (C-C motif) ligand 1  23.49 22.03 
TNFAIP6 Tumour necrosis factor alpha-induced protein 6 23.20 29.44 
F3 Coagulation factor III (thromboplastin tissue factor) 21.56 16.41 
PTGS2 Prostaglandin-endoperoxide synthase 2 (COX2) 21.28 21.05 
IL-23A Interleukin 23 alpha subunit p19 21.12 48.78 
TNFAIP6 Tumour necrosis factor alpha-induced protein 6 20.68 25.78 
CCL4 Chemokine (C-C motif) ligand 4 20.11 18.29 
CCL4L2 Chemokine (C-C motif) ligand 4-like 2 19.99 20.32 
CSF2 Colony stimulating factor 2 (granulocyte-macrophage) 19.12 18.34 
EREG Epiregulin 17.87 4.45 
IL24 Interleukin 24 17.16 63.76 
CCL3 Chemokine (C-C motif) ligand 3 16.86 16.72 
PLAUR Plasminogen activator, urokinase receptor 16.35 9.79 
CXCL5 Chemokine (C-X-C motif) ligand 5 15.55 51.54 
NLRP3 NLR family pyrin domain containing 3 15.36 3.72 
LOC387763 PREDICTED: hypothetical LOC387763 14.98 12.83 
IL1RN Interleukin 1 receptor antagonist  14.77 16.91 
EDN1 Endothelin 1 14.21 11.86 
LRRC50 Leucine rich repeat containing 50 14.05 18.46 
PLAUR Plasminogen activator, urokinase receptor 13.33 8.81 
HEY1 Hairy/enhancer-of-split related with YRPW motif 1 13.10 16.50 
CCL4L1 Chemokine (C-C motif) ligand 4-like 1 12.85 12.99 
NLRP3 NLR family pyrin domain containing 3 12.71 4.17 
SOCS3 Suppressor of cytokine signalling 3 12.68 13.59 
CDC2 Cell division cycle 2, G1/s and G2/M 12.22 2.22 
PDE4B Phosphodiesterase 4B, cAMP specific 11.91 9.63 
IL1RN Interleukin 1 receptor antagonist 11.91 13.26 
OSM Oncostatin M 11.89 6.97 
LOC644943 Similar to peptidylglycine alpha-amidating monoxygenase COOH-
terminal interactor 
11.66 10.83 
CXCL5 Chemokine (C-X-C motif) ligand 5 11.35 63.91 
PDE4B Phosphodiesterase 4B, cAMP specific 10.79 8.64 
ARL5B ADP-ribosylation factor-like 5B 10.45 8.29 
NLRP3 NLR family pyrin domain containing 3 10.41 3.86 
CTGF Connective tissue growth factor 9.92 4.81 
IL1B Interleukin 1 beta 9.42 9.80 
Table 5.4 Fold change in expression was calculated by dividing the average normalised intensity in of 
genes with significantly up-regulated expression (with p<0.01 cutoff using one way ANOVA with 
Benjamini-Hochberg multiple testing correction) in monocytes co-cultured with MSC for 2h or 8h vs 
monocytes alone. Values shown are the medians from the five donors. 
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To further narrow down the investigation for monocyte-derived factors with osteogenic 
activity the gene profiling data from NS-398, PGE2 or NS-398+PGE2 treated monocytes were 
analysed and used to complement the previous analysis of upregulated genes in monocytes 
co-cultured with MSCs vs monocytes alone. From all the 1268 genes regulated in monocytes 
in response to co-culturing with MSCs, just 28 were regulated in the same pattern as that 
observed with NS-398, PGE2 or NS-398+PGE2 in Figure 5.13, meaning to be upregulated in 
co-cultured monocytes, down-regulated in the presence of NS-398 and fold regulation 
reinstated with PGE2 addition in the presence of NS-398. As previously shown the 
osteoinductive effect of monocytes on MSC is mediated by soluble factors. Of the 28 NS-398 
and PGE2 regulated genes only 7 encoded for secreted factors namely IL-24, Chemokine (C-
X-X motif) ligand 5 (CXCL5), Epiregulin (EREG), OSM, IL-10, Matrix metallopeptidase 9 
(MMP9), Laminin beta 3 (LAMB3). Their regulation is shown in Table 5.5.  
 
IL-24 and CXCL5 were upregulated at 2h and further upregulated after 8h of co-culture. IL-
24 expression was not affected by the addition of PGE2 in the absence of NS-398, was 
dramatically reduced in the presence of NS-398 but reinstated with the addition of PGE2 
similar to expression levels detected in 10:1 and 10:1+PGE2 monocytes. CXCL5 expression 
was increased when PGE2 was added to monocytes, indicating a regulation by PGE2, but 
followed the regulation pattern of reduced expression in the presence of NS-398 which was 
reinstated with PGE2. In contrast to IL-24 and CXCL5, expression of EREG, OSM, IL-10, MMP9 
and LAMB3 were not further enhanced after 2h hours indicating that these could represent 
early acting genes. Nonetheless, the expression pattern of all of them agreed with the 
regulation of MSC differentiation by monocytes in the presence of NS-398 and PGE2. 
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Table 5.5 Genes up-regulated by co-culture, down-regulated by NS-398 and expression 
restored by PGE2  
Symbol 10:1 10:1 + PGE2 10:1 + NS-398 10:1 + NS-398+PGE2 
IL-24      
2h 17.16 13.45 7.18 10.27 
8h 63.76 69.56 18.69 72.61 
CXCL5     
2h 15.55 17.18 8.72 19.26 
8h 63.91 114.78 15.35 143.24 
EREG     
2h 17.87 27.20 10.01 30.56 
8h 4.47 4.71 1.85 7.14 
OSM     
2h 11.89 13.04 8.49 11.97 
8h 6.97 7.48 4.32 8.79 
IL-10     
2h 5.46 10.81 2.81 11.33 
8h 5.02 8.05 3.24 10.21 
MMP9     
2h 2.18 4.93 1.51 6.52 
8h 2.30 3.69 1.26 4.40 
LAMB3     
2h 5.45 7.46 3.41 7.35 
8h 4.25 5.64 2.31 7.07 
Table 5.5 Fold change in expression was calculated by dividing the average normalised intensity in of 
genes with significantly regulated expression (with p<0.01 cutoff using one way ANOVA with 
Benjamini-Hochberg multiple testing correction) in monocytes co-cultured with MSC (10:1), MSC and 
PGE2 (10:1+PGE2), MSC and NS-398 (10:1+NS-398) or MSC and both NS-398 and PGE2 (10:1+NS-
398+PGE2) for 2h or 8h vs monocytes alone. Values shown are the medians from the five donors. 
 
To assess the possible implication of these molecules in promoting OB differentiation in 
MSCs we tested the effect of direct addition on ALP activity in MSC cultures. From the seven 
identified candidates the first four more strongly regulated were tested namely IL-24, 
CXCL5, EREG and OSM. The lack of direct effect of IL-10 on MSC differentiation was shown 
previously (Table 3.3 & Figure 4.6A). MSCs were treated with human recombinant IL-24, 
CXCL5, EREG and OSM at increasing concentrations in control media or in osteogenic media 
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and ALP activity was quantified after seven days. As depicted in Figure 5.14A-C exogenous 
addition of recombinant IL-24, CXCL5 or EREG respectively did not have any effect on 
baseline ALP activity of MSCs either cultured in control or osteogenic media. On the other 
hand addition of OSM induced a dose dependent increase in ALP activity in the presence of 
osteogenic media and also in small degree in control media where there is no added 
osteogenic stimulus (Figure 5.14D). These findings validated OSM as the monocyte-derived 
factor mediating the ability of monocytes to promote osteogenic differentiation of MSCs. 
 
Figure 5.14 OSM induces osteogenic differentiation of MSCs 
 
 
 
 
 
 
 
 
Figure 5.14 1x104 MSC were cultured in the presence of 0.1, 1 or 10 µM of IL-24 (A), CXCL5 (B), EREG 
(C) or OSM (D) in control or osteogenic media and ALP activity was assessed after 7 days. Data 
shown are cumulative of two (for IL-24, CXCL5 and EREG) or three (for OSM) independent 
experiments and represented as mean ± S.E.M. * P<0.05, *** P<0.001 one-way ANOVA with 
Dunnett’s post-test comparison to 0ng/ml.  
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5.5 Discussion 
In this chapter it was shown that COX2 and PGE2 mediate the ability of monocytes to 
enchance osteogenic differentiation of MSCs. PGE2 has been extensively reported to 
mediate interactions between MSCs and immune cells (Aggarwal & Pittenger, 2005; Kim & 
Hematti, 2009; Maggini et al, 2010; Nemeth et al, 2009). Similarly to the upregulation of 
PGE2 in the monocyte/MSC co-cultures shown in this chapter (Figure 5.1), Nemeth and 
colleagues showed upregulation of PGE2 in co-cultures of mouse MSCs and Mφs (Nemeth et 
al, 2009). This PGE2 was responsible for altering Mφ phenotype including increased 
expression of CD206, a marker of M2 Mφs, decreased CD86 and MHCII expression (Kim & 
Hematti, 2009; Maggini et al, 2010), decreased production of inflammatory cytokines such 
as TNFα, IL-6, IL-12p70 and IFNγ but increased production of IL-10 and IL-12p40 (Aggarwal & 
Pittenger, 2005; Kim & Hematti, 2009; Maggini et al, 2010; Nemeth et al, 2009), as well as 
enhanced phagocytic ability (Maggini et al, 2010). In support of a role for PGE2 in MSC-Mφ 
interactions, inhibitors of COX enzymes, and hence PGE2 production, such as indomethacin 
or NS-398, impaired the ability of MSCs to stimulate production of IL-10 and inhibit 
production of pro-inflammatory cytokines (Aggarwal & Pittenger, 2005; Maggini et al, 2010; 
Nemeth et al, 2009). These studies show that MSCs can polarise Mφs into an anti-
inflammatory M2 phenotype which is associated with TH2 response and tissue repair. This 
phenotype could in turn be favourable to bone regeneration by promoting differentiation of 
mesenchymal progenitors to OBs. 
 
In agreement with this hypothesis, findings presented in Chapter 3 showed that in 
monocyte or Mφ/MSC co-cultures, monocyte/Mφs could increase OB differentiation of 
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MSCs. Furthermore in this chapter, similarly to the effects of MSCs on Mφs described above, 
the osteogenic effect of monocytes on MSCs was found to be mediated by COX2 and PGE2 
since increased differentiation was inhibited in the presence of COX2 specific inhibitor NS-
398 (Figure 5.5) but could be rescued by exogenously added PGE2 (Figure 5.6). PGE2 and 
COX2 are known to have important roles in bone regulating osteoclastogenesis, 
mechanotransduction and bone repair (Kawaguchi et al, 1995; Kawaguchi et al, 1994; Raisz, 
1995). For example, COX2-/- mice have decreased bone density compared to WT mice 
(Alam et al, 2005; Chen et al, 2003b; Robertson et al, 2006) and COX2-/- mice but not COX1-
/- mice display reduced bone resorption in response to PTH and 1,25-hydroxyl vitamin D3 
(Okada et al, 2000). Systemic or local injection of PGE2 stimulates bone formation 
(Suponitzky & Weinreb, 1998; Weinreb et al, 1997) while increased lamellar bone formation 
in response to mechanical loading is mediated by COX2 and can be completely inhibited by 
COX2 specific inhibitor NS-398 (Duncan & Turner, 1995; Forwood, 1996). A number of 
studies have suggested that PGE2 and COX2 directly influence OB differentiation by 
regulating the expression of bone specific transcription factors RUNX2 and Osterix 
(Ninomiya et al, 2011; Yoon et al, 2010; Zhang et al, 2002a). Finally, in COX2-/- mice there is 
a delay in fracture repair due to a persistence of undifferentiated mesenchyme and a 
primary defect in osteoblastogenesis with decreased expression of RUNX2 and Osterix 
(Zhang et al, 2002a). Similar studies further validated these findings by using COX2 specific 
inhibitors which delayed repair in fracture models (Endo et al, 2002; Simon et al, 2002) and 
conversely administration of PGE2 which increased the rate of fracture healing (Xie et al, 
2009; Zhang et al, 2002a).  
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COX2 was found to be activated in both MSCs and monocytes following their interaction 
(Figure 5.2 & 5.3). Indeed, COX2 expression has been previously shown in both 
mesenchymal osteoprogenitors in the periosteum and infiltrating immune cells including 
Mφs at sites of bone fracture (Xie et al, 2008). Furthermore, using a bone graft 
transplantation model where WT bone grafts with intact periosteum were transplanted into 
COX2-/- mice and the reverse, Xie and colleagues showed that the COX2 expression by the 
infiltrating Mφs was critical for osteogenic differentiation and endochondral bone formation  
(Xie et al, 2008). Since it is known that both MSCs and monocytes are able to produce PGE2 
(Aggarwal & Pittenger, 2005; James et al, 2001), it is likely that both cell types are 
contributing to the upregulation of PGE2 production in monocyte/MSC co-cultures, which is 
probably further enhanced since PGE2 can enhance its own production by further inducing 
COX2 expression (Kawaguchi et al, 1994; Pilbeam et al, 1993; Pilbeam et al, 1995; Suda et al, 
1998).  
 
PGE2 exerts its actions by binding to one of its four subtypes of receptors EP1, EP2, EP3 and 
EP4 (Sugimoto & Narumiya, 2007). These are G-protein coupled receptors (GPCRs) and the 
cellular response to PGE2 depends on the type of heterotrimeric G-proteins associated with 
them. EP1 is coupled to Gαq and elicits enhanced intracellular Ca
2+ levels by influencing 
phosphatidylinositol turnover (Funk et al, 1991). The EP2 and EP4 receptors are coupled to 
Gαs proteins which induce cyclic AMP (cAMP) production by adenylate cyclase and lead to 
gene regulation through protein kinase A (PKA) (Ichikawa et al, 1996). Finally, the EP3 
receptor is coupled primarily to Gαi and is inhibitory of cAMP (Fabre et al, 2001). In this 
chapter it was found that as well as by PGE2 (Figure 5.6), the NS-398 inhibitory effect on 
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monocyte-induced MSC osteogenesis was also rescued by EP2/4 receptor agonists but not 
by EP1/3 receptor agonists (Figure 5.7). Interestingly, the anabolic effects of PGE2 on bone 
have been attributed to EP2/4 receptors (Gao et al, 2009; Li et al, 2007a; Ninomiya et al, 
2011; Paralkar et al, 2003; Xie et al, 2009; Yoshida et al, 2002b), in agreement with the 
findings in this chapter.  
 
Despite the fact that PGE2 rescued NS-398 inhibition of the monocyte osteogenic effect, 
directly adding PGE2 to MSC cultures did not cause an equal ALP increase to that caused by 
the monocytes (Figure 5.8). This indicated that PGE2 could have an indirect rather than a 
direct role in this system, for example the induction of other soluble factors by the 
monocytes. It is known that in addition to catalysing the biosynthesis of PGE2, COX2 also 
participates in the production of other lipid mediators such as the lipoxins, resolvins and 
protectins, important mediators for the resolution of inflammatory responses (Levy et al, 
2001). Resolution of inflammation is now recognised as an active metabolic process that 
involves cellular interactions and is closely regulated (Serhan, 2007; Serhan, 2010; Serhan et 
al, 2007; Serhan et al, 2008). Classic pro-inflammatory mediators such as PGE2 and 
Leukotriene B4 are produced in the early stage of an inflammatory response are responsible 
for driving the inflammatory response and the cardinal signs of inflammation. However as 
the inflammatory response progresses there is a change in the type of lipid mediators being 
produced because PGE2 can induce the expression of the LOX enzymes that are responsible 
for the production of these pro-resolution mediators (Levy et al, 2001). This new group of 
molecules have been shown to promote resolution by selectively stopping neutrophil and 
eosinophil infiltration, eliciting non phlogistic recruitment of monocytes, activating Mφ 
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phagocytosis of microorganisms and apoptotic cells, increasing the exit of phagocytes from 
the inflamed site through lymphatics and stimulating the expression of molecules involved 
in anti-microbial defence (Campbell et al, 2007; Canny et al, 2002; Serhan et al, 2007; 
Serhan et al, 2002). Interestingly two of these molecules, Lipoxin A4 and Resolvin E1, have 
been used in animal models of inflammatory bone disease where they prevented loss of 
connective tissue and bone (Serhan et al, 2003). Administration of Resolvin E1 also 
promoted the healing and regeneration of lost soft tissue and bone (Hasturk et al, 2007). 
Additionally, in vitro data has shown that Resolvin E1 modulates OCL differentiation and 
bone resorption (Herrera et al, 2008). 
 
Inhibition of 5/12/15-LOX enzymes using inhibitors significantly inhibited the ability of 
monocytes to induce MSC osteogenesis strongly supporting a role for LOX products in 
mediating monocyte-induced osteogenesis (Figure 5.10 & 5.11). However, in spite of the 
promising effects of the lipoxins and resolvins in animal models none of the LOX products 
tested, including Lipoxin A4 and Resolvin E1, had a direct effect on MSC osteogenic 
differentiation (Table 5.1). Even though osteogenic ability could not be attributed to a 
specific LOX product of those tested, the inhibition of monocyte (Figure 5.10 & 5.11) or 10:1 
co-culture supernatants osteogenic ability by baicalein (Figure 5.12) strongly suggests that 
they are involved in this effect. Many new products of the LOX enzymes are being 
recognized such as the recently identified maresins (Serhan et al, 2009). These are especially 
interesting because they are primarily produced by Mφs. Interestingly, the phenotype of 
Mφs present at the resolution phase of an inflammatory response has been described. 
Bystrom and colleagues showed that COX2 was activated in pro-inflammatory M1 Mφs that 
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mediate protection against pathogens but Mφs isolated from the resolving phase of acute 
inflammation had an alternatively activated phenotype similar to M2 Mφs. This phenotype 
was characterised by reduced pro-inflammatory and enhanced anti-inflammatory cytokine 
production compared to M1 Mφs, but still retained high expression of COX2 (Bystrom et al, 
2008). This phenotype was found to be controlled by cAMP, suggesting a role for PGE2 
signalling through EP2/4 receptors, which when inhibited reverted cells back to the M1 
phenotype. These resolution phase Mφs were essential for signalling post resolution 
lymphocyte repopulation via COX2 lipids, which have been shown to be a marker of 
postinflammation restoration of tissue physiology (Rajakariar et al, 2008). This phenotype of 
resolution Mφs, resembling M2 Mφs and expressing COX2, resemble the monocyte/Mφs 
identified in this chapter to be promoting osteogenic differentiation of MSCs. This suggests 
that, in addition to being favourable to inflammatory resolution, this phenotype of 
resolution Mφs could be contributing to bone repair by inducing enhanced differentiation of 
MSCs. 
 
Since investigation of LOX products did not lead to the identification of the monocyte-
derived factor with osteogenic ability, a high throughput approach was employed. Using 
mRNA microarrays the transcriptome of monocytes cultured alone was compared to that of 
monocytes that had been cultured in contact with MSCs in the first instance. This 
comparison resulted in a large number of regulated genes (Table 5.3 & Table 5.4), which 
also included COX2 among the most upregulated genes in monocytes co-cultured with MSCs 
(Table 5.4), in support of the previous findings in this chapter. To further narrow down a list 
of candidates for the monocyte osteogenic effect, the regulation of monocyte expression 
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profile by NS-398 and PGE2 was also investigated using mRNA microarray. This analysis 
identified just seven candidate genes, IL-24, CXCL5, EREG, OSM, IL-10, MMP9 and LAMB3, 
that followed the pattern of regulation by NS-398 and PGE2 and also encoded for soluble 
factors (Table 5.5). Of these, only OSM could potently induce ALP activity in a dose response 
manner when added to MSC cultures in increasing concentrations (Figure 5.14D). 
Interestingly the magnitude of ALP activity induced by 10ng/ml of OSM was equal to levels 
induced in MSCs when they are cultured with monocytes. These findings suggest that OSM 
is the mediator of the monocyte-induced MSC osteogenesis. 
 
OSM is produced by activated monocytes/Mφ and T cells and belongs to the IL-6 family of 
cytokines which also includes IL-6, IL-11, LIF, ciliary neurotrophic factor (CNTF) and 
cardiotrophin 1 (CT-1). All members of this family signal through receptor complexes that 
use a common receptor component the glycoprotein 130 (gp130). The OSM receptor 
complex consists of gp130 as well as a second receptor which is either the LIFRβ or the 
OSMRβ, and it has been shown that OSM signalling through LIFR or OSMR results in distinct 
outcomes (Walker et al, 2010). Although, IL-6R is weakly expressed or absent from bone 
marrow stromal cell or OBs, receptor components gp130, LIFRβ and OSMRβ that are used 
by OSM were shown to be expressed by bone marrow osteoblastic cells, OB cell lines as well 
as mouse calvaria OBs, bone lining cells and osteocytes (Bellido et al, 1996; Walker et al, 
2010).  
 
In agreement with the identification of OSM as an osteogenic factor in this chapter several 
studies have shown a role for OSM in the regulation of bone metabolism and remodelling. 
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This role is exemplified by the Stüve-Wiedemann syndrome, a severe autosomal recessive 
genetic disease caused by null mutations of LIF receptor whose prominent features include 
bowing of long bones, cortical thickening and altered trabecular pattern (Dagoneau et al, 
2004). The osteogenic effect of OSM has been shown both in vitro and in vivo. 
Administration of OSM was shown to increase ALP activity and mineralisation in murine 
stromal cell line Kusa 4b10 (Walker et al, 2010), mouse bone marrow cells, where it also 
inhibited adipogenic differentiation, (Gimble et al, 1994), rat bone marrow cells (Chipoy et 
al, 2004; Malaval et al, 2005), and human adipose-derived MSCs where, in contrast to OSM, 
IL-6 and LIF did not induce mineralisation (Song et al, 2007). Genetic deletion of gp130 or 
LIFR in mice results in a neonatal lethal phenotype including osteopenia due to increased OC 
formation and decreased bone formation (Shin et al, 2004; Ware et al, 1995), and OBs 
derived from gp130-/- mice exhibit diminished ALP mRNA and protein both in vivo and in in 
vitro cultures (Shin et al, 2004). Furthermore, transgenic mice overexpressing OSM develop 
osteopetrotic bones and enlarged hind limbs, possibly by stimulation of bone formation and 
inhibition of bone resorption (Malik et al, 1995). De Hooge and colleagues used adenoviral 
constructs to direct mOSM expression in mouse knee joints and showed that it stimulated 
periosteal bone formation in vivo (de Hooge et al, 2002). Consistent with these findings 
injection of mOSM over calvarie of 5-week-old male C57BL/6 mice lead to an increase in 
calvarial thickness, mineral apposition rate, mineralizing surface/bone surface and bone 
formation rate/bone surface (Walker et al, 2010). Furthermore, neonate and adult mice 
lacking OSMR had increased bone mass due to low bone formation and bone resorption and 
OSMR-/- primary calvarial OB had reduced mineralised nodule formation and lower ALP 
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activity (Walker et al, 2010). Collectively, in vitro and in vivo evidence highlight the critical 
role of OSM as an important regulator in bone. 
 
The identification of OSM as the monocyte-derived factor with osteogenic ability also 
agreed with the fact that monocytes and Mφs are known producers of OSM (Zarling et al, 
1986). More interestingly, in agreement with the regulation of OSM expression by COX2 and 
PGE2 shown in this chapter, Repovic and colleagues have shown that PGE2 can induce OSM 
expression in microglia, the resident Mφs of the brain, as well as in monocytes and Mφs of 
mouse and human origin (Repovic & Benveniste, 2002). Further in support of the findings 
showing a role in promoting MSC osteogenesis restricted to monocyte/Mφs, PGE2 
regulation of OSM expression appears to be restricted to cells of monocytic origin because a 
number of other cell types reported to produce OSM (T cells, neutrophils, endothelial cells 
and neuroblastoma cells) failed to express OSM in response to PGE2 (Repovic & Benveniste, 
2002). Additionally, PGE2 signals through EP2/4 receptors to induce OSM expression since 
PGE2 induction of OSM could be mimicked by cholera toxin, an activator of Gs proteins, 
forskolin, an activator of adenylate cyclase, and cAMP analog dibutyryl-cAMP. Furthermore, 
PGE2 induction of OSM could be inhibited by the adelylate cyclase inhibitor 2’-5’-
dideoxyadenosine, as well as by a PKA inhibitor, H-89, and a dominant negative PKA 
construct (Repovic & Benveniste, 2002). The work by Repovic and colleagues further 
correlates with the findings shown in this chapter showing a role for PGE2 signalling through 
EP2/4 receptors in monocyte/MSC co-cultures (Figure 5.7). 
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OSM has well recognised osteogenic ability but what is the mechanism? Walker and 
colleagues have shown that in murine Kusa 4b10 stromal cells, OSM rapidly induced 
expression of OB transcription factors C/EBPδ and C/EBPβ, and consistent with Runx2 
activation by C/EBPδ, it activated transcription of a 6xOSE2 reporter construct (Walker et al, 
2010). Additionally, OSM strongly inhibited expression of sclerostin, an osteocyte-derived 
mineralisation inhibitor, both in vitro in murine and human OB cultures, and in vivo in mice 
calvariae injected with OSM (Walker et al, 2010). Another signalling pathway by which OSM 
could be regulating osteogenesis is the STAT3 pathway, which would also agree with the 
findings presented in Chapter 4 showing a role for STAT3 signalling in MSC osteogenesis. 
OSM exerts its actions by signalling via JAK/STAT and MAPK pathways. OSM can activate 
STAT3 in OBs (Levy et al, 1996) and it has been shown that stimulation of ALP activity by 
OSM was abrogated by tyrosine kinase inhibitors as well as a threonine/serine kinase 
inhibitor, but only minimally affected by a specific inhibitor of MAPK phosphorylation, 
indicating a primary role for the JAK/STAT pathways mediating OSM osteogenic properties 
(Bellido et al, 1997). Activation of STAT3 by OSM in a hepatoma cell line HepG2 could induce 
expression of c-Fos (Botelho et al, 1998) which participates in transcription complexes with 
Jun proteins and AP-1. Overexpression of Fos proteins FRA-1 or ΔFosB led to a progressive 
increase in overall bone mass by an unknown mechanism (Jochum et al, 2000; Sabatakos et 
al, 2000). Further investigations are required to determine a possible role for Jun and AP-1 
in this system. Additionally, OSM signalling through STAT3 has been shown to directly target 
WNT5a (Fujio et al, 2004; Katoh, 2007) which promotes osteogenic differentiation of MSCs. 
All these studies give evidence of the possible mechanisms by which monocytes induce MSC 
osteogenic differentiation through OSM upregulation. 
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6.1 Concluding Discussion 
With the rise of multipotent stem cells as prominent tools in regenerative medicine, there is 
great promise for the restoration or replacement of tissues and organs that fail due to 
disease or trauma. With an aging population the increasing incidence of bone disease such 
as osteoporosis, associated fragility fractures and arthritis needs to be addressed with 
strategies that aim to replace lost bone tissue. Additionally, the devastating bone loss 
associated with inflammatory disease such as RA further stresses the urgent need for simple 
yet effective therapeutic strategies to promote bone formation. In the past the use of BMPs 
or ex vivo expanded stem cells to induce bone formation has not shown the anticipated 
efficacy while also involving complex and costly protocols with added safety concerns over 
the long time for ex vivo cell expansion and possibility for transformation of cultured cells. 
Currently, the most effective therapeutic approach to bone loss is the manipulation of bone 
remodelling using bisphosphonates, which inhibit OC-mediated resorption, or PTH 1-34, 
which enhances OB function. However, PTH also increases OC activity as a negative 
feedback loop, especially when administered continuously (Hock & Gera, 1992; Tam et al, 
1982). Additionally, the use of bisphosphonates and PTH, although useful in diseases of 
systemic bone loss such as osteoporosis, would not be appropriate for situations where 
bone formation is required in specific locations such as for the repair of critical size defects 
and fractures. The ideal strategy aiming at the induction of predictable bone formation 
would be to manipulate the natural ability of the body to heal by directing stem cells and 
inducing their differentiation specifically where and when needed. This requires a better 
understanding of the many, as yet poorly understood, aspects of the regulation of OB 
differentiation.  
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An increasing body of evidence investigating direct interactions of the immune and skeletal 
systems provides an insight into the mechanisms involved with bone loss in inflammatory 
disease but can also provide an excellent system to study the regulation of OB 
differentiation. With a view to gaining a better understanding of the regulation of OB 
differentiation both in homeostasis and disease, this study aimed at elucidating interactions 
between the immune system and OB differentiation. The findings presented here could 
ultimately lead to the identification of mediators that can promote osteogenesis and the 
establishment of new clinically therapeutic agents. 
 
The main findings from this study are; 
1. Monocytes and Mφs can promote osteogenic differentiation of MSCs 
2. This is mediated by cell contact and monocyte-derived soluble factors produced as a 
result of the cells’ interactions. 
3. CD14+CD16+ monocytes and M1 polarised Mφs which are associated with an 
inflammatory phenotype inhibit MSC osteogenic differentiation. 
4. Monocyte/MSC interactions result in activation of STAT3 signaling in MSCs 
5. Constitutive activation of STAT3 in MSCs enhances their osteogenic differentiation. 
6. COX2 and PGE2 mediate the ability of monocytes to promote MSC osteogenic 
differentiation. 
7. Genome profiling recognised OSM as the mediator of the monocyte-induced MSC 
osteogenesis. 
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This study was the first to report that monocytes and Mφs directly regulate osteogenic 
differentiation of MSCs. Just as enhanced MSC osteogenesis in the presence of monocytes 
and Mφs required the osteogenic stimulus in vitro, in vivo monocytes and Mφs will probably 
promote and enhance osteogenic differentiation directed by local factors. This would 
ensure that bone formation will not occur uncontrollably or in the wrong place. Prior to this 
study there was limited evidence about the direct regulation of OB differentiation by 
immune cells. Previous reports by a single group suggested a possible role for activated T 
cells in influencing OB differentiation through soluble factors (Rifas, 2006; Rifas et al, 2003), 
however these studies have not been further validated by other groups. More recently, a 
role for HSC in regulating OB differentiation, and therefore their own haematopoietic niche, 
provided further evidence for a direct regulation of OB differentiation by immune cells (Jung 
et al, 2008). Finally, an important report from Chang and colleagues demonstrated that Mφs 
are important regulators in bone tissues contributing to the organisation of bone 
remodelling sites on bone surfaces in vivo as well as efficient mineralisation of mature OBs 
in vitro (Chang et al, 2008). This report did not investigate the contribution of Mφ on OB 
differentiation from their mesenchymal progenitors nor did it suggest a mechanism by 
which Mφ regulated OB either in vivo or in vitro. However, it described a requirement for 
cell-cell interactions. The findings presented in this thesis fill this gap by showing that 
monocytes and Mφ not only promote mineralisation but also the differentiation of OBs 
from MSCs. 
 
Interestingly, the published studies mentioned above described that regulation of OBs 
required cell-cell interactions but also involved soluble mediators. Indeed it was also shown 
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here that the ability of monocytes to enhance osteogenesis required cell contact but was 
ultimately mediated by soluble factor(s). This factor(s) was found to be produced by 
monocytes as a result of their interaction with MSCs and could enhance ALP activity as well 
as the formation of mineralised bone nodules. Human and murine Mφ cell lines have been 
previously shown to produce BMPs, such as BMP2, (Champagne et al, 2002) which are 
important inducers of osteogenic differentiation and bone formation both in vitro and in 
vivo (Bandyopadhyay et al, 2006; Friedman et al, 2006; Lee et al, 2000; Lee et al, 2003a; 
Yamaguchi et al, 2000). Although, BMPs represented obvious candidates to be mediating 
the enhanced osteogenesis in the monocyte-MSC co-cultures the levels of BMP2, BMP4, 
BMP7 as well as TFGβ1 were not increased in the co-cultures. Further discounting a role for 
BMPs in the Mφ-MSC co-cultures, data from Dr Mei Mei Wong in our laboratory showed 
that neutralisation of  BMP2, 3, 4, 7 as well as TFGβ1 in these co-cultures did not inhibit the 
ability of Mφs to enhance MSC osteogenesis (Dr Mei Mei Wong, PhD thesis). Cell-cell 
contact between murine MSCs and Mφs was previously shown to induce IL-10 production 
(Nemeth et al, 2009). In agreement with this, the present study showed that following co-
culture of MSCs and monocytes there was up-regulation of IL-10 as well as many other 
cytokines including IL-6, IL-10, IL-8, TNFα and IL-1β however none of these were responsible 
for the monocyte-induced osteogenesis.  
 
Further investigation of the monocyte osteogenic effect identified that, whilst CD14++CD16- 
and CD14+CD16+ monocyte subsets could equally promote osteogenic differentiation of 
MSCs when unactivated, they had a different effect in the presence of LPS. In the latter 
conditions CD14+CD16+ inhibited MSC differentiation. Similarly, Mφs polarised towards a 
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pro-inflammatory M1 phenotype could not promote osteogenic differentiation as compared 
to M2 polarised Mφs which greatly enhanced MSC ALP activity. These findings were 
especially interesting since CD14+CD16+ monocytes, although they constitute only 5-10 % of 
peripheral monocyte populations, have been shown to be elevated in many inflammatory 
diseases (Baeten et al, 2000; Fingerle et al, 1993; Hakkinen et al, 2000) where they are 
thought to contribute to disease pathology through their production of pro-inflammatory 
cytokines. In a similar manner, differentiation and polarisation of Mφs towards M1 pro-
inflammatory phenotype is favoured during infection and inflammation when the levels of 
GM-CSF and IFNγ are elevated (Gordon, 2003; Gordon & Taylor, 2005; Hamilton, 2008; 
Mosser, 2003). In contrast to Mφs with an M2 phenotype which produce anti-inflammatory 
cytokines and are associated with tissue repair, M1 Mφs further contribute to the 
inflammatory milieu through the production of pro-inflammatory cytokines such as IL-23, IL-
12, IL-1β, IL-6 and TNFα (Verreck et al, 2006) and in this way have also been involved with 
disease pathology (Hamilton, 2002a; Hamilton, 2008). For example, the high levels of GM-
CSF in an inflammatory milieu in the RA joint would favour M1 polarisation and thus the 
production of IL-1β, IL-6 and TNFα. These cytokines will support formation and activation of 
OCs and thus OC-mediated bone destruction. However the production of pro-inflammatory 
cytokines might not be the only mechanism by which CD14+CD16+ monocytes and 
inflammatory M1 Mφs contribute to bone destruction in RA. Data presented in this thesis 
suggest that these cells contribute to bone loss also by mediating an inhibitory effect on 
MSC differentiation to OBs in an environment where at the same time OC activity is 
promoted. It can be hypothesised that the effect on bone formation will depend on the 
balance between pro-inflammatory and anti-inflammatory monocytes and Mφs.  
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The findings presented in this thesis compliment published literature in providing an insight 
into the regulation of bone formation by monocytes and Mφs during homeostasis as well as 
in disease. In homeostasis monocytes and Mφs are an intergral part of bone tissue and 
contribute to normal OB differentiation and bone formation. In this steady state situations 
monocyte susbsets can equally enhance osteogenic differentiation and tissue Mφs, 
differentiated under the influence of M-CSF, are constituents of bone tissues with important 
contributions to bone homeostasis (Chang et al, 2008; Pettit et al, 2008). During 
inflammation, MSCs have been shown to migrate to sites of inflammation or tissue injury 
(Barbash et al, 2003; Chen et al, 2003a; Djouad et al, 2009; Granero-Molto et al, 2009; 
Kawada et al, 2004; Wang et al, 2008), where they will encounter the activated monocyte 
subsets and inflammatory Mφs. MSCs are activated by pro-inflammatory cytokines such as 
IFNγ, TFNα and IL-1, products of M1 Mφs, to exert their immunomodulatory properties (Ren 
et al, 2008) and have been shown to influence polarisation of Mφ populations towards M2-
like phenotypes (Kim & Hematti, 2009; Nemeth et al, 2009). These actions will contribute to 
the dampening down of inflammation and return to homeostasis but also have a reciprocal 
effect on MSCs because the monocyte and Mφ populations will support MSC differentiation 
thus contributing to tissue repair (Figure 6.1). Conversely, in situations of chronic 
inflammation the accumulating inflammatory monocytes and Mφs will have a detrimental 
effect on the ability on MSCs to differentiate and contribute to tissue repair. The 
inflammatory milieu will support osteoclastogenesis and thus bone destruction, through 
differentiation of CD14++CD16- monocytes, since the OC progenitor is contained in this 
population (Komano et al, 2006; Lari et al, 2009). Accumulation of CD14+CD16+ and 
inflammatory Mφs, on the other hand, which are inhibitory to MSC OB differentiation, will 
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tip the scales against OB differentiation contributing to the lack of bone formation and 
repair. 
 
Figure 6.1 Interactions between MSCs and Mφs regulate OB differentiation  
 
 
 
 
 
 
 
 
 
 
Figure 6.1 MSCs are activated by pro-inflammatory mediators such as IFNγ to exert their 
immunoregulatory abilities including Mφ polarisation towards an M2 phenotype. PGE2 has been 
shown to be involved in this process. This study indentified that M-CSF (M2) Mφs can promote the 
differentiation of MSCs to OBs adding another loop to the network of MSC - Mφ interactions. 
Promotion of a M2 Mφ phenotype is associated with tissue remodelling and repair and indeed the 
findings presented in this thesis support a role for M2 Mφs in bone repair. 
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The search for the mechanism by which monocytes promote the differentiation of MSC to 
OBs identified STAT3 activation as an important mediator of this event. Monocyte-derived 
factors in co-culture supernatants caused phosphorylation of STAT3 in MSCs. The induction 
of STAT3 in MSCs in co-culture with Mφs has been previously shown by Gur-Wahnon and 
colleagues, who showed that STAT3 signalling was also induced in the Mφs and suggested 
that this could be a mechanism by which MSCs promote an anti-inflammatory phenotype in 
Mφs (Gur-Wahnon et al, 2007). However, the effects of Mφs and STAT3 activation on MSCs 
were not explored by the Gur-Wahnon study. Further investigations presented in this thesis 
showed that monocyte subsets which differently regulated MSC osteogenic differentiation 
also differentially activated STAT3 in the presence of LPS; the osteogenic CD14++CD16- 
monocytes induced STAT3 signalling in MSC whereas the inhibitory CD14+CD16+ did not.  
 
STAT3 was further validated to be mediating the enhanced osteogenesis in MSCs induced by 
monocytes because a STAT3 dominant negative form abrogated the osteogenic effect of co-
culture supernatants whereas overexpression of a constitutively active STAT3 in MSC greatly 
increased osteogenesis. In agreement with these findings a role for STAT3 signalling in MSC 
osteogenesis has been previously reported (Bellido et al, 1997; Dagoneau et al, 2004; Itoh et 
al, 2006; Mikami et al, 2009; Mikami et al, 2010; Nishimura et al, 1998). OB-specific 
disruption of the Stat3 gene using Cre-Lox recombination and collagen I promoter Cre mice 
resulted in an osteoporotic phenotype due to reduced bone formation, whilst gp130 knock-
in mice had an osteosclerotic phenotype (Itoh et al, 2006). Furthermore, OBs derived from 
gp130-/- mice exhibited diminished ALP expression both in vitro and in vivo (Shin et al, 
2004). The influence of STAT3 signalling on osteogenic differentiation was primarily 
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investigated with connection to cytokines of the IL-6 family, which all activate the STAT3 
signalling pathway through the gp130 adaptor molecule, and their effects on bone. More 
specifically a number of studies have shown that members of this family, including IL-6, LIF, 
OSM and CNTF can promote OB differentiation and mineralisation (Bellido et al, 1997; 
Gimble et al, 1994; Nishimura et al, 1998; Song et al, 2007; Taguchi et al, 1998; Thaller et al, 
1993) but the exact mechanism is not yet identified. The microarray data presented in this 
thesis showed that STAT3 signalling in MSCs led to the upregulation of Runx2 and ALP 
expression suggesting that these two genes could be direct targets of STAT3. However, 
further studies are required to investigate this hypothesis. Additionally, STAT3CA in MSCs 
led to the upregulation of the receptors for OSM and LIF. This indicated that STAT3 
signalling could be acting in a positive feedback loop to upregulate OSM and LIF receptor 
expression on MSCs and thus making them more responsive to OSM and LIF. This could 
additionally lead to further increase in STAT3 activation and further enhancement of 
osteogenic differentiation. 
 
STAT3 signalling was shown as an important mechanism of the monocyte/Mφ driven MSC 
osteogenesis but the identification of the soluble mediator(s) with osteogenic activity 
remained elusive. PGE2 was previously shown to be upregulated in murine MSC and Mφ co-
cultures (Nemeth et al, 2009) and is also one of the mediators described in literature to be 
responsible for the immunosuppressive abilities of MSCs (Aggarwal & Pittenger, 2005). 
Furthermore, PGE2 has been reported to have many important roles in bone including OC 
and OB formation and function, bone mechanotransduction and repair (Kawaguchi et al, 
1995; Li et al, 2006b). Inhibition of PGE2 production using COX2 inhibitor NS-398 abrogated 
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the osteogenic effect of monocytes on MSCs and furthermore, the inhibitory effect of NS-
398 on monocyte-induced osteogenesis could be rescued by exogenous addition of PGE2 or 
EP2/4 receptor agonists. Indeed the bone anabolic effects of PGE2 on bone have been 
associated with signalling through EP2/4 receptors (Gao et al, 2009; Li et al, 2007a; 
Ninomiya et al, 2011; Paralkar et al, 2003; Xie et al, 2009; Yoshida et al, 2002b). However, 
PGE2 could not directly induce a significant increase in osteogenesis when added to MSC 
cultures in contrast to previous reports showing PGE2 to be stimulatory of bone formation 
(Ninomiya et al, 2011; Suponitzky & Weinreb, 1998; Weinreb et al, 1997; Zhang et al, 
2002a). Nevertheless, the regulation of monocyte osteogenic ability by NS-398 and PGE2 
indicated that these regulated the expression of soluble factor(s) with osteogenic activity. 
Indeed, a microarray approach to investigate gene profiling in monocytes, identified seven 
candidates that fulfilled the criteria of encoding for a protein soluble in nature, being 
upregulated in monocytes co-cultured with MSCs as compared to monocytes cultured 
alone, downregulated by NS-398 and reinstated with exogenous addition of PGE2. Of these 
seven candidates OSM was identified to be the mediator of monocyte-induced MSC 
osteogenesis.  
 
The identification of OSM as the mediator of the osteogenic action of monocytes on MSCs 
correlated with the fact that STAT3CA MSCs showed upregulation of OSMR and LIFR 
expression. It was also in agreement with many studies reporting that OSM can promote 
osteogenic differentiation and mineralisation both in vitro and in vivo (de Hooge et al, 2002; 
Gimble et al, 1994; Song et al, 2007; Walker et al, 2010). Furthermore, it agreed with the 
findings from Chapter 4 showing that STAT3 is a mechanism by which monocytes induce 
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MSC osteogenesis, since OSM is known to signal through the STAT3 pathway (Heinrich et al, 
1998) and has also been shown to induce STAT3 phosphorylation in murine and human 
osteoblastic cells as well as in a human osteosarcoma cell line (Levy et al, 1996). 
Furthermore, OSM is known to be produced by monocytes and Mφs (Zarling et al, 1986) and 
it has been previously shown that PGE2 can induce OSM production in these cell types 
(Repovic & Benveniste, 2002). Since the present study identified OSM as an important 
mediator of OB regulation by monocytes and Mφs, it would be interesting to investigate 
whether the distinct Mφ population, termed Osteomacs, found to be intercalated 
throughtout bone tissues and specifically located adjacent to the layer of bone lining cells 
(Chang et al, 2008) show expression of OSM. Indeed, Walker and colleagues have recently 
described that OSM is expressed throughout murine bone tissue where it regulates OBs and 
OCs acting through both the OSMR and LIFR (Walker et al, 2010). The findings presented in 
this thesis provide the link between these two studies by identifying the Mφs as the source 
of OSM in bone and showing that OSM is indeed the mediator by which Mφs regulate OBs. 
Furthermore, since depletion of Osteomacs was shown to disrupt bone forming sites and 
mineralisation in vivo (Chang et al, 2008), if eradication of OSM expression by the Mφ (for 
example using Cre-Lox technology) has the same effects this would further indicate that 
OSM is indeed the signal by which Osteomacs regulate OBs. Similarly, the elevated 
expression of COX2 in Mφs infiltrating bone fracture sites shown by Xie and colleagues to be 
important for bone repair (Xie et al, 2008), could correlate with elevated OSM production 
since it has been shown that PGE2 can induce OSM production in Mφs (Repovic & 
Benveniste, 2002). This would further demonstrate that OSM mediates bone repair though 
Mφs effects on osteoprogenitors.  
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Does OSM have potential to be used as a therapeutic agent? Administration of OSM in vivo 
led to increased bone formation suggesting its potential use as an anabolic agent (Walker et 
al, 2010). However, OSM has been shown to also stimulate OC formation, an action which 
requires the presence of OBs and production of RANKL (Palmqvist et al, 2002; Richards et al, 
2000; Suda et al, 1995; Tamura et al, 1993), as well as enhanced OC-mediated bone 
destruction in vivo in an inflammatory arthritis model (Hui et al, 2005). Furthermore, 
intraperitoneal administration of OSM blocking antibodies ameliorated disease in two 
murine models of arthritis (Plater-Zyberk et al, 2001). Indeed, OSM has been found to be 
elevated in synovial fluid of RA patients (Cawston et al, 1998; Okamoto et al, 1997) but 
unlike IL-6 it was not detected in RA patient serum (Okamoto et al, 1997) indicating that it 
has a local rather than a systemic role. Injection of OSM or adenoviral vectors expressing 
OSM in joints of goats and knee joints of mice respectively induced inflammation (Bell et al, 
1999; Langdon et al, 2000) supporting a pro-inflammatory role for OSM in joint pathology. 
However, despite synovial inflammation and up-regulated expression of IL-6 and RANKL, 
adenoviral vectors expressing OSM also led to periosteal bone apposition whereas OCs were 
not increased due to uperegulation of RANKL decoy receptor OPG (de Hooge et al, 2002). 
These reports indicate that the bone anabolic effect of OSM in the periosteum could be 
negatively influenced by other cytokines or inflammatory cells in the RA joint were bone 
erosion instead of apposition occurs. These could include osteoclastogenic cytokines such as 
IL-1 and TNF that would induce OC formation and function but also the inflammatory 
monocytes and Mφ that have been shown in this study to be inhibitory of the 
differentiation of MSC to OBs. Hence, OSM may have a role as a bone anabolic agent in 
settings of excessive inflammation such as RA if is combined with anti-inflammatory drugs. 
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Conversely, OSM could have a role in other diseases where periosteal bone apposistion 
occurs such as Reiter disease (Martel et al, 1979), juvenile chronic arthritis (Resnick et al, 
1989), erosive osteoarthritis (Martel et al, 1980) and hypertrophic osteoarthropathy 
(Altman & Tenenbaum, 1989), in which case OSM inhibition could be a favourable 
therapeutic approach.  
 
Figure 6.2 Proposed mechanism of monocyte/Mφ induced osteogenesis in MSCs 
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of COX2 and upregulation of PGE2 production. PGE2 acts on EP2/4 receptors to induce the 
expression of OSM probably through activation of Gs proteins, cAMP and PKA. OSM acts on 
MSC to induce phosphorylation of STAT3 leading to increased expression of ALP and 
enhanced osteogenesis.  
 
6.2 Future Directions 
The findings presented in this thesis provide strong evidence for a direct regulation of MSC 
osteogenic differentiation by monocytes and Mφs and also present a mechanism of how 
this takes place. This study also uncovers many possibilities for future investigations that 
could target several key areas. 
 
1. Further validation of OSM as the mediator of monocyte-induced osteogensesis.  
To further validate OSM as the mediator of monocyte/Mφ ability to regulate osteogenic 
differentiation a number of in vitro experiments are required. OSM ELISAs would validate 
the upregulation of OSM in monocyte/MSC co-culture supernatants whilst neutralisation of 
OSM in monocyte/MSC co-cultures should inhibit monocyte-induce increase in ALP activity 
and mineralisation. Additionally, the ability of OSM to induce STAT3 activation in MSCs 
should be validated using WB. Finally, using siRNA OSM knockdown in the monocytes as 
well as OSMR knockdown in the MSCs should provide further evidence for the involvement 
of OSM as the mediator of monocyte-induced osteogenesis.  
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Further to the in vitro studies, without doubt the ultimate proof of principle will come from 
in vivo investigations. Injection of OSM over calvariae of mice has already been shown to 
increase bone formation (Walker et al, 2010) thus verifying the osteogenic ability of OSM in 
vivo. In their study Walker and colleagues identified the presence of OSM in murine bone 
tissue and suggested that OSM was produced by the OBs. Data from this thesis indicate that 
monocyte/Mφs could be the source of OSM and indeed OSM could be the mediator of the 
Mφ regulation of OBs as described by Chang et al. (Chang et al, 2008). They showed that 
Mφs, identified by F4/80 immunohistochemical staining, were located immediately adjacent 
to resting endosteal and periosteal bone surfaces as well as forming canopy structures over 
mature osteocalcin and collagen I positive OBs at sites of bone formation. It would be 
interesting to show whether OSM staining would co-localise with F4/80 indicating that Mφs 
are the source of OSM in bone. Additionally, using Cre-Lox technology OSM could be 
knocked down in Mφs to investigate whether this would replicate the effect of Mφ 
depletion, namely loss of OBs at bone forming sites, shown by Chang et al.  Similarly, OSMR 
receptor but also LIFR, since Walker and colleagues showed that OSM could act on both 
receptors (Walker et al, 2010), could be specifically knocked down in the OBs to make them 
unresponsive to the OSM effect. Collectively, all these studies will complement the existing 
knowledge and validate OSM as the mediator of the regulation of OB differentiation and 
function by Mφs in vivo.    
 
One of the most important aspects of the identification of OSM as a mediator with 
osteogenic ability is its potential value as a therapeutic agent. This can be evaluated in the 
first instance in mouce models. OSM could be useful as an anabolic agent in situations 
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where bone formation is required. Administration of OSM in a mouse model of open 
fracture will assess the ability of OSM to accelerate the process of bone formation and 
repair in vivo verified using µCT analysis. Conversely, inhibition of OSM using neutralising 
antibodies could be beneficial in diseases of excessive bone formation such as osteophytes 
associated with OA, bone spurs and ankylosing spondylitis (AS). OSM antibodies for use in 
the clinic have already been developed and these can be used in mouse models such as in 
the surgical destabilization of the medial meniscus (DMM) model of OA (Moodie et al, 2011) 
or the murine progressive ankylosis (MPA) model of AS (Zhang et al, 2002b). 
 
2. Monocyte subsets and Mφ polarisation – relation to OSM, STAT3 signalling and disease 
Regarding the effects of monocyte subsets and Mφs with an inflammatory phenotype on 
MSC differentiation in vitro, it would be interesting to explore their contribution in inhibiting 
bone formation in a disease setting in vivo. For example, in a murine model of adjuvant-
induced arthritis that affects the knee joints, depletion of whole monocyte/Mφ populations 
could be followed by reintroduction of either the pro-osteogenic CD14++CD16- 
monocytes/M-CSF Mφs or the inhibitory CD14+CD16+/GM-CSF Mφs and compare the effect 
on bone destruction. Additionally, it would be important to investigate whether the 
CD14++CD16- and CD14+CD16+ monocytes, have a difference in their ability to produce OSM 
which would explain the difference in their ability to induce STAT3 signalling in MSCs. 
Similarly, differences in OSM production could also be investigated in the GM-CSF (M1) and 
M-CSF (M2) Mφs. Such differences, namely increased OSM production by the CD14++CD16- 
and M-CSF (M2) Mφs but reduced OSM production by the CD14+CD16+ and GM-CSF (M1) 
Mφs could explain the different effect of these cells on MSC osteogenic differentiation. 
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3. Investigation of MSC Migration   
Data presented in this thesis showed that MSCs migrated towards monocytes and indeed 
this could be an important aspect of the monocyte/Mφ regulation of MSC osteogenic 
differentiation. Many different chemokines were found to be upregulated in both co-culture 
supernatants as well as the gene profiling analysis of MSCs and monocytes, and these 
molecules may have an important role in the chemotaxis of MSCs to monocytes and vica 
versa. Hence the present study offers great scope for the investigation of MSC migration. 
Chemotaxis assays towards the identified chemokines, and also whether chemotaxis can be 
inhibited by antibodies against these chemokines, should help elucidate their role. Again in 
this system no molecule exists in isolation therefore another consideration is that the 
presence of other factors can make MSCs more responsive to chemotaxis by a certain 
chemokine. For example, pretreatement of muscle-derived stromal cells with TNFα 
promoted the chemotactic response to CXCL8 (Dr Graeme Glass, PhD thesis). Finally, in 
addition to the different regulation of osteogenic differentiation by monocyte subsets or 
GM-CSF (M1) and M-CSF (M2) Mφs, these could also have different ability to attract MSCs; 
this possibility could also be investigated using chemotaxis assays of MSCs.   
 
4. Mechanism of STAT3 induced osteogenesis in MSCs  
To further elucidate the mechanism by which STAT3 induces osteogenesis in MSC the 
microarray data presented in chapter 4 could be explored. STAT3-induced osteogenesis 
could be mediated by the upregulation of Runx2 identified in the gene profiling of STAT3CA 
overexpressing MSCs. Further experiments are required to identify whether RUNX2 or ALP, 
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which was also upregulated in STAT3CA MSCs, are direct targets of STAT3. Additionally, 
STAT3CA also caused the upregulation of many other genes that could be involved in 
promoting osteogenesis. One candidate emerging from the microarray study on MSCs in 
chapter 4 was the ephrins. These are membrane bound ligands of Eph receptors that are 
thought to be mediating cross talk between the OCs and OBs and have known roles in 
regulating bone metabolism (Allan et al, 2008; Irie et al, 2009; Lorenzo et al, 2008; Mundy & 
Elefteriou, 2006; Zhao et al, 2006).  
 
Gene profiling analysis identified a variety of genes that were upregulated after interaction 
of monocytes with MSCs and also in MSC overexpressing STAT3CA. A great number of 
cytokines and chemokines were also found to be upregulated in co-culture supernatants 
using ELISA. For example, IL-6 was consistently found to be upregulated in co-cultures, and 
was also identified strongly upregulated in both the MSC and monocyte gene profiling 
analyses. Furthermore, in addition to OSM six other genes were found to be upregulated in 
monocytes after co-culture with MSCs and regulated by NS-398 and PGE2. Even though 
many of these molecules identified either by ELISA or gene profiling such as IL-6, IL-10, IL-24, 
EREG and CXCL5 did not have a direct effect on osteogenic differentiation, they were tested 
individually whereas in the co-culture system a soluble factor is never acting in isolation. The 
possibility of combined effects of these soluble mediators with or without OSM is an 
interesting aspect to explore. According to the data using the LOX inhibitors, the possible 
role of LOX metabolites in combination with OSM should also be explored. 
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